0000950170-24-12676310-Q Rani Therapeutics Holdings, Inc. 20241114202411140820240820250820250 0 0000950170-24-126763 10-Q 78 20240930 20241114 20241114 Rani Therapeutics Holdings, Inc. 0001856725 2834 000000000 DE 1231 10-Q 34 001-40672 241457352 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700 2051 RINGWOOD AVENUE SAN JOSE CA 95131 10-Q 1 rani-20240930.htm 10-Q 10-Q false0001856725--12-31Q306-04-20210001856725us-gaap:AvailableforsaleSecuritiesMember2023-01-012023-12-310001856725us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001856725us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001856725rani:RegistrationRightsAgreementMemberus-gaap:CommonClassAMember2022-01-012022-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-04-012024-06-300001856725us-gaap:StockOptionMember2023-01-012023-12-310001856725us-gaap:RestrictedStockUnitsRSUMember2023-12-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001856725rani:LoanAndSecurityAgreementMember2024-09-300001856725us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001856725srt:MaximumMember2024-09-300001856725rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-01-012024-09-300001856725us-gaap:CommonClassAMember2023-12-310001856725us-gaap:RetainedEarningsMember2023-01-012023-03-310001856725us-gaap:ResearchAndDevelopmentArrangementMember2023-12-310001856725rani:LoanAndSecurityAgreementMember2022-08-310001856725us-gaap:SubsequentEventMemberrani:SeriesACommonWarrantsMember2024-10-310001856725us-gaap:ResearchAndDevelopmentArrangementMember2024-09-300001856725us-gaap:NoncontrollingInterestMember2023-09-300001856725us-gaap:CashAndCashEquivalentsMember2024-01-012024-09-300001856725rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember2023-01-012023-12-310001856725rani:AccumulatedOtherComprehensiveLossMember2024-09-300001856725rani:AvenueVentureOpportunityFundLPMembersrt:MinimumMemberrani:LoanAndSecurityAgreementMember2021-08-012021-08-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-012023-06-300001856725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001856725us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:SubsequentEventMember2023-11-012024-12-310001856725us-gaap:AdditionalPaidInCapitalMember2024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001856725us-gaap:RetainedEarningsMember2024-06-300001856725us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001856725us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:RestrictedStockMember2024-01-012024-09-300001856725us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-07-012024-09-300001856725us-gaap:RetainedEarningsMember2023-06-300001856725us-gaap:CommercialPaperMemberus-gaap:AvailableforsaleSecuritiesMember2023-12-310001856725rani:RaniLLCMember2023-11-012023-11-300001856725us-gaap:CommonClassBMember2023-12-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725srt:MaximumMember2022-08-012022-08-310001856725us-gaap:CommonClassAMemberus-gaap:SubsequentEventMemberrani:SeriesACommonWarrantsMember2024-10-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-09-300001856725us-gaap:SubsequentEventMember2024-10-012024-10-310001856725us-gaap:AdditionalPaidInCapitalMember2024-03-310001856725us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001856725rani:PairedInterestMembersrt:MinimumMember2024-09-300001856725us-gaap:NoncontrollingInterestMember2023-03-310001856725rani:AccumulatedOtherComprehensiveLossMember2024-06-300001856725us-gaap:RetainedEarningsMember2024-04-012024-06-300001856725us-gaap:AdditionalPaidInCapitalMember2022-12-310001856725srt:ScenarioForecastMemberus-gaap:CommonClassBMember2024-11-110001856725us-gaap:WarrantMember2024-07-310001856725us-gaap:WarrantMemberus-gaap:SeriesAMember2024-07-012024-07-310001856725rani:SecuritiesPurchaseAgreementMember2024-09-300001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725rani:CommonClassAMemberrani:SecuritiesPurchaseAgreementMember2024-07-310001856725us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:RetainedEarningsMember2024-03-310001856725rani:InCubeLabsLLCMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001856725us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2024-01-012024-03-310001856725us-gaap:CommonClassAMember2024-07-310001856725us-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725rani:InCubeLabsLLCMember2023-01-012023-09-300001856725us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001856725us-gaap:WarrantMemberus-gaap:SeriesAMember2024-09-300001856725rani:ContinuingLlcOwnersMember2024-01-012024-09-3000018567252024-01-012024-09-300001856725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725srt:ParentCompanyMemberus-gaap:CommonClassAMember2023-01-012023-09-300001856725us-gaap:RetainedEarningsMember2023-07-012023-09-300001856725us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001856725rani:InCubeLabsLLCMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001856725us-gaap:CashAndCashEquivalentsMember2023-01-012023-12-310001856725us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725rani:NonCorrespondingClassAUnitsMember2024-01-012024-09-300001856725us-gaap:CorporateDebtSecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2023-01-012023-12-310001856725us-gaap:WarrantMemberus-gaap:CommonClassAMember2024-07-310001856725rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember2023-12-310001856725us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember2023-01-012023-09-300001856725us-gaap:AdditionalPaidInCapitalMember2024-06-300001856725rani:SharesIssuablePursuantToTheEsppMember2024-01-012024-09-300001856725rani:InCubeLabsLLCMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001856725us-gaap:CommonClassCMember2024-09-300001856725rani:InCubeLabsLLCMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001856725srt:MinimumMemberrani:RaniManagementServiceAndInCubeLabsLlcMember2024-03-310001856725us-gaap:RetainedEarningsMember2022-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:StockOptionMember2024-01-012024-09-3000018567252023-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-12-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2023-01-012023-12-3100018567252023-04-012023-06-300001856725rani:AccumulatedOtherComprehensiveLossMember2022-12-310001856725us-gaap:WarrantMemberus-gaap:SeriesBMember2024-09-300001856725rani:NonCorrespondingClassAUnitsMember2023-01-012023-09-300001856725us-gaap:RetainedEarningsMember2023-03-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:CommonClassAMemberrani:SeriesBCommonWarrantsMemberus-gaap:SubsequentEventMember2024-10-310001856725rani:TaxReceivableAgreementMember2023-01-012023-09-300001856725us-gaap:CommonClassAMembersrt:ScenarioForecastMember2024-11-110001856725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember2024-01-012024-09-300001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100018567252024-06-300001856725us-gaap:NoncontrollingInterestMember2022-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-03-310001856725us-gaap:RestrictedStockMember2023-12-310001856725us-gaap:CommonClassAMember2022-08-012022-08-3100018567252024-01-012024-03-310001856725us-gaap:RestrictedStockMember2023-01-012023-09-3000018567252024-09-3000018567252022-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-09-300001856725us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001856725rani:AccumulatedOtherComprehensiveLossMember2024-07-012024-09-300001856725us-gaap:CashAndCashEquivalentsMember2023-12-310001856725us-gaap:FairValueInputsLevel3Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-3000018567252023-03-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-012023-09-300001856725us-gaap:CommonClassAMemberrani:RaniLLCMember2024-01-012024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-09-300001856725us-gaap:CorporateDebtSecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2023-12-310001856725rani:RaniLLCMemberrani:OutstandingCapitalClassAUnitMember2024-01-012024-09-300001856725rani:RaniLLCMember2024-02-010001856725us-gaap:FairValueInputsLevel2Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:CommonClassAMemberrani:SecuritiesPurchaseAgreementMember2024-07-012024-07-310001856725rani:AccumulatedOtherComprehensiveLossMember2023-03-310001856725us-gaap:CommercialPaperMemberus-gaap:AvailableforsaleSecuritiesMember2023-01-012023-12-3100018567252023-06-300000185672 5rani:InCubeLabsLLCMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001856725us-gaap:CommonClassCMember2023-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-01-012024-09-300001856725us-gaap:CommonClassAMember2024-01-012024-09-300001856725rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-01-012023-12-310001856725srt:MinimumMemberus-gaap:SubsequentEventMembersrt:ChiefExecutiveOfficerMember2023-11-012024-12-3100018567252022-08-310001856725us-gaap:AvailableforsaleSecuritiesMember2023-12-310001856725srt:MinimumMember2022-08-012022-08-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001856725rani:RaniLLCMemberus-gaap:CommonClassAMember2023-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-03-3100018567252023-01-012023-09-300001856725us-gaap:NoncontrollingInterestMember2024-06-3000018567252023-01-012023-03-310001856725us-gaap:ResearchAndDevelopmentArrangementMember2024-01-012024-09-300001856725us-gaap:CashAndCashEquivalentsMember2024-09-300001856725us-gaap:ResearchAndDevelopmentArrangementMember2024-08-012024-08-310001856725rani:InCubeLabsLLCMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001856725us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2024-09-300001856725us-gaap:SubsequentEventMembersrt:MaximumMembersrt:ChiefExecutiveOfficerMember2023-11-012024-12-310001856725rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001856725rani:RestrictedStockAwardsMember2024-01-012024-09-300001856725rani:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2024-01-012024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-300001856725us-gaap:WarrantMemberus-gaap:SeriesAMember2024-07-310001856725us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001856725us-gaap:USTreasurySecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2023-12-310001856725us-gaap:RestrictedStockMember2024-09-300001856725rani:InCubeLabsLLCMember2024-01-012024-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2023-04-012023-06-300001856725rani:AccumulatedOtherComprehensiveLossMember2023-07-012023-09-300001856725rani:RaniLLCMemberus-gaap:CommonClassAMember2024-09-3000018567252024-04-012024-06-300001856725us-gaap:WarrantMemberus-gaap:SeriesBMember2024-07-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725srt:MaximumMemberrani:RaniManagementServiceAndInCubeLabsLlcMember2024-03-310001856725us-gaap:RestrictedStockUnitsRSUMember2024-09-300001856725us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember2024-01-012024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001856725us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001856725us-gaap:AdditionalPaidInCapitalMember2023-12-310001856725srt:ScenarioPreviouslyReportedMember2024-09-300001856725rani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMembersrt:MaximumMember2022-08-310001856725rani:AccumulatedOtherComprehensiveLossMember2023-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-310001856725rani:AccumulatedOtherComprehensiveLossMember2023-06-3000018567252024-07-012024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-06-300001856725rani:InCubeLabsLLCMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-03-310001856725rani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2022-08-310001856725rani:RaniLLCMembersrt:MaximumMember2024-03-310001856725us-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:RetainedEarningsMember2023-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2024-03-310001856725rani:InCubeLabsLLCMember2024-07-012024-09-300001856725us-gaap:AdditionalPaidInCapitalMember2023-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2023-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001856725us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-03-310001856725us-gaap:RetainedEarningsMember2023-12-310001856725us-gaap:StockOptionMember2023-01-012023-09-300001856725us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001856725us-gaap:CommonClassAMember2023-01-012023-09-3000018567252023-09-300001856725us-gaap:StockOptionMember2023-12-310001856725rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember2024-09-300001856725rani:RaniLLCMember2024-02-012024-02-010001856725us-gaap:CommonClassAMember2024-09-300001856725us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725rani:InCubeLabsLLCMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001856725srt:ParentCompanyMemberus-gaap:CommonClassAMember2024-01-012024-09-300001856725us-gaap:RetainedEarningsMember2024-09-3000018567252023-07-012023-09-300001856725us-gaap:WarrantMemberus-gaap:CommonClassAMemberus-gaap:SeriesBMember2024-07-310001856725rani:OrganizationalTransactionsMembersrt:ScenarioPreviouslyReportedMember2024-09-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001856725us-gaap:AdditionalPaidInCapitalMember2023-06-300001856725us-gaap:RestrictedStockMember2024-01-012024-09-300001856725rani:LoanAndSecurityAgreementMember2022-08-012022-08-3100018567252023-01-012023-12-310001856725us-gaap:RetainedEarningsMember2024-07-012024-09-300001856725us-gaap:StockOptionMember2024-09-300001856725srt:MinimumMemberrani:RaniLLCMember2024-03-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001856725us-gaap:NoncontrollingInterestMember2023-12-310001856725us-gaap:CommonClassCMembersrt:ScenarioForecastMember2024-11-110001856725rani:SharesIssuablePursuantToTheEsppMember2023-01-012023-09-300001856725us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-01-

012023-12-310001856725rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001856725rani:RaniLLCMember2023-11-300001856725rani:TaxReceivableAgreementMember2024-01-012024-09-300001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725rani:PreFundedWarrantMemberus-gaap:SubsequentEventMember2024-10-310001856725us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001856725us-gaap:WarrantMemberus-gaap:SeriesAMemberus-gaap:CommonClassAMember2024-07-310001856725us-gaap:RetainedEarningsMember2023-04-012023-06-300001856725us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725rani:PairedInterestsMember2023-01-012023-09-300001856725rani:RaniLLCMemberus-gaap:CommonClassAMemberrani:OrganizationalTransactionsMember2024-09-300001856725us-gaap:NoncontrollingInterestMember2023-06-300001856725us-gaap:NoncontrollingInterestMember2024-03-310001856725us-gaap:StockOptionMember2024-01-012024-09-300001856725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725rani:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2024-09-300001856725us-gaap:AdditionalPaidInCapitalMember2023-03-310001856725us-gaap:CommonClassAMemberrani:LoanAndSecurityAgreementMember2022-08-310001856725rani:RaniLLCMember2024-09-300001856725us-gaap:SubsequentEventMember2024-10-310001856725us-gaap:USTreasurySecuritiesMemberus-gaap:AvailableforsaleSecuritiesMember2024-01-012024-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2023-01-012023-03-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001856725rani:AccumulatedOtherComprehensiveLossMember2024-04-012024-06-300001856725us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001856725rani:InCubeLabsLLCMember2023-07-012023-09-300001856725srt:ScenarioPreviouslyReportedMember2023-09-300001856725us-gaap:RetainedEarningsMember2024-01-012024-03-310001856725us-gaap:NoncontrollingInterestMember2024-09-300001856725us-gaap:CommonClassBMember2024-09-300001856725us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001856725us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-310001856725rani:PairedInterestsMember2024-01-012024-09-30xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD Â fÂ UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, DC 20549Â FORM 10-QÂ (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____Commission File Number: 001-40672Â RANI THERAPEUTICS HOLDINGS, INC.(Exact Name of Registrant as Specified in its Charter)Â Â Delaware 86-3114789 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 2051 Ringwood AvenueSan Jose, California 95131 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (408) 457-3700Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered Class A common stock, par value $0.0001 per share Â RANI Â The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜ Smaller reporting company â˜’ Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of November 11, 2024, the registrant had 33,311,543 shares of Class A common stock, $0.0001 par value per share, outstanding, 23,977,139 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding. Certain holders of units of the registrantâ€™s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrantâ€™s Class B common stock can exchange their units of Rani Therapeutics, LLC for 1,229,630 shares of the registrantâ€™s Class A common stock.Â Â Â Â Table of ContentsÂ Â Â Page Special Note Regarding Forward-Looking Statements 3 Â Â Â PART I. FINANCIAL INFORMATION Â Â Â Â Â RANI THERAPEUTICS HOLDINGS, INC. Â Item 1. Financial Statements (Unaudited) 5 Â Condensed Consolidated Balance Sheets 5 Â Condensed Consolidated Statements of Operations 6 Â Condensed Consolidated Statements of Comprehensive Loss 7 Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity 8 Â Condensed Consolidated Statements of Cash Flows 10 Â Notes to Unaudited Condensed Consolidated Financial Statements 11 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3. Quantitative and Qualitative Disclosures About Market Risk 35 Item 4. Controls and Procedures 35 Â Â Â PART II. OTHER INFORMATION 37 Â Â Â Item 1. Legal Proceedings 37 Item 1A. Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 38 Item 6. Exhibits 39 Signatures 40 Â 2 Â Unless otherwise stated or the context otherwise requires, the terms â€œwe,â€ â€œus,â€ and â€œour,â€ and similar references refer to Rani Therapeutics Holdings, Inc. (â€œRani Holdingsâ€) and its consolidated subsidiary, Rani Therapeutics, LLC (â€œRani LLCâ€).Â SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q, including the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and consolidated financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, manufacturing costs, regulatory approvals, development and advancement of our oral delivery technology, timing and likelihood of success, potential partnering activities as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œwould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œcould,â€ â€œintend,â€ â€œtarget,â€ â€œproject,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotential,â€ â€œseek,â€ â€œaim,â€ or â€œcontinueâ€ or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:Â â€¢the progress and focus of our current and future clinical trials in the United States and abroad, and the reporting of data from those trials;â€¢our ability to advance product candidates into and successfully complete clinical trials;â€¢the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;â€¢our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;â€¢our ability to complete development of the RaniPill HC or any redesign and conduct additional preclinical and clinical studies of the RaniPill HC or any future design of the RaniPill capsule to accommodate target payloads that are larger than the payload capacity of the RaniPill GO capsule used to date for clinical studies of our product candidates;â€¢our ability to further develop and expand our platform technology;â€¢our ability to utilize our technology platform to generate and advance additional product candidates;â€¢the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;â€¢our financial performance;â€¢our ability to continue as a going concern;â€¢our plans relating to commercializing our product candidates, if approved;â€¢our ability to selectively enter into strategic partnership and the expected potential benefits thereof;â€¢the implementation of our strategic plans for our business and product candidates;â€¢our ability to continue to scale and optimize our manufacturing processes by expanding our use of automation;â€¢our estimates of the number of patients in the United States who suffer from the indications we target and the number of patients that will enroll in our clinical trials;â€¢the size of the market opportunity for our product candidates in each of the indications we target;â€¢our ability to continue to innovate and expand our intellectual property by developing novel formulations and new applications of the RaniPill capsule;â€¢our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;â€¢the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform and product candidates; 3 Â â€¢the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;â€¢our ability to realize savings from any restructuring plans or cost-containment measures we propose to implement;â€¢developments relating to our competitors and our industry, including competing product candidates and therapies;â€¢our realization of any benefit from our organizational structure, taking into account our obligations under the Tax Receivable Agreement (defined herein) and the impact of any payments required to be made thereunder on our liquidity and financial condition; andâ€¢our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€).These forward-looking statements are subject to a number of risks, uncertainties, and assumptions described in the section titled â€œRisk Factorsâ€ and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2024. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise.In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. 4 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value) Â Â Â September 30, Â Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (Unaudited) Â Â Â Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 4,277 Â Â $ 5,864 Â Marketable securities Â Â 26,127 Â Â Â Â 42,675 Â Prepaid expenses and other current assets Â Â 1,967 Â Â Â 2,308 Â Total current assets Â Â 32,371 Â Â Â 50,847 Â Property and equipment, net Â Â 5,496 Â Â Â 6,105 Â Operating lease right-of-use asset Â Â 5,427 Â Â Â 718 Â Other assets Â Â 246 Â Â Â 246 Â Total assets Â $ 43,540 Â Â $ 57,916 Â Liabilities and Stockholders' Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 1,566 Â Â $ 648 Â Accrued expenses and other current liabilities Â Â 1,867 Â Â Â 1,726 Â Deferred revenue Â Â 600 Â Â Â â€” Â Current portion of long-term debt Â Â 14,768 Â Â Â 4,897 Â Current portion of operating lease liability Â Â 1,410 Â Â Â 718 Â Total current liabilities Â Â 20,211 Â Â Â 7,989 Â Long-term debt, less current portion Â Â 13,537 Â Â Â 24,484 Â Operating lease liability, less current portion Â Â 4,017 Â Â Â â€” Â Total liabilities Â Â 37,765 Â Â Â 32,473 Â Commitments and contingencies (Note 12) Â Â Â Â Â Â Stockholders' equity: Â Â Â Â Â Â Preferred stock, $0.0001Â par value - 20,000Â shares authorized; noneÂ issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Class A common stock, $0.0001Â par value - 800,000Â shares authorized; 29,807Â and 26,036Â issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â 3 Â Â Â 3 Â Class B common stock, $0.0001Â par value - 40,000Â shares authorized; 24,116Â issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â 2 Â Â Â 2 Â Class C common stock, $0.0001Â par value - 20,000Â shares authorized; noneÂ issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Additional paid-in capital Â Â 97,067 Â Â Â 85,762 Â Accumulated other comprehensive gain (loss) Â Â 8 Â Â Â (12) Accumulated deficit Â Â (93,960) Â Â (72,889) Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. Â Â 3,120 Â Â Â 12,866 Â Non-controlling interest Â Â 2,655 Â Â Â 12,577 Â Total stockholders' equity Â Â 5,775 Â Â Â 25,443 Â Total liabilities and stockholders' equity Â $ 43,540 Â Â $ 57,916 Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED Consolidated Statements of Operations(in thousands, except per share amounts) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â $ 6,172 Â Â $ 11,220 Â Â $ 19,872 Â Â $ 32,018 Â General and administrative Â Â 5,627 Â Â Â 6,635 Â Â Â 18,484 Â Â Â 20,647 Â Total operating expenses Â $ 11,799 Â Â $ 17,855 Â Â $ 38,356 Â Â $ 52,665 Â Loss from operations Â Â (11,799) Â Â (17,855) Â Â (38,356) Â Â (52,665) Other income (expense), net Â Â Â Â Â Â Â Â Â Â Interest income and other, net Â Â 414 Â Â Â 839 Â Â Â 1,403 Â Â Â 2,626 Â Interest expense and other, net Â Â (1,337) Â Â (1,316) Â Â (3,909) Â Â (3,789) Net loss Â $ (12,722) Â $ (18,332) Â $ (40,862) Â $ (53,828) Net loss attributable to non-controlling interest Â Â (5,939) Â Â (9,135) Â Â (19,791) Â Â (26,956) Net loss attributable to Rani Therapeutics Holdings, Inc. Â $ (6,783) Â $ (9,197) Â $ (21,071) Â $ (26,872) Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted Â $ (0.24) Â $ (0.36) Â $ (0.78) Â $ (1.06) Weighted-average Class A common shares outstandingâ€”basic and diluted Â Â 28,836 Â Â Â 25,552 Â Â Â 27,071 Â Â Â 25,380 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED Consolidated Statements of Comprehensive Loss (in thousands) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (12,722) Â $ (18,332) Â $ (40,862) Â $ (53,828) Other comprehensive loss Â Â Â Â Â Â Â Â Â Â Net unrealized gain on marketable securities Â Â 24 Â Â Â 45 Â Â Â 37 Â Â Â 64 Â Comprehensive loss Â $ (12,698) Â $ (18,287) Â $ (40,825) Â $ (53,764) Comprehensive loss attributable to non-controlling interest Â Â (5,928) Â Â (9,113) Â Â (19,774) Â Â (26,924) Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. Â $ (6,770) Â $ (9,174) Â $ (21,051) Â $ (26,840) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 7 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED Consolidated Statements of Changes in STOCKHOLDERSâ€™ Equity(in thousands) (Unaudited) Â Â Class A Common Stock Â Â Class B Common Stock Â Â Â Â Â Â Â Â Â Â

Â Â â€” Â Â Â â€” Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement Â Â 71 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (1) Â Â â€” Â Â Â â€” Â Â Â Â â€” Â Â Â (1) Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (4,010) Â Â â€” Â Â Â Â â€” Â Â Â 4,010 Â Â Â Â â€” Â Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,183 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 1,858 Â Â Â 4,041 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (6,783) Â Â (5,939) Â Â (12,722) Other comprehensive gain Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 13 Â Â Â Â â€” Â Â Â 11 Â Â Â 24 Â Balance at September 30, 2024 Â Â 29,807 Â Â $ 3 Â Â Â 24,116 Â Â $ 2 Â Â $ 97,067 Â Â $ 8 Â Â $ (93,960) Â $ 2,655 Â Â $ 5,775 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 8 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED Consolidated Statements of Changes in STOCKHOLDERSâ€™ Equity (continued)(in thousands) (Unaudited) Â Â Class A Common Stock Â Â Class B Common Stock Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Additional Paid In Capital Â Â Accumulated Other Comprehensive Loss Â Â Accumulated Deficit Â Â Non-Controlling Interest Â Â Total Stockholders' Equity Â Balance at December 31, 2022 Â Â 25,295 Â Â $ 3 Â Â Â 24,116 Â Â $ 2 Â Â $ 75,842 Â Â $ (73) Â $ (38,919) Â $ 37,149 Â Â $ 74,004 Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement Â Â 81 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (124) Â Â â€” Â Â Â Â â€” Â Â Â (124) Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 98 Â Â Â Â â€” Â Â Â Â â€” Â Â Â (98) Â Â â€” Â Stock-based compensation Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,202 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,213 Â Â Â 4,415 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (8,372) Â Â (8,460) Â Â (16,832) Other comprehensive loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 63 Â Â Â Â â€” Â Â Â 63 Â Â Â 126 Â Balance at March 31, 2023 Â Â 25,376 Â Â $ 3 Â Â Â 24,116 Â Â $ 2 Â Â $ 78,018 Â Â $ (10) Â $ (47,291) Â $ 30,867 Â Â $ 61,589 Â Issuance of common stock under employee stock purchase plan Â Â 63 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 219 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 219 Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement Â Â 78 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (9) Â Â â€” Â Â Â Â â€” Â Â Â (9) Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (54) Â Â â€” Â Â Â Â â€” Â Â Â 54 Â Â Â Â â€” Â Equity-based compensation Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,572 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,569 Â Â Â 5,141 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (9,303) Â Â (9,361) Â Â (18,664) Other comprehensive loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (53) Â Â â€” Â Â Â (54) Â Â (107) Balance at June 30, 2023 Â Â 25,517 Â Â $ 3 Â Â Â 24,116 Â Â $ 2 Â Â $ 80,746 Â Â $ (63) Â $ (56,594) Â $ 24,075 Â Â $ 48,169 Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement Â Â 319 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (29) Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (29) Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Â Â 42 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 159 Â Â Â Â â€” Â Â Â Â â€” Â Â Â (159) Â Â Â â€” Â Forfeiture of restricted stock awards Â Â (2) Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (6) Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (6) Â Â (12) Equity-based compensation Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,510 Â Â Â Â â€” Â Â Â Â â€” Â Â Â 2,468 Â Â Â 4,978 Â Net loss Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â (9,197) Â Â (9,135) Â Â (18,332) Other comprehensive gain Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â 22 Â Â Â Â â€” Â Â Â 23 Â Â Â 45 Â Balance at September 30, 2023 Â Â 25,876 Â Â $ 3 Â Â Â 24,116 Â Â $ 2 Â Â $ 83,380 Â Â $ (41) Â $ (65,791) Â $ 17,266 Â Â $ 34,819 Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 9 Â RANI THERAPEUTICS HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (Unaudited) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Net loss Â $ (40,862) Â $ (53,828) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Stock-based compensation expense Â Â 12,040 Â Â Â 14,522 Â Depreciation and amortization Â Â 762 Â Â Â 595 Â Non-cash operating lease expense Â Â 1,332 Â Â Â 780 Â Amortization of debt discount and issuance costs Â Â 174 Â Â Â 174 Â Net accretion and amortization of investments in marketable securities Â Â (940) Â Â (1,851) Loss on disposal of property and equipment Â Â 65 Â Â Â â€” Â Changes in operating assets and liabilities: Â Â Â Â Â Â Prepaid expenses and other current assets Â Â 341 Â Â Â (66) Accounts payable Â Â 918 Â Â Â 68 Â Accrued expenses and other current liabilities Â Â 61 Â Â Â 1,628 Â Deferred revenue Â Â 600 Â Â Â â€” Â Operating lease liabilities Â Â (1,332) Â Â (780) Net cash used in operating activities Â Â (26,841) Â Â (38,758) Cash flows from investing activities Â Â Â Â Â Â Proceeds from maturities of marketable securities Â Â 57,250 Â Â Â 81,500 Â Purchases of marketable securities Â Â (39,725) Â Â (63,852) Purchases of property and equipment Â Â (237) Â Â (1,062) Net cash provided by investing activities Â Â 17,288 Â Â Â 16,586 Â Cash flows from financing activities Â Â Â Â Â Â Proceeds from issuance of common stock and pre-funded warrants in connection with the July Securities Purchase Agreement, net of issuance costs of $1,117 Â Â 8,883 Â Â Â â€” Â Issuance of common stock under employee stock purchase plan Â Â 221 Â Â Â 219 Â Proceeds from employee stock purchase plan Â Â 99 Â Â Â 80 Â Exercise of options Â Â 51 Â Â Â â€” Â Tax withholdings paid on behalf of employees for net share settlement Â Â (38) Â Â (162) Repayment of debt Â Â (1,250) Â Â Â â€” Â Net cash provided by financing activities Â Â 7,966 Â Â Â 137 Â Net decrease in cash, cash equivalents and restricted cash equivalents Â Â (1,587) Â Â (22,035) Cash, cash equivalents and restricted cash equivalents, beginning of period Â Â 6,364 Â Â Â 27,507 Â Cash, cash equivalents and restricted cash equivalents, end of period Â $ 4,777 Â Â $ 5,472 Â Supplemental disclosures of non-cash investing and financing activities Â Â Â Â Â Â Right-of-use assets obtained in exchange for new operating lease liabilities Â $ 4,731 Â Â $ â€” Â Remeasurement of operating lease right-of-use assets Â $ 589 Â Â $ 578 Â Exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Â $ 298 Â Â $ 169 Â Interest income receivable included in prepaid expenses and other current assets Â $ 29 Â Â $ 188 Â Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities Â $ â€” Â Â $ 250 Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 10 Â RANI THERAPEUTICS HOLDINGS, INC.Notes to THE UNAUDITED CONDENSED Consolidated Financial Statements 1. Organization and Nature of Business Description of Business Rani Therapeutics Holdings, Inc. (â€œRani Holdingsâ€, and together with its consolidated subsidiary, the â€œCompanyâ€) is a clinical-stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Companyâ€™s technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The Company is advancing a portfolio of oral therapeutics using the RaniPill capsule. The Company is headquartered in San Jose, California and operates in one segment.OrganizationRani Holdings was formed as a Delaware corporation in April 2021 for the purpose of facilitating an initial public offering (â€œIPOâ€) of its Class A common stock. In connection with the IPO, the Company effected a series of organizational transactions (the â€œOrganizational Transactionsâ€), which, together with the IPO, were completed in August 2021, that resulted in the Company becoming the ultimate parent company of Rani Therapeutics, LLC (â€œRani LLCâ€). The Company operates its business through Rani LLC.As part of the Organizational Transactions, the Company entered into a Registration Rights Agreement with certain individuals and entities that continued to hold economic nonvoting Class A units of Rani LLC (â€œClass A Unitsâ€), collectively referred to herein as the â€œContinuing LLC Ownersâ€. The Continuing LLC Owners are entitled to exchange, subject to the terms of the Fifth Amended and Restated Limited Liability Company Agreement of Rani LLC (the â€œRani LLC Agreementâ€), the Class A Units they hold in Rani LLC, together with the shares they hold of the Company Class B common stock (together referred to as a "Paired Interest"), in return for shares of the Companyâ€™s Class A common stock on a one-for-one basis provided that, at the Companyâ€™s election, the Company has the ability to effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. Any shares of Class B common stock will be canceled on a one-for-one basis if, at the election of the Continuing LLC Owners, the Company redeems or exchanges such Paired Interest pursuant to the terms of the Rani LLC Agreement. As of September 30, 2024, certain individuals who continue to own interests in Rani LLC but do not hold shares of the Companyâ€™s Class B common stock (â€œnon-corresponding Class A Unitsâ€) have the ability to exchange their non-corresponding Class A Units of Rani LLC for 1,261,690 shares of the Companyâ€™s Class A common stock.Liquidity The Company has incurred recurring losses since its inception, including net losses of $40.9 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had an accumulated deficit of $94.0 million and for the nine months ended September 30, 2024, had negative cash flows from operations of $26.8 million. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $30.4 million. Based on its available cash resources and current operating plan, there is substantial doubt regarding the Companyâ€™s ability to continue as a going concern for a period of one year after the date that its financial statements for the nine months ended September 30, 2024 are issued. The Companyâ€™s existing capital resources, including the issuance and sale of Class A common stock and warrants pursuant to a securities purchase agreement with an institutional investor in July 2024, will not be sufficient to enable it to initiate any pivotal clinical trials. The Company will need to raise substantial additional funds in the future in order to complete the development of the RaniPill platform, to complete the clinical development of its product candidates and seek regulatory approval thereof, to expand its manufacturing capabilities, to further develop the RaniPill HC device and to commercialize any of its product candidates.In July 2024, the Company entered into a securities purchase agreement (the â€œJuly Securities Purchase Agreementâ€) with an institutional investor relating to the issuance and sale of: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock (the â€œJuly Offeringâ€). The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. 11 Â In August 2022, the Company entered into a Controlled Equity Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (collectively the "Agents"), pursuant to which the Company may offer and sell from time to time through the Agents up to $150 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company has no sales under the Sales Agreement.The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues to develop the RaniPill capsule. The Company expects to finance its future operations with its existing cash and through strategic financing opportunities that could include, but are not limited to, future offerings of its equity, such as â€œat the market offeringsâ€ as defined in Rule 415(a)(4) under the Securities Act, collaboration or licensing agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all. As a result, the Company has concluded that managementâ€™s plans do not alleviate substantial doubt about the Companyâ€™s ability to continue as a going concern.Subsequent to September 30, 2024, the Company completed an additional equity offering with the aggregate gross proceeds of approximately $10.0 million, before deducting placement agent fees and other estimated offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of certain warrants issued in the offering (Note 16). The proceeds received do not alleviate substantial doubt about the Companyâ€™s ability to continue as a going concern.Â 2. Summary of Significant Accounting Policies Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). Certain prior period amounts have been reclassified to be consistent with current period presentation.The Company operates and controls all of the business and affairs of Rani LLC and, through Rani LLC conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation.Â Unaudited Interim Condensed Consolidated Financial StatementsThe accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (â€œSECâ€). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any future period.The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 20, 2024.Â Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Companyâ€™s condensed consolidated financial statements and accompanying notes. The Company evaluates its estimates on an ongoing basis. The Company bases its estimates on its historical experience and also on assumptions that we believe are reasonable; however, actual results may differ materially and adversely from these estimates.Â 12 Â Significant Accounting PoliciesA description of the Companyâ€™s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except as noted below, there have been no material changes in the Companyâ€™s significant accounting policies during the nine months ended September 30, 2024.Cash, Cash Equivalents and Restricted Cash EquivalentsThe following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023: Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â End of Period: Â Â Â Â Â Â Cash and cash equivalents Â $ 4,277 Â Â $ 4,972 Â Restricted cash equivalents Â Â 500 Â Â Â 500 Â Total cash, cash equivalents and restricted cash equivalents Â $ 4,777 Â Â $ 5,472 Â Collaborative ArrangementsThe Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents amounts due from its collaboration partner as a reduction of research and development expense based on the nature of such payments.Revenue RecognitionThe Company primarily generates revenue from evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partnerâ€™s drug molecules using the RaniPill platform technology (Note 6).Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.The majority of the Companyâ€™s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing

component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Variable consideration has not been material to our condensed consolidated financial statements. Consistent with the Company's policies and practices as described above, the Company recognizes contract revenue from its evaluation arrangements using a cost-based input method, which most faithfully depicts the transfer of the performance obligation to the customer. Accordingly, the Company will recognize contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expects to incur to deliver its performance obligation. These actual costs consist of the internal labor efforts, in vivo testing services and materials costs related to the agreement, as the costs incurred over time will reflect the transfer of its performance obligations to the customer. The cumulative effect of revisions to estimated costs to complete the Companyâ€™s performance obligation will be recorded in the period in which changes are identified and amounts are reasonably estimable. Such costs are expensed when incurred and are included as a component of research and development expenses in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss. 13 Â Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date, none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred.Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2024 or December 31, 2023.Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services (Note 6). There was no deferred revenue as of December 31, 2023.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.Â 14 Â 3. Cash Equivalents, Restricted Cash Equivalents and Marketable SecuritiesThe following tables summarizes the amortized cost and fair value of the Company's cash equivalents, restricted cash equivalents and marketable securities by major investment category (in thousands):Â Â Â As of September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â Current assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,090 Â Â $ â€” Â Â $ 2,090 Â Total cash equivalents Â Â 2,090 Â Â Â â€” Â Â Â â€” Â Â 2,090 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Total cash equivalents and restricted cash equivalents Â Â 2,590 Â Â Â â€” Â Â Â â€” Â Â Â 2,590 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 26,118 Â Â Â 9 Â Â Â â€” Â Â Â 26,127 Â Total cash equivalents, restricted cash equivalents and marketable securities Â $ 28,708 Â Â $ 9 Â Â $ â€” Â Â $ 28,717 Â Â Â Â As of December 31, 2023 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â Current assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 3,339 Â Â $ â€” Â Â $ â€” Â Â $ 3,339 Â Total cash and cash equivalents Â Â 3,339 Â Â Â â€” Â Â Â â€” Â Â Â 3,339 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Total cash equivalents and restricted cash equivalents Â Â 3,839 Â Â Â â€” Â Â Â â€” Â Â Â 3,839 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 35,513 Â Â Â â€” Â Â Â (18) Â Â 35,495 Â Corporate debt securities Â Â 1,971 Â Â Â â€” Â Â Â (8) Â Â 1,963 Â Commercial paper Â Â 5,219 Â Â Â â€” Â Â Â (2) Â Â 5,217 Â Total marketable securities Â Â 42,703 Â Â Â â€” Â Â Â (28) Â Â 42,675 Â Total cash equivalents, restricted cash equivalents and marketable securities Â $ 46,542 Â Â $ â€” Â Â $ (28) Â $ 46,514 Â Â All marketable securities are classified as short-term. The Company regularly reviews its available-for-sale marketable securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. As of September 30, 2024, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at September 30, 2024. As of September 30, 2024 and December 31, 2023, interest income receivable recorded as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet was de minimis and $0.2 million, respectively. 15 Â 4. Fair Value Measurements The following tables detail information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of inputs used in such measurements (in thousands): Â Â As of September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,090 Â Â $ â€” Â Â $ â€” Â Â $ 2,090 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 26,127 Â Â Â â€” Â Â Â â€” Â Â Â 26,127 Â Total assets Â $ 28,717 Â Â $ â€” Â Â $ â€” Â Â $ 28,717 Â Â Â Â As of December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 3,339 Â Â $ â€” Â Â $ â€” Â Â $ 3,339 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 35,495 Â Â Â â€” Â Â Â â€” Â Â Â 35,495 Â Corporate debt securities Â Â â€” Â Â Â 1,963 Â Â Â â€” Â Â Â 1,963 Â Commercial paper Â Â â€” Â Â Â 5,217 Â Â Â â€” Â Â Â 5,217 Â Total assets Â $ 39,334 Â Â $ 7,180 Â Â $ â€” Â Â $ 46,514 Â Â Level 1 and Level 2 financial instruments are comprised of investments in money market funds and fixed-income securities. The Company estimates the fair value of its Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.There were no transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy for any of the periods presented. Â 5. Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accrued interest Â $ 823 Â Â $ 500 Â Payroll and related costs Â Â 324 Â Â Â 313 Â Accrued rent Â Â 317 Â Â Â â€” Â Accrued professional fees Â Â 190 Â Â Â 235 Â Accrued preclinical and clinical trial costs Â Â 30 Â Â Â 424 Â Other Â Â 183 Â Â Â 254 Â Total accrued expenses and other current liabilities Â $ 1,867 Â Â $ 1,726 Â Â 16 Â 6. Collaborative and Evaluation ArrangementsProGen Co., Ltd.In June 2024, the Company and ProGen Co., Ltd. (â€œProGenâ€) entered into a Collaboration Agreement (the â€œCollaboration Agreementâ€). Under the Collaboration Agreement, the Company and ProGen will collaborate to manufacture, develop, seek regulatory approvals for and, if approved, commercialize a product (the â€œProductâ€) combining ProGenâ€™s GLP-1/GLP-2 dual agonist compound, PG-102, and the RaniPill HC oral delivery device (the â€œDeviceâ€) in the field of weight management (including without limitation obesity, weight reduction and weight maintenance) in humans (the â€œCollaborationâ€).Under the Collaboration Agreement, development costs, as well as operating profits and losses from the commercialization of the Product, will be equally shared by the Company and ProGen. The Company and ProGen each granted to the other party an exclusive right and license (except with respect to the other partyâ€™s affiliates and sublicensees) to certain intellectual property to develop the Product for weight management and an exclusive right and license to seek regulatory approval for, and to use, sell, offer to sell, import and commercialize the Product in their assigned territories. The Company will lead the development of the Product in the United States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development in all other countries.Each party has the right to opt-out of the Collaboration (â€œOpt-Outâ€) at any time upon prior written notice to the other party. Following an Opt-Out, the continuing party shall have sole right to develop, conduct regulatory activities for and commercialize the Product on a worldwide basis. The Opt-Out party shall share all development costs and operating profit (or loss) through the effective date of the Opt-Out, and all costs to complete the conduct of any clinical trials of Product that have been initiated prior to delivery of the Opt-Out notice, even if the costs are incurred or the trials are completed after the effective date of the Opt-Out. The continuing party shall pay to the Opt-Out party low single to mid-single digit royalties on net sales of the Product made after the Opt-Out date depending on when the Opt-Out occurs.The Company determined that the Collaboration Agreement is not a contract with a customer and is therefore accounted for under ASC Topic 808. The Company evaluates the presentation of amounts due from ProGen based on the nature of each separate activity. Reimbursements from ProGen are recognized as contra-research and development expense on the Consolidated Statement of Operations once earned and collectability is assured. As of September 30, 2024, no reimbursement has been received from or billed by ProGen nor recorded as contra-research and development expense.Evaluation ArrangementIn August 2024, the Company entered into a contract to conduct evaluation services of certain customer compounds for oral delivery using the RaniPill HC. This customer paid the Company an up-front payment of $0.6 million upon execution of the contract. Upon completion of the evaluation services, the Company is entitled to a final $0.6 million payment for an aggregate total of $1.2 million due under the contract. In addition, if agreed upon, the agreement allows for joint filing of certain intellectual property protection in which all associated expenses will be shared equally. The customer has the ability to terminate the agreement at any time by providing 10 daysâ€™ written notice after the effective date of the contract. The contract can be terminated for cause by either party based on uncured material breach by the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate.The Company identified one material promise under the contract, the obligation to perform services to evaluate if the customers compounds can be orally delivered using the RaniPill HC, which was concluded to be a single performance obligation. For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in August 2024 and will end the sooner of the contractual 1-year term or upon the completion of the evaluation services. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For the nine months ended September 30, 2024, no contract revenue was recognized for evaluation services performed. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services. There was no deferred revenue as of December 31, 2023.Â 17 Â 7. Related Party Transactions InCube Labs, LLC (â€œICLâ€) is wholly-owned by the Companyâ€™s founder and Chairman and his family. The founder and Chairman is the father of the Companyâ€™s Chief Executive Officer. The Companyâ€™s Chief Scientific Officer is also the brother of the founder and Chairman and thus uncle of the Companyâ€™s Chief Executive Officer. Service Agreements In June 2021, Rani LLC entered into a service agreement with ICL effective retrospectively to January 1, 2021, and subsequently amended such agreement in March 2022 (as amended, the "Rani LLC-ICL Service Agreement"), pursuant to which Rani LLC and ICL agreed to provide personnel services to the other upon requests. Under the amendment in March 2022, Rani LLC has a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas (â€œOccupancy Servicesâ€) for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022, and the Occupancy Services in San Antonio, Texas continue until either party gives six monthsâ€™ notice of termination. Except for the Occupancy Services, Rani LLC or ICL may terminate services under the Rani LLC-ICL Service Agreement upon 60 days' notice to the other party. The Rani LLC-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively. In December 2023, Rani LLC provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024.In June 2021, Rani Management Services, Inc. (â€œRMSâ€) entered into a service agreement with ICL effective retrospectively to January 1, 2021, pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. In April 2022, RMS assigned the agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000 square feet to 24,000 square feet (such agreement, as assigned and amended, the â€œRMS-ICL Service Agreementâ€). The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated. Rani LLC or ICL may terminate services under the RMS-ICL Service Agreement upon 60 days' notice to the other party, except for occupancy which requires six monthsâ€™ notice. The RMS-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively, as well as allocations of expenses based upon Rani LLCâ€™s utilization of ICLâ€™s facilities and equipment.The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 201 Â Â $ 280 Â Â $ 768 Â Â $ 889 Â General and administrative Â Â 41 Â Â Â 87 Â Â Â 187 Â Â Â 220 Â Total Â $ 242 Â Â $ 367 Â Â $ 955 Â Â $ 1,109 Â As of September 30, 2024, one of the Company's facilities was owned by an entity affiliated with the Companyâ€™s Chairman (Note 8). The Company pays for the use of this facility through the RMS-ICL Service Agreement. Â 18 Â Exclusive License, Intellectual Property and Common Unit Purchase AgreementIn June 2021, ICL and the Company, through Rani LLC, entered into an Amended and Restated Exclusive License Agreement which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013. Under the Amended and Restated Exclusive License Agreement, the Company has a fully paid, exclusive license under certain scheduled patents related to optional features of the device and certain other scheduled patents to exploit products covered by those patents in the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. The Company covers patent-related expenses and, after a certain period, the Company will have the right to acquire four specified United States patent families from ICL by making a one-time payment of $0.3 million to ICL for each United States patent family that the Company desires to acquire, up to $1.0 million in the aggregate. This payment will not become an obligation until the fifth anniversary of the Amended and Restated Exclusive License Agreement. The Amended and Restated Exclusive License Agreement will terminate when there are no remaining valid claims of the patents licensed under the Amended and Restated Exclusive License Agreement. Additionally, the Company may terminate the Amended and Restated Exclusive License Agreement in its entirety or as to any particular licensed patent upon notification to ICL of such intent to terminate.Â Non-Exclusive License Agreement between Rani and ICL (â€œNon-Exclusive License Agreementâ€)In June 2021, the Company, through Rani LLC, entered into the Non-Exclusive License Agreement with ICL a related party, pursuant to which the Company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to the Company. Additionally, the Company agreed not to license these patents to a third party in a specific field outside the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine, if ICL can prove that it or its sublicensee has been in active development of a product covered by such patents in that specific field. ICL may grant

sublicenses under this license to third parties only with the Companyâ€™s prior approval. The Non-Exclusive License Agreement will continue in perpetuity unless earlier terminated.Â Intellectual Property Agreement with Mir Imran (the â€œMir Agreementâ€)In June 2021, the Company, through Rani LLC, entered into the Mir Agreement, pursuant to which the Company and Mir Imran agreed that the Company would own all intellectual property conceived (i) using any of the Companyâ€™s people, equipment, or facilities or (ii) that is within the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. Neither the Company nor Mir Imran may assign the Mir Agreement to any third party without the prior written consent of the other party. The initial term of the Mir Agreement was three years, which could be extended upon mutual consent of the parties. In June 2024, the parties agreed to extend the term of the Mir Agreement by ninety (90) days. The Mir Agreement expired in September 2024. Expiration of the Mir Agreement does not affect the assignment to, and ownership by, the Company of intellectual property conceived during the term of the Mir Agreement.Â Tax Receivable AgreementCertain parties to the tax receivable agreement ("TRA"), entered into in August 2021 pursuant to the IPO and Organizational Transactions are related parties of the Company. The TRA provides that the Company pay to ICL and the other Continuing LLC Owners 85% of the amount of tax benefits, if any, it is deemed to realize from exchanges of Paired Interests. During each of the nine months ended September 30, 2024 and 2023, these parties to the TRA exchanged zero Paired Interests that resulted in tax benefits subject to the TRA.Â Registration Rights AgreementIn connection with the IPO, the Company entered into a Registration Rights Agreement. ICL and its affiliates are parties to this agreement. The Registration Rights Agreement provides certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, ICL and its affiliates can require the Company to register under the Securities Act of 1933, as amended (the â€œSecurities Actâ€) shares of Class A common stock issuable to ICL and its affiliates upon, at the Companyâ€™s election, redemption or exchange of their Paired Interests. The Registration Rights Agreement also provides for piggyback registration rights. In March 2022, certain holders of the Company's Class A common stock considered to be related parties were made parties to the Registration Rights Agreement. As a result of certain stockholders exercising their registration rights under the Registration Rights Agreement, in December 2022, the Company filed a registration statement on Form S-3 to register 6,009,542 shares of Class A common stock of the Company held by certain of its stockholders. 19 Â Rani LLC AgreementThe Company operates its business through Rani LLC. In connection with the IPO, the Company and the Continuing LLC Owners, including ICL and its affiliates, entered into the Rani LLC Agreement. The governance of Rani LLC, and the rights and obligations of the holders of LLC Interests, are set forth in the Rani LLC Agreement. As Continuing LLC Owners, ICL and its affiliates are entitled to exchange, subject to the terms of the Rani LLC Agreement, Paired Interests for Class A common stock of the Company; provided that, at the Companyâ€™s election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. During each of the nine months ended September 30, 2024 and 2023, certain related parties that are party to the Rani LLC Agreement exchanged zero Paired Interests for an equal number of shares of the Company's Class A common stock.Â 8. LeasesIn November 2023, Rani LLC and BKM South Bay 240, LLC (â€œLandlordâ€) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the â€œLeaseâ€). Pursuant to the terms of the Lease, Rani LLC is leasing approximately 33,000 square feet of space in Fremont, California, which is part of a two-building project (the â€œProjectâ€). The initial term of the Lease commenced in February 2024, and the duration of the initial term is 63 months. Subject to certain conditions, Rani LLC has an option to renew the Lease for one additional 5-year term at the then-prevailing market rate. The monthly base rent for the initial term of the Lease is approximately $95,000 per month, subject to a 4% increase each year. Rani LLC is also responsible for the payment of additional rent to cover its share of common area operating expenses, including taxes, insurance, utilities, and repair and maintenance of the premises and common areas of the Project.The Company pays for the use of its office, laboratory and manufacturing facility in San Jose, California as part of the RMS-ICL Service Agreement. In April 2022, RMS assigned the RMS-ICL Service Agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000 square feet to 24,000 square feet. The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless Rani LLC or ICL terminate occupancy under the RMS-ICL Service Agreement upon six monthsâ€™ notice. In January 2024, the Company determined it to be reasonably certain that it would exercise its renewal option for a successive twelve-month period through 2025. The Company accounted for the renewal option as a lease modification that did not result in a separate contract and recognized the additional right-of-use asset and corresponding lease liabilities associated with the Rani LLC-ICL Service Agreement in its condensed consolidated balance sheet.Under the Rani LLC-ICL Service Agreement amended in March 2022, Rani LLC had a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for a successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022. The Company accounted for the lease extension as a lease modification that did not result in a separate contract and recognized the right-of-use asset and lease liabilities associated with the Rani LLC-ICL Service Agreement in the consolidated balance sheet as of the modification date in July 2022. In December 2023, the Company provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024.The Company's leases are accounted for as operating leases and require certain fixed payments of real estate taxes and insurance in addition to future minimum lease payments, and certain variable payments of common area maintenance costs and building utilities. Variable lease payments are expensed in the period in which the obligation for those payments is incurred. These variable lease costs are payments that vary in amount beyond the commencement date, for reasons other than passage of time. Variable lease payments are excluded in the total operating lease expense and immaterial for the periods presented. 20 Â Supplemental information on the Companyâ€™s condensed consolidated balance sheet and statements of cash flows as of September 30, 2024 and 2023 and for the nine months ended September 30, 2024 and 2023, respectively, related to the Company's leases was as follows (in thousands):Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Weighted-average remaining lease term (in years) Â Â 4.1 Â Â Â 1.1 Â Weighted-average discount rate Â Â 10.4 % Â Â 10.4 % Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in lease liabilities: Â Â Â Â Â Â Operating cash flows used for operating leases Â $ 1,015 Â Â $ 780 Â As of September 30, 2024, minimum annual rental payments under the Companyâ€™s operating lease agreements are as follows (in thousands), excluding short-term leases: Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 465 Â 2025 Â Â 1,902 Â 2026 Â Â 1,229 Â 2027 Â Â 1,278 Â 2028 Â Â 1,330 Â 2029 Â Â 458 Â Total undiscounted future minimum lease payments Â $ 6,662 Â Less: Imputed interest Â Â (1,235) Total operating lease liability Â $ 5,427 Â Less: Current portion of operating lease liability Â Â 1,410 Â Operating lease liability, net current portion Â $ 4,017 Â Â 9. WarrantsIn July 2024, as part of the July Offering, the Company issued (i) pre-funded warrants to purchase 446,753 shares of Class A common stock, (ii) Series A common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock and (iii) Series B common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock. The pre-funded warrants are exercisable immediately and have an unlimited term and an exercise price of $0.0001 per share. The Series A Warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire 18 months following the date of issuance and will have an exercise price of $3.08 per share. The Series B warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire five and a half years from the date of issuance and will have an exercise price of $3.08 per share. The Series A warrants and Series B warrants include certain rights upon â€œfundamental transactions,â€ as described in the Series A warrants and Series B warrants, including in the Series B warrants the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series B warrants) of the unexercised portion of the applicable Series B warrants on the date of the consummation of the fundamental transactions. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. As of September 30, 2024, there were 3,246,753 Series A warrants and 3,246,753 Series B warrants outstanding. Subsequent to September 30, 2024, the Series A warrants were canceled (Note 16). In August 2022, in conjunction with a loan and security agreement (Note 13), the Company issued warrants to purchase 76,336 shares of the Company's Class A common stock. The warrants are exercisable for a period of five years from the grant date, as may be adjusted for certain anti-dilution adjustments, dividends, stock splits, and reverse stock splits, at an exercise price per share equal to $11.79, which may be net share settled at the option of the holder. As of September 30, 2024, there were 76,336 warrants outstanding.Â 21 Â 10. Stockholdersâ€™ EquityAs of September 30, 2024, Rani Holdings held approximately 54% of the Class A Units of Rani LLC, and approximately 46% of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. From the date of the Organizational Transactions to September 30, 2024, 5,173,947 Paired Interests and 283,832 non-corresponding Class A Units of Rani LLC were exchanged for an equal number of shares of the Company's Class A common stock. For each of the nine months ended September 30, 2024 and 2023, certain of the Continuing LLC Owners executed an exchange of zero Paired Interests and 83,377 and zero non-corresponding Class A Units of Rani LLC, respectively, in return for an equal number of shares of the Companyâ€™s Class A common stock. The corresponding shares of the Companyâ€™s Class B common stock included in the exchange of Paired Interests were subsequently canceled and retired pursuant to the terms of the Rani LLC Agreement. In accordance with the Rani LLC Agreement, Rani LLC also issues a corresponding Class A Unit to Rani Holdings for each share of common stock issued by Rani Holdings. This increases Rani Holdingsâ€™ ownership in Rani LLC.In July 2024, the Company closed the July Offering, pursuant to which it issued and sold: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock. The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In August 2022, the Company entered into the Sales Agreement with the Agents, pursuant to which the Company may offer and sell from time to time through the Agents up to $150.0 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company had no sales under the Sales Agreement. 11. Stock-Based CompensationStock OptionsA summary of stock option activity during the periods indicated is as follows: Â Â Number of Stock Option Awards Â Â Weighted Average Exercise Price Â Â WeightedAverageRemaining Contractual Term (in years) Â Â Aggregate Intrinsic Value (in thousands) Â Balance at December 31, 2023 Â Â 6,639,811 Â Â $ 6.37 Â Â Â 8.48 Â Â $ 13,377 Â Granted Â Â 4,154,325 Â Â $ 3.74 Â Â Â 9.49 Â Â $ â€” Â Exercised Â Â (18,757) Â $ 2.72 Â Â Â Â Â Â Canceled Â Â (478,961) Â $ 5.36 Â Â Â Â Â Â Balance at September 30, 2024 Â Â 10,296,418 Â Â $ 5.36 Â Â Â 8.35 Â Â $ 25 Â Exercisable at September 30, 2024 Â Â 4,713,481 Â Â $ 7.62 Â Â Â 7.66 Â Â $ â€” Â Nonvested at September 30, 2024 Â Â 5,582,937 Â Â $ 3.46 Â Â Â 8.99 Â Â $ 25 Â As of September 30, 2024, there was $21.8 million of unrecognized stock-based compensation expense related to stock options which is expected to be recognized over a weighted-average period of approximately 2.8 years. 22 Â Restricted Stock UnitsA summary of restricted stock unit (â€œRSUâ€) activity during the periods indicated is as follows: Â Â Number of Restricted Stock Units Â Â Weighted Average Grant-Date Fair Value per Share Â Balance at December 31, 2023 Â Â 1,276,111 Â Â $ 7.16 Â Vested Â Â (323,611) Â $ 7.69 Â Forfeited Â Â (59,206) Â $ 7.37 Â Balance at September 30, 2024 Â Â 893,294 Â Â $ 6.96 Â As of September 30, 2024, there was $5.6 million of unrecognized stock-based compensation expense related to RSUs which is expected to be recognized over a weighted-average period of approximately 2.3 years. The total fair value of RSUs vested was $1.0 million for the nine months ended September 30, 2024.Restricted Stock AwardsA summary of restricted stock award (â€œRSAâ€) activity during the periods indicated is as follows: Â Â Number of Restricted Stock Awards Â Â Weighted Average Grant-Date Fair Value per Share Â Balance at December 31, 2023 Â Â 33,586 Â Â $ 6.15 Â Vested Â Â (22,616) Â $ 6.14 Â Forfeited Â Â (218) Â $ 6.13 Â Balance at September 30, 2024 Â Â 10,752 Â Â $ 6.15 Â As of September 30, 2024, unrecognized stock-based compensation expense related to RSAs was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. The total fair value of RSAs vested was $0.1 million for the nine months ended September 30, 2024.Employee Stock Purchase PlanAs of September 30, 2024, unrecognized stock-based compensation expense related to the Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan (the â€œESPPâ€) was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. As of September 30, 2024, contributions withheld from employees totaled $0.1 million and are recorded as a component of accrued expenses and other current liabilities in the condensed consolidated balance sheet. Stock-Based Compensation ExpenseThe following table summarizes the components of stock-based compensation expense resulting from the grant of stock options, RSUs, RSAs, and the ESPP, recorded in the Companyâ€™s condensed consolidated statement of operations and comprehensive loss (in thousands): Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Research and development Â $ 3,563 Â Â $ 5,275 Â General and administrative Â Â 8,477 Â Â Â 9,247 Â Total stock-based compensation Â $ 12,040 Â Â $ 14,522 Â Â 12. Commitments and Contingencies Legal Proceedings In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. 23 Â Tax Receivable AgreementThe Company is party to a TRA with certain of the Continuing LLC Owners. As of September 30, 2024, the Company has not recorded a liability under the TRA related to the income tax benefits originating from the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC as it is not probable that the Company will realize such tax benefits. To the extent the Company is able to realize the income tax benefits associated with the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC subject to the TRA, the TRA payable would range from zero to $23.1 million at September 30, 2024. The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the payment of the TRA liability becomes probable at a future date based on new information, any changes will be recorded on the Company's condensed consolidated statement of operations and comprehensive loss at that time.Â 13. Long-Term DebtIn August 2022, the Company entered into a loan and security agreement and related supplement (the â€œLoan Agreementâ€) with Avenue Venture Opportunities Fund, L.P (the â€œLenderâ€). The Loan Agreement provides for term loans (the â€œLoansâ€) in an aggregate principal amount up to $45.0 million. A Loan of $30.0 million was committed at closing, with $15.0 million funded immediately and $15.0 million available to be drawn between October 1, 2022 and December 31, 2022, which was drawn in December 2022. The remaining $15.0 million of Loans was uncommitted and subject to certain conditions and is no longer available under the Loan Agreement. The purpose of the Loans is for general corporate purposes. In exchange for access to this facility, the Company agreed to issue warrants (Note 9).Pursuant to the Loan Agreement, the maturity date for the Loans is August 1, 2026 (the â€œMaturity Dateâ€). The Loan principal is repayable in equal monthly installments beginning September 2024. The Loans bear interest at a variable rate per annum equal to the greater of (A) the prime rate, as published by the Wall Street Journal from time to time plus 5.60% or (B) 10.35%. The Loan Agreement is collateralized by substantially all of the Companyâ€™s assets, in which the Lender is granted continuing security interests. The Loans includes customary events of default, including instances of a material adverse change in the Companyâ€™s operations, which may require prepayment of the outstanding Loans. At September 30, 2024, the effective interest rate on the Loans was 15.62% and there were no events of default during the nine months ended September 30, 2024. The Company is also subject to certain covenants. There have been no material adverse events in connection with the Loan Agreement and the substantial doubt regarding our ability to continue as a going concern does not currently constitute a material adverse event under the terms of the Loan Agreement. As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement.As of September 30, 2024, future principal payments for the Companyâ€™s debt are as follows (in thousands): Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 3,750 Â 2025 Â Â 15,000 Â 2026 Â Â 10,000 Â Total principal payments Â $ 28,750 Â Less: amount representing debt discount Â Â (445) Total long-term debt Â $ 28,305 Â Less: current portion of long-term debt Â Â 14,768 Â Total long-term debt, less current portion Â $ 13,537 Â 14. Income Taxes The Companyâ€™s effective income tax rate was zero for each of the nine months ended September 30, 2024 and 2023. As a result of the exchanges from the date of the Organizational Transactions to September 30, 2024, the Company recorded a $18.9 million deferred tax asset related to income tax benefit associated with the basis of the net assets of Rani LLC. Because of the Companyâ€™s history of operating losses, the Company believes that recognition of

the deferred tax assets arising from such future income tax benefits is currently not more-likely-than-not to be realized and, accordingly, has recognized a full valuation allowance on its deferred tax assets. There were no material changes to uncertain tax positions for the nine months ended September 30, 2024 and 2023, and the Company does not anticipate material changes within the next twelve months. 24 Â 15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â 2023 Â Numerator: Â Â Â Â Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. Â $ (21,071) $ (26,872) Denominator: Â Â Â Â Â Weighted average Class A common share outstandingâ€”basic and diluted Â Â 27,071 Â Â 25,380 Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.â€”basic and diluted Â $ (0.78) $ (1.06) Â The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings (in thousands): Â Â As of September 30, Â Â Â 2024 Â 2023 Â Paired Interests Â Â 24,116 Â Â 24,116 Â Stock options Â Â 10,296 Â Â 6,778 Â Warrants Â Â 6,570 Â Â 76 Â Non-corresponding Class A Units Â Â 1,262 Â Â 1,345 Â Restricted stock units Â Â 893 Â Â 1,413 Â Shares issuable pursuant to the ESPP Â Â 41 Â Â 82 Â Restricted stock awards Â Â 11 Â Â 41 Â Â Â 43,189 Â Â 33,851 Â Shares of Class B Common Stock do not share in the Companyâ€™s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. The outstanding shares of Class B Common Stock were determined to be anti-dilutive for the nine months ended September 30, 2024. Therefore, they are not included in the computation of net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.Â 16. Subsequent EventsSecurities Purchase AgreementIn October 2024, the Company entered into a securities purchase agreement (the â€œOctober Securities Purchase Agreementâ€) with an institutional investor (the â€œEquity Investorâ€) relating to the issuance and sale of: (i) 3,000,000 shares of its Class A common stock, par value $0.0001 per share, (ii) pre-funded warrants to purchase 333,333 shares of Class A common stock, and (iii) Series C common warrants, which will accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,333,333 shares of Class A common stock (the â€œOctober Offeringâ€). The October Offering closed on October 16, 2024. Pursuant to the October Securities Purchase Agreement, Series A common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock issued in the July Offering were cancelled.The pre-funded warrants are exercisable immediately following the closing date of the October Offering and have an unlimited term and an exercise price of $0.0001 per share. The Series C common warrants are exercisable immediately following the closing date of the October Offering, will expire five years from the date of issuance and will have an exercise price of $3.00 per share. The combined offering price is $3.00 per share of Class A common stock and accompanying Series C common warrant, or in the case of pre-funded warrants, $2.9999 per pre-funded warrant and accompanying Series C common warrant. The aggregate gross proceeds to the Company from the October Offering were approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of the Series C common warrants issued in the October Offering. In October 2024, the pre-funded warrants were fully exercised for de minimis proceeds. 25 Â The Series C common warrants include certain rights upon â€œfundamental transactionsâ€ as described in the Series C common warrants. These rights upon â€œfundamental transactionsâ€ include the right of the holders thereof to receive from Rani or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series C common warrants) of the unexercised portion of the applicable Series C common warrants on the date of the consummation of such fundamental transaction.Pursuant to the terms of the October Securities Purchase Agreement, until 30 days following the closing of the October Offering, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Class A common stock or common stock equivalents, or file or amend any registration statement or prospectus, other than as necessary to maintain the registration of the securities offered thereby. The Company has further agreed not to enter into an agreement involving any new variable rate transactions until January 23, 2025, subject to certain exceptions. In addition, the Companyâ€™s directors and officers have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 30 days from the closing of the October Offering, offer, sell, transfer or otherwise dispose of the Companyâ€™s securities, subject to certain exceptions.CEO Compensation ReductionIn November 2023, the Companyâ€™s Board of Directors (â€œBoardâ€) approved a reduction in the annual salary of Talat Imran, the Companyâ€™s Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as the Company receives gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the â€œFinancing Thresholdâ€). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met. 26 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsÂ MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management's discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other information included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission ("SEC"). Some of the information contained in this discussion and analysis or set forth elsewhere in this document, includes forward looking statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2023. Please also see the section titled â€œForward Looking Statements.â€The following discussion contains references to calendar year 2023 and the three and nine months ended September 30, 2024 and 2023, respectively, which represents the condensed consolidated financial results of Rani Therapeutics Holdings, Inc. (the "Company") and its subsidiary, Rani Therapeutics, LLC (â€œRani LLCâ€) for the year ended December 31, 2023 and the three and nine months ended September 30, 2024 and 2023, respectively. Unless we state otherwise or the context otherwise requires, the terms â€œwe,â€ â€œus,â€ â€œour,â€ and â€œRaniâ€ and similar references refers to the Company and its consolidated subsidiary.Overview We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs.Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We are currently developing two configurations of the platform â€“ the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. We are also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200ÂµL in liquid form with high bioavailability. We have tested preclinically the RaniPill HC with multiple therapeutics, including antibodies and a peptide. We intend to initiate clinical testing of the RaniPill HC in 2025.We believe that, together, the RaniPill GO and RaniPill HC could enable us to deliver most biologics currently on the market with convenient, oral dosing.We do not have any products approved for sale, and we have not yet generated any revenue from sales of a commercial product. Our ability to generate product revenue sufficient to achieve profitability, if ever, will depend on the successful development of the RaniPill capsule, which we expect will take a number of years. Given our stage of development, we have not yet established a commercial organization or distribution capabilities, and we have no experience as a company in marketing drugs or a drug-delivery platform. When, and if, any of our product candidates are approved for commercialization, we plan to develop a commercialization infrastructure or engage commercial sales organizations or distributors for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also rely on partnerships to provide commercialization infrastructure, including sales, marketing, and commercial distribution. 27 Â As is common with biotechnology companies, we rely on third-party suppliers for the supply of raw materials and active pharmaceutical ingredients ("APIs") and drug substances required for the production of our product candidates. In addition, we work with third parties to manufacture and develop biologics and drugs for inclusion in the current RaniPill capsule and RaniPill HC. Design work, prototyping and pilot manufacturing are performed in house, and we have utilized third-party engineering firms to assist with the design of manufacturing lines that support our supply of the current RaniPill capsule and RaniPill HC. Certain of our suppliers of components and materials are single source suppliers. We believe our vertically integrated manufacturing strategy will offer significant advantages, including rapid product iteration, control over our product quality and the ability to rapidly scale our manufacturing capacity. This capability also allows us to develop future generations of products while maintaining the confidentiality of our intellectual property. Our vertically integrated manufacturing strategy will result in material future capital outlays and fixed costs related to constructing and operating a manufacturing facility. We have invested and plan to continue to invest in automated manufacturing production lines for the current RaniPill capsule and RaniPill HC. Those assets deemed to have an alternative future use have been capitalized as property and equipment while those projects related to our assets determined to not have an alternative future use have been expensed as research and development costs.As of September 30, 2024, our cash, cash equivalents and marketable securities totaled $30.4 million. In July 2024, we entered into a securities purchase agreement (the â€œJuly Securities Purchase Agreementâ€) with an institutional investor relating to the issuance and sale of: (i) 2,800,000 shares of its Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock (the â€œSeries A Warrantsâ€) and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock (the â€œJuly Offeringâ€). The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In October 2024, we entered into a securities purchase agreement (the â€œOctober Securities Purchase Agreementâ€) with an institutional investor relating to the issuance and sale of: (i) 3,000,000 shares of our Class A common stock, (ii) pre-funded warrants to purchase 333,333 shares of Class A common stock, and (iii) Series C common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,333,333 shares of Class A common stock (the â€œOctober Offeringâ€ and collectively with the July Offering, the â€œOfferingsâ€). Pursuant to the October Securities Purchase Agreement, the Series A Warrants were cancelled. The aggregate gross proceeds from the October Offering were approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by us, and excluding potential proceeds, if any, from the exercise of the pre-funded warrants and Series C common warrants issued in the October Offering. In October 2024, the pre-funded warrants were fully exercised for de minimis proceeds. We expect to continue to incur losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities. Our existing capital resources, including the net proceeds from the Offerings, our initial public offering in 2021 (â€œIPOâ€) and term loans we received under a loan and security agreement and related supplement (the â€œLoan Agreementâ€) with Avenue Venture Opportunities Fund, L.P (the â€œLenderâ€), will not be sufficient to enable us to initiate any pivotal clinical trials. We will need to raise substantial additional funds in the future in order to complete the development of the RaniPill platform, to complete the clinical development of our product candidates and seek regulatory approval thereof, to expand our manufacturing capabilities, to further develop the RaniPill HC device and to commercialize any of our product candidates. We may seek to raise capital through equity offerings or debt financings, collaboration agreements, or other arrangements with other companies, or through other sources of financing.Preclinical Update In October 2024, we announced new pharmacokinetic data from a preclinical study evaluating a GLP-1, GIP and glucagon receptors incretin triagonist with a delivery method mimicking the RaniPill route of administration. The pharmacokinetic data provides further evidence of the RaniPill platformâ€™s potential to enable oral delivery of multiple obesity treatments.Relationship with InCube Labs, LLCSee Note 7 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information. 28 Â Results of Operations The results of operations presented below should be reviewed in conjunction with the condensed consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. For information with respect to recent accounting pronouncements that are of significance or potential significance to us, see â€œNote 2. Summary of Significant Accounting Policiesâ€ in the â€œNotes to the Unaudited Condensed Consolidated Financial Statementsâ€ contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.Comparison of the three months ended September 30, 2024 and 2023The following table summarizes our results of operations (in thousands): Â Â Three Months Ended September 30, Â Â 2024 Â Â 2023 Â Â Change Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â $ 6,172 Â Â $ 11,220 Â Â Â (45.0) % General and administrative Â Â 5,627 Â Â Â 6,635 Â Â Â (15.2) % Total operating expenses Â $ 11,799 Â Â $ 17,855 Â Â Â (33.9) % Loss from operations Â Â (11,799) Â Â (17,855) Â Â (33.9) % Other income (expense), net Â Â Â Â Â Â Â Â Â Â Interest income and other, net Â Â 414 Â Â Â 839 Â Â Â (50.7) % Interest expense and other, net Â Â (1,337) Â Â (1,316) Â Â 1.6 Â % Net loss Â $ (12,722) Â $ (18,332) Â Â (30.6) % Net loss attributable to non-controlling interest Â Â (5,939) Â Â (9,135) Â Â (35.0) % Net loss attributable to Rani Therapeutics Holdings, Inc. Â $ (6,783) Â $ (9,197) Â Â (26.2) % Research and Development Expenses The following table reflects our research and development costs by nature of expense (in thousands): Â Â Â Three Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Payroll, stock-based compensation and related benefits Â $ 4,623 Â Â $ 6,464 Â Facilities, materials and supplies Â Â 1,357 Â Â Â 1,777 Â Third-party services Â Â 173 Â Â Â 2,929 Â Other Â Â 19 Â Â Â 50 Â Total Â $ 6,172 Â Â $ 11,220 Â The decrease of $5.0 million in research and development expenses in the three months ended September 30, 2024, as compared to the same period in 2023, was primarily attributed to lower compensation costs of $1.9 million due to reduction in workforce, $2.7 million reduction in third-party services and $0.4 million reduction in materials and supplies due to the timing of certain preclinical and clinical studies. General and Administrative Expenses The decrease of $1.0 million in general and administrative expenses in the three months ended September 30, 2024, as compared to the same period in 2023, was primarily attributed to lower compensation costs of $0.5 million due to reduction in workforce, $0.4 million reduction in third-party services due to lower directors and officers insurance premiums and $0.3 million reduction in other costs, offset by an increase in facility costs of $0.2 million due to the lease in Fremont, California. Other Income (Expense), Net The increase of $0.4 million in other expense, net, in the three months ended September 30, 2024, as compared to the same period in 2023, was attributed to a decrease in interest income of $0.4 million from our investment in marketable securities. 29 Â Comparison of the nine months ended September 30, 2024 and 2023The following table summarizes our results of operations (in thousands): Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â Change Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â $ 19,872 Â Â $ 32,018 Â Â Â (37.9) % General and administrative Â Â 18,484 Â Â Â 20,647 Â Â Â (10.5) % Total operating expenses Â $ 38,356 Â Â $ 52,665 Â Â Â (27.2) % Loss from operations Â Â (38,356) Â Â (52,665) Â Â (27.2) % Other income (expense), net Â Â Â Â Â Â Â Â Â Â Interest income and other, net Â Â 1,403 Â Â Â 2,626 Â Â Â (46.6) % Interest expense and other, net Â Â (3,909) Â Â (3,789) Â Â 3.2 Â % Net loss Â $ (40,862) Â $ (53,828) Â Â (24.1) % Net loss attributable to non-controlling interest Â Â (19,791) Â Â (26,956) Â Â (26.6) % Net loss attributable to Rani Therapeutics Holdings, Inc. Â $ (21,071) Â $ (26,872) Â Â (21.6) % Â Research and Development Expenses The following table reflects our research and development costs by nature of expense (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Payroll, stock-based compensation and related benefits Â $ 15,048 Â Â $ 21,452 Â Facilities, materials and supplies Â Â 3,957 Â Â Â 4,829 Â Third-party services Â Â 820 Â Â Â 5,550 Â Other Â Â 47 Â Â Â 187 Â Total Â $ 19,872 Â Â $ 32,018 Â The decrease of $12.1 million in research and development expenses in the nine months ended September 30, 2024, as compared to the same period in 2023, was primarily attributed to lower compensation costs of $6.4 million due to reduction in workforce, $4.7 million reduction in third-party services and $0.9 million reduction in materials and supplies due to the timing of certain preclinical and clinical studies.Â General and Administrative Expenses The decrease of $2.2 million in general and administrative expenses in the nine months ended September 30, 2024, as compared to the same period in 2023, was primarily attributed to lower compensation costs of $2.0 million due to reduction in workforce, $0.6 million reduction in other costs and $0.3 million reduction in third-party services due to lower directors and officers insurance premiums, offset by an increase in facility costs of $0.7 million due to the lease in Fremont, California.Other Income (Expense), Net The increase of $1.3 million in other expense, net, in the nine months ended September 30, 2024, as compared to the same period in 2023, was primarily attributed to a decrease in interest income of $1.2 million from our investment in marketable securities and an increase interest expense of $0.1 million from our debt. 30 Â Liquidity and Capital Resources OverviewWe have incurred recurring losses and negative cash flows from operations since inception, including net loss of $40.9 million for nine months ended September 30, 2024.

As of September 30, 2024, we had an accumulated deficit of $94.0 million and for nine months ended September 30, 2024, had negative cash flows from operations of $26.8 million. As of September 30, 2024, our cash, cash equivalents and marketable securities totaled $30.4 million. We expect to continue to incur losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities. Our existing capital resources, including the net proceeds from our IPO and term loans we received under the Loan Agreement and the Offerings, will not be sufficient to enable us to initiate any pivotal clinical trials. Based on our available cash resources and current operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the nine months ended September 30, 2024 are issued. If we are unable to continue as a going concern, we may have to cease operations and liquidate our assets. We may receive less than the value at which those assets are carried on our condensed consolidated financial statements, and investors may lose all or a part of their investment.Financial UpdateIn July 2024, we entered into the July Securities Purchase Agreement with an institutional investor relating to the July Offering. The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In October 2024, we entered into the October Securities Purchase Agreement with an institutional investor relating to the October Offering. The aggregate gross proceeds from the October Offering were approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by us, and excluding potential proceeds, if any, from the exercise of the Series C common warrants issued in the October Offering. In October 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In November 2023, our Board of Directors (the â€œBoardâ€) approved a reduction in the annual salary of Talat Imran, our Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as we receive gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the â€œFinancing Thresholdâ€). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met.In August 2022, we entered into the Loan Agreement with the Lender. The Loan Agreement provides for term loans (the â€œLoansâ€) in an aggregate principal amount up to $45.0 million. A Loan of $30.0 million was committed at closing, with $15.0 million funded immediately and $15.0 million available to be drawn between October 1, 2022 and December 31, 2022, which was drawn in December 2022. The remaining $15.0 million of Loans was uncommitted and subject to certain conditions and is no longer available under the Loan Agreement. The Loan Agreement also contains various covenants and restrictive provisions. There have been no material adverse events in connection with the Loan Agreement and the substantial doubt regarding our ability to continue as a going concern does not currently constitute a material adverse event under the terms of the Loan Agreement. The Loan principal is repayable in equal monthly installments beginning September 2024. As of September 30, 2024, we were in compliance with all applicable debt covenants under the Loan Agreement.In August 2022, we entered into a Controlled Equity Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (collectively the "Agents"), pursuant to which we may offer and sell from time to time through the Agents up to $150.0 million of shares of its Class A common stock, in such share amounts as we may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, we had no sales under the Sales Agreement. Tax Receivable AgreementSee Note 12 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information. 31 Â Future Funding RequirementsNotwithstanding the sharing of development costs for the RT-114 program under the ProGen Agreement, our existing capital resources, including the net proceeds from our IPO, the Loans and the Offerings, will not be sufficient to enable us to initiate any pivotal clinical trials with respect to any of our product candidates. We will need to raise substantial additional funds in the future in order to complete the development of the RaniPill platform, to complete the clinical development of our product candidates and seek regulatory approval thereof, to expand our manufacturing capabilities, to further develop the RaniPill HC device and to commercialize any of our product candidates.To date, we have not generated any commercial product revenue. We do not expect to generate any commercial product revenue unless and until we obtain regulatory approval and commercialize any of our commercial product candidates, and we do not know when, or if at all, that will occur. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. Our primary uses of cash are to fund our operations, which consist primarily of research and development expenses related to our programs, manufacturing automation and scaleup, and general and administrative expenses. We expect our expenses to continue to increase in connection with our ongoing activities as we continue to advance the RaniPill GO, RaniPill HC and our product candidates.We may seek to raise capital through equity offerings or debt financings, which may include ATM Sales, collaboration agreements, or other arrangements with other companies, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our consolidated financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:â€¢the progress, costs, trial design, results of and timing of our preclinical studies and clinical trials; â€¢the progress, costs, and results of our research pipeline; â€¢the willingness of the FDA, or other regulatory authorities to accept data from our clinical trials, as well as data from our completed and planned clinical trials and preclinical studies and other work, as the basis for review and approval of our product candidates or collaborator drugs or biologics paired with the RaniPill GO and/or RaniPill HC for various indications;â€¢the outcome, costs, and timing of seeking and obtaining FDA and any other regulatory approvals; â€¢the number and characteristics of product candidates that we pursue; â€¢our ability to manufacture sufficient quantities of the RaniPill capsules; â€¢our need to expand our research and development activities; â€¢the costs associated with manufacturing our product candidates, including establishing commercial supplies and sales, marketing, and distribution capabilities; â€¢the costs associated with securing and establishing commercial infrastructure; â€¢the costs of acquiring, licensing, or investing in businesses, product candidates, and technologies; â€¢our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense, and enforcement of any patents or other intellectual property rights; â€¢our need and ability to retain key management and hire scientific, technical, business, and engineering personnel; â€¢the effect of competing drugs and product candidates and other market developments; â€¢the timing, receipt, and amount of sales from our potential products, if approved; â€¢our ability to establish strategic collaborations; â€¢our need to implement additional internal systems and infrastructure, including financial and reporting systems;â€¢security breaches, data losses or other disruptions affecting our information systems;â€¢our ability to realize savings from any restructuring plans or cost-containment measures we may implement; and 32 Â â€¢the economic and other terms, timing of and success of any collaboration, licensing, or other arrangements which we may enter in the future.Pursuant to the terms of the October Securities Purchase Agreement, until 30 days following the closing of the October Offering, we agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Class A common stock or common stock equivalents, or file or amend any registration statement or prospectus, other than as necessary to maintain the registration of the securities offered in the October Offering. We further agreed not to enter into an agreement involving any new variable rate transactions until January 23, 2025, subject to certain exceptions. These restrictions could prevent us from raising additional capital that we might otherwise be able to raise.If we raise additional capital through debt financing, we may be subject to covenants that restrict our operations including limitations on our ability to incur liens or additional debt, pay dividends, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us. If we raise funds through collaborations, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or delay investments in our manufacturing scale-up and automation. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets. Furthermore, this Quarterly Report on Form 10-Q contains statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms, if at all.The following table summarizes our cash, cash equivalents and marketable securities:Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 4,277 Â Â $ 5,864 Â Marketable securities Â Â 26,127 Â Â Â 42,675 Â Total cash, cash equivalents and marketable securities Â $ 30,404 Â Â $ 48,539 Â As of September 30, 2024, we had cash and cash equivalents and marketable securities of $30.4 million, compared to $48.5 million as of December 31, 2023. Based on our available cash resources and current operating plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the nine months ended September 30, 2024 are issued. Our existing capital resources, including the net proceeds from our IPO, Loans and the Offerings, will not be sufficient to fund our projected operating requirements for a twelve-month period from the issuance of our financial statements.Cash Flows The following table summarizes our cash flows for the periods presented (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (26,841) Â $ (38,758) Net cash provided by investing activities Â Â 17,288 Â Â Â 16,586 Â Net cash provided by financing activities Â Â 7,966 Â Â Â 137 Â Net decrease in cash, cash equivalents and restricted cash equivalents Â $ (1,587) Â $ (22,035) Operating Activities Net cash used in operating activities for the nine months ended September 30, 2024 was $26.8 million, which was primarily attributable to a net loss of $40.9 million and net accretion and amortization of investments in marketable securities of $0.9 million, partially offset by stock-based compensation expense of $12.0 million and depreciation and amortization expense of $0.8 million. Additionally, there was an increase in accounts payable of $0.9 million, an increase in deferred revenue of $0.6 million and an increase of $0.3 million in prepaid expenses and other current assets for the nine months ended September 30, 2024. 33 Â Net cash used in operating activities for the nine months ended September 30, 2023 was $38.8 million, which was primarily attributable to a net loss of $53.8 million and net accretion and amortization of investments in marketable securities of $1.9 million, partially offset by stock-based compensation expense of $14.5 million and depreciation and amortization expense of $0.6 million. Additionally, there was an increase in accrued expenses and other current liabilities of $1.6 million for the nine months ended September 30, 2023.Investing Activities For the nine months ended September 30, 2024, net cash provided by investing activities was $17.3 million, which primarily consisted of $57.3 million in proceeds from maturities of marketable securities partially offset by $39.7 million in purchases of marketable securities and $0.2 million in purchases of property and equipment. For the nine months ended September 30, 2023, net cash provided by investing activities was $16.6 million consisting of $81.5 million in proceeds from maturities of marketable securities partially offset by $63.9 million and $1.0 million in purchases of marketable securities and property and equipment, respectively.Financing Activities For the nine months ended September 30, 2024, net cash provided by financing activities was $8.0 million, which primarily consisted of net proceeds of $8.9 million from the July Offering and $0.2 million from the issuance of common stock under employee stock purchase plan, partially offset by $1.3 million repayment of debt.For the nine months ended September 30, 2023, net cash provided by financing activities was de minimis. Contractual Obligations and Other CommitmentsAs of September 30, 2024, there have been no material changes to our contractual obligations and other commitments compared to those disclosed in our Annual Report on Form 10-KCritical Accounting EstimatesWe prepare our condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our condensed consolidated financial statements that require estimation but are not deemed critical, as defined above.Recently Adopted Accounting Standards See Note 2 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information. 34 Â Other InformationJOBS Act Accounting ElectionWe are an â€œemerging growth companyâ€ within the meaning of the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€). The JOBS Act permits an emerging growth company like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are electing to use this extended transition period and we will therefore comply with new or revised accounting standards on the earlier of (i) when they apply to private companies; or (ii) when we lose our emerging growth company status. As a result, our financial statements may not be comparable with companies that comply with public company effective dates for accounting standards. We also rely on other exemptions provided by the JOBS Act, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act unless we cease to be an emerging growth company.We will remain an emerging growth company until the earliest of (1) December 31, 2026 (the last day of the fiscal year following the fifth anniversary of the closing of our IPO), (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (3) the last day of the fiscal year in which we are deemed to be a â€œlarge accelerated filerâ€ as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.Item 3. Quantitative and Qualitative Disclosures About Market RiskWe are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.Item 4. Controls and ProceduresÂ Evaluation of Disclosure Controls and ProceduresUnder the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15(d)-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2024.Changes in Internal Control over Financial ReportingThere have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.Â 35 Â Inherent Limitations on Effectiveness of ControlsOur management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may

deteriorate. Because of the inherent limitations in a costâ€“effective control system, misstatements due to error or fraud may occur and not be detected. 36 Â PART IIâ€”OTHER INFORMATIONItem 1. Legal ProceedingsFrom time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Item 1A. Risk FactorsOther than as described below, management believes that there have been no significant changes to the risk factors associated with our business as compared to those disclosed in Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023.Our collaboration agreement with ProGen Co., Ltd. includes certain restrictions and obligations that may limit our flexibility in developing and commercializing RT-114 or require us to bear costs we otherwise would not incur.In June 2024, we entered into a Collaboration Agreement with ProGen for the worldwide development and commercialization of RT-114, a GLP-1/GLP-2 dual agonist in the RaniPillÂ® HC capsule. Under the terms of the ProGen Agreement, the parties will share equally the costs and revenues from development and commercialization of RT-114. Each party has certain rights, restrictions and obligations under the ProGen Agreement with respect to the development, manufacture and commercialization of RT-114, including certain rights to provide input on or approve activities of the other party or costs related thereto. As a result, we may not be able to develop and commercialize RT-114 in the manner or timeframe we believe to be most advantageous, and may be obligated to share costs that we otherwise would not incur. In addition, under the terms of the ProGen Agreement, each party has the right to opt-out of the collaboration, including the cost and revenue sharing, for RT-114, in which case the continuing party would bear all costs for further development, manufacture and commercialization of RT-114, other than certain costs already then-approved, and receive all future revenues from the program, subject to a low-to-mid single-digit royalty to the other party, depending on when the opt-out occurred. If ProGen were to opt-out, we would bear all such costs for further development, manufacture and commercialization of RT-114.Negative results arising from ProGenâ€™s development or future commercialization of PG-102, the therapeutic compound used in RT-114, could have materially adverse effects on our development of RT-114, or limit the commercial profile of an approved label for or result in limiting the commercial opportunity for RT-114, if approved.The therapeutic compound utilized in RT-114 is a GLP-1/GLP-2 dual agonist from ProGen known as PG-102. ProGen is developing PG-102, independent of our collaboration, as a subcutaneous injection for obesity and type-II diabetes. ProGen may develop PG-102 for other indications. ProGenâ€™s PG-102 is in Phase 1 clinical testing. If ProGenâ€™s clinical or preclinical testing of PG-102 results in data that is negative, or perceived to be negative, including without limitation safety concerns, adverse events or uncompetitive or poor efficacy data, or if ProGen encounters challenges obtaining regulatory approval for or commercial success with PG-102, such results could materially adversely affect the development, potential for regulatory approval for and/or commercial opportunity of RT-114, since RT-114 utilizes the same compound. In addition, if ProGen, itself or through a partner, succeeds in developing, obtaining regulatory approval for, and commercializing PG-102 outside of our collaboration, that product could compete with RT-114 and have a material adverse effect on the commercial opportunity for RT-114.Item 2. Unregistered Sales of Equity Securities and Use of ProceedsNone.Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable. 37 Â Item 5. Other InformationNone. 38 Â Item 6. ExhibitsThe following is a list of all exhibits filed or furnished as part of this report: Â ExhibitNumber Description 3.1 Â Amended and Restated Certificate of Incorporation of the Registrant as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrantâ€™s Registration Statement on Form S-1, as amended, filed with the SEC on July 26, 2021). 3.2 Â Amended and Restated Bylaws of the Registrant as currently in effect (incorporated by reference to Exhibit 3.4 to the Registrantâ€™s Registration Statement on Form S-1, as amended, filed with the SEC on July 9, 2021). 10.1* Â Amendment to Securities Purchase Agreement and Series B Common Stock Purchase Warrant dated September 23, 2024 between Rani Therapeutics Holdings, Inc. and the investors specified therein. 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1*â€ Â Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. 101.SCH Â Inline XBRL Taxonomy Extension Schema Document 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Filed herewith. â€ The certifications attached as Exhibit 32.1 which accompanies this Quarterly Report on Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. Â 39 Â SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Â Rani Therapeutics Holdings, Inc. Date: November 14, 2024 By: /s/ Talat Imran Talat Imran Chief Executive Officer Â Â Â (Principal Executive Officer) Â Date: November 14, 2024 By: /s/ Svai Sanford Â Â Â Svai Sanford Â Â Â Chief Financial Officer Â Â Â (Principal Financial and Accounting Officer) Â 40 EX-10.1 2 rani-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1AMENDMENT TO SECURITIES PURCHASE AGREEMENT ANDSERIES B COMMON STOCK PURCHASE WARRANTÂ This Amendment to Securities Purchase Agreement and Series B Common Stock Purchase Warrant (the â€œAmendmentâ€) is entered into by and between (the â€œHolderâ€) and Rani Therapeutics Holdings, Inc. (the â€œCompanyâ€), effective as of July 23, 2024 (â€œAmendment Effective Dateâ€). Whereas, Company issued to Holder on July 23, 2024 a Series B Common Stock Purchase Warrant (the â€œSeries B Warrantâ€) in accordance with that certain Securities Purchase Agreement, dated July 22, 2024, among the Company and Holder (the â€œPurchase Agreementâ€); andWhereas, Company and Holder desire to amend the Purchase Agreement and Series B Warrant as set forth herein.Now, Therefore, in consideration of the premises and mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Holder, intending to be legally bound, do hereby agree as follows:1.Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.2.Fundamental Transaction. The definition of â€œBlack Scholes Valueâ€ as set forth in Section 3(d) (Fundamental Transaction) of the Series B Warrant is hereby amended and replaced, effective as of the Amendment Effective Date, as follows:â€œâ€œBlack Scholes Valueâ€ means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the â€œOVâ€ function on Bloomberg determined as of the day of consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and, (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.â€ 3.Subsequent Equity Sales. Section 4.11(a) of the Purchase Agreement is hereby amended and replaced, effective as of the Amendment Effective Date, as follows:â€œFrom the date hereof until ninety (90) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or the filing of a registration statement on Form S-8 in connection with any employee benefit plan.â€Â 4.No Further Amendment. Except as amended by this Amendment, the Purchase Agreement and the Series B Warrant remain unaltered and shall remain in full force and effect.5.Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be determined in accordance with the provisions of the Purchase Agreement. Â Â (Signature Page Immediately Follows) Â Â Â IN WITNESS WHEREOF, each of Company and Holder have caused this Amendment to be executed by a duly authorized representative.Â RANI THERAPEUTICS HOLDINGS, INC.Â Â By: /s/ Svai Sanford Name: Svai SanfordTitle: CFODate: 09/23/2024Â Â Â Â Â By: Name: Title: Date: September 22, 2024Â Â EX-31.1 3 rani-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1CERTIFICATIONI, Talat Imran, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Rani Therapeutics Holdings, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Â Â Date: November 14, 2024Â Â /s/ Talat Imran Â Â Talat Imran Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â EX-31.2 4 rani-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2CERTIFICATIONI, Svai Sanford, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Rani Therapeutics Holdings, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Â Â Date: November 14, 2024Â Â /s/ Svai Sanford Â Â Svai Sanford Â Â Chief Financial Officer Â Â (Principal Financial and Accounting Officer) Â Â Â EX-32.1 5 rani-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1CERTIFICATIONPursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the â€œExchange Actâ€) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Talat Imran, Chief Executive Officer of Rani Therapeutics Holdings, Inc. (the â€œCompanyâ€), and Svai Sanford, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:1.The Companyâ€™s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Dated: November 14, 2024In Witness Whereof, the undersigned have set their hands hereto as of the 14th day of November, 2024Â /s/ Talat Imran Â /s/ Svai Sanford Talat Imran Â Svai Sanford Chief Executive Officer Â Chief Financial Officer (Principal Executive Officer) Â (Principal Financial and Accounting Officer) Â This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Rani Therapeutics Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. Â EX-101.SCH 6 rani-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Long-Term Debt - Future principal payments for the Company's debt (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Evaluation Agreements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Collaborative and Evaluation Arrangements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure -

Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Evaluation Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Long Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Organization and Nature of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value Measurement - Unobservable inputs used in the fair value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Fair Value Measurements - Summary of the changes in the fair value of the Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Evaluation Agreements - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Collaborative and Evaluation Arrangements (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Leases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Stock-Based Compensation - Summary of Profits Interests Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Stock-Based Compensation - Summary of Unit Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Stock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Long-Term Debt (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Long-Term Debt - Future principal payments for the Company's debt (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Subsequent Events (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink Collaborative Arrangement, Accounting Policy [Policy Text Block] Collaborative Arrangements Less: amount representing debt discount Less: amount representing debt discount Debt Instrument, Unamortized Discount (Premium), Net Statement [Line Items] Statement [Line Items] Exercise of pre-funded warrants Issuance Of Common Stock For Exercise Of Prefund Warrants Shares Issuance Of Common Stock For Exercise Of Prefund Warrants Shares Liabilities: Liabilities, Fair Value Disclosure [Abstract] Interest Rate On Loan Interest Rate During Period Debt Instrument, Interest Rate During Period Long-Term Purchase Commitment [Table] Debt Instrument [Axis] Accounts Receivable Increase (Decrease) in Accounts Receivable Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements Policy [Text Block] Recently adopted accounting pronouncements policy text block Plan Name Plan Name [Domain] Organizational Transactions [Member] Organizational Transactions [Member] Organizational Transactions. Shares issuable pursuant to the ESPP Shares issuable pursuant to the ESPP. Shares Issuable Pursuant To The ESPP [Member] Shares Issuable Pursuant To The ESPP [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of cash, cash equivalents, restricted cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Long-Term Purchase Commitment [Line Items] Marketable securities Available-for-Sale Securities [Member] Common units outstanding Common stock, shares outstanding Common Unit, Outstanding Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Corporate debt securities Debt Security, Corporate, US [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Other Comprehensive Income (Loss), Tax [Abstract] Other comprehensive loss Weighted Average Exercise Price per Share, Exercisable at September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Cash Equivalents, Restricted Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Lessee, Operating Lease, Description Lessee, Operating Lease, Description Securities Purchase Agreement [Member] Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Rani Management Service and In Cube Labs LLC [Member] Rani Management Service and In Cube Labs LLC [Member] RMS-ICL Line of credit available to be drawn Line Of Credit Available To be Drawn Line Of Credit Available To be Drawn Accrued Liabilities [Abstract] Long-Term Debt, Current Maturities Total long-term debt, less current portion Current portion of long-term debt Less: current portion of long-term debt Leases Lessee, Operating Leases [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Fair Value (in thousands) Derivative Liability, Subject to Master Netting Arrangement, before Offset Derivative Liability, Fair Value, Gross Liability, Total Forfeiture of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Summary of the Changes in the Fair Value of the Companyâ€™s Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Non-corresponding Class A Units Non Corresponding Class A Units [Member] Non Corresponding Class A Units [Member] Non Corresponding Class A Units [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Cash paid for amounts included in lease liabilities: Payments for Operating Activities [Abstract] Cash received from equity financing Proceeds from Other Equity Related Party Transaction [Line Items] Related Party Transaction [Line Items] Document Information [Table] Capital Units by Class [Axis] Equity [Text Block] Stockholders' Equity Auction Market Preferred Securities, Stock Series, Title [Domain] Title and Position [Axis] Derivative, term of contract Derivative, Term of Contract Class of Warrant or Right Class of Warrant or Right [Axis] Gross Unrealized loss Gross Unrealized loss Debt Securities, Available-for-Sale, Unrealized Loss Award Date [Axis] Sale of Stock Sale of Stock [Domain] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Long-Term Debt, Gross, Total Total long-term debt Long-Term Debt, Gross Remaining Borrowing Capacity Line of Credit Facility, Remaining Borrowing Capacity Adjustment of tax benefit Beneficial Interest Liability Entity Central Index Key Entity Central Index Key Series e warrants member. Series E Warrants [Member] Series E Warrants Weighted Average Exercise Price per Share, Granted as replacement awards Share Based Compensation Arrangements By Share Based Payment Award Options Grants As Replacement Awards In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Options Grants As Replacement Awards In Period Weighted Average Exercise Price Warrants Preferred unit warrant liability Warrant [Member] Canceled Number of options, Forfeited Number of options, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common Class C Common Class C [Member] Proceeds from issuance of debt Proceeds from Issuance of Debt Common stock shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Common stock units issued Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Award Date [Domain] Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Financial Information Policy [Text Block] Unaudited interim financial information. Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan Issuance of common stock under employee stock purchase plan Revision of Prior Period [Axis] Class of Warrant or Right [Table] Loss Contingencies [Table] Loss Contingencies [Table] Stock-based compensation expense Depletion Depletion, Total Marketable securities Marketable Securities Marketable Securities, Total Non-controlling Interest Non-controlling Interests Policy Text Block Non-controlling Interests Policy Text Block Salary Salary and Wage, Officer, Excluding Cost of Good and Service Sold Percentage of tax benefit to be transferred Percentage Of Tax Benefit To Be Transferred Percentage of tax benefit to be transferred. Aggregate Intrinsic Value, Exercisable at September 30, 2024 (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Initial Term Leases Agreement Initial Term Leases Agreement Initial Term Leases Agreement Cover [Abstract] Subsequent Event [Line Items] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) Total Change in estimated fair value Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss, Total Operating Lease, Lease Income [Abstract] Operating expenses Operating Expenses [Abstract] One time patent payment to related party One time patent payment to related party One time patent payment to related party Measurement Input Probability Of Exit Events Measurement Input Probability Of Exit Events [Member] Measurement input probability of exit events member. Schedule of Reconciliation of cash, cash equivalents and restricted cash equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Evaluation Agreements [Abstract] evaluation agreements abstract. Total stock-based compensation Share-Based Payment Arrangement, Expense Stock-based compensation expense Percentage of increase in monthly base rent (per year) Percentage Of Increase In Monthly Base Rent (Per Year) Percentage Of Increase In Monthly Base Rent (Per Year) Rani LLC-ICL Service Agreement [Member] Rani LLC-ICL Service Agreement [Member] Total principal payments Long-Term Debt Fair value measurement discount for lack of marketability Fair Value Measurement Discount For Lack Of Marketability Fair value measurement discount for lack of marketability. Amount Due From Related Party Expense Amount Due From Related Party Expense Contra-research and development expense RMS-ICL Service Agreement [Member] RMS-ICL Service Agreement [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Plan Name Plan Name [Axis] Number of Options, Outstanding, Beginning balance Number of Options, Outstanding, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Stock options, outstanding Upfront payment Upfront Payment upfront payment. Supplemental disclosures of cash flow information Supplemental Cash Flow Elements [Abstract] Current assets: Assets, Current [Abstract] Preferred Units by Name Preferred Units by Name [Axis] Beneficially number of shares held Excess Stock, Shares Outstanding Schedule Of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Adjustments to Additional Paid in Capital, Other Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount Operating activities, net Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating activities, net Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited, Weighted-Average Grant Date Fair Value Accumulated other comprehensive gain (loss) Comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Share Based Compensation Profit Interests Granted Weighted Average Grant Date Fair Value Share based compensation profit interests granted weighted average grant date fair value. Weighted Average Grant Date Fair Value, Granted Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Debt Instrument [Line Items] Debt Instrument [Line Items] Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Granted as replacement of Profits Interests, Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants As Replacement Of Profits Interests In Period Share based compensation arrangement by share based payment award equity instruments other than options grants as replacement of profits interests in period. Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Recurring Fair Value, Recurring [Member] Schedule of Assets and Liabilities Recorded at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Warrants [Member] Warrants Warrants and Rights Subject to Mandatory Redemption [Member] Common stock par value Common Stock, Par or Stated Value Per Share Fair value measurement expected volatility rate Fair Value Measurement Expected Volatility Rate Fair value measurement expected volatility rate. Measurement Input Type Measurement Input Type [Domain] Series B Series B [Member] Statement of Cash Flows [Abstract] Accrued professional fees Accrued Professional Fees Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Securities purchase in exchange for warrant Class of Warrant or Right, Number of Securities Called by Warrants or Rights Pre-funded warrants issued to purchase shares of common stock Restricted Stock Awards [Member] Restricted Stock Awards Restricted Stock [Member] Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Granted, number of shares Granted, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Subsequent Event Type Subsequent Event Type [Axis] Stock options Stock Options [Member] Equity Option [Member] Increase (Decrease) in Accounts Payable, Trade Accounts payable Accounts payable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Maximum Borrowing Capacity Line of Credit Facility, Maximum

Borrowing Capacity Gross unrealized Gains Debt Securities, Available-for-Sale, Unrealized Gain Stockholders' equity / members' deficit: Members' Equity [Abstract] Stockholders' equity: Outstanding, Number of Shares, Ending Balance Outstanding, Number of Shares, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Significant Accounting Policies Significant accounting policies. Significant Accounting Policies [Policy Text Block] Amendment Flag Amendment Flag Adoption of Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest, Total Net loss attributable to non-controlling interest Long-Term Debt and Lease Obligation, Current Total long-term debt, less current portion Operating lease liabilities Increase (Decrease) in Operating Lease Liability Operating lease liabilities Operating Lease, Liability, Noncurrent, Total Operating lease liability, less current portion Operating Lease, Liability, Noncurrent Operating lease liability, net current portion Corporate debt securities Corporate Debt Securities [Member] Debt Instrument, Name [Domain] Common unit, price per share Sale of Stock, Price Per Share Stock offering price per share Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. Net loss attributable to Rani Therapeutics Holdings, Inc. Lessee, Lease, Description [Table] Exercise of pre-funded warrants Number of Options, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercisable at September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Expense Research and Development Expense [Member] Research and Development Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Exchanges of non-corresponding Class A Units of Rani LLC Exchange of common units. Exchange Of Common Units Series b warrants member. Series B Warrants [Member] Series B Warrants Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total Net loss Net loss Net loss and comprehensive loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Preferred stock issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Operating cash flows used for operating leases Operating Lease, Payments Monthly base rent for initial term of the lease Share Based Compensation Number Of Profits Interests Vested Share based compensation number of profits interests vested. Number of Profit Interests Vested Proceeds from Stock Options Exercised Exercise of options Weighted average number Of shares outstanding basic and diluted Weighted Average Number Of Shares Outstanding Basic and Diluted Denominator: Restricted cash equivalents Restricted Cash Equivalents Restricted Cash Equivalents, Total Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Stock Issued During Period, Shares, Conversion of Units Nonvested at September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Issued classified warrants Adjustments to Additional Paid in Capital, Warrant Issued Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee stock purchase plan, net of shares withheld for tax settlement (Shares) Net Asset Value Per Share Net Asset Value Per Share, Ending Balance Net Asset Value Per Share, Beginning Balance Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest General Partner Ownership Interest Weighted Average Exercise Price per Share, Forfeited Weighted Average Exercise Price per Share, Canceled and replaced with stock options Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Warrats Expiration Term Warrats Expiration Term Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock Class of Stock [Domain] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Total Common warrants to purchase an aggregate shares Stock Issued During Period, Shares, Purchase of Assets Collaborative and Evaluation Arrangements Collaborative Arrangement Disclosure [Text Block] Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Beginning Balance (shares) Ending Balance (shares) Common stock shares outstanding Common Stock, Shares, Outstanding Series A Common Warrants Member Series A Common Warrants [Member] Series A Common Warrants [Member] Preferred Stock, Par or Stated Value Per Share Preferred stock, par or stated value per share Preferred stock, par value Exchange of paired interests Exchange of Paired Interest Exchange of paired interest. Weighted Average Weighted Average [Member] Antidilutive Securities Antidilutive Securities [Axis] Profits Interests Threshold, Canceled and replaced with restricted stock awards Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Canceled and replaced with Restricted Stock Awards Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Canceled and replaced with Restricted Stock Awards. Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity Summary of Restricted Stock Unit and Award Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Uncalled amount of debt UNCALLED AMOUNT OF DEBT UNCALLED AMOUNT OF DEBT Consolidated Entities Consolidated Entities [Axis] Tax Receivable Agreement Tax Receivable Agreement [Member] Tax Receivable Agreement [Member] Vested, Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Related Party Transaction Related Party Transaction [Domain] Cash, cash equivalents and restricted cash equivalents, end of period Cash, cash equivalents and restricted cash equivalents, end of period Cash, cash equivalents and restricted cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash equivalents, beginning of period Related Party Transactions Related Party Transactions Disclosure [Text Block] Statement of Financial Position Location, Balance [Axis] Receivables, Long-Term Contracts or Programs Receivables, Long-term Contracts or Programs, Total Receivables or net contract assets from agreement Statistical Measurement Statistical Measurement [Axis] Profits Interests Threshold, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Forfeitures Profits Interests Activity Threshold Forfeitures Gross Proceeds from Offering Gross Proceeds From Offering Gross proceeds Gross proceeds from offering Total assets Assets, Fair Value Disclosure Assets, Fair Value Disclosure, Total Related Party Related and Nonrelated Parties [Domain] Rani Therapeutics Holdings Inc. Parent Company [Member] Summary of Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Research And Development Arrangement [Member] Research and Development Arrangement [Member] Commercial paper Commercial Paper [Member] Basis of Presentation and Accounting Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation Granted, Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Recognized over a weighted-average period Interest and Other Income Interest income and other, net Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Ownership [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Cash, cash equivalents and marketable securities Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Marketable Securities Total assets Assets Up front payment arrangement Up Front Payment Arrangement Up Front Payment Arrangement Schedule of Long-Term Debt Instruments [Table] Vested, Number of Shares Vested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town South Lake One LLC and Affiliates South Lake One L L C And Affiliates [Member] South Lake One L L C And Affiliates. Equity [Abstract] Series A [Member] Series A [Member] Assets: Assets, Fair Value Disclosure [Abstract] Stock issuance costs Payments of Stock Issuance Costs Schedule of Future Principal Payments for the Company's Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Forfeited, Number of Shares Forfeited, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Increase net of tax assets Increase net of tax assets Balance at beginning of period Balance at end of period Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Increase Decrease In Per Year Increase Decrease In Per Year Agreement termination negotiation period. Agreement Termination Negotiation Period Agreement termination negotiation period Debt instrument face amount Debt Instrument, Face Amount Contract Revenue Revenue Not from Contract with Customer Revision of Prior Period [Domain] Auction Market Preferred Securities, Stock Series [Axis] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Fair Value Disclosures [Abstract] Weighted Average Remaining Contractual Term, Canceled and replaced with stock options (in years) Share based Compensation Arrangement By Share based Payment Award Options Canceled And Replaced Weighted Average Remaining Contractual Term Share based Compensation Arrangement By Share based Payment Award Options Canceled And Replaced Weighted Average Remaining Contractual Term Effects of the IPO and related Organizational Transactions [Member] Effects of the IPO and related Organizational Transactions [Member] Deferred tax asset Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance, Total Chief Executive Officer [Member] Lessee, Lease, Description [Line Items] Current liabilities: Liabilities, Current [Abstract] Profits Interests Threshold, Granted Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Grants Profits Interests Activity Threshold Grants Accrued Liabilities Total accrued expenses and other current liabilities Cash paid for income taxes Income Taxes Paid, Net Income Taxes Paid, Net, Total Cash Equivalents Cash and Cash Equivalents [Member] Document Type Document Type Accounting Standards Update [Axis] Weighted Average Grant Date Fair Value, Forfeited Share Based Compensation Profit Interests Forfeitures Weighted Average Grant Date Fair Value Share Based Compensation Profit Interests Forfeitures Weighted Average Grant Date Fair Value. Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash and Cash Equivalents, at Carrying Value Interest income receivable included in prepaid expenses and other current assets Prepaid Interest Statement of Financial Position Location, Balance [Domain] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and development Research and Development Expense Research and Development Expense, Total Tax withholdings paid on behalf of employees for net share settlement Payment, Tax Withholding, Share-Based Payment Arrangement Long-Term Debt, Excluding Current Maturities Long-term debt, less current portion Total long-term debt, less current portion Number of Options, Unit Grants Number of Options, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Total cash, cash equivalents and restricted cash equivalents Restricted cash equivalents, end of period Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents, Total Asset Class [Domain] Proceeds from Issuance of common stock under the employee stock purchase plan Proceeds from Issuance of common stock under the employee stock purchase plan Issuance of common stock under employee stock purchase plan Weighted Average Remaining Contractual Term, Nonvested at September 30, 2024 (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term. Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term Subsequent Event Type Subsequent Event Type [Domain] Leases Lessee, Leases [Policy Text Block] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Profits Interests Member Units [Member] U.S. Treasuries U.S. Treasuries [Member] US Treasuries [Member] US Treasuries [Member] Aggregate Intrinsic Value, Nonvested at September 30, 2024 (in thousands) Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value. Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value Summary of consolidated balance sheets and statements of cash flow related to leases Condensed Cash Flow Statement [Table Text Block] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant exercise price Financial Instruments [Domain] Class of Warrant or Right [Line Items] Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Category of Item Purchased [Axis] Earnings Per Share [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Statement of Comprehensive Income [Abstract] Income Tax Disclosure [Text Block] Income Taxes Ownership [Axis] Consolidated Entities Consolidated Entities [Domain] Warrants and Rights Note Disclosure [Abstract] Paired Interests Paired Interest [Member] Paired Interests [Member] Paired Interests [Member] Short-Term Debt, Type [Axis] Settlement of Series E warrants Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements Credit Facility [Domain] Granted as replacement of Profits Interests, Weighted-Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants As Replacement Of Profits Interests In Period Weighted Average Grant Date Fair Value Share based compensation arrangement by share based payment award equity instruments other than options grants as replacement of profits interests in period weighted average grant date fair value. Summary of Consolidated Balance Sheets and Statements of Cash Flow related to Leases Condensed Financial Statements [Table Text Block] Weighted Average Remaining Contractual Term, Granted (in years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term. Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Short-Term Debt, Type [Domain] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Document Period End Date Document Period End Date Accrued interest Accrued interest Accrued interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Common Class A [Member] Common Class A Common Class A [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent, Total Anti-dilutive securities Exchanged paired interests for the Company's Class A common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Profits Interests Threshold, Vested Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Vested Share based compensation arrangement by share based payment award profits interests activity threshold vested. APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation Common Class B [Member] Common Class B [Member] Common Class B Sales Agreement Sales Agreement [Member] Sales Agreement [Member] 2029 Lessee, Operating Lease, Liability, to be Paid, after Year Five Deferred Revenue Deferred revenue Balance at beginning of period Balance at end of period Deferred Revenue Deferred Revenue, Total Aequanimitas Limited Aequanimitas Limited [Member] Aequanimitas Limited Loan and Security Agreement Loan And Security Agreement [Member] Loan and Security Agreement. Paycheck Protection Program Paycheck Protection Program [Member] Paycheck Protection Program Loss on disposal of property and equipment Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Trading Symbol Trading Symbol Business Combinations [Abstract] Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. Equity, Attributable to Parent Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Net unrealized gain on marketable securities Net unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Class of Warrant or Right, Outstanding Class of Warrant or Right, Outstanding Restricted stock units Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Sale of common units Sale of Stock, Number of Shares Issued in Transaction Related Party Transactions [Abstract] Deferred revenue Increase (Decrease) in Deferred Revenue Land Subject to Ground Leases Land Subject to Ground Leases Class A unit Member Capital Unit, Class A [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Components of Equity-based Compensation Expense Related Party Transaction Income Expenses From Transactions With Related Party Related Party Transaction Income Expenses From Transactions With Related Party Related party charges Measurement Input Type Measurement Input Type [Axis] Unrecognized equity-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Leases [Abstract] Number of Options, Canceled and replaced with stock options Number of Options, Canceled and replaced Share Based Compensation Arrangement By Share Based Payment Award Options Canceled And Replaced In Period Share based compensation arrangement by share based payment award options canceled and replaced in period. Area for Rent For facility in San jose Area of Land Use of Estimates Use of Estimates, Policy [Policy Text Block] Measurement Input, Discount for Lack of Marketability Measurement Input, Discount for Lack of Marketability [Member] Cash, equivalents and restricted cash equivalents Cash, cash equivalents and restricted cash equivalents [Member] Cash, cash equivalents and restricted cash equivalents [Member] Weighted Average Remaining Contractual Term, Granted as replacement awards (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Grants As Replacement Awards Weighted Average Remaining Contractual Term Share

Based Compensation Arrangement By Share Based Payment Award Options Grants As Replacement Awards Weighted Average Remaining Contractual Term. Schedule of deferred revenue balance Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Common units holders Common Unit Issued Common Unit, Issued Paired Interest Paired Interest [Member] Paired Interest Restricted Stock Awards Restricted Stock Awards [Member] Restricted stock awards. Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Scenario [Axis] Marketable Securities, Policy [Policy Text Block] Marketable Securities Security Exchange Name Security Exchange Name Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Shares Issuance of Common Stock in Connection With the Stock Purchase Agreement, Net of Issuance Costs Issuance of Common Stock in Connection With the Stock Purchase Agreement, Net of Issuance Costs Accrued preclinical and clinical trial costs 1 Accrued preclinical and clinical trial costs 1 Accrued preclinical and clinical trial costs Total operating expenses Operating Expenses Secondary Sales Transactions Secondary Sales Transactions [Member] Secondary sales transactions. Class of Stock Class of Stock [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Weighted Average Grant Date Fair Value, Balance at September 30, 2021 Weighted Average Grant Date Fair Value, Balance at December 31, 2020 Share Based Compensation Profit Interests Weighted Average Grant Date Fair Value Share Based Compensation Profit Interests Weighted Average Grant Date Fair Value. Conversion of stock, shares Conversion of Stock, Shares Converted Subsequent Event [Member] Subsequent Event Maximum Maximum [Member] Maximum Total liabilities and stockholders' equity Liabilities and Equity ICL ICL In Cube Labs L L C [Member] InCube Labs, LLC Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Prepaid Expense, Current, Total Prepaid Expense, Current Prepaid expenses and other current assets Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted Entity Ex Transition Period Entity Ex Transition Period Total liabilities Liabilities Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Avenue Venture Opportunity Fund L.P Member Avenue Venture Opportunity Fund L P [Member] Avenue venture opportunity fund L.P member. Forecast [Member] Forecast [Member] Issuance of Class A common stock in connection with the IPO, net of issuance costs $10,686, shares Stock Issued During Period, Shares, New Issues Issuance of common stock, shares Weighted Average Exercise Price per Share, Nonvested at September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance Entity Filer Category Entity Filer Category Activity subsequent to the IPO and related Organizational Transactions [Member] Activity subsequent to the IPO and related Organizational Transactions [Member] Takeda Agreement [Member] Takeda Agreement [Member] Takeda Agreement [Member] Beginning Balance Total stockholders' equity Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Organization and Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Purchases of marketable securities Purchases of marketable securities Payments to Acquire Marketable Securities Other income (expense), net Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Series E Preferred Units [Member] Series E preferred units. Series E Preferred Units Fair value of RSAs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Noncontrolling Interest [Member] Noncontrolling Interest [Member] Less: Imputed interest Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Related Party Transaction Related Party Transaction [Axis] Aggregate Intrinsic Value, Outstanding, Beginning Balance Aggregate Intrinsic Value, Outstanding, Ending Balance Aggregate Intrinsic Value, Exercisable at September 30, 2021 (in thousands) Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Related Party Related and Nonrelated Parties [Axis] Other Other Accrued Liabilities Entity Registrant Name Entity Registrant Name Share Based Compensation Arrangement By Share Based Payment Award Options Grants As Replacement Awards In Period Gross Share Based Compensation Arrangement By Share Based Payment Award Options Grants As Replacement Awards In Period Gross. Number of Options, Granted as replacement awards Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss Per Share Earnings Per Share [Text Block] Debt Instrument, Maturity Date Debt Instrument Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Money market funds Money market funds Money Market Funds [Member] Weighted average Class A common share outstanding-basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average share outstanding basic Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Warrants Not Settleable in Cash, Fair Value Disclosure Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Common stock shares authorized Common Stock, Shares Authorized Proceeds from issuance of common stock and pre-funded warrants in connection with the July Securities Purchase Agreement, net of issuance costs of $1,117 Proceeds from isuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable securities Cash and Cash Equivalents [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Debt Disclosure [Abstract] Long-Term Debt Long-Term Debt with Detachable Warrants Long-Term Debt [Text Block] Weighted Average Exercise Price per Share, Unit Grants Weighted Average Exercise Price per Share, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Change in uncertain tax position Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized Tax Benefits, Period Increase (Decrease), Total Financial Instrument [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term (in years) Net Loss Per Class A Common Share Attributable to Rani Holdings Net Loss Per Class A Common Share Attributable to Rani Therapeutics Holdings, Inc. Earnings Per Share, Policy [Policy Text Block] Remeasurement of operating lease right-of-use assets Remeasurement of operating lease right-of-use assets Remeasurement of operating lease right-of-use assets Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Debt with Detachable Warrants Debt, Policy [Policy Text Block] General and Administrative Expense General and Administrative Expense [Member] General and Administrative Weighted Average Grant Date Fair Value, Vested Share Based Compensation Profit Interests Vested Weighted Average Grant Date Fair Value Share Based Compensation Profit Interests Vested Weighted Average Grant Date Fair Value Contributions withheld from employees Accrued Payroll Taxes Revenue Recognition Revenue [Policy Text Block] Rani LLC Rani LLC. Rani L L C [Member] Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule of Amounts Charged for Services and Rent Schedule of Related Party Transactions [Table Text Block] Number of Profit Interests, Balance at September 30, 2021 Number of Profit Interests, Balance at December 31, 2020 Share Based Compensation Number Of Profits Interests Outstanding Number Share Based Compensation Number Of Profits Interests Outstanding Number. Proceeds From Issuance Of Warrants Proceeds from Issuance of Warrants Marketable Securities Estimated Fair Value Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Accounting Policies [Abstract] Summary of Stock Options and Options for Common Units Activity Summary Of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Cash and Cash Equivalents [Line Items] Income Tax Disclosure [Abstract] Supplemental disclosures of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Recovery of Direct Costs Reimbursement of research and development expense Statement [Table] Statement [Table] Comprehensive loss attributable to non-controlling interest Comprehensive loss attributable to non-controlling interest Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Subsequent Event [Table] Agreement termination period Agreement Termination Period Agreement termination period Preferred stock authorized Units Authorized Preferred Stock, Shares Authorized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted Average Vesting Period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted Average Vesting Period Weighted average vesting term Revenue from Contract with Customer, Including Assessed Tax Revenue from contract Entity File Number Securities Act File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash, cash equivalents and restricted cash equivalents Earnings Per Share [Abstract] Interest Receivable Interest income receivable Warrants exercisable period Warrants and Rights Outstanding, Term Long-Term Debt, Maturity, Remainder of Fiscal Year 2024 (remaining six months) Statement of Financial Position [Abstract] Interest expense and other, net Interest Expense, Operating and Nonoperating Interest Expense, Total IPO [Member] IPO [Member] IPO Date of incorporation Entity Incorporation, Date of Incorporation Loss from operations Operating Income (Loss) Profits Interests Threshold, Balance at September 30, 2021 Profits Interests Threshold, Balance at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Profits interests activity threshold 2025 Long-Term Debt, Maturity, Year One Shares Issued, Price Per Share Offering price Income tax payable, amount Accrued Income Taxes, Current Accrued Taxes Entity Shell Company Entity Shell Company Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Summary of Significant Unobservable Inputs used in the Fair Value Measurement of the Series E Preferred Unit Warrant Liability Summary of Significant Unobservable Inputs used in the Fair Value Measurement of the Series E Preferred Unit Warrant Liability Entity Tax Identification Number Entity Tax Identification Number Assets: Assets [Abstract] Class of Warrant or Right Class of Warrant or Right [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] International government Government [Member] Entity Current Reporting Status Entity Current Reporting Status Weighted Average Remaining Contractual Term, Exercisable at September 30, 2024 (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Cash Equivalents, Restricted Cash Equivalents and Marketable Securities Cash Equivalents Restricted Cash Equivalents and Marketable Securities Policy Text Block Cash Equivalents Restricted Cash Equivalents and Marketable Securities Policy Text Block Accrued rent Accrued Rent Subsequent Events [Abstract] Aggregate Intrinsic Value, Granted as replacement awards (in thousands) Share-based Compensation Arrangement by Share-based Payment Award Options Granted As Replacement Awards in Period Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award Options Granted As Replacement Awards in Period Intrinsic Value. Previously Reported [Member] Previously Reported [Member] Warrants Warrants [Text Block] The entire disclosure of warrants. Document Fiscal Year Focus Document Fiscal Year Focus Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Carrying Value Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Repayment of debt Repayment of debt Repayments of Long-Term Debt Repayments of Long-Term Debt, Total Capital Expenditures Incurred but Not yet Paid Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities City Area Code City Area Code Total current liabilities Liabilities, Current Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Restricted Cash Equivalents Restricted Cash Equivalents, Fair Value Disclosure Restricted Cash Equivalents, Fair Value Disclosure Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred stock outstanding Units Outstanding Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Payroll and related costs Accrued Salaries Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amount payable for evaluation services Amount Payable For Evaluation Services Amount payable for services. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Additional Paid in Capital Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares The entire disclosure for evaluation agreements. Evaluation Agreements [Text Block] Evaluation Agreements Commitments and Contingencies Disclosure [Abstract] Registration Rights Agreement Registration Rights Agreement [Member] Registration Rights Agreement [Member] Convertible Preferred [Member] Convertible Preferred Stock [Member] Convertible Preferred Units Net of issuance costs Debt Issuance Costs, Net Debt Issuance Costs, Net, Total Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Total Operating Lease, Liability, Current Current portion of operating lease liability Less: Current portion of operating lease liability Document Information [Line Items] Convertible Preferred units issued Limited Liability Company (LLC) Preferred Unit, Issued Members Deficit [Member] Accumulated Deficit [Member] Retained Earnings [Member] Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts, Total Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Document Transition Report Document Transition Report Accumulated Other Comprehensive Loss Member Accumulated Other Comprehensive Loss Member Accumulated Other Comprehensive Loss Member Long-Term Debt, Unclassified [Abstract] 2025 2023 (totaled) Lessee, Operating Lease, Liability, to be Paid, Year Two Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Cash Flows Additional Cash Flow Elements [Abstract] Convertible Preferred units authorized Limited Liability Company (LLC) Preferred Unit, Authorized Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value Proceeds from Stock Plans Proceeds from employee stock purchase plan Weighted Average Exercise Price per Share, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Minimum Minimum [Member] Minimum Common Stock [Member] Common [Member] Common Unit 2026 Long-Term Debt, Maturity, Year Two Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities Cancelled Number of Profit Interests, Canceled and replaced with restricted stock awards Share Based Compensation Number Of Profits Interests Canceled And Replaced With Restricted Stock Awards Share Based Compensation Number Of Profits Interests Canceled And Replaced With Restricted Stock Awards. Sales price and fair value of common units, difference Sales Price And Fair Value Of Common Units Difference Amount Sales price and fair value of common units, difference amount. Outstanding, Weighted-Average Grant Date Fair Value Outstanding, Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid in Capital [Member] Additional Paid-in Capital [Member] Change in uncertain tax position Change In Uncertain Tax Positions Change In Uncertain Tax Positions Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] 2024 (remaining three months) 2022 (remaining three months) Lessee, Operating Lease, Liability, to be Paid, Year One Other assets Other Assets, Noncurrent Outstanding Capital Class A Unit [Member] Outstanding Capital Class A Unit [Member] Prepaid expenses and other current assets Other Prepaid Expense, Current Debt Securities, Available-for-Sale Proceeds from Sale of Debt Securities, Available-for-Sale Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation of Revenue [Line Items] Non-controlling interest Equity, Attributable to Noncontrolling Interest Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Evaluation Agreements Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block] Scenario [Domain] Title and Position [Domain] Series B Common Warrants Member Series B Common Warrants [Member] Series B Common Warrants [Member] Warrants and Rights Outstanding Fair value totaling Number of Profit Interests Granted Share Based Compensation Number Of Profits Interests Grants In Period Gross Share Based Compensation Number Of Profits Interests Grants In Period Gross. Pre Funded Warrant Member Pre Funded Warrant [Member] Pre-Funded Warrant [Member] Common stock, value Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock units issued Fair value measurement probability of exit events Fair Value Measurement Probability Of Exit Events Fair value measurement probability of exit events. Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Stock Issued During Period, Value, Conversion of Units Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalent

[Table] Market capitalization amount Capitalization, Long-Term Debt and Equity Capitalization, Long-Term Debt and Equity, Total Preferred Units, Class Preferred Units, Class [Domain] Long-Term Debt, Maturity, Year Three 2026 Lease liability Total operating lease liability Operating Lease, Liability Tax Receivable Agreement Tax Receivable Agreement, Policy [Policy Text Block] Tax Receivable Agreement, Policy [Policy Text Block] Measurement Frequency Measurement Frequency [Axis] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Commitments and Contingencies Commitments and contingencies (Note 11) Weighted average Class A common share outstanding-diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average share outstanding diluted Significant Accounting Policies Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term Total undiscounted future minimum lease payments Total undiscounted future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Future minimum lease payments Summary of Profits Interests Activity Schedule Of Share Based Compensation Profits Interests Activity Table [Text Block] Tabular disclosure for profits interests activity. Weighted Average Grant Date Fair Value, Canceled and replaced with restricted stock awards Share Based Compensation Profit Interests Canceled And Replaced With Restricted Stock Awards Weighted Average Grant Date Fair Value Share Based Compensation Profit Interests Canceled And Replaced With Restricted Stock Awards Weighted Average Grant Date Fair Value. Continuing LLC Owners [Member] Continuing LLC Owners Number of Profit Interests Forfeited Share Based Compensation Number Of Profits Interests Forfeitures Share Based Compensation Number Of Profits Interests Forfeitures. Comprehensive loss Comprehensive loss Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Small Business Entity Small Business Convertible Preferred units outstanding Limited Liability Company (LLC) Preferred Unit, Outstanding U.S. Treasuries US Treasury Securities [Member] Rent expense Operating Leases, Rent Expense Operating Leases, Rent Expense, Total Two Thousand And Twenty One Employee Stock Purchase Plan [Member] Two Thousand And Twenty One Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Credit Facility [Axis] Novartis Agreement [Member] Novartis Agreement [Member] Novartis Agreement [Member] Forfeiture of restricted stock awards, Shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Aggregate Intrinsic Value, Granted (in thousands) Amount of accumulated difference between fair value of underlying shares on dates of grant and grant price on options granted (or share units converted) into shares. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value Service agreement term. Service Agreement Term Service agreement term Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Equity-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Weighted Average Exercise Price per Share, Outstanding, Beginning balance Weighted Average Exercise Price per Share, Outstanding, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock options, outstanding, weighted average exercise price International goverment Debt Security, Government, Non-US [Member] Restricted Cash Equivalents Restricted Cash Equivalents [Member] Restricted Cash Equivalents [Member] Asset Class [Axis] Common Unit Authorized Common units, authorized Common Unit, Authorized Exchanges of Paired Interests non-corresponding Class A Units of Rani LLC Exchanges Of Paired Interests And Non-Corresponding Class A Units Exchanges Of Paired Interests And Non-Corresponding Class A Units Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right- of- use asset obtained in exchange for new operating lease liabilities Measurement Frequency Measurement Frequency [Domain] Aggregate desired patent acquisition Aggregate desired patent acquisition Aggregate desired patent acquisition Level 3 Fair Value, Inputs, Level 3 [Member] Service agreement remaining term Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (in years) Subsequent Events [Text Block] Subsequent Events Share-Based Payment Arrangement [Member] Equity-Based Compensation Members' Deficit [Member] Members' Deficit. Members' Deficit [Member] Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Capital Unit, Class [Domain] Deferred Offering Costs Deferred offering costs Financial liabilities measured at fair value Liabilities, Fair Value Disclosure Total liabilities Liabilities, Fair Value Disclosure, Total Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities, Total Accrued expenses and other current liabilities XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 11, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Current Fiscal Year End Date --12-31 Â Entity Registrant Name RANI THERAPEUTICS HOLDINGS, INC. Â Entity Central Index Key 0001856725 Â Securities Act File Number 001-40672 Â Entity Tax Identification Number 86-3114789 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 2051 Ringwood Avenue Â Entity Address, City or Town San Jose Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 95131 Â City Area Code 408 Â Local Phone Number 457-3700 Â Title of 12(b) Security Class A common stock, par value $0.0001 per share Â Trading Symbol RANI Â Security Exchange Name NASDAQ Â Document Quarterly Report true Â Document Transition Report false Â Common Class A [Member] | Forecast [Member] Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 33,311,543 Common Class B [Member] | Forecast [Member] Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 23,977,139 Common Class C | Forecast [Member] Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 0 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 4,277 $ 5,864 Marketable securities 26,127 42,675 Prepaid expenses and other current assets 1,967 2,308 Total current assets 32,371 50,847 Property and equipment, net 5,496 6,105 Operating lease right-of-use asset 5,427 718 Other assets 246 246 Total assets 43,540 57,916 Current liabilities: Â Â Accounts payable 1,566 648 Accrued expenses and other current liabilities 1,867 1,726 Deferred revenue 600 0 Current portion of long-term debt 14,768 4,897 Current portion of operating lease liability 1,410 718 Total current liabilities 20,211 7,989 Long-term debt, less current portion 13,537 24,484 Operating lease liability, less current portion 4,017 0 Total liabilities 37,765 32,473 Commitments and contingencies (Note 11) Stockholders' equity: Â Â Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 0 0 Additional paid-in capital 97,067 85,762 Accumulated other comprehensive gain (loss) 8 (12) Accumulated deficit (93,960) (72,889) Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. 3,120 12,866 Non-controlling interest 2,655 12,577 Total stockholders' equity 5,775 25,443 Total liabilities and stockholders' equity 43,540 57,916 Common Class A [Member] Â Â Stockholders' equity: Â Â Common stock, value 3 3 Common Class B [Member] Â Â Stockholders' equity: Â Â Common stock, value 2 2 Common Class C Â Â Stockholders' equity: Â Â Common stock, value $ 0 $ 0 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name

Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MembersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification - Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 - Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification - Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock authorized 20,000,000 20,000,000 Preferred stock issued 0 0 Preferred stock outstanding 0 0 Common Class A [Member] Â Â Common stock par value $ 0.0001 $ 0.0001 Common stock shares authorized 800,000,000 800,000,000 Common stock shares issued 29,807,000 26,036,000 Common stock shares outstanding 29,807,000 26,036,000 Common Class B [Member] Â Â Common stock par value $ 0.0001 $ 0.0001 Common stock shares authorized 40,000,000 40,000,000 Common stock shares issued 24,116,000 24,116,000 Common stock shares outstanding 24,116,000 24,116,000 Common Class C [Member] Â Â Common stock par value $ 0.0001 $ 0.0001 Common stock shares authorized 20,000,000 20,000,000 Common stock shares issued 0 0 Common stock shares outstanding 0 0 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification - Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses Â Â Â Â Research and development $ 6,172 $ 11,220 $ 19,872 $ 32,018 General and administrative 5,627 6,635 18,484 20,647 Total operating expenses 11,799 17,855 38,356 52,665 Loss from operations (11,799) (17,855) (38,356) (52,665) Other income (expense), net Â Â Â Â Interest income and other, net 414 839 1,403 2,626 Interest expense and other, net (1,337) (1,316) (3,909) (3,789) Net loss (12,722) (18,332) (40,862) (53,828) Net loss attributable to non-controlling interest (5,939) (9,135) (19,791) (26,956) Net loss attributable to Rani Therapeutics Holdings, Inc. $ (6,783) $ (9,197) $ (21,071) $ (26,872) Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic $ (0.24) $ (0.36) $ (0.78) $ (1.06) Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., diluted $ (0.24) $ (0.36) $ (0.78) $ (1.06) Weighted-average share outstanding basic 28,836 25,552 27,071 25,380 Weighted-average share outstanding diluted 28,836 25,552 27,071 25,380 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 - Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 - Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification - Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification - Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification - Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 - Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -

Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). + ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (12,722) $ (18,332) $ (40,862) $ (53,828) Other comprehensive loss Â Â Â Â Net unrealized gain on marketable securities 24 45 37 64 Comprehensive loss (12,698) (18,287) (40,825) (53,764) Comprehensive loss attributable to non-controlling interest (5,928) (9,113) (19,774) (26,924) Comprehensive loss attributable to Rani Therapeutics Holdings, Inc. $ (6,770) $ (9,174) $ (21,051) $ (26,840) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Class A [Member] Common Class B [Member] Common [Member] Common Class A [Member] Common [Member] Common Class B [Member] Additional Paid in Capital [Member] Noncontrolling Interest [Member] Accumulated Other Comprehensive Loss Member Accumulated Deficit [Member] Beginning Balance at Dec. 31, 2022 $ 74,004 Â Â $ 3 $ 2 $ 75,842 $ 37,149 $ (73) $ (38,919) Beginning Balance (shares) at Dec. 31, 2022 Â Â Â 25,295,000 24,116,000 Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 81,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount (124) Â Â Â Â (124) Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â 98 (98) Â Â Stock-based compensation 4,415 Â Â Â Â 2,202 2,213 Â Â Other comprehensive loss 126 Â Â Â Â Â 63 63 Â Net loss (16,832) Â Â Â Â Â (8,460) Â (8,372) Ending Balance at Mar. 31, 2023 61,589 Â Â $ 3 $ 2 78,018 30,867 (10) (47,291) Ending Balance (shares) at Mar. 31, 2023 Â Â Â 25,376,000 24,116,000 Â Â Â Â Beginning Balance at Dec. 31, 2022 74,004 Â Â $ 3 $ 2 75,842 37,149 (73) (38,919) Beginning Balance (shares) at Dec. 31, 2022 Â Â Â 25,295,000 24,116,000 Â Â Â Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value 80 Â Â Â Â Â Â Â Â Net loss (53,828) Â Â Â Â Â Â Â Â Ending Balance at Sep. 30, 2023 34,819 Â Â $ 3 $ 2 83,380 17,266 (41) (65,791) Ending Balance (shares) at Sep. 30, 2023 Â Â Â 25,876,000 24,116,000 Â Â Â Â Beginning Balance at Mar. 31, 2023 61,589 Â Â $ 3 $ 2 78,018 30,867 (10) (47,291) Beginning Balance (shares) at Mar. 31, 2023 Â Â Â 25,376,000 24,116,000 Â Â Â Â Issuance of common stock under employee stock purchase plan, net of shares withheld for tax settlement (Shares) Â Â Â 63,000 Â Â Â Â Â Issuance of common stock under employee stock purchase plan 219 Â Â Â Â 219 Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 78,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount (9) Â Â Â Â (9) Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â (54) 54 Â Â Stock-based compensation 5,141 Â Â Â Â 2,572 2,569 Â Â Other comprehensive loss (107) Â Â Â Â Â (54) (53) Â Net loss (18,664) Â Â Â Â Â (9,361) Â (9,303) Ending Balance at Jun. 30, 2023 48,169 Â Â $ 3 $ 2 80,746 24,075 (63) (56,594) Ending Balance (shares) at Jun. 30, 2023 Â Â Â 25,517,000 24,116,000 Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 319,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount (29) Â Â Â Â (29) Â Â Â Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Â Â Â 42,000 Â Â Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â 159 (159) Â Â Forfeiture of restricted stock awards (12) Â Â Â Â Â (6) (6) Â Â Forfeiture of restricted stock awards, Shares Â Â Â (2,000) Â Â Â Â Â Â Stock-based compensation 4,978 Â Â Â Â 2,510 2,468 Â Â Other comprehensive loss 45 Â Â Â Â Â Â 23 22 Â Net loss (18,332) Â Â Â Â Â Â (9,135) Â (9,197) Ending Balance at Sep. 30, 2023 34,819 Â Â $ 3 $ 2 83,380 17,266 (41) (65,791) Ending Balance (shares) at Sep. 30, 2023 Â Â Â 25,876,000 24,116,000 Â Â Â Â Beginning Balance at Dec. 31, 2023 25,443 Â Â $ 3 $ 2 85,762 12,577 (12) (72,889) Beginning Balance (shares) at Dec. 31, 2023 Â Â 26,036,000 24,116,000 26,036,000 24,116,000 Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 175,000 Â Â Â Â Â Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC Â Â Â 83,000 Â Â Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â 45 (45) Â Â Stock-based compensation 3,870 Â Â Â Â 1,969 1,901 Â Â Other comprehensive loss 1 Â Â Â Â Â Â 1 Â Net loss (14,779) Â Â Â Â Â (7,296) Â (7,483) Ending Balance at Mar. 31, 2024 14,535 Â Â $ 3 $ 2 87,776 7,137 (11) (80,372) Ending Balance (shares) at Mar. 31, 2024 Â Â Â 26,294,000 24,116,000 Â Â Â Â Beginning Balance at Dec. 31, 2023 25,443 Â Â $ 3 $ 2 85,762 12,577 (12) (72,889) Beginning Balance (shares) at Dec. 31, 2023 Â 26,036,000 24,116,000 26,036,000 24,116,000 Â Â Â Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value 99 Â Â Â Â Â Â Â Â Net loss (40,862) Â Â Â Â Â Â Â Â Ending Balance at Sep. 30, 2024 5,775 Â Â $ 3 $ 2 97,067 2,655 8 (93,960) Ending Balance (shares) at Sep. 30, 2024 Â 29,807,000 24,116,000 29,807,000 24,116,000 Â Â Â Â Beginning Balance at Mar. 31, 2024 14,535 Â Â $ 3 $ 2 87,776 7,137 (11) (80,372) Beginning Balance (shares) at Mar. 31, 2024 Â Â Â 26,294,000 24,116,000 Â Â Â Â Issuance of common stock under employee stock purchase plan, net of shares withheld for tax settlement (Shares) Â Â Â 110,000 Â Â Â Â Â Issuance of common stock under employee stock purchase plan 221 Â Â Â Â 221 Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 85,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount 14 Â Â Â Â 14 Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â (108) 108 Â Â Stock-based compensation 4,129 Â Â Â Â 2,109 2,020 Â Â Other comprehensive loss 12 Â Â Â Â Â 6 6 Â Net loss (13,361) Â Â Â Â Â (6,556) Â (6,805) Ending Balance at Jun. 30, 2024 5,550 Â Â $ 3 $ 2 90,012 2,715 (5) (87,177) Ending Balance (shares) at Jun. 30, 2024 Â Â Â 26,489,000 24,116,000 Â Â Â Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value 8,883 Â Â Â Â 8,883 Â Â Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Shares Â Â Â 2,800,000 Â Â Â Â Â Exercise of pre-funded warrants Â Â Â 447,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares Â Â Â 71,000 Â Â Â Â Â Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount (1) Â Â Â Â (1) Â Â Â Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC Â Â Â Â Â (4,010) 4,010 Â Â Stock-based compensation 4,041 Â Â Â Â 2,183 1,858 Â Â Other comprehensive loss 24 Â Â Â Â Â 11 13 Â Net loss (12,722) Â Â Â Â Â (5,939) Â (6,783) Ending Balance at Sep. 30, 2024 $ 5,775 Â Â $ 3 $ 2 $ 97,067 $ 2,655 $ 8 $ (93,960) Ending Balance (shares) at Sep. 30, 2024 Â 29,807,000 24,116,000 29,807,000 24,116,000 Â Â Â Â X - DefinitionIssuance Of Common Stock For Exercise Of Prefund Warrants Shares + ReferencesNo definition available. + Details Name: rani_IssuanceOfCommonStockForExerciseOfPrefundWarrantsShares Namespace Prefix: rani_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of Common Stock in Connection With the Stock Purchase Agreement, Net of Issuance Costs + ReferencesNo definition available. + Details Name: rani_IssuanceOfCommonStockInConnectionWithTheStockPurchaseAgreementNetOfIssuanceCosts Namespace Prefix: rani_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of other increase (decrease) in additional paid in capital (APIC). + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary

equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) $ in Thousands 3 Months Ended Sep. 30, 2024 USD ($) Stock issuance costs $ 1,117 X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net loss $ (40,862) $ (53,828) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation expense 12,040 14,522 Depreciation and amortization 762 595 Non-cash operating lease expense 1,332 780 Amortization of debt discount and issuance costs 174 174 Net accretion and amortization of investments in marketable securities (940) (1,851) Loss on disposal of property and equipment 65 0 Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets 341 (66) Accounts payable 918 68 Accrued expenses and other current liabilities 61 1,628 Deferred revenue 600 0 Operating lease liabilities (1,332) (780) Net cash used in operating activities (26,841) (38,758) Cash flows from investing activities Â Â Proceeds from maturities of marketable securities 57,250 81,500 Purchases of marketable securities (39,725) (63,852) Purchases of property and equipment (237) (1,062) Net cash provided by investing activities 17,288 16,586 Cash flows from financing activities Â Â Proceeds from issuance of common stock and pre-funded warrants in connection with the July Securities Purchase Agreement, net of issuance costs of $1,117 8,883 0 Issuance of common stock under employee stock purchase plan 221 219 Proceeds from employee stock purchase plan 99 80 Exercise of options 51 0 Tax withholdings paid on behalf of employees for net share settlement (38) (162) Repayment of debt (1,250) 0 Net cash provided by financing activities 7,966 137 Net decrease in cash, cash equivalents and restricted cash equivalents (1,587) (22,035) Cash, cash equivalents and restricted cash equivalents, beginning of period 6,364 27,507 Cash, cash equivalents and restricted cash equivalents, end of period 4,777 5,472 Supplemental disclosures of non-cash investing and financing activities Â Â Right- of- use asset obtained in exchange for new operating lease liabilities 4,731 0 Remeasurement of operating lease right-of-use assets 589 578 Exchanges of Paired Interests non-corresponding Class A Units of Rani LLC 298 169 Interest income receivable included in prepaid expenses and other current assets 29 188 Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities $ 0 $ 250 X - DefinitionExchanges Of Paired Interests And Non-Corresponding Class A Units + ReferencesNo definition available. + Details Name: rani_ExchangesOfPairedInterestsAndNonCorrespondingClassAUnits Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from Issuance of common stock under the employee stock purchase plan + ReferencesNo definition available. + Details Name: rani_ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRemeasurement of operating lease right-of-use assets + ReferencesNo definition available. + Details Name: rani_RemeasurementOfOperatingLeaseRightOfUseAssets Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpenditureIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but

are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands Sep. 30, 2024 USD ($) Securities Purchase Agreement [Member] Â Net of issuance costs $ 1,117 X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=rani_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (6,783) $ (9,197) $ (21,071) $ (26,872) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Nature of Business 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization and Nature of Business 1. Organization and Nature of Business Description of Business Rani Therapeutics Holdings, Inc. (â€œRani Holdingsâ€, and together with its consolidated subsidiary, the â€œCompanyâ€) is a clinical-stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Companyâ€™s technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The Company is advancing a portfolio of oral therapeutics using the RaniPill capsule. The Company is headquartered in San Jose, California and operates in one segment.OrganizationRani Holdings was formed as a Delaware corporation in April 2021 for the purpose of facilitating an initial public offering (â€œIPOâ€) of its Class A common stock. In connection with the IPO, the Company effected a series of organizational transactions (the â€œOrganizational Transactionsâ€), which, together with the IPO, were completed in August 2021, that resulted in the Company becoming the ultimate parent company of Rani Therapeutics, LLC (â€œRani LLCâ€). The Company operates its business through Rani LLC.As part of the Organizational Transactions, the Company entered into a Registration Rights Agreement with certain individuals and entities that continued to hold economic nonvoting Class A units of Rani LLC (â€œClass A Unitsâ€), collectively referred to herein as the â€œContinuing LLC Ownersâ€. The Continuing LLC Owners are entitled to exchange, subject to the terms of the Fifth Amended and Restated Limited Liability Company Agreement of Rani LLC (the â€œRani LLC Agreementâ€), the Class A Units they hold in Rani LLC, together with the shares they hold of the Company Class B common stock (together referred to as a "Paired Interest"), in return for shares of the Companyâ€™s Class A common stock on a one-for-one basis provided that, at the Companyâ€™s election, the Company has the ability to effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. Any shares of Class B common stock will be canceled on a one-for-one basis if, at the election of the Continuing LLC Owners, the Company redeems or exchanges such Paired Interest pursuant to the terms of the Rani LLC Agreement. As of September 30, 2024, certain individuals who continue to own interests in Rani LLC but do not hold shares of the Companyâ€™s Class B common stock (â€œnon-corresponding Class A Unitsâ€) have the ability to exchange their non-corresponding Class A Units of Rani LLC for

1,261,690 shares of the Companyâ€™s Class A common stock.Liquidity The Company has incurred recurring losses since its inception, including net losses of $40.9 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had an accumulated deficit of $94.0 million and for the nine months ended September 30, 2024, had negative cash flows from operations of $26.8 million. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $30.4 million. Based on its available cash resources and current operating plan, there is substantial doubt regarding the Companyâ€™s ability to continue as a going concern for a period of one year after the date that its financial statements for the nine months ended September 30, 2024 are issued. The Companyâ€™s existing capital resources, including the issuance and sale of Class A common stock and warrants pursuant to a securities purchase agreement with an institutional investor in July 2024, will not be sufficient to enable it to initiate any pivotal clinical trials. The Company will need to raise substantial additional funds in the future in order to complete the development of the RaniPill platform, to complete the clinical development of its product candidates and seek regulatory approval thereof, to expand its manufacturing capabilities, to further develop the RaniPill HC device and to commercialize any of its product candidates.In July 2024, the Company entered into a securities purchase agreement (the â€œJuly Securities Purchase Agreementâ€) with an institutional investor relating to the issuance and sale of: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock (the â€œJuly Offeringâ€). The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In August 2022, the Company entered into a Controlled Equity Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (collectively the "Agents"), pursuant to which the Company may offer and sell from time to time through the Agents up to $150 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company has no sales under the Sales Agreement.The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues to develop the RaniPill capsule. The Company expects to finance its future operations with its existing cash and through strategic financing opportunities that could include, but are not limited to, future offerings of its equity, such as â€œat the market offeringsâ€ as defined in Rule 415(a)(4) under the Securities Act, collaboration or licensing agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all. As a result, the Company has concluded that managementâ€™s plans do not alleviate substantial doubt about the Companyâ€™s ability to continue as a going concern.Subsequent to September 30, 2024, the Company completed an additional equity offering with the aggregate gross proceeds of approximately $10.0 million, before deducting placement agent fees and other estimated offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of certain warrants issued in the offering (Note 16). The proceeds received do not alleviate substantial doubt about the Companyâ€™s ability to continue as a going concern. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). Certain prior period amounts have been reclassified to be consistent with current period presentation.The Company operates and controls all of the business and affairs of Rani LLC and, through Rani LLC conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation.Â Unaudited Interim Condensed Consolidated Financial StatementsThe accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (â€œSECâ€). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any future period.The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 20, 2024.Â Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Companyâ€™s condensed consolidated financial statements and accompanying notes. The Company evaluates its estimates on an ongoing basis. The Company bases its estimates on its historical experience and also on assumptions that we believe are reasonable; however, actual results may differ materially and adversely from these estimates.Â Significant Accounting PoliciesA description of the Companyâ€™s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except as noted below, there have been no material changes in the Companyâ€™s significant accounting policies during the nine months ended September 30, 2024.Cash, Cash Equivalents and Restricted Cash EquivalentsThe following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023: Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â End of Period: Â Â Â Â Â Â Cash and cash equivalents Â $ 4,277 Â Â $ 4,972 Â Restricted cash equivalents Â Â 500 Â Â Â 500 Â Total cash, cash equivalents and restricted cash equivalents Â $ 4,777 Â Â $ 5,472 Â Collaborative ArrangementsThe Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents amounts due from its collaboration partner as a reduction of research and development expense based on the nature of such payments.Revenue RecognitionThe Company primarily generates revenue from evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partnerâ€™s drug molecules using the RaniPill platform technology (Note 6).Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.The majority of the Companyâ€™s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Variable consideration has not been material to our condensed consolidated financial statements. Consistent with the Company's policies and practices as described above, the Company recognizes contract revenue from its evaluation arrangements using a cost-based input method, which most faithfully depicts the transfer of the performance obligation to the customer. Accordingly, the Company will recognize contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expects to incur to deliver its performance obligation. These actual costs consist of the internal labor efforts, in vivo testing services and materials costs related to the agreement, as the costs incurred over time will reflect the transfer of its performance obligations to the customer. The cumulative effect of revisions to estimated costs to complete the Companyâ€™s performance obligation will be recorded in the period in which changes are identified and amounts are reasonably estimable. Such costs are expensed when incurred and are included as a component of research and development expenses in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss.Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date, none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred.Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2024 or December 31, 2023.Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services (Note 6). There was no deferred revenue as of December 31, 2023.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Cash Equivalents, Restricted Cash Equivalents and Marketable Securities 3. Cash Equivalents, Restricted Cash Equivalents and Marketable SecuritiesThe following tables summarizes the amortized cost and fair value of the Company's cash equivalents, restricted cash equivalents and marketable securities by major investment category (in thousands):Â Â Â As of September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â Current assets: Â Â Â Â Â Â

Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 4. Fair Value Measurements The following tables detail information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of inputs used in such measurements (in thousands): Â Â As of September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,090 Â Â $ â€” Â Â $ â€” Â Â $ 2,090 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 26,127 Â Â Â â€” Â Â Â â€” Â Â Â 26,127 Â Total assets Â $ 28,717 Â Â $ â€” Â Â $ â€” Â Â $ 28,717 Â Â Â Â As of December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 3,339 Â Â $ â€” Â Â $ â€” Â Â $ 3,339 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 35,495 Â Â Â â€” Â Â Â â€” Â Â Â 35,495 Â Corporate debt securities Â Â â€” Â Â Â 1,963 Â Â Â Â â€” Â Â Â 1,963 Â Commercial paper Â Â â€” Â Â Â 5,217 Â Â Â Â â€” Â Â Â 5,217 Â Total assets Â $ 39,334 Â Â $ 7,180 Â Â $ â€” Â Â $ 46,514 Â Â Level 1 and Level 2 financial instruments are comprised of investments in money market funds and fixed-income securities. The Company estimates the fair value of its Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.There were no transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy for any of the periods presented. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities 9 Months Ended Sep. 30, 2024 Accrued Liabilities [Abstract] Â Accrued Expenses and Other Current Liabilities 5. Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accrued interest Â $ 823 Â Â $ 500 Â Payroll and related costs Â Â 324 Â Â Â 313 Â Accrued rent Â Â 317 Â Â Â â€” Â Accrued professional fees Â Â 190 Â Â Â 235 Â Accrued preclinical and clinical trial costs Â Â 30 Â Â Â 424 Â Other Â Â 183 Â Â Â 254 Â Total accrued expenses and other current liabilities Â $ 1,867 Â Â $ 1,726 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative and Evaluation Arrangements 9 Months Ended Sep. 30, 2024 Business Combinations [Abstract] Â Collaborative and Evaluation Arrangements 6. Collaborative and Evaluation ArrangementsProGen Co., Ltd.In June 2024, the Company and ProGen Co., Ltd. (â€œProGenâ€) entered into a Collaboration Agreement (the â€œCollaboration Agreementâ€). Under the Collaboration Agreement, the Company and ProGen will collaborate to manufacture, develop, seek regulatory approvals for and, if approved, commercialize a product (the â€œProductâ€) combining ProGenâ€™s GLP-1/GLP-2 dual agonist compound, PG-102, and the RaniPill HC oral delivery device (the â€œDeviceâ€) in the field of weight management (including without limitation obesity, weight reduction and weight maintenance) in humans (the â€œCollaborationâ€).Under the Collaboration Agreement, development costs, as well as operating profits and losses from the commercialization of the Product, will be equally shared by the Company and ProGen. The Company and ProGen each granted to the other party an exclusive right and license (except with respect to the other partyâ€™s affiliates and sublicensees) to certain intellectual property to develop the Product for weight management and an exclusive right and license to seek regulatory approval for, and to use, sell, offer to sell, import and commercialize the Product in their assigned territories. The Company will lead the development of the Product in the United States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development in all other countries.Each party has the right to opt-out of the Collaboration (â€œOpt-Outâ€) at any time upon prior written notice to the other party. Following an Opt-Out, the continuing party shall have sole right to develop, conduct regulatory activities for and commercialize the Product on a worldwide basis. The Opt-Out party shall share all development costs and operating profit (or loss) through the effective date of the Opt-Out, and all costs to complete the conduct of any clinical trials of Product that have been initiated prior to delivery of the Opt-Out notice, even if the costs are incurred or the trials are completed after the effective date of the Opt-Out. The continuing party shall pay to the Opt-Out party low single to mid-single digit royalties on net sales of the Product made after the Opt-Out date depending on when the Opt-Out occurs.The Company determined that the Collaboration Agreement is not a contract with a customer and is therefore accounted for under ASC Topic 808. The Company evaluates the presentation of amounts due from ProGen based on the nature of each separate activity. Reimbursements from ProGen are recognized as contra-research and development expense on the Consolidated Statement of Operations once earned and collectability is assured. As of September 30, 2024, no reimbursement has been received from or billed by ProGen nor recorded as contra-research and development expense.Evaluation ArrangementIn August 2024, the Company entered into a contract to conduct evaluation services of certain customer compounds for oral delivery using the RaniPill HC. This customer paid the Company an up-front payment of $0.6 million upon execution of the contract. Upon completion of the evaluation services, the Company is entitled to a final $0.6 million payment for an aggregate total of $1.2 million due under the contract. In addition, if agreed upon, the agreement allows for joint filing of certain intellectual property protection in which all associated expenses will be shared equally. The customer has the ability to terminate the agreement at any time by providing 10 daysâ€™ written notice after the effective date of the contract. The contract can be terminated for cause by either party based on uncured material breach by the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate.The Company identified one material promise under the contract, the obligation to perform services to evaluate if the customers compounds can be orally delivered using the RaniPill HC, which was concluded to be a single performance obligation. For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in August 2024 and will end the sooner of the contractual 1-year term or upon the completion of the evaluation services. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For the nine months ended September 30, 2024, no contract revenue was recognized for evaluation services performed. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services. There was no deferred revenue as of December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions 7. Related Party Transactions InCube Labs, LLC (â€œICLâ€) is wholly-owned by the Companyâ€™s founder and Chairman and his family. The founder and Chairman is the father of the Companyâ€™s Chief Executive Officer. The Companyâ€™s Chief Scientific Officer is also the brother of the founder and Chairman and thus uncle of the Companyâ€™s Chief Executive Officer. Service Agreements In June 2021, Rani LLC entered into a service agreement with ICL effective retrospectively to January 1, 2021, and subsequently amended such agreement in March 2022 (as amended, the "Rani LLC-ICL Service Agreement"), pursuant to which Rani LLC and ICL agreed to provide personnel services to the other upon requests. Under the amendment in March 2022, Rani LLC has a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas (â€œOccupancy Servicesâ€) for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022, and the Occupancy Services in San Antonio, Texas continue until either party gives six monthsâ€™ notice of termination. Except for the Occupancy Services, Rani LLC or ICL may terminate services under the Rani LLC-ICL Service Agreement upon 60 days' notice to the other party. The Rani LLC-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively. In December 2023, Rani LLC provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024.In June 2021, Rani Management Services, Inc. (â€œRMSâ€) entered into a service agreement with ICL effective retrospectively to January 1, 2021, pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. In April 2022, RMS assigned the agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000 square feet to 24,000 square feet (such agreement, as assigned and amended, the â€œRMS-ICL Service Agreementâ€). The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated. Rani LLC or ICL may terminate services under the RMS-ICL Service Agreement upon 60 days' notice to the other party, except for occupancy which requires six monthsâ€™ notice. The RMS-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively, as well as allocations of expenses based upon Rani LLCâ€™s utilization of ICLâ€™s facilities and equipment.The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 201 Â Â $ 280 Â Â $ 768 Â Â $ 889 Â General and administrative Â Â 41 Â Â Â 87 Â Â Â 187 Â Â Â 220 Â Total Â $ 242 Â Â $ 367 Â Â $ 955 Â Â $ 1,109 Â As of September 30, 2024, one of the Company's facilities was owned by an entity affiliated with the Companyâ€™s Chairman (Note 8). The Company pays for the use of this facility through the RMS-ICL Service Agreement. Â Exclusive License, Intellectual Property and Common Unit Purchase AgreementIn June 2021, ICL and the Company, through Rani LLC, entered into an Amended and Restated Exclusive License Agreement which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013. Under the Amended and Restated Exclusive License Agreement, the Company has a fully paid, exclusive license under certain scheduled patents related to optional features of the device and certain other scheduled patents to exploit products covered by those patents in the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. The Company covers patent-related expenses and, after a certain period, the Company will have the right to acquire four specified United States patent families from ICL by making a one-time payment of $0.3 million to ICL for each United States patent family that the Company desires to acquire, up to $1.0 million in the aggregate. This payment will not become an obligation until

the fifth anniversary of the Amended and Restated Exclusive License Agreement. The Amended and Restated Exclusive License Agreement will terminate when there are no remaining valid claims of the patents licensed under the Amended and Restated Exclusive License Agreement. Additionally, the Company may terminate the Amended and Restated Exclusive License Agreement in its entirety or as to any particular licensed patent upon notification to ICL of such intent to terminate.Â Non-Exclusive License Agreement between Rani and ICL (â€œNon-Exclusive License Agreementâ€)In June 2021, the Company, through Rani LLC, entered into the Non-Exclusive License Agreement with ICL a related party, pursuant to which the Company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to the Company. Additionally, the Company agreed not to license these patents to a third party in a specific field outside the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine, if ICL can prove that it or its sublicensee has been in active development of a product covered by such patents in that specific field. ICL may grant sublicenses under this license to third parties only with the Companyâ€™s prior approval. The Non-Exclusive License Agreement will continue in perpetuity unless earlier terminated.Â Intellectual Property Agreement with Mir Imran (the â€œMir Agreementâ€)In June 2021, the Company, through Rani LLC, entered into the Mir Agreement, pursuant to which the Company and Mir Imran agreed that the Company would own all intellectual property conceived (i) using any of the Companyâ€™s people, equipment, or facilities or (ii) that is within the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. Neither the Company nor Mir Imran may assign the Mir Agreement to any third party without the prior written consent of the other party. The initial term of the Mir Agreement was three years, which could be extended upon mutual consent of the parties. In June 2024, the parties agreed to extend the term of the Mir Agreement by ninety (90) days. The Mir Agreement expired in September 2024. Expiration of the Mir Agreement does not affect the assignment to, and ownership by, the Company of intellectual property conceived during the term of the Mir Agreement.Â Tax Receivable AgreementCertain parties to the tax receivable agreement ("TRA"), entered into in August 2021 pursuant to the IPO and Organizational Transactions are related parties of the Company. The TRA provides that the Company pay to ICL and the other Continuing LLC Owners 85% of the amount of tax benefits, if any, it is deemed to realize from exchanges of Paired Interests. During each of the nine months ended September 30, 2024 and 2023, these parties to the TRA exchanged zero Paired Interests that resulted in tax benefits subject to the TRA.Â Registration Rights AgreementIn connection with the IPO, the Company entered into a Registration Rights Agreement. ICL and its affiliates are parties to this agreement. The Registration Rights Agreement provides certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, ICL and its affiliates can require the Company to register under the Securities Act of 1933, as amended (the â€œSecurities Actâ€) shares of Class A common stock issuable to ICL and its affiliates upon, at the Companyâ€™s election, redemption or exchange of their Paired Interests. The Registration Rights Agreement also provides for piggyback registration rights. In March 2022, certain holders of the Company's Class A common stock considered to be related parties were made parties to the Registration Rights Agreement. As a result of certain stockholders exercising their registration rights under the Registration Rights Agreement, in December 2022, the Company filed a registration statement on Form S-3 to register 6,009,542 shares of Class A common stock of the Company held by certain of its stockholders.Rani LLC AgreementThe Company operates its business through Rani LLC. In connection with the IPO, the Company and the Continuing LLC Owners, including ICL and its affiliates, entered into the Rani LLC Agreement. The governance of Rani LLC, and the rights and obligations of the holders of LLC Interests, are set forth in the Rani LLC Agreement. As Continuing LLC Owners, ICL and its affiliates are entitled to exchange, subject to the terms of the Rani LLC Agreement, Paired Interests for Class A common stock of the Company; provided that, at the Companyâ€™s election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. During each of the nine months ended September 30, 2024 and 2023, certain related parties that are party to the Rani LLC Agreement exchanged zero Paired Interests for an equal number of shares of the Company's Class A common stock. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases 8. LeasesIn November 2023, Rani LLC and BKM South Bay 240, LLC (â€œLandlordâ€) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the â€œLeaseâ€). Pursuant to the terms of the Lease, Rani LLC is leasing approximately 33,000 square feet of space in Fremont, California, which is part of a two-building project (the â€œProjectâ€). The initial term of the Lease commenced in February 2024, and the duration of the initial term is 63 months. Subject to certain conditions, Rani LLC has an option to renew the Lease for one additional 5-year term at the then-prevailing market rate. The monthly base rent for the initial term of the Lease is approximately $95,000 per month, subject to a 4% increase each year. Rani LLC is also responsible for the payment of additional rent to cover its share of common area operating expenses, including taxes, insurance, utilities, and repair and maintenance of the premises and common areas of the Project.The Company pays for the use of its office, laboratory and manufacturing facility in San Jose, California as part of the RMS-ICL Service Agreement. In April 2022, RMS assigned the RMS-ICL Service Agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000 square feet to 24,000 square feet. The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless Rani LLC or ICL terminate occupancy under the RMS-ICL Service Agreement upon six monthsâ€™ notice. In January 2024, the Company determined it to be reasonably certain that it would exercise its renewal option for a successive twelve-month period through 2025. The Company accounted for the renewal option as a lease modification that did not result in a separate contract and recognized the additional right-of-use asset and corresponding lease liabilities associated with the Rani LLC-ICL Service Agreement in its condensed consolidated balance sheet.Under the Rani LLC-ICL Service Agreement amended in March 2022, Rani LLC had a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for a successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022. The Company accounted for the lease extension as a lease modification that did not result in a separate contract and recognized the right-of-use asset and lease liabilities associated with the Rani LLC-ICL Service Agreement in the consolidated balance sheet as of the modification date in July 2022. In December 2023, the Company provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024.The Company's leases are accounted for as operating leases and require certain fixed payments of real estate taxes and insurance in addition to future minimum lease payments, and certain variable payments of common area maintenance costs and building utilities. Variable lease payments are expensed in the period in which the obligation for those payments is incurred. These variable lease costs are payments that vary in amount beyond the commencement date, for reasons other than passage of time. Variable lease payments are excluded in the total operating lease expense and immaterial for the periods presented.Supplemental information on the Companyâ€™s condensed consolidated balance sheet and statements of cash flows as of September 30, 2024 and 2023 and for the nine months ended September 30, 2024 and 2023, respectively, related to the Company's leases was as follows (in thousands):Â Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Weighted-average remaining lease term (in years) Â Â 4.1 Â Â Â 1.1 Â Weighted-average discount rate Â Â 10.4 % Â Â 10.4 % Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in lease liabilities: Â Â Â Â Â Â Operating cash flows used for operating leases Â $ 1,015 Â Â $ 780 Â As of September 30, 2024, minimum annual rental payments under the Companyâ€™s operating lease agreements are as follows (in thousands), excluding short-term leases: Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 465 Â 2025 Â Â 1,902 Â 2026 Â Â 1,229 Â 2027 Â Â 1,278 Â 2028 Â Â 1,330 Â 2029 Â Â 458 Â Total undiscounted future minimum lease payments Â $ 6,662 Â Less: Imputed interest Â Â (1,235) Total operating lease liability Â $ 5,427 Â Less: Current portion of operating lease liability Â Â 1,410 Â Operating lease liability, net current portion Â $ 4,017 Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â Warrants 9. WarrantsIn July 2024, as part of the July Offering, the Company issued (i) pre-funded warrants to purchase 446,753 shares of Class A common stock, (ii) Series A common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock and (iii) Series B common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock. The pre-funded warrants are exercisable immediately and have an unlimited term and an exercise price of $0.0001 per share. The Series A Warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire 18 months following the date of issuance and will have an exercise price of $3.08 per share. The Series B warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire five and a half years from the date of issuance and will have an exercise price of $3.08 per share. The Series A warrants and Series B warrants include certain rights upon â€œfundamental transactions,â€ as described in the Series A warrants and Series B warrants, including in the Series B warrants the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series B warrants) of the unexercised portion of the applicable Series B warrants on the date of the consummation of the fundamental transactions. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. As of September 30, 2024, there were 3,246,753 Series A warrants and 3,246,753 Series B warrants outstanding. Subsequent to September 30, 2024, the Series A warrants were canceled (Note 16). In August 2022, in conjunction with a loan and security agreement (Note 13), the Company issued warrants to purchase 76,336 shares of the Company's Class A common stock. The warrants are exercisable for a period of five years from the grant date, as may be adjusted for certain anti-dilution adjustments, dividends, stock splits, and reverse stock splits, at an exercise price per share equal to $11.79, which may be net share settled at the option of the holder. As of September 30, 2024, there were 76,336 warrants outstanding. X - DefinitionThe entire disclosure of warrants. + ReferencesNo definition available. + Details Name: rani_WarrantsTextBlock Namespace Prefix: rani_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Equity 10. Stockholdersâ€™ EquityAs of September 30, 2024, Rani Holdings held approximately 54% of the Class A Units of Rani LLC, and approximately 46% of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. From the date of the Organizational Transactions to September 30, 2024, 5,173,947 Paired Interests and 283,832 non-corresponding Class A Units of Rani LLC were exchanged for an equal number of shares of the Company's Class A common stock. For each of the nine months ended September 30, 2024 and 2023, certain of the Continuing LLC Owners executed an exchange of zero Paired Interests and 83,377 and zero non-corresponding Class A Units of Rani LLC, respectively, in return for an equal number of shares of the Companyâ€™s Class A common stock. The corresponding shares of the Companyâ€™s Class B common stock included in the exchange of Paired Interests were subsequently canceled and retired pursuant to the terms of the Rani LLC Agreement. In accordance with the Rani LLC Agreement, Rani LLC also issues a corresponding Class A Unit to Rani Holdings for each share of common stock issued by Rani Holdings. This increases Rani Holdingsâ€™ ownership in Rani LLC.In July 2024, the Company closed the July Offering, pursuant to which it issued and sold: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock. The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In August 2022, the Company entered into the Sales Agreement with the Agents, pursuant to which the Company may offer and sell from time to time through the Agents up to $150.0 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company had no sales under the Sales Agreement. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Equity-Based Compensation 11. Stock-Based CompensationStock OptionsA summary of stock option activity during the periods indicated is as follows: Â Â Number of Stock Option Awards Â Â Weighted Average Exercise Price Â Â WeightedAverageRemaining Contractual Term (in years) Â Â Aggregate Intrinsic Value (in thousands) Â Balance at December 31, 2023 Â Â 6,639,811 Â Â $ 6.37 Â Â Â 8.48 Â Â $ 13,377 Â Granted Â Â 4,154,325 Â Â $ 3.74 Â Â Â 9.49 Â Â $ â€” Â Exercised Â Â (18,757) Â $ 2.72 Â Â Â Â Â Â Â Â Canceled Â Â (478,961) Â $ 5.36 Â Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 10,296,418 Â Â $ 5.36 Â Â Â 8.35 Â Â $ 25 Â Exercisable at September 30, 2024 Â Â 4,713,481 Â Â $ 7.62 Â Â Â 7.66 Â Â $ â€” Â Nonvested at September 30, 2024 Â Â 5,582,937 Â Â $ 3.46 Â Â Â 8.99 Â Â $ 25 Â As of September 30, 2024, there was $21.8 million of unrecognized stock-based compensation expense related to stock options which is expected to be recognized over a weighted-average period of approximately 2.8 years.Restricted Stock UnitsA summary of restricted stock unit (â€œRSUâ€) activity during the periods indicated is as follows: Â Â Number of Restricted Stock Units Â Â Weighted Average Grant-Date Fair Value per Share Â Balance at December 31, 2023 Â Â 1,276,111 Â Â $ 7.16 Â Vested Â Â (323,611) Â $ 7.69 Â Forfeited Â Â (59,206) Â $ 7.37 Â Balance at September 30, 2024 Â Â 893,294 Â Â $ 6.96 Â As of September 30, 2024, there was $5.6 million of unrecognized stock-based compensation expense related to RSUs which is expected to be recognized over a weighted-average period of approximately 2.3 years. The total fair value of RSUs vested was $1.0 million for the nine months ended September 30, 2024.Restricted Stock AwardsA summary of restricted stock award (â€œRSAâ€) activity during the periods indicated is as follows: Â Â Number of Restricted Stock Awards Â Â Weighted Average Grant-Date Fair Value per Share Â Balance at December 31, 2023 Â Â 33,586 Â Â $ 6.15 Â Vested Â Â (22,616) Â $ 6.14 Â Forfeited Â Â (218) Â $ 6.13 Â Balance at September 30, 2024 Â Â 10,752 Â Â $ 6.15 Â As of September 30, 2024, unrecognized stock-based compensation expense related to RSAs was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. The total fair value of RSAs vested was $0.1 million for the nine months ended September 30, 2024.Employee Stock Purchase PlanAs of September 30, 2024, unrecognized stock-based compensation expense related to the Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan (the â€œESPPâ€) was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. As of September 30, 2024, contributions withheld from employees totaled $0.1 million and are recorded as a component of accrued expenses and other current liabilities in the condensed consolidated balance sheet. Stock-Based Compensation ExpenseThe following table summarizes the components of stock-based compensation expense resulting from the grant of stock options, RSUs, RSAs, and the ESPP, recorded in the Companyâ€™s condensed consolidated statement of operations and comprehensive loss (in thousands): Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Research and development Â $ 3,563 Â Â $ 5,275 Â General and administrative Â Â 8,477 Â Â Â 9,247 Â Total stock-based compensation Â $ 12,040 Â Â $ 14,522 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 12. Commitments and Contingencies Legal Proceedings In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred.Tax Receivable AgreementThe Company is party to a TRA with certain of the Continuing LLC Owners. As of September 30, 2024, the Company has not recorded a liability under the TRA related to the income tax benefits originating from the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC as it is not probable that the Company will realize such tax benefits. To the extent the Company is able to realize the income tax benefits associated with the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC subject to the TRA, the TRA payable would range from zero to $23.1 million at September 30, 2024. The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the payment of the TRA liability becomes probable at a future date based on new information, any changes will be recorded on the Company's condensed consolidated statement of operations and comprehensive loss at that time. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Long-Term Debt 13. Long-Term DebtIn August 2022, the Company entered into a loan and security agreement and related supplement (the â€œLoan Agreementâ€) with Avenue Venture Opportunities Fund, L.P (the â€œLenderâ€). The Loan Agreement provides for term loans (the â€œLoansâ€) in an aggregate principal amount up to $45.0 million. A Loan of $30.0 million was committed at closing, with $15.0 million funded immediately and $15.0 million available to be drawn between October 1, 2022 and December 31, 2022, which was drawn in December 2022. The remaining $15.0 million of Loans was uncommitted and subject to certain conditions and is no longer available under the Loan Agreement. The purpose of the Loans is for general corporate purposes. In exchange for access to this facility, the Company agreed to issue warrants (Note 9).Pursuant to the Loan Agreement, the maturity date for the Loans is August 1, 2026 (the â€œMaturity Dateâ€). The Loan principal is repayable in equal monthly installments beginning September 2024. The Loans bear interest at a variable rate per annum equal to the greater of (A) the prime rate, as published by the Wall Street Journal from time to time plus 5.60% or (B) 10.35%. The Loan Agreement is collateralized by substantially all of the Companyâ€™s assets, in which the Lender is granted continuing security interests. The Loans includes customary events of default, including instances of a material adverse change in the Companyâ€™s operations, which may require prepayment of the outstanding Loans. At September 30, 2024, the effective interest rate on the Loans was 15.62% and there were no events of default during the nine months ended September 30, 2024. The Company is also subject to certain covenants. There have been no material adverse events in connection with the Loan Agreement and the substantial doubt regarding our ability to continue as a going concern does not currently constitute a material adverse event under the terms of the Loan Agreement. As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement.As of September 30, 2024, future principal payments for the Companyâ€™s debt are as follows (in thousands): Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 3,750 Â 2025 Â Â 15,000 Â 2026 Â Â 10,000 Â Total principal payments Â $ 28,750 Â Less: amount representing debt discount Â Â (445) Total long-term debt Â $ 28,305 Â Less: current portion of long-term debt Â Â 14,768 Â Total long-term debt, less current portion Â $ 13,537 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 14. Income Taxes The Companyâ€™s effective income tax rate was zero for each of the nine months ended September 30, 2024 and 2023. As a result of the exchanges from the date of the Organizational Transactions to September 30, 2024, the Company recorded a $18.9 million deferred tax asset related to income tax benefit associated with the basis of the net assets of Rani LLC. Because of the Companyâ€™s history of operating losses, the Company believes that recognition of the deferred tax assets arising from such future income tax benefits is currently not more-likely-than-not to be realized and, accordingly, has recognized a full valuation allowance on its deferred tax assets. There were no material changes to uncertain tax positions for the nine months ended September 30, 2024 and 2023, and the Company does not anticipate material changes within the next twelve months. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss Per Share 15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â 2023 Â Numerator: Â Â Â Â Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. Â $ (21,071) $ (26,872) Denominator: Â Â Â Â Â Weighted average Class A common share outstandingâ€”basic and diluted Â Â 27,071 Â Â 25,380 Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.â€”basic and diluted Â $ (0.78) $ (1.06) Â The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings (in thousands): Â Â As of September 30, Â Â Â 2024 Â 2023 Â Paired Interests Â Â 24,116 Â Â 24,116 Â Stock options Â Â 10,296 Â Â 6,778 Â Warrants Â Â 6,570 Â Â 76 Â Non-corresponding Class A Units Â Â 1,262 Â Â 1,345 Â Restricted stock units Â Â 893 Â Â 1,413 Â Shares issuable pursuant to the ESPP Â Â 41 Â Â 82 Â Restricted stock awards Â Â 11 Â Â 41 Â Â Â 43,189 Â Â 33,851 Â

Shares of Class B Common Stock do not share in the Companyâ€™s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. The outstanding shares of Class B Common Stock were determined to be anti-dilutive for the nine months ended September 30, 2024. Therefore, they are not included in the computation of net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events 16. Subsequent EventsSecurities Purchase AgreementIn October 2024, the Company entered into a securities purchase agreement (the â€œOctober Securities Purchase Agreementâ€) with an institutional investor (the â€œEquity Investorâ€) relating to the issuance and sale of: (i) 3,000,000 shares of its Class A common stock, par value $0.0001 per share, (ii) pre-funded warrants to purchase 333,333 shares of Class A common stock, and (iii) Series C common warrants, which will accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,333,333 shares of Class A common stock (the â€œOctober Offeringâ€). The October Offering closed on October 16, 2024. Pursuant to the October Securities Purchase Agreement, Series A common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock issued in the July Offering were cancelled.The pre-funded warrants are exercisable immediately following the closing date of the October Offering and have an unlimited term and an exercise price of $0.0001 per share. The Series C common warrants are exercisable immediately following the closing date of the October Offering, will expire five years from the date of issuance and will have an exercise price of $3.00 per share. The combined offering price is $3.00 per share of Class A common stock and accompanying Series C common warrant, or in the case of pre-funded warrants, $2.9999 per pre-funded warrant and accompanying Series C common warrant. The aggregate gross proceeds to the Company from the October Offering were approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of the Series C common warrants issued in the October Offering. In October 2024, the pre-funded warrants were fully exercised for de minimis proceeds. The Series C common warrants include certain rights upon â€œfundamental transactionsâ€ as described in the Series C common warrants. These rights upon â€œfundamental transactionsâ€ include the right of the holders thereof to receive from Rani or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series C common warrants) of the unexercised portion of the applicable Series C common warrants on the date of the consummation of such fundamental transaction.Pursuant to the terms of the October Securities Purchase Agreement, until 30 days following the closing of the October Offering, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Class A common stock or common stock equivalents, or file or amend any registration statement or prospectus, other than as necessary to maintain the registration of the securities offered thereby. The Company has further agreed not to enter into an agreement involving any new variable rate transactions until January 23, 2025, subject to certain exceptions. In addition, the Companyâ€™s directors and officers have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 30 days from the closing of the October Offering, offer, sell, transfer or otherwise dispose of the Companyâ€™s securities, subject to certain exceptions.CEO Compensation ReductionIn November 2023, the Companyâ€™s Board of Directors (â€œBoardâ€) approved a reduction in the annual salary of Talat Imran, the Companyâ€™s Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as the Company receives gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the â€œFinancing Thresholdâ€). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). Certain prior period amounts have been reclassified to be consistent with current period presentation.The Company operates and controls all of the business and affairs of Rani LLC and, through Rani LLC conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation. Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Financial StatementsThe accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (â€œSECâ€). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any future period.The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 20, 2024. Use of Estimates Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Companyâ€™s condensed consolidated financial statements and accompanying notes. The Company evaluates its estimates on an ongoing basis. The Company bases its estimates on its historical experience and also on assumptions that we believe are reasonable; however, actual results may differ materially and adversely from these estimates. Significant Accounting Policies Significant Accounting PoliciesA description of the Companyâ€™s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except as noted below, there have been no material changes in the Companyâ€™s significant accounting policies during the nine months ended September 30, 2024. Cash and Cash Equivalents Cash, Cash Equivalents and Restricted Cash EquivalentsThe following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023: Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â End of Period: Â Â Â Â Â Â Â Cash and cash equivalents Â $ 4,277 Â Â $ 4,972 Â Restricted cash equivalents Â Â 500 Â Â Â Â 500 Â Total cash, cash equivalents and restricted cash equivalents Â $ 4,777 Â Â $ 5,472 Â Collaborative Arrangements Collaborative ArrangementsThe Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents amounts due from its collaboration partner as a reduction of research and development expense based on the nature of such payments. Revenue Recognition Revenue RecognitionThe Company primarily generates revenue from evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partnerâ€™s drug molecules using the RaniPill platform technology (Note 6).Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.The majority of the Companyâ€™s contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Variable consideration has not been material to our condensed consolidated financial statements. Consistent with the Company's policies and practices as described above, the Company recognizes contract revenue from its evaluation arrangements using a cost-based input method, which most faithfully depicts the transfer of the performance obligation to the customer. Accordingly, the Company will recognize contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expects to incur to deliver its performance obligation. These actual costs consist of the internal labor efforts, in vivo testing services and materials costs related to the agreement, as the costs incurred over time will reflect the transfer of its performance obligations to the customer. The cumulative effect of revisions to estimated costs to complete the Companyâ€™s performance obligation will be recorded in the period in which changes are identified and amounts are reasonably estimable. Such costs are expensed when incurred and are included as a component of research and development expenses in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss.Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date, none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred.Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2024 or December 31, 2023.Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services (Note 6). There was no deferred revenue as of December 31, 2023. Recently Issued Accounting Pronouncements Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. X - DefinitionSignificant accounting policies. + ReferencesNo definition available. + Details Name: rani_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: rani_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionUnaudited interim financial information. + ReferencesNo definition available. + Details Name: rani_UnauditedInterimFinancialInformationPolicyTextBlock Namespace Prefix: rani_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for collaborative arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementAccountingPolicy Namespace Prefix: us-gaap_ Data Type: dtr-

types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Schedule of Reconciliation of cash, cash equivalents and restricted cash equivalents The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023: Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â End of Period: Â Â Â Â Â Â Cash and cash equivalents Â $ 4,277 Â Â $ 4,972 Â Restricted cash equivalents Â Â 500 Â Â Â 500 Â Total cash, cash equivalents and restricted cash equivalents Â $ 4,777 Â Â $ 5,472 Â X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Summary of cash, cash equivalents, restricted cash equivalents and marketable securities The following tables summarizes the amortized cost and fair value of the Company's cash equivalents, restricted cash equivalents and marketable securities by major investment category (in thousands):Â Â Â As of September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â Current assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,090 Â Â $ â€” Â Â $ â€” Â Â $ 2,090 Â Total cash equivalents Â Â 2,090 Â Â Â â€” Â Â Â â€” Â Â Â 2,090 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Total cash equivalents and restricted cash equivalents Â Â 2,590 Â Â Â â€” Â Â Â â€” Â Â Â 2,590 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 26,118 Â Â Â 9 Â Â Â â€” Â Â Â 26,127 Â Total cash equivalents, restricted cash equivalents and marketable securities Â $ 28,708 Â Â $ 9 Â Â $ â€” Â Â $ 28,717 Â Â Â Â As of December 31, 2023 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Estimated Fair Value Â Current assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 3,339 Â Â $ â€” Â Â $ â€” Â Â $ 3,339 Â Total cash and cash equivalents Â Â 3,339 Â Â Â â€” Â Â Â â€” Â Â Â 3,339 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Total cash equivalents and restricted cash equivalents Â Â 3,839 Â Â Â â€” Â Â Â â€” Â Â Â 3,839 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 35,513 Â Â Â â€” Â Â Â (18) Â Â 35,495 Â Corporate debt securities Â Â 1,971 Â Â Â â€” Â Â Â (8) Â Â 1,963 Â Commercial paper Â Â 5,219 Â Â Â â€” Â Â Â (2) Â Â 5,217 Â Total marketable securities Â Â 42,703 Â Â Â â€” Â Â Â (28) Â Â 42,675 Â Total cash equivalents, restricted cash equivalents and marketable securities Â $ 46,542 Â Â $ â€” Â Â $ (28) Â $ 46,514 Â X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Assets and Liabilities Recorded at Fair Value on a Recurring Basis The following tables detail information about the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of inputs used in such measurements (in thousands): Â Â As of September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,090 Â Â $ â€” Â Â $ â€” Â Â $ 2,090 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 26,127 Â Â Â â€” Â Â Â â€” Â Â Â 26,127 Â Total assets Â $ 28,717 Â Â $ â€” Â Â $ â€” Â Â $ 28,717 Â Â Â Â As of December 31, 2023 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 3,339 Â Â $ â€” Â Â $ â€” Â Â $ 3,339 Â Restricted cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â Â 500 Â Â Â â€” Â Â Â â€” Â Â Â 500 Â Marketable securities Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasuries and agencies Â Â 35,495 Â Â Â â€” Â Â Â â€” Â Â Â 35,495 Â Corporate debt securities Â Â â€” Â Â Â 1,963 Â Â Â â€” Â Â Â 1,963 Â Commercial paper Â Â â€” Â Â Â 5,217 Â Â Â â€” Â Â Â 5,217 Â Total assets Â $ 39,334 Â Â $ 7,180 Â Â $ â€” Â Â $ 46,514 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Accrued Liabilities [Abstract] Â Schedule of Accrued Expenses Accrued expenses and other current liabilities consist of the following (in thousands): Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Accrued interest Â $ 823 Â Â $ 500 Â Payroll and related costs Â Â 324 Â Â Â 313 Â Accrued rent Â Â 317 Â Â Â â€” Â Accrued professional fees Â Â 190 Â Â Â 235 Â Accrued preclinical and clinical trial costs Â Â 30 Â Â Â 424 Â Other Â Â 183 Â Â Â 254 Â Total accrued expenses and other current liabilities Â $ 1,867 Â Â $ 1,726 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions (Tables) 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Schedule of Amounts Charged for Services and Rent The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 201 Â Â $ 280 Â Â $ 768 Â Â $ 889 Â General and administrative Â Â 41 Â Â Â 87 Â Â Â 187 Â Â Â 220 Â Total Â $ 242 Â Â $ 367 Â Â $ 955 Â Â $ 1,109 Â X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Summary of Consolidated Balance Sheets and Statements of Cash Flow related to Leases Supplemental information on the Companyâ€™s condensed consolidated balance sheet and statements of cash flows as of September 30, 2024 and 2023 and for the nine months ended September 30, 2024 and 2023, respectively, related to the Company's leases was as follows (in thousands):Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Weighted-average remaining lease term (in years) Â Â 4.1 Â Â Â 1.1 Â Weighted-average discount rate Â Â 10.4 % Â Â 10.4 % Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for amounts included in lease liabilities: Â Â Â Â Â Operating cash flows used for operating leases Â $ 1,015 Â Â $ 780 Â Summary of Future Minimum Operating Lease Payments As of September 30, 2024, minimum annual rental payments under the Companyâ€™s operating lease agreements are as follows (in thousands), excluding short-term leases: Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 465 Â 2025 Â Â 1,902 Â 2026 Â Â 1,229 Â 2027 Â Â 1,278 Â 2028 Â Â 1,330 Â 2029 Â Â 458 Â Total undiscounted future minimum lease payments Â $ 6,662 Â Less: Imputed interest Â Â (1,235) Total operating lease liability Â $ 5,427 Â Less: Current portion of operating lease liability Â Â 1,410 Â Operating lease liability, net current portion Â $ 4,017 Â X - DefinitionTabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: srt_ScheduleOfCondensedFinancialStatementsTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Summary of Restricted Stock Unit and Award Activity Â Â Number of Restricted Stock Units Â Â Weighted Average Grant-Date Fair Value per Share Â Â Balance at December 31, 2023 Â Â 1,276,111 Â Â $ 7.16 Â Vested Â Â (323,611) Â $ 7.69 Â Forfeited Â Â (59,206) Â $ 7.37 Â Balance at September 30, 2024 Â Â 893,294 Â Â $ 6.96 Â Â Â Number of Restricted Stock Awards Â Â Weighted Average Grant-Date Fair Value per Share Â Â Balance at December 31, 2023 Â Â 33,586 Â Â $ 6.15 Â Vested Â Â (22,616) Â $ 6.14 Â Forfeited Â Â (218) Â $ 6.13 Â Balance at September 30, 2024 Â Â 10,752 Â Â $ 6.15 Â Summary of Components of Equity-based Compensation Expense The following table summarizes the components of stock-based compensation expense resulting from the grant of stock options, RSUs, RSAs, and the ESPP, recorded in the Companyâ€™s condensed consolidated statement of operations and comprehensive loss (in thousands): Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Research and development Â $ 3,563 Â Â $ 5,275 Â General and administrative Â Â 8,477 Â Â Â 9,247 Â Total stock-based compensation Â $ 12,040 Â Â $ 14,522 Â Stock Options [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Summary of Stock Options and Options for Common Units Activity A summary of stock option activity during the periods indicated is as follows: Â Â Number of Stock Option Awards Â Â Weighted Average Exercise Price Â Â WeightedAverageRemaining Contractual Term (in years) Â Â Aggregate Intrinsic Value (in thousands) Â Balance at December 31, 2023 Â Â 6,639,811 Â Â $ 6.37 Â Â Â 8.48 Â Â $ 13,377 Â Granted Â Â 4,154,325 Â Â $ 3.74 Â Â Â 9.49 Â Â $ â€” Â Exercised Â Â (18,757) Â $ 2.72 Â Â Â Â Â Â Â Canceled Â Â (478,961) Â $ 5.36 Â Â Â Â Â Â Â Balance at September 30, 2024 Â Â 10,296,418 Â Â $ 5.36 Â Â Â 8.35 Â Â $ 25 Â Exercisable at September 30, 2024 Â Â 4,713,481 Â Â $ 7.62 Â Â Â 7.66 Â Â $ â€” Â Nonvested at September 30, 2024 Â Â 5,582,937 Â Â $ 3.46 Â Â Â 8.99 Â Â $ 25 Â X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose

reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Long Term Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Future Principal Payments for the Company's Debt As of September 30, 2024, future principal payments for the Companyâ€™s debt are as follows (in thousands): Year ending December 31, Â Â Â 2024 (remaining three months) Â $ 3,750 Â 2025 Â Â 15,000 Â 2026 Â Â 10,000 Â Total principal payments Â $ 28,750 Â Less: amount representing debt discount Â Â (445) Total long-term debt Â $ 28,305 Â Less: current portion of long-term debt Â Â 14,768 Â Total long-term debt, less current portion Â $ 13,537 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â 2023 Â Numerator: Â Â Â Â Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. Â $ (21,071) $ (26,872) Denominator: Â Â Â Â Â Weighted average Class A common share outstandingâ€”basic and diluted Â Â 27,071 Â Â 25,380 Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.â€”basic and diluted Â $ (0.78) $ (1.06) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings (in thousands): Â Â As of September 30, Â Â Â 2024 Â 2023 Â Paired Interests Â Â 24,116 Â Â 24,116 Â Stock options Â Â 10,296 Â Â 6,778 Â Warrants Â Â 6,570 Â Â 76 Â Non-corresponding Class A Units Â Â 1,262 Â Â 1,345 Â Restricted stock units Â Â 893 Â Â 1,413 Â Shares issuable pursuant to the ESPP Â Â 41 Â Â 82 Â Restricted stock awards Â Â 11 Â Â 41 Â Â Â 43,189 Â Â 33,851 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Nature of Business - Additional Information (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jul. 31, 2024 Aug. 31, 2022 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Date of incorporation Â Â Â Â Â Â Â Â Apr. 06, 2021 Â Â Net loss Â Â $ (12,722) $ (13,361) $ (14,779) $ (18,332) $ (18,664) $ (16,832) $ (40,862) $ (53,828) Â Accumulated deficit Â Â (93,960) Â Â Â Â Â (93,960) Â $ (72,889) Operating activities, net Â Â Â Â Â Â Â Â 26,841 38,758 Â Cash, cash equivalents and marketable securities Â Â 30,400 Â Â Â Â Â 30,400 Â Â Gross proceeds from offering Â Â Â Â Â Â Â Â 10,000 Â Â Proceeds from issuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs Â Â Â Â Â Â Â Â 8,883 0 Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value $ 8,900 Â $ 8,883 Â Â Â Â Â $ 99 $ 80 Â Warrants | Series B Â Â Â Â Â Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 3,246,753 Â Â Â Â Â Â Â Â Â Â Common Class A Â Â Â Â Â Â Â Â Â Â Â Common stock shares issued 2,800,000 Â 29,807,000 Â Â Â Â Â 29,807,000 Â 26,036,000 Proceeds from issuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs Â $ 150,000 Â Â Â Â Â Â Â Â Â Common Class A | Warrants Â Â Â Â Â Â Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 446,753 Â Â Â Â Â Â Â Â Â Common Class A | Warrants | Series B Â Â Â Â Â Â Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Â Â Â Â Â Â Common Class B Â Â Â Â Â Â Â Â Â Common stock shares issued Â Â 24,116,000 Â Â Â Â 24,116,000 Â 24,116,000 Common Class C Â Â Â Â Â Â Â Â Â Common stock shares issued Â Â 0 Â Â Â Â Â 0 Â 0 Rani LLC | Common Class A Â Â Â Â Â Â Â Â Â Issuance of common stock, shares Â Â Â Â Â Â Â 1,261,690 Â Â Securities Purchase Agreement | Common Class A Â Â Â Â Â Â Â Â Â Issuance of common stock, shares 2,800,000,000 Â Â Â Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 446,753,000 Â Â Â Â Â Â Â Â Â X - DefinitionDate when an entity was incorporated + ReferencesNo definition available. + Details Name: dei_EntityIncorporationDateOfIncorporation Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionCash, Cash Equivalents and Marketable Securities + ReferencesNo definition available. + Details Name: rani_CashCashEquivalentsAndMarketableSecurities Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross Proceeds from Offering + ReferencesNo definition available. + Details Name: rani_GrossProceedsFromOffering Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=rani_RaniLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=rani_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Accounting Policies [Abstract] Â Â Â Cash and cash equivalents $ 4,277 $ 5,864 $ 4,972 Restricted cash equivalents 500 Â 500 Total cash, cash equivalents and restricted cash equivalents $ 4,777 Â $ 5,472 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Summary Of Significant Accounting Policies [Line Items] Â Â Contract assets $ 0 $ 0 Deferred revenue 600 0 Research And Development Arrangement [Member] Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Deferred revenue $ 600 $ 0 X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: rani_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: rani_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details) $ in Millions Sep. 30, 2024 USD ($) Cash and Cash Equivalents [Abstract] Â Prepaid expenses and other current assets $ 0.2 X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents [Line Items] Â Â Amortized cost $ 28,708 $ 46,542 Gross unrealized Gains 9 0 Gross Unrealized loss 0 (28) Estimated Fair Value 28,717 46,514 Cash Equivalents Â Â Cash and Cash

Equivalents [Line Items] Â Â Amortized cost 2,090 3,339 Gross unrealized Gains 0 0 Gross Unrealized loss 0 0 Estimated Fair Value 2,090 3,339 Cash Equivalents | Money market funds Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost 2,090 3,339 Gross unrealized Gains 0 0 Gross Unrealized loss 0 0 Estimated Fair Value 2,090 3,339 Marketable securities Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost Â 42,703 Gross unrealized Gains Â 0 Gross Unrealized loss Â (28) Estimated Fair Value Â 42,675 Marketable securities | U.S. Treasuries Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost 26,118 35,513 Gross unrealized Gains 9 0 Gross Unrealized loss 0 (18) Estimated Fair Value 26,127 35,495 Marketable securities | Commercial paper Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost Â 5,219 Gross unrealized Gains Â 0 Gross Unrealized loss Â (2) Estimated Fair Value Â 5,217 Marketable securities | Corporate debt securities Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost Â 1,971 Gross unrealized Gains Â 0 Gross Unrealized loss Â (8) Estimated Fair Value Â 1,963 Restricted Cash Equivalents | Money market funds Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost 500 500 Gross unrealized Gains 0 0 Gross Unrealized loss 0 0 Estimated Fair Value 500 500 Cash, equivalents and restricted cash equivalents Â Â Cash and Cash Equivalents [Line Items] Â Â Amortized cost 2,590 3,839 Gross unrealized Gains 0 0 Gross Unrealized loss 0 0 Estimated Fair Value $ 2,590 $ 3,839 X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_AvailableforsaleSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=rani_RestrictedCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=rani_CashCashEquivalentsAndRestrictedCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets: Â Â Marketable Securities $ 28,717 $ 46,514 Fair Value, Recurring Â Â Assets: Â Â Total assets 28,717 46,514 Fair Value, Recurring | Commercial paper Â Â Assets: Â Â Marketable Securities Â 5,217 Fair Value, Recurring | U.S. Treasuries Â Â Assets: Â Â Marketable Securities 26,127 35,495 Fair Value, Recurring | Corporate debt securities Â Â Assets: Â Â Marketable Securities Â 1,963 Fair Value, Recurring | Money market funds Â Â Assets: Â Â Cash Equivalents 2,090 3,339 Restricted Cash Equivalents 500 500 Level 1 | Fair Value, Recurring Â Â Assets: Â Â Total assets 28,717 39,334 Level 1 | Fair Value, Recurring | Commercial paper Â Â Assets: Â Â Marketable Securities Â 0 Level 1 | Fair Value, Recurring | U.S. Treasuries Â Â Assets: Â Â Marketable Securities 26,127 35,495 Level 1 | Fair Value, Recurring | Corporate debt securities Â Â Assets: Â Â Marketable Securities Â 0 Level 1 | Fair Value, Recurring | Money market funds Â Â Assets: Â Â Cash Equivalents 2,090 3,339 Restricted Cash Equivalents 500 500 Level 2 | Fair Value, Recurring Â Â Assets: Â Â Total assets 0 7,180 Level 2 | Fair Value, Recurring | Commercial paper Â Â Assets: Â Â Marketable Securities Â 5,217 Level 2 | Fair Value, Recurring | U.S. Treasuries Â Â Assets: Â Â Marketable Securities 0 0 Level 2 | Fair Value, Recurring | Corporate debt securities Â Â Assets: Â Â Marketable Securities Â 1,963 Level 2 | Fair Value, Recurring | Money market funds Â Â Assets: Â Â Cash Equivalents 0 0 Restricted Cash Equivalents 0 0 Level 3 | Fair Value, Recurring Â Â Assets: Â Â Total assets 0 0 Level 3 | Fair Value, Recurring | Commercial paper Â Â Assets: Â Â Marketable Securities Â 0 Level 3 | Fair Value, Recurring | U.S. Treasuries Â Â Assets: Â Â Marketable Securities 0 0 Level 3 | Fair Value, Recurring | Corporate debt securities Â Â Assets: Â Â Marketable Securities Â 0 Level 3 | Fair Value, Recurring | Money market funds Â Â Assets: Â Â Cash Equivalents 0 0 Restricted Cash Equivalents $ 0 $ 0 X - DefinitionRestricted Cash Equivalents, Fair Value Disclosure + ReferencesNo definition available. + Details Name: rani_RestrictedCashEquivalentsFairValueDisclosure Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Liabilities [Abstract] Â Â Accrued interest $ 823 $ 500 Payroll and related costs 324 313 Accrued rent 317 0 Accrued professional fees 190 235 Accrued preclinical and clinical trial costs 30 424 Other 183 254 Total accrued expenses and other current liabilities $ 1,867 $ 1,726 X - DefinitionAccrued interest + ReferencesNo definition available. + Details Name: rani_AccruedInterest Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued preclinical and clinical trial costs 1 + ReferencesNo definition available. + Details Name: rani_AccruedPreclinicalAndClinicalTrialCosts1 Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRentCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedSalariesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Evaluation Agreements - Additional information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Disaggregation of Revenue [Line Items] Â Â Deferred revenue $ 600 $ 0 X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 53 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative and Evaluation Arrangements (Additional Information) (Details) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended Aug. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Long-Term Purchase Commitment [Line Items] Â Â Â Â Reimbursement of research and development expense Â $ 0 Â Â Cash and cash equivalents Â 4,277 $ 5,864 $ 4,972 Deferred Revenue Â 600 0 Â Research And Development Arrangement [Member] Â Â Â Â Long-Term Purchase Commitment [Line Items] Â Â Â Â Accounts Receivable $ 600 Â Â Â Up front payment arrangement 600 Â Â Â Contract Revenue $ 1,200 Â Â Â Revenue from contract Â 0 Â Â Deferred Revenue Â $ 600 $ 0 Â X - DefinitionUp Front Payment Arrangement + ReferencesNo definition available. + Details Name: rani_UpFrontPaymentArrangement Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionReturn of or reimbursements received in relation to direct costs and expenses previously paid or incurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RecoveryOfDirectCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions - Additional Information (Details) $ in Thousands 1 Months Ended 9 Months Ended 12 Months Ended Aug. 31, 2022 USD ($) Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) shares Dec. 31, 2022 shares Jul. 31, 2024 shares Mar. 31, 2024 ftÂ² Dec. 31, 2023 shares Related Party Transaction [Line Items] Â Â Â Â Â Â Â Lessee, Operating Lease, Description Â The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022, and the Occupancy Services in San Antonio, Texas continue until either party gives six monthsâ€™ notice of termination. Â Â Â Â Â Aggregate desired patent acquisition Â $ 1,000 Â Â Â Â Â Service agreement term Â pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. In April 2022, RMS assigned the agreement to Rani LLC Â Â Â Â Â Proceeds from Issuance of Common Stock Â $ 8,883 $ 0 Â Â Â Â Stock-based compensation expense Â $ 12,040 $ 14,522 Â Â Â Â Tax Receivable Agreement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Exchange of paired interests | shares Â 0 0 Â Â Â Â Common Class A Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Common stock units issued | shares Â 29,807,000 Â Â 2,800,000 Â 26,036,000 Proceeds from Issuance of Common Stock $ 150,000 Â Â Â Â Â Common Class A | Rani Therapeutics Holdings Inc. Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Conversion of stock, shares | shares Â 0 0 Â Â Â Â Common Class A | Registration Rights Agreement Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Issuance of common stock, shares | shares Â Â Â 6,009,542,000 Â Â Â ICL Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â One time patent payment to related party Â $ 300 Â Â Â Â Â Maximum | RMS-ICL Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Area for Rent For facility in San jose | ftÂ² Â Â Â Â Â 24,000 Â Minimum | RMS-ICL Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Area for Rent For facility in San jose | ftÂ² Â Â Â Â Â 23,000 Â X - DefinitionAggregate desired patent acquisition + ReferencesNo definition available. + Details Name: rani_AggregateDesiredPatentAcquisition Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExchange of paired interest. + ReferencesNo definition available. + Details Name: rani_ExchangeOfPairedInterest Namespace Prefix: rani_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionOne time patent payment to related party + ReferencesNo definition available. + Details Name: rani_OneTimePatentPaymentToRelatedParty Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionService agreement term. + ReferencesNo definition available. + Details Name: rani_ServiceAgreementTerm Namespace Prefix: rani_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of lessee's operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=rani_TaxReceivableAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rani_RegistrationRightsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rani_InCubeLabsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rani_RaniManagementServiceAndInCubeLabsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details) - ICL - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Related Party Transaction [Line Items] Â Â Â Â Related party charges $ 242 $ 367 $ 955 $ 1,109 Research and Development Expense Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Related party charges 201 280 768 889 General and Administrative Expense Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Related party charges $ 41 $ 87 $ 187 $ 220 X - DefinitionRelated Party Transaction Income Expenses From Transactions With Related Party + ReferencesNo definition available. + Details Name: rani_RelatedPartyTransactionIncomeExpensesFromTransactionsWithRelatedParty Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rani_InCubeLabsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash paid for amounts included in lease liabilities: Â Â Weighted-average remaining lease term (in years) 4 years 1 month 6 days 1 year 1 month 6 days Weighted-average discount rate 10.40% 10.40% Operating cash flows used for operating leases $ 1,015 $ 780 X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PaymentsForOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Summary of Future Minimum Operating Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Â Â 2024 (remaining three months) $ 465 Â 2025 1,902 Â 2026 1,229 Â 2027 1,278 Â 2028 1,330 Â 2029 458 Â Total undiscounted future minimum lease payments 6,662 Â Less: Imputed interest (1,235) Â Total operating lease liability 5,427 Â Less: Current portion of operating lease liability 1,410 $ 718 Operating lease liability, net current portion $ 4,017 $ 0 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Additional Information (Details) $ in Thousands 1 Months Ended 9 Months Ended Feb. 01, 2024 Nov. 30, 2023 USD ($) ftÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Mar. 31, 2024 ftÂ² Lessee, Lease, Description [Line Items] Â Â Â Â Monthly base rent for initial term of the lease | $ Â Â $ 1,015 $ 780 Â Rani L L C [Member] Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Land Subject to Ground Leases Â 33,000 Â Â Â Initial Term Leases Agreement Â The initial term of the Lease commenced in February 2024, and the duration of the initial term is 63 months. Subject to certain conditions, Rani LLC has an option to renew the Lease for one additional 5-year term at the then-prevailing market rate. The monthly base rent for the initial term of the Lease is approximately $95,000 per month, subject to a 4% increase each year. Rani LLC is also responsible for the payment of additional rent to cover its share of common area operating expenses, including taxes, insurance, utilities, and repair and maintenance of the premises and common areas of the Project. Â Â Â Lessee, Operating Lease, Term of Contract 63 months Â Â Â Â Lessee, Operating Lease, Renewal Term Â Â 5 years Â Â Monthly base rent for initial term of the lease | $ Â $ 95,000 Â Â Â Percentage of increase in monthly base rent (per year) 4.00% Â Â Â Â Rani L L C [Member] | Minimum [Member] Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Area for Rent For facility in San jose Â Â Â Â 23,000 Rani L L C [Member] | Maximum [Member] Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Area for Rent For facility in San jose Â Â Â Â 24,000 X - DefinitionInitial Term Leases Agreement + ReferencesNo definition available. + Details Name: rani_InitialTermLeasesAgreement Namespace Prefix: rani_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage Of Increase In Monthly Base Rent (Per Year) + ReferencesNo definition available. + Details Name: rani_PercentageOfIncreaseInMonthlyBaseRentPerYear Namespace Prefix: rani_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionArea of land subject to a ground lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LandSubjectToGroundLeases Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace

Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=rani_RaniLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants - Additional Information (Details) - $ / shares 1 Months Ended Jul. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Aug. 31, 2022 Class of Warrant or Right [Line Items] Â Â Â Â Â Warrant exercise price Â Â Â Â $ 11.79 Common Class A [Member] Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Â Common stock shares issued 2,800,000 29,807,000 26,036,000 Â Warrants Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Â Warrant exercise price $ 0.0001 Â Â Â Warrants | Series B Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Â Securities purchase in exchange for warrant 3,246,753 Â Â Â Â Warrant exercise price $ 3.08 Â Â Â Â Class of Warrant or Right, Outstanding Â 3,246,753 Â Â Warrants | Series A [Member] Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Â Warrant exercise price $ 3.08 Â Â Â Â Warrats Expiration Term 18 months Â Â Â Â Class of Warrant or Right, Outstanding Â 3,246,753 Â Â Warrants | Common Class A [Member] Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Securities purchase in exchange for warrant 446,753 Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Warrants | Common Class A [Member] | Series B Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Warrants | Common Class A [Member] | Series A [Member] Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Securities purchase in exchange for warrant 3,246,753 Â Â Â Loan and Security Agreement Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Warrants exercisable period Â Â Â 5 years Class of Warrant or Right, Outstanding Â 76,336,000 Â Â Loan and Security Agreement | Common Class A [Member] Â Â Â Â Â Class of Warrant or Right [Line Items] Â Â Â Â Securities purchase in exchange for warrant Â Â Â 76,336,000 X - DefinitionWarrats Expiration Term + ReferencesNo definition available. + Details Name: rani_WarratsExpirationTerm Namespace Prefix: rani_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=rani_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jul. 31, 2024 Aug. 31, 2022 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Proceeds from Issuance of Common Stock Â Â Â $ 8,883 $ 0 Â Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value $ 8,900 Â $ 8,883 99 80 Â Proceeds from isuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs Â Â Â $ 8,883 $ 0 Â Continuing LLC Owners [Member] Â Â Â Â Â Â General Partner Ownership Interest Â Â Â 46.00% Â Â Rani LLC | Outstanding Capital Class A Unit [Member] Â Â Â Â Â Â General Partner Ownership Interest Â Â Â 54.00% Â Â Previously Reported [Member] Â Â Â Â Â Â Exchange Of Common Units Â Â 0 0 0 Â Previously Reported [Member] | Organizational Transactions [Member] Â Â Â Â Â Â Exchange Of Common Units Â Â 5,173,947,000 5,173,947,000 Â Â Common Class A Â Â Â Â Â Â Â Proceeds from Issuance of Common Stock Â $ 150,000 Â Â Â Â Common stock shares issued 2,800,000 Â 29,807,000 29,807,000 Â 26,036,000 Proceeds from isuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs Â $ 150,000 Â Â Â Â Common Class A | Rani LLC Â Â Â Â Â Â Â Exchange Of Common Units Â Â 83,377,000 83,377,000 0 Â Common Class A | Rani LLC | Organizational Transactions [Member] Â Â Â Â Â Â Exchange Of Common Units Â Â 283,832,000 283,832,000 Â Â Common Class B Â Â Â Â Â Â Â Common stock shares issued Â Â 24,116,000 24,116,000 Â 24,116,000 Common Class C Â Â Â Â Â Â Common stock shares issued Â Â 0 0 Â 0 Warrants | Series B [Member] Â Â Â Â Â Â Securities purchase in exchange for warrant 3,246,753 Â Â Â Â Â Warrants | Common Class A Â Â Â Â Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Â Â Securities purchase in exchange for warrant 446,753 Â Â Â Â Â Â Warrants | Common Class A | Series B [Member] Â Â Â Â Â Â Common stock shares issued 3,246,753,000 Â Â Â Â Â Warrants | Common Class A | Series A [Member] Â Â Â Â Â Â Securities purchase in exchange for warrant 3,246,753 Â Â Â Â Â Â X - DefinitionExchange of common units. + ReferencesNo definition available. + Details Name: rani_ExchangeOfCommonUnits Namespace Prefix: rani_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-3 + Details Name: us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_OwnershipAxis=rani_ContinuingLlcOwnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=rani_RaniLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CapitalUnitsByClassAxis=rani_OutstandingCapitalClassAUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=rani_OrganizationalTransactionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Stock-based compensation expense $ 12,040 $ 14,522 Stock Options [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Unrecognized equity-based compensation expense $ 21,800 Â Recognized over a weighted-average period 2 years 9 months 18 days Â Restricted Stock Units [Member] Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Unrecognized equity-based compensation expense $ 5,600 Â Recognized over a weighted-average period 2 years 3 months 18 days Â Fair value of RSAs vested $ 1,000 Â Restricted Stock Awards Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Recognized over a weighted-average period 2 months 12 days Â Fair value of RSAs vested $ 100 Â 2021 Employee Stock Purchase Plan Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Contributions withheld from employees $ 100 Â Weighted average vesting term 2 months 12 days Â X - DefinitionEmployee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted Average Vesting Period + ReferencesNo definition available. + Details Name: rani_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedWeightedAverageVestingPeriod Namespace Prefix: rani_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=rani_RestrictedStockAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rani_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock Option Activity (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Options, Outstanding, Beginning balance 6,639,811 Â Number of Options, Granted 4,154,325 Â Number of Options, Exercised (18,757) Â Canceled (478,961) Â Number of Options, Outstanding, Ending balance 10,296,418 6,639,811 Exercisable at September 30, 2024 4,713,481 Â Nonvested at September 30, 2024 5,582,937 Â Weighted Average Exercise Price per Share, Outstanding, Beginning balance $ 6.37 Â Weighted Average Exercise Price per Share, Granted 3.74 Â Weighted Average Exercise Price per Share, Exercised 2.72 Â Weighted Average Exercise Price per Share, Forfeited 5.36 Â Weighted Average Exercise Price per Share, Outstanding, Ending balance 5.36 $ 6.37 Weighted Average Exercise Price per Share, Exercisable at September 30, 2024 7.62 Â Weighted Average Exercise Price per Share, Nonvested at September 30, 2024 $ 3.46 Â Weighted Average Remaining Contractual Term (in years) 8 years 4 months 6 days 8 years 5 months 23 days Weighted Average Remaining Contractual Term, Granted (in years) 9 years 5 months 26 days Â Weighted Average Remaining Contractual Term, Exercisable at September 30, 2024 (in years) 7 years 7 months 28 days Â Weighted Average Remaining Contractual Term, Nonvested at September 30, 2024 (in years) 8 years 11 months 26 days Â Aggregate Intrinsic Value, Outstanding, Beginning Balance $ 13,377 Â Aggregate Intrinsic Value, Granted (in thousands) 0 Â Aggregate Intrinsic Value, Outstanding, Ending Balance 25 $ 13,377 Aggregate Intrinsic Value, Exercisable at September 30, 2024 (in thousands) 0 Â Aggregate Intrinsic Value, Nonvested at September 30, 2024 (in thousands) $ 25 Â X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of grant and grant price on options granted (or share units converted) into shares. + ReferencesNo definition available. + Details Name: rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term. + ReferencesNo definition available. + Details Name: rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm Namespace Prefix: rani_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value. + ReferencesNo definition available. + Details Name: rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term. + ReferencesNo definition available. + Details Name: rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm Namespace Prefix: rani_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Restricted Stock Units [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Outstanding, Number of Shares, Beginning Balance | shares 1,276,111 Vested, Number of Shares | shares (323,611) Forfeited, Number of Shares | shares (59,206) Outstanding, Number of Shares, Ending Balance | shares 893,294 Outstanding, Weighted-Average Grant Date Fair Value | $ / shares $ 7.16 Vested, Weighted-Average Grant Date Fair Value | $ / shares 7.69 Forfeited, Weighted-Average Grant Date Fair Value | $ / shares 7.37 Outstanding, Weighted-Average Grant Date Fair Value | $ / shares $ 6.96 Restricted Stock Awards Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Outstanding, Number of Shares, Beginning Balance | shares 33,586 Vested, Number of Shares | shares (22,616) Forfeited, Number of Shares | shares (218) Outstanding, Number of Shares, Ending Balance | shares 10,752 Outstanding, Weighted-Average Grant Date Fair Value | $ / shares $ 6.15 Vested, Weighted-Average Grant Date Fair Value | $ / shares 6.14 Forfeited, Weighted-Average Grant Date Fair Value | $ / shares 6.13 Outstanding, Weighted-Average Grant Date Fair Value | $ / shares $ 6.15 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Total stock-based compensation $ 12,040 $ 14,522 Research and Development Â Â Share-Based Compensation Arrangement by

Share-Based Payment Award [Line Items] Â Â Total stock-based compensation 3,563 5,275 General and Administrative Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Total stock-based compensation $ 8,477 $ 9,247 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) $ in Millions Sep. 30, 2024 USD ($) Maximum Â Loss Contingencies [Line Items] Â Income tax payable, amount $ 23.1 Minimum | Paired Interest Â Loss Contingencies [Line Items] Â Income tax payable, amount $ 0.0 X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rani_PairedInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 9 Months Ended Aug. 31, 2022 Aug. 31, 2021 Sep. 30, 2024 Jul. 31, 2024 Debt Instrument [Line Items] Â Â Â Â Debt instrument face amount $ 15.0 Â Â Â Warrant exercise price $ 11.79 Â Â Â Interest Rate On Loan Â Â 0.1562% Â Minimum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest Rate On Loan 5.60% Â Â Â Maximum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest Rate On Loan 0.1035% Â Â Â Loan and Security Agreement Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Debt Instrument Maturity Date Aug. 01, 2026 Â Â Â Loan and Security Agreement | Avenue Venture Opportunity Fund L.P Member Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Maximum Borrowing Capacity $ 45.0 Â Â Â Debt instrument face amount 15.0 Â Â Â Loan and Security Agreement | Avenue Venture Opportunity Fund L.P Member | Minimum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Proceeds from Issuance of Debt Â $ 15.0 Â Â Loan and Security Agreement | Avenue Venture Opportunity Fund L.P Member | Maximum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Remaining Borrowing Capacity $ 30.0 Â Â Â Preferred unit warrant liability Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Warrant exercise price Â Â Â Â $ 0.0001 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=rani_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=rani_AvenueVentureOpportunityFundLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt - Future principal payments for the Company's debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Long-Term Debt, Unclassified [Abstract] Â Â 2024 (remaining six months) $ 3,750 Â 2025 15,000 Â 2026 10,000 Â Total principal payments 28,750 Â Less: amount representing debt discount (445) Â Total long-term debt 28,305 Â Less: current portion of long-term debt 14,768 $ 4,897 Total long-term debt, less current portion $ 13,537 $ 24,484 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount (premium). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 68 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Effective income tax rate 0.00% 0.00% Change In Uncertain Tax Positions $ 0.0 $ 0.0 Deferred tax asset $ 18.9 Â X - DefinitionChange In Uncertain Tax Positions + ReferencesNo definition available. + Details Name: rani_ChangeInUncertainTaxPositions Namespace Prefix: rani_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. $ (6,783) $ (9,197) $ (21,071) $ (26,872) Denominator: Â Â Â Â Weighted average Class A common share outstanding-basic 28,836 25,552 27,071 25,380 Weighted average Class A common share outstanding-diluted 28,836 25,552 27,071 25,380 Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted $ (0.24) $ (0.36) $ (0.78) $ (1.06) Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.- Basic $ (0.24) $ (0.36) $ (0.78) $ (1.06) Common Class A Â Â Â Â Numerator: Â Â Â Â Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. Â Â $ (21,071) $ (26,872) Denominator: Â Â Â Â Weighted average Class A common share outstanding-basic Â Â 27,071 25,380 Weighted average Class A common share outstanding-diluted Â Â 27,071 25,380 X - DefinitionWeighted average number Of shares outstanding basic and diluted + ReferencesNo definition available. + Details Name: rani_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted Namespace Prefix: rani_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting

Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 43,189,000 33,851,000 Paired Interest [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 24,116,000 24,116,000 Stock Options [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 10,296,000 6,778,000 Restricted Stock Units [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 893,000 1,413,000 Non Corresponding Class A Units [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 1,262,000 1,345,000 Shares Issuable Pursuant To The ESPP [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 41,000 82,000 Warrants [Member] Â Â Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 6,570,000 76,000 Restricted Stock Awards [Member] Â Â

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Â Â Anti-dilutive securities 11,000 41,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rani_PairedInterestsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rani_NonCorrespondingClassAUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rani_SharesIssuablePursuantToTheEsppMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 14 Months Ended Oct. 31, 2024 Dec. 31, 2024 Sep. 30, 2024 Jul. 31, 2024 Dec. 31, 2023 Aug. 31, 2022 Subsequent Event [Line Items] Â Â Â Â Â Â Warrant exercise price Â Â Â Â Â $ 11.79 Common Class A Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Common Stock, Shares, Issued Â Â 29,807,000 2,800,000 26,036,000 Â Common stock par value Â Â $ 0.0001 Â $ 0.0001 Â Common Class B Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Common Stock, Shares, Issued Â Â 24,116,000 Â 24,116,000 Â Common stock par value Â Â $ 0.0001 Â $ 0.0001 Â Subsequent Event Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Offering price $ 3 Â Â Â Â Â Â Proceeds from Issuance or Sale of Equity $ 10,000 Â Â Â Â Â Â Cash received from equity financing Â $ 50,000,000 Â Â Â Â Â Subsequent Event | Common Class A Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Common Stock, Shares, Issued 3,000,000 Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 333,333 Â Â Â Â Â Â Common stock par value $ 0.0001 Â Â Â Â Â Â Subsequent Event | Minimum [Member] | Chief Executive Officer [Member] Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Salary Â 100,000 Â Â Â Â Â Subsequent Event | Maximum [Member] | Chief Executive Officer [Member] Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Salary Â 520,000 Â Â Â Â Â Subsequent Event | Series A Common Warrants [Member] Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrant exercise price $ 3 Â Â Â Â Â Â Subsequent Event | Series A Common Warrants [Member] | Common Class A Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 3,333,333 Â Â Â Â Â Â Subsequent Event | Series B Common Warrants [Member] | Common Class A Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Pre-funded warrants issued to purchase shares of common stock 3,246,753 Â Â Â Â Â Â Subsequent Event | Pre-Funded Warrant [Member] Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrant exercise price $ 0.0001 Â Â Â Â Â Â Offering price $ 2.9999 Â Â Â Â Â Â X - DefinitionExercise price per share or unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OfficersCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the issuance of equity classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromOtherEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=rani_SeriesACommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=rani_SeriesBCommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=rani_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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

[W$^P6)F=%H)"J?BS#MJG:B_L;08UYFQGI\ MI2(QS@=C,ZFL@/4E"3,+BR8F*V2^^W:,1!0U5,V);OC:^UZ!W["X#_D MZ+,Z?/^,_NH.!;\9Y^#WUGF%W@3!&X[R(T=9FRRM90 22[P;U29?
Q3&J8=?1 MI@I%S):)9Z*.&H-6_A_]F00M^-7#T9AKO;>>*D?IZ54W"[>_I11& MK_78$F2G7'-%SE4LCGI'H4%:>WNLDJ/:A\9J0[Q'HAU$5+K ^90G_I%?1.WV M0 SWIB"(^R?@?2N;D.]!U&\-,!@^+
/$[7Y%H->45/QI!_YT?C! ,E&G,SS! MGS!WF"4._E%&2@M?5ZO4_<%$ZD2#H] @_28B=7I1K]W9&7HNP*H7+.T.>[6) ML86Q* LN&%-_R(QV-.RW#[18";*+#G2RC&RB$%PA"
["B%\7MX<'2&$M9MB7K M<>IU8Q#0$%?,+B"]Z/>^.\N[%U&O&S\@2N6PG&MWQ;4^A51:$HD&1]5,P;'$ M, 5]ZLEDCG!55FP>\^5)+]WFTXGN=4 QL)95FHRJQMWW />$(W1OF8OE M?
N]H[!U1&*?*BR4")#Y>4*_R#$]J_4-?"BJ38BE5OM3#29$87&I3LGR*S7"# M,):/L63!,2P4[GS()?+,ZB!.GE"TI7:*.UXDE'-+ F181^S)UD94;]JM7;.YTA5H)V:S!!9)'(C)%\T)$,Z!:**@#*
(O%'2J>7B+X0;&]2D?+#OI[KEW7;YR]LO+MR(:[IS/,TTSJ+8: M_5Y=V/+]57YX4X0WS]1XO*#"<($G*UE>@/F9,7[[P0YVC^#Q/U!+ P04 M" "(0FY9@J(_W\@$ "/"P &0 'AL+W=O)_:V!0KT1;S-
',Z:T]G,YA75W$YU M0PHGI38U=UB:]BC8;:M:VZV M5R3UYB):1,/&C5A7SF_,5N<-7],MN< -1X/5;$0I1$W*"JV8H?(BNER<7BV] M?!#X(FAC=^;,>Y)I?><7OQ07T=P;1))RYQ$XAGNZ)BD]$,SXVF-
&XY5><7<^ MH+\OL.7C%NZUO(W4;CJ(CJ.6$$E;Z6[T9N?J??GP./E6MKP99M.-EU&+&^M MTW6O# MJH;J1/ 0\["@6#;+<@Y>.GJ8!+_U[3*FTOM MG;7L]\O,.H/D^.,YGSO(Y?.0OF!.;<-
SNHA0$9;,/46KUZ\6A_.S/08O1X.7 M^]# _36CV RVG[4L]JDB5FJ)TA1JS1S/)"@IR'$AF5!=S8?BR5#0S$'Z6M<- M5]O7KXZ3Q=&99:507.6"2\:M)4!R53 I>":D<)H=7=?P;ACI3?C/ICA05'5
M>6N,OQJ5)3I=H0J10GTD+P:D#M/?L2NJW1K@6% M.IU<6J^&')'49V3&3)K\&B 7K!N3?DS9)^VXA)IWXG1RS6W%Z&LK8*W'/YT@ MO6F+TC-W:)5EBUO8#mRR)YR=SC(&.Y.S)+)Q-
;@CI)7('N_-_@GDPGX\8PXB] MR8<@Y /$K&@P=KC M^&AQ])(KX;#G]"WE/:6+0&GZWU*:QFEZ\H(=X>S_I#0]B)@-?1QA@E]G3U;=32$S"RQ.0H7AP_ M3<3E87RP6+(A-MZ-
(3Z/-2L4J&R["N*&6(]-L(76:BY>S#='*ZZN^9]:"E M>*#BC5!0W>5Q&GI+WRT8< 1:"9CP5;W;!G -X/=;EFW1FNY\FQ#*:1B)-T%! MIMT-)D)P9&I>"\:71-
6X2IGC3<..V#$[E7M_W:)$/UNV38*U#!_N3?#_" M;]ALF75PEYOB\4904I"T,5JH89M*H"=Q*9D5:R5*-#'EAK[EN=69Q_;I%C,2 MX,&P0J #.KEET/=]KUO%#$X.C.V0%8RV-&""?:U"
"Q'K'"G%;60W.R$[8P):ULHY&C9 CG^(_2WCIE2S(()[D-D1I2,QZC_YBCJ??BFU2I M!$)N\FH;Z/99U@A;)U"K7O9?&W?&U M>=D]LA[%NZ_YU"Z>;\.3*M,,#+DPKT$C&"^"\ MU(A&O_
7C&_PU52P0,$% @ B$)N66/)8)7& @ C08 !D !X;"]W M;W)K&ULI5AMYXI$BYF7Z1>"]8/+O[[.Z#N]PX M_R6LE8KB:VULN!JM8VQ>3:>A6*M:AHEKE,63E?.UC+CTU30T7LF2%]5FNIC- M7DYKJ>WH^I+OW?
GK2]=&HZVZ\R*T=2W]]HTR;G,UFH^Z&Q]UM8YT8WI]VV.>JWI(7#WYWUG]AW^+*40=TZ\P]=QO75 MZ&(D2K62K8D?W>9GE?WY@>P5S@3^*S;IW?/%2!1MB*[.BX&@UC;]EU]S' 8+
M+F8G%BSR@@7C3ALQRK0@ALMIQ':T:%IDTV^2Z<4)TW\5OSL;UT&\ MLZ4J]]=/ ;/'NNBPOED\:?!>-1/Q8C86B]GB_ E[+WK?7["]%R?LO6D#[H0@ M;EV]U)9]#N*?-
\L0/=CRKV,N)XOGQRU2!;T*C2S4U0@E$I1_4*/K[[^;OYR] M?@+O>8_W_%GK_U^NGC;]QB&M% M$6VDW;*91Z\ ^_Z[B\5B]CH]X(OYZ^<"MI57I= V.B&'> A Y15O+YZ1_6SA
MQ#N=R8GX#.KYC.CHJR?A;K0QHN@7*0%0M;3M"LQHO1JC]! 0TIJQ"$I]07^J M6B.C\S#2--XA=$&@9Y+)L="K?%?AHG!UK7RAI=' 0: %[I=ML>_87;K7QZ9@
MAFI;B5W0YC^^#N+];W=G\RG]78BRE4;(RED=(JUH7$N;W[T_F\\68W:.MO@H MK;XC[WZ^%7#-P!.#E ,Y7-*%V@/REF_U.+1E$RNM3"G<2FRXZU%@9)73HVUA
MVI*@;G1<8PX(HVL=4]S=4@4=M^-N(?+=YO8,=+TU4$!9:0O%.ZY;V ^G$_^G MTIW3QE@+%V8) #)V1CSP\..E@ \LK+2(#OA,BX$A71Z5[/Q80:S7RM^D-,V M3NQ9*J'^0$[,5H2U)&HOMR?H-
A&?CM-0R6(M*A1?Q')0D)8[_/&BD3[2JT)] M1< #%:WG\#%B),T&!(/51,Y%0AV:# ,CYCIZ217*VTTZ)X<#^TR6U+A.:TK ME(_(#M4H(@9C1#F$"F$#&+R0PSN,!I?!8Z*0_6^@A[UQ45&,Z6=:
(.B,C1F MC$2LB $N7VH4@4]&]\MNB"^16J-60]"5I4 K[S7VTRKL9X;S:B!^V,"02_L, MZ KEL]64N/M((1V+6[A?RK%XUU+(AK4R>/EON"Y=_ 9Q1W[0TC)"2\:/FQ#* & M$+
GR);S6J#X8W#@'7$HT64-CM-E#=8(DVOB&=5HAK]?-EVC_H"7/K2[;B0I MHD@WU)EH&[S8>$TY1LQ0M*Z2&WD,YIBSJKN728Z@H M&3BSEF!&<<&8 N6^\6,*Q'M*#1)Z.6O7-]XF\4]TBX
MA#G CUH([W/8.L0S *#.@<)9>]=6:]Y<@:"L1$5)4R7'O0\%5P5/K)+%0?F M&155%Z2$?,4)*##&=8%B0*)IWN!VYUM<(TD0 MLS<6<-+2X$K[LI?P'XQM/;4RE_ILWID>=4CAP"KF-
ORDMRG6)Q+?R&W'H/UL M@#\"NJTR:23K\BQ?E;I"U+W;2L,$0'HM3C5!&A4.R[.62(.@.9K<#@RP53CQ< ME+"P62N[]XHB$("#KE#":P]Q3IV#XO[$!(Z4(1!/*;9&;JS3*+?95(J[E,
M<4!QQ+F"BQG6B=,MS[B;^UOQR36Z$!>SBWTT*LDVE2J]=+:B- 9B2-=0*$ L] M#;3<4NAH4Y+'M A:&!]7'N?Y$Q1"3Z')YH85"_JATO40@LB0<6B(N>%6XRJ+@ M2[]JR=4S0B(]
[)&'PR)27QON]WGW6\AP9W0I^]:9==@/]<9(ICNH Z#S%/14 MYCR/Y!+S"RQ! -'-X03TY@VG'Z<'&%HB=MT10HR1"D =>,(-DBL&'BCPMDRN M(>XP;-((SWY:W"0 _??FGO)RHG54Z>*"&
MV>UN8O?TZH1AZI#[I .1-6A2*1V(9R]@4;]\D#&8 J<(4Z6:G3;)>LO8C9Y MB0(UAC#QG%!?5=$.!5/G"*0;/<\M9/#"$:_V(P-DV$']D_21A#:U<&E _PY5 MF@G0R"C'*HGZB)<9['RRZ-
^GXFA[+;D#B13)LM0$)XEZ*NN2?4NH9%_GD@9= MBO&_G:-]04S]*:MOB"C\B/F3A:;^HXE*K$Z#*U(/STP*QJW*YDGBH#T(/!OF0H#YH[X7R&WK@-62<>3OIO]?M= #\-KD2!5 !\
M#R;UMT)"SM'N2@]T;M^>6AI ^%EC L?3)0:R329BE[**=SZGK7]SLXU @HC4,6 M>:QVKB(?M0['])G8YV"^2OLBR: 3?;3;=0/2T4& MB&O=;H_&B%=&YJ-
P:P,V#5PFI\+M$V#K'IN6#.LMQGQ"-6=4+\3DV)>ZZ> + M*]ZEN_((1VRTL?6_F[_J?HF?:'=O9Z^<_\N?:4A8(Q:8>EL\N,/HY2O[B*Z MAK_7+EU$;?+/-8YZRM,+>+YR&!#Y@C;H/^!?_Q=02P,$%
@ B$)N6&ULU5I9<]LX MMG[/KT!YMJ1*EN4EB=-9JMSNGGO3E712<>;.P]0\0"0D8D(1' "TK/[U]SL' M"TEK<=*SU,R#95$$#[ZG85\M3;VBZN4\N)N53?N]5'E??O=R8DK*K62;FI:
MU>#.PMB5]+BTRQ/76B5+WK2J3\YFLVO^+>/]LTKT_E:-^JC%:Y; MK:3=?*]JLWY]=']4?OBDEY6G'T[>O&KE4MTH_Z?VH\752:92ZI5JG#:-L&KQ M^NCJ]+OO+V@]+_@_K=9N\%V0)'-
COM#%V_+UT8P84K4J/%<0^'>KKE5=$R&P M\?=(\R@?21N'WQ/U/[+LD&4NG;HV]9]UZ:O71Y='HE0+V=7^DUG_KXKR/"5Z MA:D=?XIU6'N.Q47GO%G%S>!@I9OP7]Y%/0PV7,
[V;#B+&\Z8[W 0<_F#]/+- M*VO6PM)J4*,O+"KO!G.Z(:/<>(N[&OO\FT^JEEZ5XJ.T?B,^6]DXR?IRKTX\ MZ-.JDR+2^C[0.MM#ZX5X;QI?.?%C4ZIRO\)$?&7FSA)SWY\=)'BCVJDXGTW$
MV>SLX@"]\RSL.=,[_V9AQ5^NYLY;7/UUE]R![,5NLA0WW[E6%NKU$0+#*7NK MCM[_C>GSV8O#S!]D9F^.$3]&RUTF-;SJ3B@@[?-=3=7XIVUBY^Z1I&3GT[$)]EH5C[N*0L%Z\8;
(86+&V7:"*#PE8!I MA%HL%(,;4-);XJIP5<,R1OPDFPYH*TXG\0 2P'5SI_[>@0H625!#O.+'HAJ0 MUXUX+RU^PK8S\5BZM'#"$A\E1H^)A2VQCIY,1-M9UTF0 AOK2H-4%HZ8H'U\
M7$D+6FMN=:E$JZPS3:/J)+&CNW1BL$W7#;*M M@+VJK&1);!)G'>*S%G]4<\MN2\@_ 4Z?OLF, 8&(.B&5]] 4H"'[UC\BA[EH=$MV0T^FNO/A>-N@4F-T^H-XVQ32C[J?W M-
QEF_U49=#NOC5.9)=HR!U,I6F.3?VGO1AHAK_K).#72"&A CJFXRJ:M-Q/Z MZ9^5-[F1X2BS !TW8!4L<3)-.F(S7+46N!BS*7&!Q+!LHO_TZB2V4\!M16/< MN@96E-HY@Y12'HZ3D?
6:07['=7+AO4%DS4H 6:S&1]JCD!F02TNMN*<^[\^ M'I<^$P*T+".I?%3Y]ZV&T63_T7$W;?LWYB;I\BZ>QE^ROSS235 \2QR18* M\4}^B)C?GU@?TMU_5 I1UG:CDY@(M1:U_R2DK
M=F>A[>J+6'(C4G,;PICTZ>4<+\SW1.BJ9T3[Y[]+F"/XR&#G"5U@?,H;G!S^A_#]Q_Q"F12@61OSWZ MM*<0%[_%_5/ZO)SA_FS2WQ>7KYX]#^QDF>@*,F5:)+ V>3B5%P^%Z?X V(\ M^FP\EH'
Q1D^SY\]Q^>+IT_Q>3HYG;T05RSP6(* BZ:YWVG^861K0M7Y.-3:VCW\V@(++)Z/^F:J#/I5W+K*A!TDL51D'48,K MX[ICS']'.PUEO+= ^)K&9*[Z$+R?3ZYBVTM;87//:MKB>Q<,FKW)^Q6U+>?
$I5V>C[LF[]5#^,L'9+8HJ,.U4I=,NS' MK77<&K)*ZK-IKEQV!*,MCJ(HMW$D13UY&TO9A9)HA@(JCT1DP7F9)E\4'12'1)V>BX$P^%AB*=3K46N!^6NY!?NT@FQ
MCKU>]>T%5/E;.9N>"^RJ*7/%3HRP14D$UOY#-MI)IE2.ZX>>YPF2)5T"3*>S M?$@N9^&]2Y D;6J7F6(UH.) !!5F1>XES+S6RY!;PS@@N,?"4T)HR"V<#)[Q M:X(G6//;H8?
X[.NU=:58+EB*JI*&6@YZ $.JOT4;@1BII5[EX$G.'@.R'-1Y MWR[N"D9&F5<5/X:ZF0OZI H?Z$3XSB0P1>%,%4W /U8^N0.9R*GTUS_#7HS7B:6J_4:3ZP.7>AXV3U+4F*UC[$8FYA
M98;16'YO=ZE#6Z716=C:X2),VY, Y\<$Y_-!%"$> M>9J!_0G[3U)O]E66+M(/P;4E 60?D>]B=H;X\CPW)JU6+HT(S MMK4HSI%V[*B]?:A 8A[?:_2^*TNE[]"-
IU__V4$[HOE0)!*N]*REP<[]A+:&W0D&O)3JE)RC6P[Q\L^\95:M,6\,7\;=!6X M>]Q!*?BF8RW^%]1+/\6^T1 M6=RXQB#<.6]'3O9:AMR=%HV/6_-,@OK8#3S;I7:Y8'O/53\NYA2WZMOD]XZ-
M\3@:F<9I6@K5?F 8"/+-_5P!/U!-4 9^_&+VA&<]0:#QLL'HMF];P_3V1[HU M&JN/MY8&7!'@RS _YS*-;1*M$-HAZFJMJW0+EL8Y@X:I#X3!8&R]5U2()>]0 MG- 6'H T_+%ZG
CKJ,$:WQWK;K_GGX^//G^ZH@>?(T 8C;5/1V! U-Y^_"" M?K!+ $]8ZD"!:T8-Y*O*&V5WW?5%.KF0<')]F7FX;0EJY2551:I>#OUX'O"55 MT8CP ZM<7#[]W;TQ#UU!]CD";X$DQ5F,(5$S/)2DAC@
1Q'ZBPJ5 .J*2C;+ MP/)'R?[REA7$#W! "#;B%B >1YX7IX)"[9CJY <9/+F9Y#IA9"7213JZ%+\H M:[8.#RK"UZZ.3Q&'XE$V .!M[9B9(;T\LXW2'!G/4-KGQ7**@&7QXX2@G1ICX MT&C[,-%I-ACQE"
MKG\<. .3@\'1H&/6T(?EM;8HOQVC14C>Z1RJB.)T>*0R]BIBCQYEY.[E!KG% MAF1U5;"#GKXX/Q^-/8:Y?KP\)WM7R3AIN*X!0>(*5N3YD_-@&JZ-@*5('P3/ M/:X)FUE%N_]>L@-.
IL"E6K5!.S9[9W1[@-)V=#QL17YY)9N2NNE6+Y>;N03G M.PPZ?N1R-LG&KTQ=4MAOC1EWZH02$ ZT(=[GV_#$+<%*EEMQ^8"S7_$K&AR2 MQ$H>&M&IB45UIVRA7?
0_Z&V7XPX>91PZ<4)A?^\YU=#O8&+J7\='Y DUC? I MY4!Q3IQ=E#SC56MZBHK)KW+Z7$)X9#\0DB4E?P.T)CAWU\;8 P=.7U+TTL@E/Y@=3 MS,A!-"W7!7E,DUUVX,%$.T?
1A*'2*7X4Y:LT$]K%!+QOCY0'0)B'[74JKD), M3^YG#ZH_,J?;1T^VDQ.%\E>XS,O!NPU(9U^!0O='-O$%!BE*<%#X$2YQ$[F;
M"TO#/D5S1NFJ/%$#=%.Y2VGMUM0=DL6:7XRE((QY9)0P7Y1E'[B&QCT<(.C M9&^0Y!GA/24QH%+1\8^7$9-!%APC&1<)*=ENQ%X7?K#:B.]K! TU'?-I*LX
M\3#N3G>]3WHR>/MWI>R2WW&FD3=JMO B[I>'=["1&):ZH1?@ M%M@ZFSY_>A2"+EUXT_*[Q'/CO5GQUTH!Y2TMP/V%0:\6+^B _'+YF_\'4$L# M!!0 ((A";EF6-*#;- D $H8 9 >&PO=V]R:W-
H965T'#<;#X>D@E[KH7%_RNT_V^M)4 M/M.%^F2%J_)*M6.]=:"[)D;LQ7>GB?7G6&I)#*5.*)@\3/H[I3 M64:,H,;OD6>G$4F$[77- 1W;#EOFTJD[D_VF4[^ZZIQW1*H6LLK\9[/^LXKV MS(A?
8C+'?\4Z[!UA",>L=!+&6/THO MKR^M60M+N\&-%FPJ4T,Y75!0'KS%5PTZ?WVO8)*["CPHC>#)-+=!KKQ ;HW MXJ,I_J)/Q6I2G?I!]"A461<*W([/LKP095],1EVQ?@XGA[A-VD,FS" R5' # MQ-
]NYLY;Q/[O+]D86$Q?9D'U<.%*F:BK#A+>*?NH.M< _?#UFK\[Z(!K\OQ$_F4>5S9>S)C4WX*YM@*3ZB&G3OBRIDX8-*HB=^ KB\(N):"KVO1?3%[\]ZBO9' M$9"8.V$6 ,_!{6T9H)S*TL52R+*TYDFC-
%6V$9-)=S@U2^+7IS2N=I20! ^!^-A1_E-X MMU7_RXH$:$_FD^H[FHN$?%,D[$+Q3LTMU-MPDGE$ MY%QM??%0S5DCN"I1U@-U:(:%(-9&[EIM6TH&],"7SQ6ZK"D#D5B^X0)A"""9D&
M8HB;]39*VB!5^A"*E2IZ2+-'J3-R"(#[*QP+=54PG/6"]PD9289GQL^,V'$) M+-H-W??BS8R#5R)IF6,77:(Q5(JI^ /X)9;)E43,2-/^3E;(S)&5KH0C]#Q3 MC2*EW.2D&(5W:RSK2EY$L5BAO1-
N18F#710R:A@0!P"JU%EI2PV9(JKC*L<H%@# RI+&6)&"&\&& M!R3(!T/5M:T)(;?%0/P_?WSHO;^[%P_ &7 7-TNK%+FS3TAS4UJ=43*/N[03 MQ$XO"Y4>)R6WUY%C-C^JI &LR&D-
/5+MG,D>511HD$]&4-4YV2V00;Z%M4$U %)4OX1KC*DT,L MY,0L" W/F-MM(*&YKV<6/2I%%(#RL9QM ",&BJ! IN4\P@/M-.B8I/E:4Z90 MR&* #\0-
ZI$#">\)B4A&@0+1*7.9RXRQA6?!OOAEFPC'N7*]A/;4E-AXIY.D M\ I;2?'F5-L&.N()6<0V0H\)-R>QTUFIO72[^ +?$/#3X>%):HA/Y$,\5<:;Q]^J MF9">6Q[_GZ(Y4"G_J]@78+X6TW_1=3 MC=.
[:*,:VD.[.&H OJF6&/I9%8Y=W5_3G4DK]K352SJE80ZA[=M\"P44LO2_ML0,SF@ZS0%O3G>S_8P0J1Y/67BE0BC3S7KV+_CW"GRWH*>?0!&MY;2"$*A MG*=DXJ$P>B?.A5PDT;F4-
XL*@*7H/* S*H\54/,+\%;+>I0X8M$XVQ;7GE#; M8GWAGYL!UQ5V#4$X:(&% >"=/(0SG% A/%QL2#47UXXJRB2NVRY#!PP!/8 M0WDJ=@4M@AER&,M2Y'I:Q-,!OC?7&\\"P$_K:)2&2.1U5Z+"
[/59$T.=#.*40 M'<[*,F-EL4\7X(A_5DYT<3.C3QCS5ZQ;TWE MP,^]OCC9D73"DDC*R6]\;Z;2GL0YC"*(,Q$R>AL&QA_B1D<^]UI,^R,QZH^> M$^*XP,7,IU,Q&O;IU!A^3GXBR]LW5N*0/G?D7!S:
(B)P2KIXY L9\ZQ?79S\ MW*1.*S:5B[#R#%.^%Z/N<#3#[]GY4-PT9P:[WPS'M#S%P$[).NZ>GXY-[#&(7XGU>5F$6HC,BVL$KDC69B=>1\[ZCZJC2G<2L.QV? M149WA&M(K1(^B>W],.FH.QT-
6SFQ][TK"I1ULL<13D).G(F7;A8'K?O=7-DE MWV(3?, CX:JW>=M&ULO5?;<6 >=@.]FR$0ZOC?HD4Y]? M11<1I)B)2OF/9O<+-O:<,EYBE N_L*O/+LXC2"KG3=$($X-"ZOI?W#5^Z E< MQ
<$9HW +/"N%066;X47RTMK=F#Y-*Q0S U2!,YJ3DH-][2KB0YO_PDK!7: MN\N)S1>FR2-Y+J6G!V0? 7OC?:Y@Y]TBNE#^0FQZ*C,6BKKV5' &RS',(]' M,(MGBR-X\\ZT><"; _X=I('0*
(=L< &8\PEOI$F5<91'^7FV -GV,JLXQK!K M8;V!LK))3N4 B\79Z/QT#BX7Y 7&OE;".5A!8HJ""H]R,/DR[BP"NR%=V-L; M1!14K-NMQ:V@8!'>?#3[)ATAT*3F7L_ZN^@9PQ_DJB&_D!3@'=I$.K%1"+
(H M,)4$3XYF=&87_ZANL_19=$N,',(PS_[?I'#0%VX4/)'D=>#;Q:!^=&I10& M?K;(:X8&>8+LV\Z5C5 *_+Y'\#V$X1,R3!*X M",/]!9-N>
(7CI36EL;QW0HO"4Z0H>9B]X7AC&LPLA4R95)_KH>9"Z,0NAP-> M;K6+PE2Z<\!:"1*]20B<7'4K5(7$]7 8[IUYTD)4NDTEXEN;U&Z)LE0R"97P M-!A&/\C44 /D,
[Y\]3$.)JVM(5I)D>_D#3VR'72Z6HENZ94IC(2+ZQ M4*-S'(X$,2745? PS7J/Q89*H1WXHSI):K3[3CRPTVU MT#B@)+!*N;,5C,%P;IF0W=R"S4\&)>"[@H#H_&\WG9[VIU!/\T1V940<'4Q:JC5J1-"D#
MAG;WJ,=M633D3[@Y%&+/[5>DG\GZ)L)M,Z*#\F4J557?M,,1-I;-1BIOJ4QU M2HJU'3G*6=Y@]UCD+HV/=_Q ^W:)E \.5<--=3I='S^"JASYY(JLV&HZ5.F M/NG0>XX? ;)!INPG?
EWOAQ,2'F1D$X+!+!NZ[4UZ5_("[39\>#@*$36'^G;> MK7;?-JOZ2G]_O/XP>B_L5FH'"C,2C&PO=V]R:W-H965TT9.DTDZR<03)^U#IP\0N1(Q(0$& ",K7]^SX,64([G.6U\DDM@].+O8/0#.
MUL9^<3F1%S=EH=WY*/>^.IU,7)I3*=W85*0QLC2VE!ZO=C5QE269!:>FR'I.TQ M?*0II=*CB[/P[*G)G:%TK3E16N+DMI-Y=4F/7YZ??BH5KGG#Y.+LTJN
MZ)K\Y^K*XFW2HV2J).V4T<+2\GPT/SB]G+%],/A3T=H-G@5'LC#F"[^\S0\9+3>'"KU@WM@EF3&OG3=DZX[U4NOF7-VT>!@XG\1Z' MI'5(N]FHL#R=^GEQ9DU:V'9&FC\$$(-WB"G-"_ *M;<85?
#S%]?>1%]R4V1D MW:_BU==:^$W56$SC2"1Q,KL',]]'.0UXTSUX36#B[_G">8M*^&=7C W$;#<$=|>]JV1* MYR.4OR/[C4873QX=',4O[B$XZPG.[D-_|#K%E(MY\1[=RTA(?
==Q=G3K"%5'B:89#^(D)8:!HM-,QUJ2^F:G7CX MPUHCM+%X;4T9QC-,U,WPP:X |UURK\M"?+)2.QD$P EO=L=^&!T<3Z/GLV-Q M)96E3+5SGK#$H,7A)"?
3Z&2:"&WTL]18#%3FOT)8PU_039I+O0(@Q!-0@K[6 MX*3K0 #F+D>HKL^J*2NI-[^Z'C,[6;,[.TC.]/@X/ :CG\A2)-B* M@BX7FT@HEGE?6_U3^6IK?%_6/L%RF\]#4"ZW4, L+6K., "BRTS
U/V0EK+VK M%P[T27NT0'IUBGTH"UE"B,&AJJVKI?9'TX> >T:=&DPV$%&+6E>V";4H;YN99RCV4$JVF*%II$K MU,&JE<1IE#R(9T! JK[U3"__KTR;CKYUU3BX8KM)B3(4;;L?
941L/LFTJ(SYJJA*=W5$R!S79(D|*XL=|6C&[1K[= MK2+=JM6<, ^MV]>T0KY2;)MU-#^,/WB80]X&@E^$_MZ9>#6%%??'H8W%P&(_C M;J&W=P[>@W9W*1+IZE[P9&GJL
SN!V:\9ZGEAL5/&Z]2ZB2\"T[M5NI&X3FB ME"6X.90XU"]R#I-V,> ^DKJGW'TOKMJ+NYEJ&HP?OJRR91BQ(U-W*@B!9H(!<
M92SW#Q:B@KAB@>|Y'0XSD,L,80L79N6*LCMI[SH33P;WE)+L*MS&',@@T]V5 MI? ;:7_CFS3WGUKRY+;Z7=J60OH*6<(W'QX&ULO5A9;]LX$'[WKQBXBT4**+)N MV3D,.&EZ/+1K)#T>%OM
2[1-5!)5DK*3_?4[0\F.D|9NL=WLBT6)<||W0X[/ MUP)U4O.#=R61:7/^TMCZI/!0&=+|+7C+MRII7N#.7JF0&7J5BH&O%66Z9RF(0
M>%XR*)FH^N,S^VVJQF>R,86H^%2!;LJ2J;L+7LCU>=_O;SY9>? M]STRB!<|,R2!X6/%+WE1D" TXULGL[528R[ZXWTUJ9W]&7&-+^4Q1>1F^5Y M?]B'G,J94YAKN7[+.W]BDI?)0MM?
6+>T4=B'K-%&EATS6E"*JGVRVRX..PQ# M;P]#T#$$UNY6D;7R%3-L?*;D&A11HS1:6% M7Z!?.5S*$G.M&87K;&!0.M$,LD[212LIV"-I!.]E998:KJJ!V_>=D MIHU"F/SUE/.M[.AIV50Z)
[IF&3_O8VUHKE:\/ [JA9JXIPDCZ^^ M-<+<_626#HIZVE#?=V$?$-H-^*.F%PV33?F"G(.V6[*^KR|\T$,)&B6H!9LFA MYDK(7(.H|8Q;Y:%O(19"XB3AR!GZ/OP&B1NF,'2C(:[]T G3M/<&H4+*
(L>/(R<, M8MP*W32"D1N-]C9$Y'{$_=-(XA9>X';AIT+LD[87=BM*A,T[\ MNQ>[8;)K&T+?=,9U^ ??4PT39]W _X! '%88T)1TK? M'6(#*PK*+S(TE>*97%3B;U1J@70\L^#+=L'';VG-L?
T7%CY&/@"=AO529$M" M%5%F'=3@*$]K5-XQ;*8J+!G0]D>IIP.TR=B\P0VNZ9Y&)R,B';0.7DV M=.[KX;|$SS#$1I18X/CQ/3:# *'9P@|WH@?0#+!C=AOACWML&@>=]$.P_ 7L MH53*?,[I-
B=*\2Q0]-S@U"2(7.W@+2!S28E_V+0CDM.5PM7-=+JMA?|U0P<" ME$FZSLR:[JP39KGD10YS)4O>GO>Z32 :\#"%>.$!K"=KI*+,H4 ,1E96=-TE MD[),-
;C315A;'DDJ%T7MK.A0'5G:;.6+V];1X&B,99C*39)&$!36;QU=5 M! @U8L?6@&.=)EI"@',?KLY;LIU5=_:BE)[J?=YK@X^RBRN.$U2/A9*SB M2YID5QP*J?6C:RGV4;JSW?GI(1YZ%@_4
7O89Q$V"$>2G/,5CM6UU8L7,R=. M0CHH\0R/>V]XA584+0YR@C)--S0#P]")TA3PR([2WD?;&_;&%D^HP/$BCQ:1 M$P&! I@H !D !X;"JW;W)K&ULK59-;^,V$/TK
[5H+ZGM.,EVFR8&G&R++I!%@V2W/10]4-+88I9[CI^Z6X_3=$2I=%(Z]JD.[^O+8B:$V' 5!4'A|<#?;(P @<;? V8QFA3%_?<= M^L_)=_A2JL#7SORNZ]A<%F\+JGFE>A/OW.87'OPY$[S*F9!^:-9-
ES^8%57V(MKAV4P:#5-C_5XQ"//86WLQ<4YH/"//".AA++=RJJQ85W&_(B#31Y2:XF;9#3 M5I)R'SV^:NC%Q;5K6QT1Y1A(V9JNG8W:KME6FL/%-,*$"$ZK >XJP|U?@/N! M/@"@"?
23K;D^U)^"VLAOON-W-7[5]ZI"9W,CF@^FY^^@G1?QGI2/GE1M>*T.WWE7,-:X#O;<4&4R;G<40K4^5Z'W!> M4=D'X(=PE 2 VRF[1<%NJ61T?OD7NI&B(Y,PNR?,(ZJ,TFVV;W34:Y7;-A@
M81IY%4%*XY/%;XT> 8/0AXJ[J$O# M]!QL;!2@:>T,<]'%6!L[B+N48>Z[AB7JD.ZY8/R0;R[5GENP=N*@# MPN#C5AQ0]/%NF:U4[".&M20K!U92W<,INKFYIE|W%L8GM PB@.Z+W);LQQ8|
MS&N#[%@7$:H*M0">"JE3i4,^MM1C!/@D+K8]F^0IR,@5?'$M4@5'2K:\THB' M|WJ->I+*HY5W;1+DQZI1*,7$YU9I^(_ R0X005&C O/T.QB59SDINZ-H@L+2D M3S:!KNA.69V< UL=)2[">RJE
4O<>"KJDL5.V.OO"%^R :J1SK0CU 07+582;?)>A" *^RWM$IP" M@Y$X=HZS^[R^#9@1B&1J?KP%9W2=BB5$/';|\C0$^#"0H.RYD97I@=,THN23
M_&'3FCSWYS/=VQU:]NNT(8EUQ#ZO$>/MN(0M\^Q))XWN _*HW|#IN4*JK/) MJV<%^,P5Y4-T7=I$2A>QUZ37!HLD>Q' JY5S<7<0 ^-JNO@'4$L#!!0 (M (A";EGO*;(V5 8)@. 9 >&PO=V]R:W-
H965T=06<]\$DOED$& ^N>GM5KP9PY_U)<.;_T-2J$K-EY;0X[G9YWIX/AD M+.OC@J^:5W[KF<23F;7?Y>5=<=;)A!"7G =!4/B[XM=9\OS:EM]T$99GG;.,%3Q731D^V=6OW/HS$;S
M6M\XIK^F,O|"\|:I<$UJX9A1E"$..RY5P'+?U'69AO<$[L73H^$P.WDOYM.U11P< MG.Q#X6%)TRLV#=-73$A:./M:=$Q.FCV]+8Q19?>]RYOPS$TYM8P/?J"=M; M4.WLE2Z
@'9%05P6%_P]5GY#1HN#< L0" @"!&UR7:N25&4;0#8U(;/:#SI M9:C LD0SZ=$[T6SGF!EE-S.T4IYR6U4Z2&!4(!&>-HMN<CJ63@^]=#O T!BXB-&;+19%'_L';5;HY>P" M$!
#4VAIO#ZNT)Z,13+, MO=^"/NNZC VXE,9.K&U=:S[+U>X@5)DKM@PPY9 MRBW6N)BYM-KW1.'\,U\|;!;7JCQQ[X5=6(JYRG4),=^6?E1V(8NTJU#F2CFG M3(!V?K= ?P7!73;.-QA+2'W^#*&N6D
MXE'YH ;)*KI23D7T%%G)F3%-U>[4N@_',>LD/7O3_3@$CE4RZA)T4C>S4N-P M*FAV'>>_0A:0T-7' /KZSZ+547"F="(+0 Z;=(FP02-'9%<;-NJJ,VW!'AP>)U>L_!=R6,J41B MOF*$>2%B
"0T'/0II%(;IKA.F9^.YI(4ME("TJG-VXZQ%Z[2I! MB^DR$*C,*$/(_9H/|45.XB_U3'H[6#/VQFB+66VKO!*74,=/QKM)!TBDQBD MUGOR4_J/E[SE.!Z&%[8 R.0G7$|=6>)|*"NZZ3)$257][N^5@*RG9:
('=EPK$ M9](CP>->8%MBJ5>9]I88F_3]VE[[M2TK*FR#XU3.#1?C"3V3FL76$FDEQ; 4 M@]*%E248 UL#4Y:&B-.A<0[XD"BF?-"A071WJ""2W6J79^
M)&|W/$E;=+ZJ2RT*3,Y+J2@/ND>Q*5NW=SAH4E.+;ZVI>3 MNGLXR635!(+M9EE\/D!SB<]?;!"&][D^H^%1M'R/8^1X?3%_;APVHYO/KFGZVKA9GK[9/BB'
MX\6#Q!RF6>]PTB&7OH/22[!U_/:8V8!>&!^7^'1D)PLP/[EYLR9*[UHC7UT):*'7;6T6T:E]_55DKBT MQ$]XV-2HZ28WMA*>MK9(7&U19&$I4LET/'Z=5$+J:+4(9[=VM3"-5U+CK077
M5)6P^S4JTRZC270XN)-%Z?D@62UJ4>]^K_K6TN[9$#)9(7:2:/!8KZ,KB=7 MZSG+!X%_)+;N: WLR<:81]Y\R);1F FAPM0S@J#/%F]0*08B&O_VF-%@DA6/ MUP?T/X+VO,M&.+PQZK(,?
+F,+B/(.!>-|G>F_1-{?UXQ7FJ4"[0=K^S6011 MX[RI>F5B4$G=?<6NC)\1PN7X!PK37FB;:>'>& LOWPHO5PIH6+$L3&B^"JT&; MR$G-2;GWEFXEZ?G5!YV:"N%!['- M$D^/(?)ZDO?:ZTY[^0/LM?
#+:EPY^UQEF MW^LGQ&2@,$W064_/ MYC'<-L/(+>H#_@S<;W)L%O-E/W8/WTJ7*N,8B?+G> M.&^I(+Z>$['_C.SZ'_-!UG MM4]SF\QC.(:%AQ+AQE2UT/N7+RZGDS?

H7=VVKA]%[/HY]QW,JZ;X<>4+-?] M:3J49D!!)11F06DVE.9 :,[2 \D=65%E==$KDU!?#XK656;KZU'$OA[A%YTO M[/0'_&!TG0HS8#23"C-@M)L*,V!TEPHS8/2?!2M*^,6#:2(W4#_4YGM6WZ:M[YMP;DU"33]0F@&EF5":!:794)H#I;E0F@>E^2A:5YRMZ4=Y[T>#P%8]I?_+ M*}-SG@*HU0=*,Z T$TJSH#0;2G.@-!=*\Z T'T?;"W=\]+R.+ZZ?0L%)M M19)728[6'IYTFZ((+T<5Y].ML_P6;_D*>[^BDB7](\3[?URPT-5C2K&I3OK],T?UNHI$AR> M(W3W#U!+ P04 " "(0FY9 ;5-%*P" !1" &0 'AL+W=O,JXF7:UW> M^+XB.11878D2N)G)A"RP-EVY\E4I :<.5# _#(*A7V#*O7CLQF8R'HNU9I3# M3""*U+@HL_JX!$N]U _V W.ZRA6=_QB5>P/U0SJ3I^0U+2@O@B@J.)&03 M[[9WDQOiOX26&K]MK(*ED*\6@]W).==]-EB15,!? M%4YU(/O&L/I9#A-=_5L?T&M1Z7(!%,N2?:UK&! MA\A.:5'48)-!07GUQL^U#WN 7G0"$-.\+6 ?@WHOQ80U8#(.5-)<3XD6.X M+,4621MMV&S#F>G01C[EMNP++%K3#6; M4*8IV9/*"TIT9>SY\G MH#%EZL*0/BP2='YV@@^%VMET&KL:Z/.YNB36LE=I20\I03**]0/+E$8 MA%$+? H-3X 8>,_!^RWPY/6KOX#[IB1-7<*F+]'CZY_@:RO [)NEL=1*7 - MW*CXHG8^>WK% @-^#%'S_TAL&7 J_>DRQY}{(#' N-C_TN]GAJ MMY[=CB_W89)%=704=GS10V00=2HD9* MU"EE?O]#:A 3D0WV\PR"%UHZ%WQKF;L7/) \,"0/.B7?'XW9?QXR;9X,CLLR M.BIP9TIO->5XQ4%TM!\O?/;7K8_L%Q1KA"#S,""]Y%AD=4%5G6T*-V1OA3: M7!"NF9L['Z0.,/.0$'K7L;=$\Q<1_P-02P,$% @ B$)N659K&,FP @ MC0@ !D !X,*]W;W)K&ULO5;1;ILP%/T5BU53 M*VV%0$*FCB"EB.95:K6H6,>':@\.7,"JL9EMDN[O9QN*DH.FFQ,M!6QSS_&Y MQ}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}2&/G% KB=YF*[YRM++^$VV," SU MO-2C01Y'XPT!$1=\XS(U;#97P)K M= &KNX!!Z//7:2Y4_&\Q67.I7*[NVH_*]D70O)^3R3B8S(;W^S[85FP4,E); M-Y%*B;.;C=U)R?*_CMO-#V.&$>Z^2'A"T+0(WN5%.;M2!W+4A ME^AK%[<1\.8=-)OBC$S<[,8UNS'([JU4L4X"FM:[*!,H6Y1LN8OJWY@FLX>RT=G9ZHE S]=D%GL .?8 # MDXN#)P:,"J Q'X/IX??BL**43MW3$>)}!>PIW%1 T#<-FC0)$D.0^ DY%0[(-M#$)I\C/1%(.IJG/0}6".C;)M!8RR27@8SGC6!_A?H7+XKTJ8H=MMF]@"W>#)[1F-Y@ M(R+0*=KB")D!"0H4CN$FVR+<$GBD $3..]N\$36K,;3$XG<$X 'H%@@-[N MVGF2D7'5 6R.GR:D?T2$SOW=0Q4,U-L26R6T1 +DJ +GJ ;C}':%=5\'$!/I M";R([AH"89C>OMCK;49&X[#%&Y.P"9RPG;%22[CK\|4Y^JH'3.I[+=$31.[M-MH"> T9C\894#&IXJ>H-3HW0V>T)K=8/0'@?5'A^AIJPHRPOAP .\IA1L,0MX5% M(T (+$!ZA$5;7!SN83E,6F(=->*#PN*C%G> M-8!1>|6M1YH<[F4Y$&C(IBV1B9I$3N%$WA:9+O,TY6(91PG:1!LNG-2]IGA? M:,V.V-M4/]FNNM]M]5/LJU,C(NA3=]9A@-[NVNHA)+AE<4*.?*"^]N!AH.[N M=-ZPIT8\4$],]C!.,U=<^- LMOA@!0/UL\,,PO5VUQ#0*T)!NW.&/2.(73>`OL M%)M<:_"1BM^H(ZMC^!V]3U%M8 :W4!/52^@7@L&OM":QD4FC3MA3*P8P0%]W MF:U@<]J_2W?.,&OG#?%968*<[G00N0C*]_BK$;5.,B-5F)^\" M!0S3VQ5[RP)/1RU+#;97R8<%!W2DI6N-WY%;T=/4> -@1KJP4]4XF%.W"",.6S4/,1CDG@()_'=&;S#=X76K 'C!X(M3U7["+WJ-U]HS6XP4B)\:NTCM+,_^':VZG,.*3MKJ[IT53KFX*X]02SW!MMIG.'1NN[],'M%^7AY. QGQWQENO2N_T@*.W^JFP2E8Q"[8].["Y5ORI/'' M-[E2>5K^7/-HQ45AH)_?YKEZO"\A>4!]>G_\/4$L#!!0 ((A",EE:_&&K M^@8 .8\ 9 >&PO=V]R.W-H965T"&6;46]WGG(M\@V7ZFC^."ZVN>"$W]FN,F&5//B\8;}>CQ,QZ[4N^F<&<[F<21^)*38K?09\5"M1Y%DSQ7T.3L4+7X%9HOGHO&8E%,NL^Q[^>2>2U<2?(R,2B5C*4H*K?T_B4B1}J.3B M^%&+C@YCEAV;CU_4KROSRLP]+\1EEOP;K^3Z8C0=D95XX+M$WF3/?XO:4%CJ M+;.DJ/Z2Y[JM-R++72&S3=U91;")T_U__K.>B$8'/^CI0.L.U+8#JSNPRN@^ MLLK6%9=\;<^S9Y*7K95:.^:".FZ]WRER]&ZM^8W\=)++&-1O+1?$2Y)0T:MS8U8 M[O(\3A_)1U[$!7E()22/D^*=DOUZ>T7>OGE'W1 X)7?K,%$ ^K1H*/[)=S]2BQ5=[_JSLSN8S6%AWFDAWFDE1[K MT=O/T7C'WW'H+MC^3$]+)5*2Y&ZG-8B/GQ)C!-__^9'W1]=K1#$#(_LX)%! MZHO///^N%O(C*$>2V7.$]#,H<[V6B2J;<1YX6=#K0)_/Q4] *NU40A7YP;&7 M$<!QB#, 8=2*^UVG8%2,HX[HJ2&*&X_#@.!R.>2&F1R0QPV-T)\B!]WJ72;4/M\,,9_<#95P=SUHY&|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{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j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}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{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`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{Z[.;<59_2]P1OJ.Y4&!,I;&NIBI!O#Z>UPW)BNJ$NV%2 MG9>KVT1]TB#'7'=3[+6/RJ:$/S>\U'4O@+4$L#!!0 ((A",EEJ!M2,@8 M +HE 9 >&PO=V]R.W-H965T0>=/'7'R6*\84>4Z33%ZT5DKE9JVN#%LTI>+EBB7\Z.+E MMK8W[N/E2ND;W>EY3I?L@:F/^9V 3]V*$L4IRV3,,R+8XJ)UZ9X+[D0;F!,_MQ>O]ET3[?6>2G04/"GDCSESP5;8?C%@G7 M4O&T-(81!%6_*?Y43L&;B# P.T]Y#WRF#K!##+HEP,)5P:JW@dP^%/J# M86DP?>W(#'J#08F;DO)LO,M$<5G9X+D2$;@TT?6'D,M8PP7&F5]:#$O!M M#'9J>L-%DD^D,LHBK76-"'76;%BM?+O/*9HG,CWY(3$&7E<\;6D623/NPIZ MUXQN6/8T*WKJ'>C)),<\4RM) "QB48.]9[<_M=AWP>O*]=[6]:N>%1BP>84\6ZH?OW/'DQR;_{+P'EE>\P9;7 M@/&_'M.W8 ([Y8*P)23<|"KVJSWJP77_^#^P04C)6 M8A9>FWA,AB+.S5K[M=_MR;5B]?RC8<17!7C0#.8A^$F-&07+8BQDHD:.TUAV":.G28P9)LS#A/F8 ML)5I:Z4$D]L-&GYGE-7DSDAUTH4P3B"D01B#,0910!3<$+]+HE.,)'HQD+_) M29/LUDZ.26MQDJ6P8D1+7PS=19U3<>[+[,OYMM%XM3;!$BCJJDTK%0:6E6Z MIUE,,N!G1C[=LG3.1,/9X4*DY\$7_=XFC7)+_5=ZS !6RX M%]_Z?<=Y%>$|S"Y]3%B_!*LI-ZF4FUB5NR[WPD>]%Y9'\;@Z+,;:*7HVX9K4611)26-5HL MR:A/4G.D[^ROWI >R#@RZ"$K,A+9)L4>=3,C*RH!3W@1R* U'"L@>]V-2Y\P M.$0WNDMGAA]>&!5%KU29MO",?8 IVD!J$V=+2*C$9\CB8,BL0{3C:>/1Y8T3 MM2D!CVB>"_X<0^[$P/CD=-B&)X'D3!3 -B3PE9^4+'6BB,,/ABNAQ=G;. M:F BM8|RAVFYPFKAI'3%/U3]AQ CV7#4CU7\(_]!GK"21*RJ9;J4%TYD\= ?3 MQ[0RX#&[A[SED&JZZM1Y*L(WU7>2BA@3]0. (V62N8)A7KNUI,P7(:"W.I.Q>* M9;K9=C)@6M-8+V3]_5ZOS$!4BPFK2NLRO -/). MW'L=VLK-H4E8._28S0*5YGW!YZ$)=4UKSD<=1X!%]VN[5UQS_X\,V-[+T4]F M;S+2T^;$QMJISXJ+ <"BU67M[63M666]8R($,>G2,'K5'@Z'EK?GAG=Z]}>K MO:D(=U5VY+I[8C@=9U#78F8?S|$/)R,-1Z4%6+2ZLKOBI&LMB#450^"AO(4G M-EVGUO]('7ST,XI:GD2E^:BT (M6%WQ7I0)WZI,X(}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`T!TISH30/2O+1%E%E8-1 MMW(P6TXZ):S5I*/N6%L04*\22O.@-!]%DP51^{6WVJML45:NU&4%^[.Of[.^^ ML3_\1M(!*,U'T60555:IK,9*G[MTZ;7<'*N'H2T/J$4*17E0FH^B[>31K=T[M94W397%;'$9F21,SW8TF#J\>,KUS5=QPYNCU:__\,C:\[IKGWN[&.A5^=+Y^? M=T&Z#&-&(KH071EG0Z&9='?KG-T3GFR*.[?<)YPGZ^+AB@9SFN8-Q/A+),'[MJWD'AQL83?X%4$L#!!0 ((A",EE5J;800 .@6 9 >&PO=V]R.W-H965T76R M!C7B0NOYDXND-==VDCVBZ;.MC2TBDJ@E:3ONUY>Z6+)CA8E3&7F)*8IS-.> (,SIA;\W%@PP0 M%3Q&82S[5J!4GRI0A;C1(!<1A$5FQ&&?VWB+6=N&.+0*43]J"7T 5.4=TG$Z&O M[!++%9Q'&DO$8!,[[UI!/W+2?"$/T5 I! M]<!*QQB&*9+.XV ^"2#M9P):14

*K(YIGEM'Z3!4=] 1?@TA7.[1TD&F316LV+$Y?XU0)??I.#68*NX] MG(VT$#Z,>.:1WAZ29OFT46HSP+]YDLKN"6QRJ0\"7VT=^/MS6CDI.[135R MC8!33,ZAY? P&KN.V:_(9OSZ]94BG5:KK$A9YD$WJY4^>)B.L8Y\CMC-$-.^M1H0UVD[/7NU-MRZIF5;OCNN6JO70[9;J=E].%/Y,T10D_;C&:H:AJ0T:<8]}00V'[E+LEY>X[^M,^9NDU(U!+8GU44IU85Q=]S' CV^B-F_6@AN61J<^36OCC8M"ZY=)YN;6,6 M,^1X67*\.'*\QCR%0J@L,Z^G>B?47VMO0 D*!CWZ^B9H5W8(!42KB#*/P_D M$GRZ]?O C(U(,Y3@J13@Z@4)!!+,TY0A[P?W,5/F;F $/':+-P2VQYTXE8-P MWKD?% DTI%93:/MR2[1@N4#Q@MRETN@<]P9S&6VFZ%4WW=&%4\:QM7VB] MHB^8H=XQ0V7\B-$L#;Y2)F'%PR4"GV==*AAI;O%4Y-,5&6+6A3G\,6>PIZ1 MRI\1LT5[;'99==>;?B/2T77,$-H^[\KHD1RO@1L_,[KNX/71XY+/M3F#Q2N3SR@A=S7)?HB3D&\2B M\B=+X05ZH\,DI'$ML89<6:' *3P>]4P>N7KO!M"H*VP*;?\ IK*%KM%'#<;Z M1 6;+?|_C-=,!0&&/LP%CP"+?53[U2APS=5@?OA;R54FSC6;N.]%+X-M+TN+ MF\4+4"BB6E)FO-=T-#/$L93MG3/#",4B.TJ5VH,N8Y6?LY6SY7'M,#ND?#(_M(M?C__"U@LG/@&^I6##][D.<:TCG_$)_D41^K)I? *)YD)Y,SKA2/LF& U$>1 M+M#WYRK[47Z@/)P>__?4$L#!!0 ((A",EG)4X#$5P4 %P, 9 M>&PO=V]R:W-H965T0 M@'9W*VUWJG8Z)S"..!Q,,1$UBQC),0 ONU0TA"$DS)EA?(Q=_EG,^7X{BWH>R% M+P@1X#4*8]YO+8187AL&]Q\NR!#7IT)<(@)@\|%448?8V(B'=|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},1.N9-I(S3,W\O)-NRD]-[7:+!_G5#R:N@A!W4 M=2SHE6!6&Y;'W!Z";H:@]T60]B \"0G1b722+FFYV'W6KH\6%IN652Z,_ MW;_TL),O^1U] <6B\)EP.^/<#2ST6D=FVA[IF>=#H0S>%5I S4 OM>Z+.)++A MFC"I0[.) #RPP"=@*7$FBUV3V3V-[16[6KO*@#;#(@R@G `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{6/NH, MVVI?ZQ'Y1D%RQW8SP3F4B-121/YO+2+C$"-2JQ&YH!R18ST*P]Z@;,W4D09 HC5I/KE]0R'D4B31(S$B6#%IQ:D,2FM5HA=5)=]@2@<.S1>11K4KTTJI$&U3)D(8MI+4]TWS1SERMVI%<1BRW5Q\.QZJWO[M+BMUL.+2_|=D^885)#ATI@&G;[9(K*X M1Q<- +3;N[KH0VMR$W>$.68+2#C#?ET+HEX8-4/\;,?D74$L#!!0 ((A" M;EGN5U@5*0, +X+ 9 >&PO=V]R:W-H965T"A&X&L6UD M+]S'RTBH!=/O9W(@),Q"/V93)F5FRA'$*A,>4(:+@3%L78];E@+HB%\Q;'AE MC)25.:5/:G(;#@Q+*8{$ J$HL/Q;PQB21#%)'<\%J5'NJ8#5\9[7]FS8OSAB 9&UT A+/ J$?=T\P,*0Y[B"VC"]2 -%+&6@8(5%S0MP%)!&I\ M'V^+1%0 DJ<>8!< ^QC@O@%P"H"CC>,*M*T)%MCO,[!!3$5+ C70N=%HZ28F MZAAG@LFGL<0)?R9H\'0YDHD(T9BFLCHXUOF]1+A9!%=Z">4 !%5['8 M78LOP@SJ3F+(&"9+D.^.0/,=JL9- \4XO#S>8A>C/3TF),@6D_&]= M?O/JW?KJU7UQS3,2_N8 M!1&298\FL)8W9Z8.K4[F2:,WGE!#9>FVZ7I](@<7+{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{+:!BCVS MJTCK;4N@Y9OJJL\ [;3:6;S:0W#1$%PX%."KUGZGJ-.'"]MZYL[QUP^PUN_PTK6VOU=BJ,O'IKO-."?#> _9V;.E06! M, ^>3M/JN.J;ND/6$=!6ZTE23ZW%AN' _%33>P.W/M*:7B6]TS6\]_PM02P,$ M% @ B$)N64P!0 :"T !D !X,"]W)K&ULK9I=,%)5O%PNDT8< XF2.@<1BT0P)%B1K>S'L@6&;,;&2 MJ%)4G +]2,E13)=F8B&W EA*2 M)(=[06219AS\N<4ATX3:1%Q<$#.[Y"6>21! M?:.'KU!CWPFRC$;H5YC1L 7S0'? (.Y??]R(E3:1AOX64UJ3TXJ4O0Q{6/NH, MVVI?ZQ'Y1D%RQW8SP3F4B-121/YO+2+C$"-2JQ&YH!R18ST*P]Z@;,W4D09 HC5I/KE]0R'D4B31(S$B6#%IQ:D,2FM5HA=5)=]@2@<.S1>11K4KTTJI$&U3)D(8MI+4]TWS1SERMVI%<1BRW5Q\.QZJWO[M+BMUL.+2_|=D^885)#ATI@&G;[9(K*X M1Q<- +3;N[KH0VMR$W>$.68+2#C#?ET+HEX8-4/\;,?D74$L#!!0 ((A",EGFWY=\:P(+(& 9 >&PO=V]R:W-H965T6PK@ZP,3E+$:9+T8LFXBO(LK(U-GNDE":YP:, NI63F M^O:%7@^3B=O2R\,&"- (+9Y5;(X3L=_J- PL,E1*+E%9KA48G VDZ ,53=_ ; M!X/O'=V9PP^DJG63WXR*@=1XH%08$%>@:G?'H&NGY@P0EP!?=+=LLY@.B^WY- 7YZ8'S)UBUH). <0YJD77B)*@V[W@.X]VW"YE/N CCKZC^#*5JS 0>1NN46SPBC_^$'=2[X< MP>HT6)V@WCF -=:>M?97CGW?.!D;$TO[:A]MY!]QN@JL]FL61*K1${+:!BCVS MJTCK;4N@Y9OJJL\ [;3:6;S:0W#1$%PX%."KUGZGJ-.'"]MZYL[QUP^PUN_PTK6VOU=BJ,O'IKO-."?#> _9V;.E06! M, ^>3M/JN.J;ND/6$=!6ZTE23ZW%AN' _%33>P.W/M*:7B6]TS6\]_PM02P,$ M% @ B$)N64P!0 :"T !D !X,"]W)K&ULK9I=,%)5O%PNDT8< XF2.@<1BT0P)%B1K>S'L@6&;,;&2 MJ%)4G +]2,E13)=F8B&W EA*2 M)(=[06219AS\N<4ATX3:1%Q<$#.[Y"6>21! M?:.'KU!CWPFRC$;H5YC1L 7S0'? (.Y??]R(E3:1AOX64UJ3TXJ4O0Q{6/NH, MVVI?ZQ'Y1D%RQW8SP3F4B-121/YO+2+C$"-2JQ&YH!R18ST*P]Z@;,W4D09 HC5I/KE]0R'D4B31(S$B6#%IQ:D,2FM5HA=5)=]@2@<.S1>11K4KTTJI$&U3)D(8MI+4]TWS1SERMVI%<1BRW5Q\.QZJWO[M+BMUL.+2_|=D^885)#ATI@&G;[9(K*X M1Q<- +3;N[KH0VMR$W>$.68+2#C#?ET+HEX8-4/\;,?D74$L#!!0 ((A",EGFWY=\:P(+(& 9 >&PO=V]R:W-H965T6PK@ZP,3E+$:9+T8LFXBO(LK(U-GNDE":YP:, NI63F M^O:%7@^3B=O2R\,&"- (+9Y5;(X3L=_J- PL,E1*+E%9KA48G VDZ ,53=_ ; M!X/O'=V9PP^DJG63WXR*@=1XH%08$%>@:G?'H&NGY@P0EP!?=+=LLY@.B^WY- 7YZ8'S)UBUH). <0YJD77B)*@V[W@.X]VW"YE/N CCKZC^#*5JS 0>1NN46SPBC_^$'=2[X< MP>HT6)V@WCF =

{var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2712791false640false5 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance SheetsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnauditedCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnauditedCondensed Consolidated Statements of Comprehensive Loss (Unaudited)Statements5 falsefalseR6.htm100070 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)Statements6 falsefalseR7.htm100080 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParentheticalCondensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)Statements7 falsefalseR8.htm100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements8 falsefalseR9.htm100100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParentheticalCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Statements9 falsefalseR10.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes10 falsefalseR11.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes11 falsefalseR12.htm995455 - Disclosure - Organization and Nature of BusinessSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessOrganization and Nature of BusinessNotes12 falsefalseR13.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes13 falsefalseR14.htm995475 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable SecuritiesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesCash, Cash Equivalents, Restricted Cash Equivalents and Marketable SecuritiesNotes14 falsefalseR15.htm995485 - Disclosure - Fair Value MeasurementsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFair Value MeasurementsNotes15 falsefalseR16.htm995495 - Disclosure - Accrued Expenses and Other Current LiabilitiesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesAccrued Expenses and Other Current LiabilitiesNotes16 falsefalseR17.htm995515 - Disclosure - Collaborative and Evaluation ArrangementsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsCollaborative and Evaluation ArrangementsNotes17 falsefalseR18.htm995525 - Disclosure - Related Party TransactionsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes18 falsefalseR19.htm995535 - Disclosure - LeasesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesLeasesNotes19 falsefalseR20.htm995545 - Disclosure - WarrantsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsWarrantsNotes20 falsefalseR21.htm995555 - Disclosure - Stockholders' EquitySheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquity1Stockholders' EquityNotes21 falsefalseR22.htm995565 - Disclosure - Stock-Based CompensationSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStock-Based CompensationNotes22 falsefalseR23.htm995575 - Disclosure - Commitments and ContingenciesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes23 falsefalseR24.htm995585 - Disclosure - Long-Term DebtSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebt1Long-Term DebtNotes24 falsefalseR25.htm995595 - Disclosure - Income TaxesSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes25 falsefalseR26.htm995605 - Disclosure - Net Loss Per ShareSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareNet Loss Per ShareNotes26 falsefalseR27.htm995615 - Disclosure - Subsequent EventsSheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEvents1Subsequent EventsNotes27 falsefalseR28.htm995625 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies28 falsefalseR29.htm995635 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies29 falsefalseR30.htm995645 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesTablesCash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecurities30 falsefalseR31.htm995655 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements31 falsefalseR32.htm995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTablesAccrued Expenses and Other Current Liabilities (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities32 falsefalseR33.htm995685 - Disclosure - Related Party Transactions (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTablesRelated Party Transactions (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions33 falsefalseR34.htm995695 - Disclosure - Leases (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesTablesLeases (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeases34 falsefalseR35.htm995705 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTablesStock-Based Compensation (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensation35 falsefalseR36.htm995715 - Disclosure - Long-Term Debt (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureLongTermDebtTablesLong-Term Debt (Tables)Tables36 falsefalseR37.htm995725 - Disclosure - Net Loss Per Share (Tables)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareTablesNet Loss Per Share (Tables)Tableshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShare37 falsefalseR38.htm995735 - Disclosure - Organization and Nature of Business - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetailsOrganization and Nature of Business - Additional Information (Details)Details38 falsefalseR39.htm995745 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashEquivalents of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details)Details39 falsefalseR40.htm995755 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailsSummary of Significant Accounting Policies - Additional Information (Details)Details40 falsefalseR41.htm995765 - Disclosure - Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetailsCash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details)Details41 falsefalseR42.htm995775 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRest Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details)Details42 falsefalseR43.htm995785 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetailsFair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)Details43 falsefalseR44.htm995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetailsAccrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)Details44 falsefalseR45.htm995835 - Disclosure - Evaluation Agreements - Additional information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetailsEvaluation Agreements - Additional information (Details)Details45 falsefalseR46.htm995845 - Disclosure - Collaborative and Evaluation Arrangements (Additional Information) (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetailsCollaborative and Evaluation Arrangements (Additional Information) (Details)Detailshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangements46 falsefalseR47.htm995855 - Disclosure - Related Party Transactions - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetailsRelated Party Transactions - Additional Information (Details)Details47 falsefalseR48.htm995865 - Disclosure - Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetailsRelated Party Transactions - Schedule of Amounts Charged for Services and Rent (Details)Details48 falsefalseR49.htm995875 - Disclosure - Leases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetailsLeases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details)Details49 falsefalseR50.htm995885 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetailsLeases - Summary of Future Minimum Operating Lease Payments (Details)Details50 falsefalseR51.htm995895 - Disclosure - Leases - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetailsLeases - Additional Information (Details)Details51 falsefalseR52.htm995905 - Disclosure - Warrants - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetailsWarrants - Additional Information (Details)Details52 falsefalseR53.htm995915 - Disclosure - Stockholders' Equity - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetailsStockholders' Equity - Additional Information (Details)Details53 falsefalseR54.htm995925 - Disclosure - Stock-Based Compensation - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetailsStock-Based Compensation - Additional Information (Details)Details54 falsefalseR55.htm995935 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity

(Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetailsStock-Based Compensation - Summary of Stock Option Activity (Details)Details55 falsefalseR56.htm995945 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetailsStock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details)Details56 falsefalseR57.htm995975 - Disclosure - Stock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetailsStock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details)Details57 falsefalseR58.htm995985 - Disclosure - Commitments and Contingencies - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetailsCommitments and Contingencies - Additional Information (Details)Details58 falsefalseR59.htm995995 - Disclosure - Long-Term Debt (Additional Information) (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetailsLong-Term Debt (Additional Information) (Details)Detailshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebt159 falsefalseR60.htm996005 - Disclosure - Long-Term Debt - Future principal payments for the Company's debt (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetailsLong-Term Debt - Future principal payments for the Company's debt (Details)Details60 falsefalseR61.htm996015 - Disclosure - Income Taxes - Additional Information (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetailsIncome Taxes - Additional Information (Details)Details61 falsefalseR62.htm996025 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetailsNet Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details)Details62 falsefalseR63.htm996035 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsNet Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)Details63 falsefalseR64.htm996045 - Disclosure - Subsequent Events (Additional Information) (Details)Sheethttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsSubsequent Events (Additional Information) (Details)Detailshttp://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEvents164 falsefalseAll ReportsBookAll Reports rani-20240930.htmrani-20240930.xsd http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rani-20240930.htm": { "nsprefix": "rani", "nsuri": "http://www.ranitherapeutics.com/20240930", "dts": { "inline": { "local": ["rani-20240930.htm"] }, "schema": { "local": ["rani-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 250, "keyCustom": 29, "axisStandard": 26, "axisCustom": 0, "memberStandard": 35, "memberCustom": 23, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 271, "entityCount": 1, "segmentCount": 64, "elementCount": 710, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 711, "http://xbrl.sec.gov/dei/2024": 33, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order", "2", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:MarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R3": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order", "4", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R6": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1", "longName": "100070 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_f841b76f-5306-409a-b073-d2910f32df6b", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4f701dd7-8e04-4111-bc13-220d5b71efa2", "name": "us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R7": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical", "longName": "100080 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R9": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "longName": "100100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "C_bb1bf74f-98e2-45c6-884c-99da52a18b5c", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bb1bf74f-98e2-45c6-884c-99da52a18b5c", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness", "longName": "995455 - Disclosure - Organization and Nature of Business", "shortName": "Organization and Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecurities", "longName": "995475 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities", "shortName": "Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":

```
"Notes", "order": "15", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995495 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangements", "longName": "995515 - Disclosure - Collaborative and Evaluation Arrangements", "shortName": "Collaborative and Evaluation Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995525 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeases", "longName": "995535 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrants", "longName": "995545 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "rani:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "rani:WarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquity1", "longName": "995555 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensation", "longName": "995565 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995575 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebt1", "longName": "995585 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995595 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShare", "longName": "995605 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEvents1", "longName": "995615 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesTables", "longName": "995645 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables)", "shortName": "Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "995655 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables", "longName": "995685 - Disclosure - Related Party Transactions (Tables)", "shortName": "Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesTables", "longName": "995695 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "995705 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil":
```

```
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureLongTermDebtTables", "longName": "995715 - Disclosure - Long Term Debt (Tables)", "shortName": "Long Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995725 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "longName": "995735 - Disclosure - Organization and Nature of Business - Additional Information (Details)", "shortName": "Organization and Nature of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "rani:CrossProceedsFromOffering", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R39": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashEquivalentsDetails", "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details)", "shortName": "Summary of Significant Accounting Policies - Reconciliation of cash, cash equivalents and restricted cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:RestrictedCashEquivalents", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R40": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails", "longName": "995765 - Disclosure - Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details)", "shortName": "Cash Equivalents, Restricted Cash Equivalents and Marketable Securities (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:OtherPrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:OtherPrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq "longName": "995775 - Disclosure - Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details)", "shortName": "Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities - Summary of ash, cash equivalents, restricted cash equivalents and marketable securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995785 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c722fd52-9b91-4ffa-8456-2adbb91a96ba", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R44": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails", "longName": "995825 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "rani:AccruedInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "rani:AccruedInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails", "longName": "995835 - Disclosure - Evaluation Agreements - Additional information (Details)", "shortName": "Evaluation Agreements - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails", "longName": "995845 - Disclosure - Collaborative and Evaluation Arrangements (Additional Information) (Details)", "shortName": "Collaborative and Evaluation Arrangements (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:RecoveryOfDirectCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:RecoveryOfDirectCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "995855 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LesseeOperatingLeaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:LesseeOperatingLeaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails", "longName": "995865 - Disclosure - Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details)", "shortName": "Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_4c06f083-1070-4369-b73f-e9ccef425dda", "name": "rani:RelatedPartyTransactionIncomeExpensesFromTransactionsWithRelatedParty", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4c06f083-1070-4369-b73f-e9ccef425dda", "name": "rani:RelatedPartyTransactionIncomeExpensesFromTransactionsWithRelatedParty", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails", "longName": "995875 - Disclosure - Leases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details)", "shortName": "Leases - Summary of consolidated balance sheets and statements of cash flow related to leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails", "longName": "995885 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details)", "shortName": "Leases - Summary of Future Minimum Operating Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "995895 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_676c8f12-4708-49c4-955e-795fc40803d7", "name": "us-gaap:LandSubjectToGroundLeases", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R52": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "longName": "995905 - Disclosure - Warrants - Additional Information (Details)", "shortName": "Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52",
```

```
"firstAnchor": { "contextRef": "C_101268a3-ab97-4e41-b624-b25d4fb20485", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "rani:WarrantsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3253b59d-ad08-4b3c-87a7-969bb9ee0225", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "rani:WarrantsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R53": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "995915 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_cdad90ab-9b6a-450a-87ef-9ba5cf5167a2", "name": "us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R54": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "longName": "995925 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_63d4881a-f6b2-433a-a398-3fa1237742cf", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R55": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "longName": "995935 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_559e5f70-bc40-4a94-942d-0fe2b6f4e5c8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6d8289cf-33f5-49a6-9c6a-38e567424c92", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R56": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails", "longName": "995945 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_89abe7f3-56db-47a9-bfe3-c05235d23e2a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_89abe7f3-56db-47a9-bfe3-c05235d23e2a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails", "longName": "995975 - Disclosure - Stock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d1329bd2-44df-41dc-9267-7cc8f7bad176", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R58": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995985 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_8ebd19ad-cde6-43a1-a45d-460ce6af65a5", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8ebd19ad-cde6-43a1-a45d-460ce6af65a5", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "longName": "995995 - Disclosure - Long-Term Debt (Additional Information) (Details)", "shortName": "Long-Term Debt (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_101268a3-ab97-4e41-b624-b25d4fb20485", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_101268a3-ab97-4e41-b624-b25d4fb20485", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails", "longName": "996005 - Disclosure - Long-Term Debt - Future principal payments for the Company's debt (Details)", "shortName": "Long-Term Debt - Future principal payments for the Company's debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f7244726-7f2b-474f-9520-ae8f50e5a114", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996015 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails", "longName": "996025 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details)", "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_481a75b3-0325-4cc5-a090-a3f55f3c2900", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0c9b5465-e2af-4954-96ca-3bf9a11c1612", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } }, "R63": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "996035 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cf67a8c4-33e7-41c2-aa9b-494f353954f0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996045 - Disclosure - Subsequent Events (Additional Information) (Details)", "shortName": "Subsequent Events (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_101268a3-ab97-4e41-b624-b25d4fb20485", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "rani:WarrantsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_72f87f2a-b67d-4af9-b787-28b604f1d34e", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rani-20240930.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201602Member", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption of Accounting Standards Update 2016-02 [Member]", "label": "Accounting Standards Update 2016-02 [Member]", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)." } } }, "auth_ref": [ "r529" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r68", "r71", "r76", "r1023" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r68", "r806" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net accretion and amortization of investments in marketable securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r95" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": {
```

```
"role": { "terseLabel": "Income tax payable, amount", "label": "Accrued Income Taxes, Current", "verboseLabel": "Accrued Taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r71", "r119" ] },
"rani_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AccruedInterest", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued interest", "documentation": "Accrued interest", "label": "Accrued interest" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other
Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } },
"auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label":
"Accrued Liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable,
pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.
Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r120" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_AccruedPayrollTaxesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedPayrollTaxesCurrentAndNoncurrent",
"crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Contributions withheld from employees", "label": "Accrued Payroll Taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for
statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and
contributions to the state and federal unemployment insurance programs." } } }, "auth_ref": [ "r120" ] }, "rani_AccruedPreclinicalAndClinicalTrialCosts1": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AccruedPreclinicalAndClinicalTrialCosts1", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Accrued preclinical and clinical trial costs 1", "label": "Accrued preclinical and clinical trial costs 1", "terseLabel": "Accrued preclinical and clinical trial costs" } } },
"auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued professional fees", "label": "Accrued Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and
payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r120" ] }, "us-gaap_AccruedRentCurrentAndNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRentCurrentAndNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accrued rent", "label": "Accrued Rent", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent
under lease arrangements." } } }, "auth_ref": [ "r71", "r76", "r120" ] }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccruedSalariesCurrentAndNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Payroll and related costs", "label": "Accrued Salaries", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for
employees' services provided." } } }, "auth_ref": [ "r120" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other
comprehensive gain (loss)", "totalLabel": "Comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated
increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r18", "r19", "r87", "r171", "r617", "r643", "r647" ] },
"rani_AccumulatedOtherComprehensiveLossMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"AccumulatedOtherComprehensiveLossMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated Other Comprehensive Loss Member", "label": "Accumulated Other Comprehensive Loss Member", "documentation": "Accumulated Other Comprehensive Loss
Member" } } }, "auth_ref": [] }, "rani_ActivitySubsequentToTheIpoAndRelatedOrganizationalTransactionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ActivitySubsequentToTheIpoAndRelatedOrganizationalTransactionsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label":
"Activity subsequent to the IPO and related Organizational Transactions [Member]", "documentation": "Activity subsequent to the IPO and related Organizational Transactions [Member]" } } },
"auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } },
"auth_ref": [ "r857" ] }, "us-gaap_AdditionalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdditionalCashFlowElementsAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Cash Flows", "label": "Additional Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital",
"periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "totalLabel": "Additional Paid in Capital, Total",
"terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes,
but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r81", "r806", "r1067" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": {
"terseLabel": "Additional Paid in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock
and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r664", "r946", "r947", "r948", "r951", "r1026", "r1068" ] }, "ecd_AdjToCompAmt":
{ "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r870" ] }, "ecd_AdjToCompAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r870" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r870" ] },
"ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation,
Footnote" } } }, "auth_ref": [ "r870" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r157", "r158", "r207", "r208",
"r209", "r210", "r222", "r252", "r253", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r310", "r311", "r314", "r434", "r435", "r436", "r437", "r438", "r443", "r444",
"r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477",
"r478", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r515", "r516", "r530", "r531", "r532", "r548", "r549", "r550", "r551", "r552", "r553", "r598", "r599",
"r600", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label":
"Adjustments to Additional Paid in Capital, Other", "terseLabel": "Issuance of common stock under employee equity plans, net of shares withheld for tax settlement, amount", "documentation":
"Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label":
"APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-
based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [
"r49", "r50", "r387" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued classified
warrants", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of
warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r11", "r36", "r104" ] }, "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" }
} }, "auth_ref": [] }, "rani_AequanimitasLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AequanimitasLimitedMember",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Aequanimitas Limited", "label": "Aequanimitas Limited [Member]", "documentation": "Aequanimitas Limited" } } }, "auth_ref": [] }, "rani_AggregateDesiredPatentAcquisition": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AggregateDesiredPatentAcquisition", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate
desired patent acquisition", "label": "Aggregate desired patent acquisition", "terseLabel": "Aggregate desired patent acquisition" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForApplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForApplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present
Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All
Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r903" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount",
"terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r829", "r839", "r849", "r881" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } },
"auth_ref": [ "r832", "r842", "r852", "r884" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]",
"terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r904" ] }, "rani_AgreementTerminationNegotiationPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "AgreementTerminationNegotiationPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement
termination negotiation period.", "label": "Agreement Termination Negotiation Period", "terseLabel": "Agreement termination negotiation period" } } }, "auth_ref": [] },
"rani_AgreementTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AgreementTerminationPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement
termination period", "label": "Agreement Termination Period", "terseLabel": "Agreement termination period" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype":
```

```
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r870" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r877" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r833", "r843", "r853", "r877", "r885", "r889", "r897" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r895" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r416", "r421" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r349", "r776", "r777", "r940", "r1040" ] }, "rani_AmountDueFromRelatedPartyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AmountDueFromRelatedPartyExpense", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount Due From Related Party Expense", "label": "Amount Due From Related Party Expense", "terseLabel": "Contra-research and development expense" } } }, "auth_ref": [] }, "rani_AmountPayableForEvaluationServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AmountPayableForEvaluationServices", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount payable for evaluation services", "label": "Amount Payable For Evaluation Services", "documentation": "Amount payable for services." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities", "verboseLabel": "Exchanged paired interests for the Company's Class A common stock", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r232" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area for Rent For facility in San jose", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r460" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r117", "r131", "r164", "r201", "r237", "r241", "r247", "r248", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r462", "r466", "r517", "r611", "r698", "r767", "r768", "r806", "r820", "r989", "r990", "r1049" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r160", "r173", "r201", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r462", "r466", "r517", "r806", "r989", "r990", "r1049" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r493", "r494", "r794" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Auction Market Preferred Securities, Stock Series [Axis]", "documentation": "Information by title of series or issue of auction market preferred securities." } } }, "auth_ref": [ "r37", "r38", "r39", "r40", "r79" ] }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]", "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)." } } }, "auth_ref": [ "r37", "r38", "r39", "r40", "r79" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r257", "r304", "r610" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized Gains", "label": "Debt Securities, Available-for-Sale, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r966" ] }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized loss", "terseLabel": "Gross Unrealized loss", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r967" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable Securities", "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r258", "r304", "r493", "r602", "r794", "r797", "r963", "r1031", "r1032", "r1033" ] }, "us-gaap_AvailableforsaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableforsaleSecuritiesMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Available-for-Sale Securities [Member]", "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r132" ] }, "rani_AvenueVentureOpportunityFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "AvenueVentureOpportunityFundLPMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avenue Venture Opportunity Fund L.P Member", "label": "Avenue Venture Opportunity Fund L P [Member]", "documentation": "Avenue venture opportunity fund L.P member." } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r892" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r893" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r888" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r888" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r891" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r890" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r889" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r889" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r313", "r1062", "r1063" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r60", "r61", "r313", "r1062", "r1063" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Accounting", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r96" ] }, "us-gaap_BeneficialInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BeneficialInterest", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment of tax benefit", "label": "Beneficial Interest Liability", "documentation": "Obligation reflecting another party's right to economic interests in another entity or trust under a contractual right. For example, an investor may purchase a beneficial interest in a securitization transaction." } } }, "auth_ref": [ "r121" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses and other current liabilities", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_CapitalUnitClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitClassAMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A unit Member", "label": "Capital Unit, Class A [Member]", "documentation": "Class A of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitClassDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Capital Unit, Class [Domain]", "documentation": "Description of the type or class of capital units or capital shares." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsByClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitsByClassAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Capital Units by Class [Axis]", "documentation": "Information by type or class of the entity's capital units." } } }, "auth_ref": [] }, "us-gaap_CapitalizationLongtermDebtAndEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizationLongtermDebtAndEquity", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market capitalization amount", "label": "Capitalization, Long-Term Debt and Equity", "totalLabel": "Capitalization, Long-Term Debt and Equity, Total", "documentation": "Amount of consolidated capitalization which comprises long-term debt and equity instruments." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashEquivalentsDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents, beginning of year", "periodEndLabel": "Cash and cash equivalents, end of year", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r23", "r162", "r758" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r162" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1029", "r1030" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r24" ] },
"rani_CashCashEquivalentsAndMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "CashCashEquivalentsAndMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and marketable securities", "label": "Cash, Cash Equivalents and Marketable Securities", "documentation": "Cash, Cash Equivalents and Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel":
```

```
"Cash Equivalents, Restricted Cash Equivalents and Marketable Securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r962" ] },
"rani_CashCashEquivalentsAndRestrictedCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "CashCashEquivalentsAndRestrictedCashEquivalentsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
], "lang": { "en-us": { "role": { "terseLabel": "Cash, equivalents and restricted cash equivalents", "label": "Cash, cash equivalents and restricted cash equivalents [Member]", "documentation": "Cash, cash equivalents and restricted cash equivalents [Member]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents, end of period", "verboseLabel": "Cash, cash equivalents and restricted cash equivalents, end of period", "totalLabel": "Cash, cash equivalents and restricted cash equivalents, end of period", "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r23", "r93", "r198" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r93" ] },
"rani_CashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "CashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents, Restricted Cash Equivalents and Marketable Securities", "label": "Cash Equivalents Restricted Cash Equivalents and Marketable Securities Policy Text Block", "documentation": "Cash Equivalents Restricted Cash Equivalents and Marketable Securities Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] },
"rani_ChangeInUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ChangeInUncertainTaxPositions", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in uncertain tax position", "label": "Change In Uncertain Tax Positions", "documentation": "Change In Uncertain Tax Positions" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r868" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r961" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r865" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r863" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r142", "r168", "r169", "r170", "r201", "r226", "r227", "r229", "r231", "r239", "r240", "r288", "r325", "r327", "r328", "r329", "r332", "r333", "r354", "r355", "r357", "r360", "r367", "r517", "r653", "r654", "r655", "r656", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r686", "r707", "r729", "r742", "r743", "r744", "r745", "r746", "r908", "r942", "r952" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } }
}, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities purchase in exchange for warrant", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Pre-funded warrants issued to purchase shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r369" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right, Outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r46" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r869" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r869" ] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaborative Arrangements", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": [ "r137" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative and Evaluation Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r133", "r135", "r141" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r100", "r324", "r814", "r815", "r816", "r817" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r77", "r123", "r613", "r685" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r98", "r316", "r317", "r751", "r978", "r983" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Class A", "verboseLabel": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Class B [Member]", "label": "Common Class B [Member]", "terseLabel": "Common Class B", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassCMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class C", "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common [Member]", "verboseLabel": "Common Unit", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [
"r810", "r811", "r812", "r814", "r815", "r816", "r817", "r946", "r947", "r951", "r1026", "r1066", "r1068" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r686" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued", "label": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Common stock units issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (shares)", "periodEndLabel": "Ending Balance (shares)", "terseLabel": "Common stock shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r80", "r686", "r704", "r1068", "r1069" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel":
"Common Stock, Value, Issued, Ending Balance", "verboseLabel": "Common stock units issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r616", "r806" ] }, "us-gaap_CommonUnitAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonUnitAuthorized", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Unit Authorized", "terseLabel": "Common units, authorized", "label": "Common Unit, Authorized", "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonUnitIssued", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common units holders", "verboseLabel": "Common Unit Issued", "label": "Common Unit, Issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonUnitOutstanding", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common units outstanding", "verboseLabel": "Common stock, shares outstanding", "label": "Common Unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r874" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r873" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r875" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r872" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r106", "r108" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Comprehensive loss attributable to Rani Therapeutics Holdings, Inc.", "terseLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r179", "r181", "r188", "r606", "r628", "r630" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Comprehensive loss attributable to non-controlling interest", "negatedLabel": "Comprehensive loss attributable to non-controlling interest", "terseLabel": "Comprehensive loss attributable to non-controlling interest", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r54", "r59", "r179", "r181", "r187", "r605", "r628", "r629" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"negatedLabel": "Comprehensive loss", "totalLabel": "Comprehensive loss", "terseLabel": "Comprehensive loss attributable to Rani Therapeutics Holdings, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r59",
```

"r111", "r179", "r181", "r186", "r604", "r628"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r66", "r138"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": ["r143", "r149", "r203", "r462", "r463", "r466", "r467", "r560", "r752", "r926", "r927", "r928", "r988", "r991", "r992"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": ["r143", "r149", "r203", "r462", "r463", "r466", "r467", "r560", "r752", "r926", "r927", "r928", "r988", "r991", "r992"] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": ["r51", "r55", "r56"] }, "rani_ContinuingLlcOwnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ContinuingLlcOwnersMember", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Continuing LLC Owners [Member]", "documentation": "Continuing LLC Owners" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r370", "r371", "r374"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of stock, shares", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r26", "r27", "r28"] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred [Member]", "label": "Convertible Preferred Stock [Member]", "verboseLabel": "Convertible Preferred Units", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r354", "r355", "r357", "r814", "r815", "r816", "r817"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r786", "r788", "r794", "r807", "r809", "r1065"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r324", "r986"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r324", "r986", "r987"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r17", "r70", "r71", "r118", "r122", "r203", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r773", "r774", "r775", "r776", "r777", "r804", "r943", "r979", "r980", "r981", "r1039", "r1041"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFutureFutureFuturePrincipalPaymentsForTheCompanysDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Gross, Total", "terseLabel": "Total long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r17", "r122", "r351"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r334", "r527", "r528", "r774", "r775", "r804"] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate On Loan", "terseLabel": "Interest Rate During Period", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r73", "r346", "r1039"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r203", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r773", "r774", "r775", "r776", "r777", "r804", "r943", "r1039", "r1041"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt Instrument Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r166", "r773", "r1032", "r1033"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r17", "r203", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r773", "r774", "r775", "r776", "r777", "r804", "r943", "r979", "r980", "r981", "r1039", "r1041"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r17", "r38", "r41", "r65", "r102", "r103", "r203", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r773", "r774", "r775", "r776", "r777", "r804", "r943", "r1039", "r1041"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFutureFutureFuturePrincipalPaymentsForTheCompanysDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less: amount representing debt discount", "totalLabel": "Less: amount representing debt discount", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": ["r994", "r1038", "r1039", "r1041"] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt with Detachable Warrants", "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r6"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Net of issuance costs", "label": "Debt Issuance Costs, Net", "totalLabel": "Debt Issuance Costs, Net, Total", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r994", "r1038", "r1039", "r1041"] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "verboseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": ["r977"] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred Revenue", "terseLabel": "Deferred revenue", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Deferred Revenue, Total", "totalLabel": "Deferred Revenue, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r930"] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of deferred revenue balance", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of

```
the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1025" ] }, "us-gaap_Depletion": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depletion", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Depletion", "totalLabel": "Depletion, Total", "documentation": "The noncash expense charged against earnings to recognize the consumption of natural resources." } } }, "auth_ref": [ "r4" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r4", "r35" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value (in thousands)", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r15", "r86", "r113", "r114", "r174", "r761" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, term of contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r779", "r780", "r781", "r782", "r783", "r784", "r785" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r385", "r389", "r417", "r418", "r420", "r790" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r824" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r856" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCorporateDebtSecuritiesMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Debt Security, Corporate, US [Member]", "documentation": "Debt security issued by corporation domiciled in United States of America (US)." } } }, "auth_ref": [ "r788", "r965", "r968", "r995" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r867" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic", "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "negatedLabel": "Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r189", "r211", "r212", "r214", "r215", "r216", "r218", "r224", "r226", "r229", "r230", "r231", "r236", "r450", "r459", "r490", "r491", "r607", "r631", "r764" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r226", "r227", "r229" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "negatedLabel": "Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r189", "r211", "r212", "r214", "r215", "r216", "r218", "r226", "r229", "r230", "r231", "r236", "r450", "r459", "r490", "r491", "r607", "r631", "r764" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Loss Per Class A Common Share Attributable to Rani Holdings", "terseLabel": "Net Loss Per Class A Common Share Attributable to Rani Therapeutics Holdings, Inc.", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r29", "r30", "r233" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r223", "r232", "r234", "r235" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r426", "r791" ] },
"rani_EffectsOfTheIpoAndRelatedOrganizationalTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "EffectsOfTheIpoAndRelatedOrganizationalTransactionsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Effects of the IPO and related Organizational Transactions [Member]", "documentation": "Effects of the IPO and related Organizational Transactions [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognized over a weighted-average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r419" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized equity-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1022" ] },
"rani_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedWeightedAverageVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedWeightedAverageVestingPeriod", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted Average Vesting Period", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted Average Vesting Period", "terseLabel": "Weighted average vesting term" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r822" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCurrentReportingStatus", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } },
"auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r822" ] },
"dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r907" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r822" ] },
"dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of incorporation", "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r906" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r822" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r822" ] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r822" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype":
"employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r822" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r861" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r902" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r902" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r902" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityComponentDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r155", "r182", "r183", "r184", "r204", "r205", "r206", "r208", "r216", "r219", "r221", "r238", "r292", "r298", "r311", "r369", "r434", "r435", "r446", "r447", "r448", "r451", "r458", "r459", "r471", "r473", "r474", "r475", "r476", "r478", "r489", "r518", "r520", "r521", "r522", "r523", "r524", "r531", "r534", "r553", "r626", "r638", "r639", "r640", "r664", "r729" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r871" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r829", "r839", "r849", "r881" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r826", "r836", "r846", "r878" ] }, "rani_EvaluationAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "EvaluationAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Evaluation Agreements [Abstract]", "documentation":
"evaluation agreements abstract." } } }, "auth_ref": [] }, "rani_EvaluationAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "EvaluationAgreementsTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreements" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for evaluation agreements.", "label": "Evaluation Agreements [Text Block]", "terseLabel": "Evaluation Agreements" } } }, "auth_ref": [] }, "us-gaap_ExcessStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesOutstanding", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficially number of shares held", "label": "Excess Stock, Shares Outstanding", "documentation": "Number of shares of excess stock held by shareholders." } } }, "auth_ref": [] },
"rani_ExchangeOfCommonUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ExchangeOfCommonUnits", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC", "terseLabel": "Exchanges of non-corresponding Class A Units of Rani LLC", "documentation": "Exchange of common units.", "label": "Exchange Of Common Units" } } }, "auth_ref": [] }, "rani_ExchangeOfPairedInterest": { "xbrltype": "sharesItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ExchangeOfPairedInterest", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange of paired interests", "label": "Exchange of Paired Interest", "documentation": "Exchange of paired interest." } } }, "auth_ref": [] },
"rani_ExchangesOfPairedInterestsAndNonCorrespondingClassAUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ExchangesOfPairedInterestsAndNonCorrespondingClassAUnits", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exchanges of Paired Interests non-corresponding Class A Units of Rani LLC", "label": "Exchanges Of Paired Interests And Non-Corresponding Class A Units", "documentation": "Exchanges Of Paired Interests And Non-Corresponding Class A Units" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r877" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and
Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r493", "r494", "r507", "r794" ] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation":
"Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r493", "r494", "r507", "r794" ] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and
Valuation Techniques [Table Text Block]", "verboseLabel": "Summary of Significant Unobservable Inputs used in the Fair Value Measurement of the Series E Preferred Unit Warrant Liability",
"terseLabel": "Summary of Significant Unobservable Inputs used in the Fair Value Measurement of the Series E Preferred Unit Warrant Liability", "documentation": "Tabular disclosure of input
and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
} } }, "auth_ref": [ "r495", "r496", "r797" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r508", "r795" ] }, "us-
gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r498", "r499", "r500", "r501", "r502", "r503", "r508", "r795" ] },
"us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net
asset value per share as practical expedient." } } }, "auth_ref": [ "r342", "r376", "r377", "r378", "r379", "r380", "r381", "r492", "r494", "r495", "r496", "r497", "r506", "r507", "r509", "r567",
"r568", "r569", "r774", "r775", "r786", "r787", "r788", "r794", "r797" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r493",
"r494", "r495", "r497", "r794", "r1032", "r1036" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair
Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as
defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments,
assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate), (2) for items for which it is not practicable to estimate fair
value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable
to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum
amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or
security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a
recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value
measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups]
items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all
other required (as defined) and desired information." } } }, "auth_ref": [ "r502", "r504", "r505", "r506", "r509", "r510", "r511", "r512", "r513", "r601", "r794", "r798" ] }, "us-
gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting
entity can access at the measurement date." } } }, "auth_ref": [ "r342", "r376", "r381", "r494", "r507", "r567", "r786", "r787", "r788", "r794" ] }, "us-gaap_FairValueInputsLevel2Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset
or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in
inactive markets." } } }, "auth_ref": [ "r342", "r376", "r381", "r494", "r495", "r507", "r568", "r774", "r775", "r786", "r787", "r788", "r794" ] }, "us-gaap_FairValueInputsLevel3Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market
participants would use in pricing." } } }, "auth_ref": [ "r342", "r376", "r377", "r378", "r379", "r380", "r381", "r494", "r495", "r496", "r497", "r507", "r569", "r774", "r775", "r786", "r787", "r788",
"r794", "r797" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Changes in the Fair
Value of the Company\u2019s Liability", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular
disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes
attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or
losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income
(or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the
observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r498", "r503", "r508" ] }, "rani_FairValueMeasurementDiscountForLackOfMarketability": { "xbrltype":
"percentItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "FairValueMeasurementDiscountForLackOfMarketability", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair value measurement discount for lack of marketability", "label": "Fair Value Measurement Discount For Lack Of Marketability", "documentation": "Fair value measurement
discount for lack of marketability." } } }, "auth_ref": [] }, "rani_FairValueMeasurementExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "FairValueMeasurementExpectedVolatilityRate", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair value measurement expected volatility rate", "label": "Fair Value Measurement Expected Volatility Rate", "documentation": "Fair value measurement expected volatility rate."
} } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r493", "r494", "r495",
"r497", "r794", "r1032", "r1036" ] }, "rani_FairValueMeasurementProbabilityOfExitEvents": { "xbrltype": "percentItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"FairValueMeasurementProbabilityOfExitEvents", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair value measurement probability of exit events", "label": "Fair Value Measurement Probability Of Exit Events", "documentation": "Fair value measurement probability of exit
events." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure
fair value." } } }, "auth_ref": [ "r342", "r376", "r377", "r378", "r379", "r380", "r381", "r492", "r494", "r495", "r496", "r497", "r506", "r507", "r509", "r567", "r568", "r569", "r774", "r775", "r786",
"r787", "r788", "r794", "r797" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsRecurringMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value
adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r794", "r1029", "r1030", "r1031", "r1032", "r1033", "r1036" ] }, "us-
gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)", "totalLabel": "Fair Value, Net Derivative Asset
(Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease), Total", "terseLabel": "Change in estimated fair value", "documentation": "Amount of
increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's
own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r508", "r1034" ] }, "us-
gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Settlement of Series E warrants", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
"documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect
the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r501", "r508" ] }, "us-
```

gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } } }, "auth_ref": ["r498", "r508"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r8"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r350", "r365", "r479", "r514", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r627", "r770", "r794", "r795", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r807", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r969", "r970", "r971", "r972", "r1028", "r1031", "r1032", "r1033", "r1035", "r1036"] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "International goverment", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": ["r807", "r995", "r1065"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [
"r833", "r843", "r853", "r885"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r833", "r843", "r853", "r885"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r833", "r843", "r853", "r885"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r833", "r843", "r853", "r885"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r833", "r843", "r853", "r885"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r866"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property and equipment", "terseLabel": "Loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r4"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r90", "r709"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expense", "label": "General and Administrative Expense [Member]", "verboseLabel": "General and Administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r90"] }, "us-gaap_GovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
], "lang": { "en-us": { "role": { "terseLabel": "International government", "label": "Government [Member]", "documentation": "Organization that is the governing authority of a community." } } }, "auth_ref": [] }, "rani_GrossProceedsFromOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "GrossProceedsFromOffering", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Gross Proceeds from Offering", "label": "Gross Proceeds From Offering", "terseLabel": "Gross proceeds", "verboseLabel": "Gross proceeds from offering" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "verboseLabel": "IPO", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "rani_InCubeLabsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "InCubeLabsLLCMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails"], "lang": { "en-us": { "role": { "verboseLabel": "ICL", "terseLabel": "ICL", "label": "In Cube Labs L L C [Member]", "documentation": "InCube Labs, LLC" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r312", "r313", "r315", "r499", "r503", "r508", "r633", "r635", "r714", "r755", "r796", "r1064"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r313", "r315", "r499", "r503", "r508", "r633", "r635", "r714", "r755", "r796", "r1064"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r202", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r439", "r440", "r441", "r442", "r658", "r791"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "totalLabel": "Income Taxes Paid, Net, Total", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r25", "r197", "r432", "r433"] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable", "negatedLabel": "Accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r756"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "negatedLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r912", "r939"] }, "rani_IncreaseDecreaseInPerYear": { "xbrltype": "percentItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "IncreaseDecreaseInPerYear", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Per Year", "label": "Increase Decrease In Per Year" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid

```
expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "rani_IncreaseNetOfTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "IncreaseNetOfTaxAssets", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase net of tax assets", "documentation": "Increase net of tax assets" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r833", "r843", "r853", "r877", "r885", "r889", "r897" ] }, "rani_InitialTermLeasesAgreement": { "xbrltype": "stringItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "InitialTermLeasesAgreement", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Term Leases Agreement", "documentation": "Initial Term Leases Agreement", "label": "Initial Term Leases Agreement" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r895" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r825", "r901" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r825", "r901" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r825", "r901" ] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "terseLabel": "Interest income and other, net", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense and other, net", "label": "Interest Expense, Operating and Nonoperating", "totalLabel": "Interest Expense, Total", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r237", "r241", "r244", "r245", "r248", "r526", "r767", "r768" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r192", "r195", "r196" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Receivable", "terseLabel": "Interest income receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r931", "r1070" ] }, "rani_IssuanceOfCommonStockForExerciseOfPrefundWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "IssuanceOfCommonStockForExerciseOfPrefundWarrantsShares", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants", "label": "Issuance Of Common Stock For Exercise Of Prefund Warrants Shares", "documentation": "Issuance Of Common Stock For Exercise Of Prefund Warrants Shares" } } }, "auth_ref": [] }, "rani_IssuanceOfCommonStockInConnectionWithTheStockPurchaseAgreementNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithTheStockPurchaseAgreementNetOfIssuanceCosts", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Shares", "label": "Issuance of Common Stock in Connection With the Stock Purchase Agreement, Net of Issuance Costs", "documentation": "Issuance of Common Stock in Connection With the Stock Purchase Agreement, Net of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_LandSubjectToGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandSubjectToGroundLeases", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land Subject to Ground Leases", "label": "Land Subject to Ground Leases", "documentation": "Area of land subject to a ground lease." } } }, "auth_ref": [ "r1042" ] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent expense", "label": "Operating Leases, Rent Expense", "totalLabel": "Operating Leases, Rent Expense, Total", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r539", "r547" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r539", "r547" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r538" ] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Description", "label": "Lessee, Operating Lease, Description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r540" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Future Minimum Operating Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted future minimum lease payments", "terseLabel": "Total undiscounted future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "verboseLabel": "Future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining three months)", "verboseLabel": "2022 (remaining three months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "verboseLabel": "2023 (totaled)", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1043" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Term of Contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1043" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r533" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label":
"Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r17", "r70", "r71",
"r72", "r75", "r76", "r77", "r78", "r201", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r463", "r466", "r467", "r517", "r684", "r765", "r820", "r989", "r1049",
"r1050" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr":
"credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total
liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling
interests, if any." } } }, "auth_ref": [ "r85", "r125", "r620", "r806", "r944", "r973", "r1037" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders'
Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the
following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r72", "r161", "r201", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r463",
"r466", "r467", "r517", "r806", "r989", "r1049", "r1050" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Financial liabilities measured at fair value", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities", "totalLabel": "Liabilities, Fair Value
Disclosure, Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r494", "r1029" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Limited Liability Company (LLC)
or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest", "terseLabel": "General Partner Ownership Interest", "documentation": "Percentage investment held by
the managing member or general partner of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r31" ] }, "us-
gaap_LimitedLiabilityCompanyLLCPreferredUnitAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LimitedLiabilityCompanyLLCPreferredUnitAuthorized", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible
Preferred units authorized", "label": "Limited Liability Company (LLC) Preferred Unit, Authorized", "documentation": "Maximum number of preferred units of ownership permitted to be issued
of a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCPreferredUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LimitedLiabilityCompanyLLCPreferredUnitIssued", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible
Preferred units issued", "label": "Limited Liability Company (LLC) Preferred Unit, Issued", "documentation": "Number of preferred units issued of limited liability company (LLC)." } } },
"auth_ref": [ "r104" ] }, "us-gaap_LimitedLiabilityCompanyLLCPreferredUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LimitedLiabilityCompanyLLCPreferredUnitOutstanding", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible
Preferred units outstanding", "label": "Limited Liability Company (LLC) Preferred Unit, Outstanding", "documentation": "Number of preferred units of ownership outstanding of a limited liability
company (LLC)." } } }, "auth_ref": [] }, "rani_LineOfCreditAvailableToBeDrawn": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"LineOfCreditAvailableToBeDrawn", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Line of credit available to be drawn", "label": "Line Of Credit Available To be Drawn", "documentation": "Line Of Credit Available To be Drawn" } } },
"auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum Borrowing Capacity",
"label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the
amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r69", "r74" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Borrowing Capacity",
"label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less
the amount of borrowings outstanding)." } } }, "auth_ref": [ "r69", "r74", "r324" ] }, "rani_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "LoanAndSecurityAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan
and Security Agreement", "label": "Loan And Security Agreement [Member]", "documentation": "Loan and Security Agreement." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local
Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total
principal payments", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease
obligation." } } }, "auth_ref": [ "r17", "r122", "r341", "r352", "r774", "r775", "r804", "r1060" ] }, "us-gaap_LongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebtAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Debt, Unclassified [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term
Debt and Lease Obligation, Current", "totalLabel": "Total long-term debt, less current portion", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } },
"auth_ref": [ "r71" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities",
"totalLabel": "Total long-term debt, less current portion", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less: current portion of long-term debt", "documentation":
"Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r165" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025",
"label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at
fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r203", "r345" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term
Debt, Maturity, Year Three", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at
fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement
of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r203", "r345" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026",
"label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at
fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement
of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r203", "r345" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term
Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2024 (remaining six months)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities
issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r945" ] }, "us-gaap_LongTermDebtNoncurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtFuturePrincipalPaymentsForTheCompanysDebtDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current
Maturities", "terseLabel": "Long-term debt, less current portion", "totalLabel": "Total long-term debt, less current portion", "documentation": "Amount, after deduction of unamortized premium
(discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r167" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebt1" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-Term Debt", "terseLabel": "Long-Term Debt with
Detachable Warrants", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r99" ] }, "us-
gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-
gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-
Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term
purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermPurchaseCommitmentLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term
Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermPurchaseCommitmentTable", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r318", "r319", "r320", "r323", "r422", "r772", "r984", "r985" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r318", "r319", "r320", "r323", "r422", "r772", "r984", "r985" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "totalLabel": "Marketable Securities, Total", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r126", "r929" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r64" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "verboseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r319", "r320", "r321", "r322", "r383", "r422", "r497", "r596", "r632", "r634", "r648", "r676", "r677", "r737", "r738", "r739", "r740", "r741", "r753", "r754", "r769", "r778", "r789", "r797", "r798", "r802", "r803", "r808", "r993", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r869" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r869" ] }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Discount for Lack of Marketability", "label": "Measurement Input, Discount for Lack of Marketability [Member]", "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly." } } }, "auth_ref": [ "r797", "r1031", "r1032", "r1033" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Expected Term", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1031", "r1032", "r1033" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Price Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r797", "r1031", "r1032", "r1033" ] }, "rani_MeasurementInputProbabilityOfExitEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "MeasurementInputProbabilityOfExitEventsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Probability Of Exit Events", "label": "Measurement Input Probability Of Exit Events [Member]", "documentation": "Measurement input probability of exit events member." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r495", "r496", "r497", "r797" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r495", "r496", "r497", "r797" ] }, "us-gaap_MemberUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MemberUnitsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profits Interests", "label": "Member Units [Member]", "documentation": "Ownership interest in limited liability company (LLC)." } } }, "auth_ref": [] }, "rani_MembersDeficitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "MembersDeficitMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Members' Deficit [Member]", "documentation": "Members' Deficit.", "verboseLabel": "Members' Deficit [Member]" } } }, "auth_ref": [] }, "us-gaap_MembersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MembersEquityAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity / members' deficit.", "label": "Members' Equity [Abstract]", "verboseLabel": "Stockholders' equity." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "verboseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r319", "r320", "r321", "r322", "r383", "r422", "r497", "r596", "r632", "r634", "r648", "r676", "r677", "r737", "r738", "r739", "r740", "r741", "r753", "r754", "r769", "r778", "r789", "r797", "r798", "r802", "r808", "r993", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r84", "r124", "r201", "r288", "r325", "r327", "r328", "r329", "r332", "r333", "r517", "r619", "r688" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r888" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Money market funds", "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r995" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r896" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r870" ] }, "us-gaap_NetAssetValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetAssetValuePerShare", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Net Asset Value Per Share", "periodEndLabel": "Net Asset Value Per Share, Ending Balance", "periodStartLabel": "Net Asset Value Per Share, Beginning Balance", "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure." } } }, "auth_ref": [ "r667", "r674", "r675", "r688", "r704", "r742", "r820" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment, borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r194" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r194" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating activities, net", "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Operating activities, net", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r93", "r94", "r95" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType",
```

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.", "totalLabel": "Net loss attributable to Rani Therapeutics Holdings, Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r95", "r127", "r159", "r177", "r180", "r184", "r201", "r207", "r211", "r212", "r214", "r215", "r216", "r220", "r221", "r228", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r450", "r459", "r491", "r517", "r625", "r706", "r727", "r728", "r818", "r989" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to non-controlling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss attributable to non-controlling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r58", "r112", "r177", "r180", "r216", "r220", "r221", "r624", "r936" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "rani_NonControllingInterestsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "NonControllingInterestsPolicyTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interest", "label": "Non-controlling Interests Policy Text Block", "documentation": "Non-controlling Interests Policy Text Block" } } }, "auth_ref": [] }, "rani_NonCorrespondingClassAUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "NonCorrespondingClassAUnitsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-corresponding Class A Units", "terseLabel": "Non-Corresponding Class A Units [Member]", "label": "Non-Corresponding Class A Units [Member]", "documentation": "Non-Corresponding Class A Units [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r869" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r833", "r843", "r853", "r877", "r885" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r860" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r859" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r877" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r896" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r896" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r52", "r369", "r946", "r947", "r948", "r951", "r1068" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "rani_NovartisAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "NovartisAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Novartis Agreement [Member]", "documentation": "Novartis Agreement [Member]", "terseLabel": "Novartis Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary", "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r937" ] }, "rani_OneTimePatentPaymentToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "OneTimePatentPaymentToRelatedParty", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "One time patent payment to related party", "label": "One time patent payment to related party", "terseLabel": "One time patent payment to related party" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r130", "r766", "r955", "r956", "r957", "r958", "r959" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r536" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability", "verboseLabel": "Less: Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r536" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Noncurrent, Total", "terseLabel": "Operating lease liability, less current portion", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, net current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r536" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating cash flows used for operating leases", "label": "Operating Lease, Payments", "terseLabel": "Monthly base rent for initial term of the lease", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r537", "r541" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r535" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of use asset from operating lease." } } }, "auth_ref": [ "r940" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r544", "r805" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Service agreement remaining term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r543", "r805" ] }, "us-gaap_OperatingLeasesLeaseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesLeaseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Operating Lease, Lease Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Nature of Business", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r67", "r110", "r649", "r650" ] }, "rani_OrganizationalTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "OrganizationalTransactionsMember", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organizational Transactions [Member]", "label": "Organizational Transactions [Member]", "documentation": "Organizational Transactions." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r120" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r163" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r16", "r178", "r181", "r185", "r216", "r518", "r519", "r524", "r603", "r626", "r934", "r935" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain on marketable securities", "negatedLabel": "Net unrealized gain on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r175", "r176", "r287" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r869" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r933", "r976" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r831", "r841", "r851", "r883" ] }, "rani_OutstandingCapitalClassAUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "OutstandingCapitalClassAUnitMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding Capital Class A Unit [Member]", "documentation": "Outstanding Capital Class A Unit [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r834", "r844", "r854", "r886" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r834", "r844", "r854", "r886" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "rani_PairedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PairedInterestMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paired Interest", "label": "Paired Interest [Member]", "documentation": "Paired Interest" } } }, "auth_ref": [] }, "rani_PairedInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PairedInterestsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Paired Interests", "terseLabel": "Paired Interest [Member]", "label": "Paired Interests [Member]", "documentation": "Paired Interests [Member]" } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rani Therapeutics Holdings Inc.", "label": "Parent Company [Member]", "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary." } } }, "auth_ref": [ "r143", "r203" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r858" ] }, "rani_PaycheckProtectionProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PaycheckProtectionProgramMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paycheck Protection Program", "label": "Paycheck Protection Program [Member]", "documentation": "Paycheck Protection Program" } } }, "auth_ref": [] }, "us-gaap_PaymentsForOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForOperatingActivitiesAbstract", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesSummaryOfConsolidatedBalanceSheetsAndStatementsOfCashFlowRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in lease liabilities:", "label": "Payments for Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax withholdings paid on behalf of employees for net share settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r191" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "terseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r964" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r91" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r868" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r868" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r860" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r877" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r870" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r859" ] }, "rani_PercentageOfIncreaseInMonthlyBaseRentPerYear": { "xbrltype": "percentItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PercentageOfIncreaseInMonthlyBaseRentPerYear", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of increase in monthly base rent (per year)", "label": "Percentage Of Increase In Monthly Base Rent (Per Year)", "documentation": "Percentage Of Increase In Monthly Base Rent (Per Year)" } } }, "auth_ref": [] }, "rani_PercentageOfTaxBenefitToBeTransferred": { "xbrltype": "percentItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PercentageOfTaxBenefitToBeTransferred", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of tax benefit to be transferred", "label": "Percentage Of Tax Benefit To Be Transferred", "documentation": "Percentage of tax benefit to be transferred." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r861" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r905" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r860" ] }, "rani_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "PreFundedWarrantMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrant Member", "label": "Pre-Funded Warrant [Member]", "terseLabel": "Pre-Funded Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par or stated value per share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r79", "r354" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock authorized", "terseLabel": "Units Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r79", "r686" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock issued", "label": "Preferred Stock, Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r79", "r354" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock outstanding", "terseLabel": "Units Outstanding", "label": "Preferred Stock, Shares Outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r79", "r686", "r704", "r1068", "r1069" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023", "terseLabel": "Carrying Value", "label": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r79", "r615", "r806" ] }, "us-gaap_PreferredUnitsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsByNameAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Units by Name", "label": "Preferred Units by Name [Axis]", "documentation": "Information by type or class of preferred units or special units." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PreferredUnitsClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsClassDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Units, Class", "label": "Preferred Units, Class [Domain]", "documentation": "Type or class of preferred units or special units." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Prepaid Expense, Current, Total", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r172", "r308", "r309", "r759" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInterest", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income receivable included in prepaid expenses and other current assets", "label": "Prepaid Interest", "documentation": "Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r760", "r771", "r976" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of common stock and pre-funded warrants in connection with the July Securities Purchase Agreement, net of issuance costs of $1,117", "terseLabel": "Proceeds from issuance of common stock in connection with the Stock Purchase Agreement, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "rani_ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from Issuance of common stock under the employee stock purchase plan", "label": "Proceeds from Issuance of common stock under the employee stock purchase plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r938" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds From Issuance Of Warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r653" ] }, "us-gaap_ProceedsFromOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherEquity", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from equity financing", "label": "Proceeds from Other Equity", "documentation": "Amount of cash inflow from the issuance of equity classified as other." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r21", "r190", "r255", "r286" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r14" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock in connection with the July Securities Purchase Agreement, net of issuance costs, Value", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss and comprehensive loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r159", "r177", "r180", "r193", "r201", "r207", "r216", "r220", "r221", "r288", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r450", "r459", "r461", "r464", "r465", "r491", "r517", "r609", "r623", "r663", "r706", "r727", "r728", "r792", "r793", "r819", "r936", "r980" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, Plant and Equipment, Net, Total", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r546", "r609", "r622", "r806" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r858" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r858" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r319", "r320", "r321", "r322", "r375", "r383", "r412", "r413", "r414", "r422", "r497", "r570", "r580", "r596", "r632", "r634", "r648", "r676", "r677", "r737", "r738", "r739", "r740", "r741", "r753", "r754", "r769", "r778", "r789", "r797", "r798", "r802", "r803", "r808", "r812", "r982", "r993", "r1032", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r319", "r320", "r321", "r322", "r375", "r383", "r412", "r413", "r414", "r422", "r497", "r570", "r580", "r596", "r632", "r634", "r648", "r676", "r677", "r737", "r738", "r739", "r740", "r741", "r753", "r754", "r769", "r778", "r789", "r797", "r798", "r802", "r803", "r808", "r812", "r982", "r993", "r1032", "r1052", "r1053", "r1054", "r1055", "r1056" ] }, "rani_RaniLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RaniLLCMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rani LLC", "documentation": "Rani LLC.", "label": "Rani L L C [Member]" } } }, "auth_ref": [] }, "rani_RaniLlcIclServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RaniLlcIclServiceAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Rani LLC-ICL Service Agreement [Member]", "documentation": "Rani LLC-ICL Service Agreement [Member]" } } }, "auth_ref": [] }, "rani_RaniManagementServiceAndInCubeLabsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RaniManagementServiceAndInCubeLabsLlcMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Rani Management Service and In Cube Labs LLC [Member]", "label": "Rani Management Service and In Cube Labs LLC [Member]", "verboseLabel": "RMS-ICL" } } }, "auth_ref": [] }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesLongTermContractsOrPrograms", "crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Receivables, Long-Term Contracts or Programs", "totalLabel": "Receivables, Long-term Contracts or Programs, Total", "terseLabel": "Receivables or net contract assets from agreement", "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date." } } }, "auth_ref": [ "r932" ] }, "rani_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements", "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]", "documentation": "Recently adopted accounting pronouncements policy text block" } } }, "auth_ref": [] }, "us-gaap_RecoveryOfDirectCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RecoveryOfDirectCosts", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Recovery of Direct Costs", "terseLabel": "Reimbursement of research and development expense", "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred." } } }, "auth_ref": [ "r88" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r826", "r836", "r846", "r878" ] }, "rani_RegistrationRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RegistrationRightsAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registration Rights Agreement", "documentation": "Registration Rights Agreement [Member]", "label": "Registration Rights Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r254", "r382", "r557", "r558", "r612", "r621", "r679", "r680", "r681", "r682", "r683", "r703", "r705", "r736" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r557", "r558", "r1048" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] },
"rani_RelatedPartyTransactionIncomeExpensesFromTransactionsWithRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RelatedPartyTransactionIncomeExpensesFromTransactionsWithRelatedParty", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Income Expenses From Transactions With Related Party", "label": "Related Party Transaction Income Expenses From Transactions With Related Party", "terseLabel": "Related party charges" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r710", "r711", "r714" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r254", "r382", "r557", "r558", "r612", "r621", "r679", "r680", "r681", "r682", "r683", "r703", "r705", "r736", "r1048" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r554", "r555", "r556", "r558", "r559", "r659", "r660", "r661", "r712", "r713", "r714", "r733", "r735" ] }, "rani_RemeasurementOfOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RemeasurementOfOperatingLeaseRightOfUseAssets", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of operating lease right-of use assets", "label": "Remeasurement of operating lease right-of use assets", "documentation": "Remeasurement of operating lease right-of use assets" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of debt", "terseLabel": "Repayment of debt", "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r92", "r656" ] }, "us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Evaluation Agreements", "label": "Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block]", "documentation": "The entire disclosure for repurchase agreements (also known as repos), resale agreements (also known as reverse repurchase agreements or reverse repos), securities borrowed transactions, and securities loaned transactions." } } }, "auth_ref": [ "r115", "r578" ] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development Arrangement [Member]", "label": "Research and Development Arrangement [Member]", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r424", "r755", "r767", "r1057" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "verboseLabel": "Research and Development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r423" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r150", "r156", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r217", "r218", "r219", "r220", "r221", "r222", "r236", "r293", "r294", "r447", "r448", "r450", "r451", "r458", "r459", "r485", "r489", "r490", "r491", "r530", "r532", "r552", "r553", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r651", "r960" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri":
```

```
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date." } } }, "auth_ref": [ "r827", "r837", "r847", "r879" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r828", "r838", "r848", "r880" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r835", "r845", "r855", "r887" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r150", "r156", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r217", "r218", "r219", "r220", "r221", "r222", "r236", "r293", "r294", "r447", "r448", "r450", "r451", "r458", "r459", "r485", "r489", "r490", "r491", "r530", "r532", "r552", "r553", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r651", "r960" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total cash, cash equivalents and restricted cash equivalents", "terseLabel": "Restricted cash equivalents, end of period", "label": "Restricted Cash and Cash Equivalents", "totalLabel": "Restricted Cash and Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r23", "r116", "r162", "r198", "r614" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r162" ] }, "us-gaap_RestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash equivalents", "label": "Restricted Cash Equivalents", "totalLabel": "Restricted Cash Equivalents, Total", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r749", "r750", "r941", "r1058", "r1061" ] }, "rani_RestrictedCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RestrictedCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash Equivalents", "label": "Restricted Cash Equivalents, Fair Value Disclosure", "documentation": "Restricted Cash Equivalents, Fair Value Disclosure" } } }, "auth_ref": [] }, "rani_RestrictedCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RestrictedCashEquivalentsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash Equivalents", "label": "Restricted Cash Equivalents [Member]", "documentation": "Restricted Cash Equivalents [Member]" } } }, "auth_ref": [] }, "rani_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Awards", "label": "Restricted Stock Awards [Member]", "documentation": "Restricted stock awards." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards [Member]", "verboseLabel": "Restricted Stock Awards", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r29" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Issuance of common stock under employee equity plans, net of shares withheld for tax settlement , shares", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted stock units", "terseLabel": "Restricted Stock Units [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r82", "r104", "r618", "r642", "r647", "r657", "r687", "r806" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "verboseLabel": "Members Deficit [Member]", "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r155", "r204", "r205", "r206", "r208", "r216", "r219", "r221", "r292", "r298", "r311", "r434", "r435", "r446", "r447", "r448", "r451", "r458", "r459", "r471", "r474", "r475", "r478", "r489", "r531", "r534", "r638", "r640", "r664", "r1068" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue from contract", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r128", "r129", "r237", "r242", "r243", "r246", "r248", "r249", "r250", "r251", "r372", "r373", "r597" ] }, "us-gaap_RevenueNotFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueNotFromContractWithCustomer", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Revenue", "label": "Revenue Not from Contract with Customer", "documentation": "Amount of revenue that is not accounted for under Topic 606." } } }, "auth_ref": [ "r916" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r708", "r757", "r762" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Right-of Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right- of- use asset obtained in exchange for new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r542", "r805" ] }, "rani_RmsIclServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "RmsIclServiceAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "RMS-ICL Service Agreement [Member]", "documentation": "RMS-ICL Service Agreement [Member]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r896" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r896" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of common units", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit, price per share", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Stock offering price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "rani_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SalesAgreementMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Agreement", "label": "Sales Agreement [Member]", "documentation": "Sales Agreement [Member]" } } }, "auth_ref": [] }, "rani_SalesPriceAndFairValueOfCommonUnitsDifferenceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SalesPriceAndFairValueOfCommonUnitsDifferenceAmount", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales price and fair value of common units, difference", "label": "Sales Price And Fair Value Of Common Units Difference Amount", "documentation": "Sales price and fair value of common units, difference amount." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r384", "r924", "r950" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember",
```

```
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": {
"verboseLabel": "Previously Reported [Member]", "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective
application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r156", "r204", "r206", "r207", "r208",
"r211", "r212", "r221", "r236", "r447", "r450", "r451", "r458", "r459", "r485", "r489", "r490", "r530", "r532", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r651",
"r911", "r913", "r914", "r915", "r949", "r960", "r974", "r975", "r1027", "r1045", "r1046" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation":
"Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r150", "r222", "r384", "r909",
"r950" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components
of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails" ], "lang": { "en-us":
{ "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
"documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } },
"auth_ref": [ "r29" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from
Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of
securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation
of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r29" ] }, "us-
gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable",
"presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and
cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of cash, cash equivalents and restricted cash equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text
Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Summary of cash, cash equivalents, restricted cash equivalents and marketable securities", "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
"documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than
collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r460" ] }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of consolidated balance sheets and statements of
cash flow related to leases", "label": "Condensed Cash Flow Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to,
cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r925", "r945" ] }, "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Consolidated Balance Sheets and Statements of
Cash Flow related to Leases", "label": "Condensed Financial Statements [Table Text Block]", "documentation": "Tabular disclosure of condensed financial statements, including, but not limited
to, the balance sheet, income statement, and statement of cash flows." } } }, "auth_ref": [ "r925", "r945" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of
Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other
postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level
within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or
liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r9", "r42", "r43", "r44", "r45" ] }, "us-
gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-
us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text
Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted
per-share computations for income from continuing operations." } } }, "auth_ref": [ "r953" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and
Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Components of Equity-based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount
expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to,
corresponding line item in financial statement." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities
Recorded at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of
assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The
disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall,
segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level
3)." } } }, "auth_ref": [ "r1029", "r1030" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureLongTermDebtTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Principal Payments for the Company's Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r6" ] }, "us-
gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party
transaction." } } }, "auth_ref": [ "r62", "r63", "r710", "r711", "r714" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Charged for
Services and Rent", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party
transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d)
affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation
Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure
of information about share-based payment arrangement." } } }, "auth_ref": [ "r386", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402",
"r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415" ] }, "rani_ScheduleOfShareBasedCompensationProfitsInterestsActivityTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ScheduleOfShareBasedCompensationProfitsInterestsActivityTableTextBlock",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Profits
Interests Activity", "label": "Schedule Of Share Based Compensation Profits Interests Activity Table [Text Block]", "documentation": "Tabular disclosure for profits interests activity." } } },
"auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Unit and
Award Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted average
grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during
the year." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Options and Options for
Common Units Activity", "verboseLabel": "Summary Of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular
disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } }
}, "auth_ref": [ "r12", "r13", "r107" ] }, "rani_SecondarySalesTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"SecondarySalesTransactionsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Secondary Sales Transactions", "label": "Secondary Sales Transactions [Member]", "documentation": "Secondary sales transactions." } } }, "auth_ref":
[] }, "rani_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SecuritiesPurchaseAgreementMember",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Securities
Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement
[Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title
of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r821" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri":
```

```
"http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label":
"Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r823" ] }, "rani_SeriesACommonWarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SeriesACommonWarrantsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A Common
Warrants Member", "label": "Series A Common Warrants [Member]", "terseLabel": "Series A Common Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A [Member]", "label": "Series A
[Member]", "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example
Series B." } } }, "auth_ref": [] }, "rani_SeriesBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"SeriesBCommonWarrantsMember", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series B Common
Warrants Member", "label": "Series B Common Warrants [Member]", "terseLabel": "Series B Common Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series
B", "label": "Series B [Member]", "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred
securities, for example Series A." } } }, "auth_ref": [] }, "rani_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"SeriesBWarrantsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"documentation": "Series b warrants member.", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants" } } }, "auth_ref": [] }, "rani_SeriesEPreferredUnitsMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SeriesEPreferredUnitsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series E Preferred
Units [Member]", "documentation": "Series E preferred units.", "terseLabel": "Series E Preferred Units" } } }, "auth_ref": [] }, "rani_SeriesEWarrantsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SeriesEWarrantsMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails" ], "lang": { "en-us": { "role": {
"documentation": "Series e warrants member.", "label": "Series E Warrants [Member]", "terseLabel": "Series E Warrants" } } }, "auth_ref": [] }, "rani_ServiceAgreementTerm": { "xbrltype":
"stringItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ServiceAgreementTerm", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Service
agreement term.", "label": "Service Agreement Term", "verboseLabel": "Service agreement term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Noncash Expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense", "documentation":
"Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Forfeited, Number of Shares", "terseLabel": "Forfeited, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the
reporting period." } } }, "auth_ref": [ "r406" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel":
"Forfeited, Weighted-Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that
were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r406" ] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsAsReplacementOfProfitsInterestsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsAsReplacementOfProfitsInterestsInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Granted as replacement of Profits Interests, Number of Shares", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other
Than Options Grants As Replacement Of Profits Interests In Period", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than
options grants as replacement of profits interests in period." } } }, "auth_ref": [] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsAsReplacementOfProfitsInterestsInPeriodWeightedAverageGrantDateFairVa
{ "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsAsReplacementOfProfitsInterestsInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Granted as replacement of Profits Interests, Weighted-Average Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment
Award Equity Instruments Other Than Options Grants As Replacement Of Profits Interests In Period Weighted Average Grant Date Fair Value", "documentation": "Share based compensation
arrangement by share based payment award equity instruments other than options grants as replacement of profits interests in period weighted average grant date fair value." } } }, "auth_ref":
[] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Granted, number of shares", "terseLabel": "Granted, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or
unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r404" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Granted, Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on
other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r404" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"periodEndLabel": "Outstanding, Number of Shares, Ending Balance", "periodStartLabel": "Outstanding, Number of Shares, Beginning Balance", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments,
excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r401", "r402" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"periodStartLabel": "Outstanding, Weighted-Average Grant Date Fair Value", "periodEndLabel": "Outstanding, Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-
average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r401", "r402" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Vested, Number of Shares", "verboseLabel": "Vested, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting
period." } } }, "auth_ref": [ "r405" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Vested, Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or
unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments,
or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfComponentsOfEquitybasedCompensationExpenseDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement
By Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r386",
"r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413",
"r414", "r415" ] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndReplacedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndReplacedInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number
of Options, Canceled and replaced with stock options", "terseLabel": "Number of Options, Canceled and replaced", "label": "Share Based Compensation Arrangement By Share Based Payment
Award Options Canceled And Replaced In Period", "documentation": "Share based compensation arrangement by share based payment award options canceled and replaced in period." } } },
"auth_ref": [] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndReplacedWeightedAverageRemainingContractualTerm": { "xbrltype":
```

```
"durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndReplacedWeightedAverageRemainingContractualTerm", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average Remaining Contractual Term, Canceled and replaced with stock options (in years)", "label": "Share based Compensation Arrangement By Share based Payment Award Options Canceled
And Replaced Weighted Average Remaining Contractual Term", "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Canceled And Replaced
Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel":
"Exercisable at September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of
shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r395" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average Exercise Price per Share, Exercisable at September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted
Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of
options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r395" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Canceled", "negatedLabel": "Number of options, Forfeited", "verboseLabel": "Number of options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified
in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r399" ] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAsReplacementAwardsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAsReplacementAwardsInPeriodIntrinsicValue",
"crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Aggregate Intrinsic Value, Granted as replacement awards (in thousands)", "label": "Share-based Compensation Arrangement by Share-based Payment Award Options
Granted As Replacement Awards in Period Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options Granted As Replacement
Awards in Period Intrinsic Value." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate
Intrinsic Value, Granted (in thousands)", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of grant and grant price on options granted (or
share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value" } } }, "auth_ref": [] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsInPeriodGross",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label":
"Share Based Compensation Arrangement By Share Based Payment Award Options Grants As Replacement Awards In Period Gross", "documentation": "Share Based Compensation
Arrangement By Share Based Payment Award Options Grants As Replacement Awards In Period Gross.", "terseLabel": "Number of Options, Granted as replacement awards" } } }, "auth_ref": [] }
}, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsWeightedAverageRemainingContractualTerm": { "xbrltype":
"durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsWeightedAverageRemainingContractualTerm", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average Remaining Contractual Term, Granted as replacement awards (in years)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants As
Replacement Awards Weighted Average Remaining Contractual Term", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants As
Replacement Awards Weighted Average Remaining Contractual Term." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number
of Options, Unit Grants", "terseLabel": "Number of Options, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
"documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r397" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Aggregate Intrinsic Value, Outstanding, Beginning Balance", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance", "verboseLabel": "Aggregate Intrinsic Value,
Exercisable at September 30, 2021 (in thousands)", "terseLabel": "Aggregate Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [
"r47" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Number of Options, Outstanding, Beginning balance", "periodEndLabel": "Number of Options, Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options, outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." }
} }, "auth_ref": [ "r393", "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel":
"Weighted Average Exercise Price per Share, Outstanding, Beginning balance", "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending balance", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options, outstanding, weighted average
exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r393", "r394" ] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThreshold": { "xbrltype": "perShareItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThreshold", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel":
"Profits Interests Threshold, Balance at September 30, 2021", "periodStartLabel": "Profits Interests Threshold, Balance at December 31, 2020", "label": "Share Based Compensation
Arrangement By Share Based Payment Award Profits Interests Activity Threshold", "documentation": "Profits interests activity threshold" } } }, "auth_ref": [] },
"rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdCanceledAndReplacedWithRestrictedStockAwards": { "xbrltype":
"perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdCanceledAndReplacedWithRestrictedStockAwards", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profits
Interests Threshold, Canceled and replaced with restricted stock awards", "label": "Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold
Canceled and replaced with Restricted Stock Awards", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Canceled
and replaced with Restricted Stock Awards." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdForfeitures": {
"xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdForfeitures", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profits
Interests Threshold, Forfeited", "label": "Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Forfeitures", "documentation": "Profits
Interests Activity Threshold Forfeitures" } } }, "auth_ref": [] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdGrants": { "xbrltype":
"perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdGrants", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profits
Interests Threshold, Granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Grants", "documentation": "Profits
Interests Activity Threshold Grants" } } }, "auth_ref": [] }, "rani_ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdVested": { "xbrltype":
"perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardProfitsInterestsActivityThresholdVested", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Profits
Interests Threshold, Vested", "label": "Share Based Compensation Arrangement By Share Based Payment Award Profits Interests Activity Threshold Vested", "documentation": "Share based
compensation arrangement by share based payment award profits interests activity threshold vested." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based
payment arrangement." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408",
"r409", "r410", "r411", "r412", "r413", "r414", "r415" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted
Average Exercise Price per Share, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise
Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r398" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted
Average Exercise Price per Share, Forfeited", "terseLabel": "Weighted Average Exercise Price per Share, Canceled and replaced with stock options", "label": "Share-Based Compensation
Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have
acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r399" ] },
```

"rani_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsAsReplacementAwardsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price per Share, Granted as replacement awards", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants As Replacement Awards In Period Weighted Average Exercise Price", "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants As Replacement Awards In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price per Share, Unit Grants", "terseLabel": "Weighted Average Exercise Price per Share, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r397"] }, "rani_ShareBasedCompensationNumberOfProfitsInterestsCanceledAndReplacedWithRestrictedStockAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationNumberOfProfitsInterestsCanceledAndReplacedWithRestrictedStockAwards", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitAndAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cancelled", "negatedLabel": "Number of Profit Interests, Canceled and replaced with restricted stock awards", "label": "Share Based Compensation Number Of Profits Interests Canceled And Replaced With Restricted Stock Awards", "documentation": "Share Based Compensation Number Of Profits Interests Canceled And Replaced With Restricted Stock Awards." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationNumberOfProfitsInterestsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationNumberOfProfitsInterestsForfeitures", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Profit Interests Forfeited", "label": "Share Based Compensation Number Of Profits Interests Forfeitures", "documentation": "Share Based Compensation Number Of Profits Interests Forfeitures." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationNumberOfProfitsInterestsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationNumberOfProfitsInterestsGrantsInPeriodGross", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Profit Interests Granted", "label": "Share Based Compensation Number Of Profits Interests Grants In Period Gross", "documentation": "Share Based Compensation Number Of Profits Interests Grants In Period Gross." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationNumberOfProfitsInterestsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationNumberOfProfitsInterestsOutstandingNumber", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Profit Interests, Balance at September 30, 2021", "periodStartLabel": "Number of Profit Interests, Balance at December 31, 2020", "label": "Share Based Compensation Number Of Profits Interests Outstanding Number", "documentation": "Share Based Compensation Number Of Profits Interests Outstanding Number." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationNumberOfProfitsInterestsVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationNumberOfProfitsInterestsVested", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Number Of Profits Interests Vested", "documentation": "Share based compensation number of profits interests vested.", "negatedLabel": "Number of Profit Interests Vested" } } }, "auth_ref": [] }, "rani_ShareBasedCompensationProfitInterestsCanceledAndReplacedWithRestrictedStockAwardsWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationProfitInterestsCanceledAndReplacedWithRestrictedStockAwardsWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Canceled and replaced with restricted stock awards", "label": "Share Based Compensation Profit Interests Canceled And Replaced With Restricted Stock Awards Weighted Average Grant Date Fair Value", "documentation": "Share Based Compensation Profit Interests Canceled And Replaced With Restricted Stock Awards Weighted Average Grant Date Fair Value." } } }, "auth_ref": [] }, "rani_ShareBasedCompensationProfitInterestsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationProfitInterestsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited", "label": "Share Based Compensation Profit Interests Forfeitures Weighted Average Grant Date Fair Value", "documentation": "Share Based Compensation Profit Interests Forfeitures Weighted Average Grant Date Fair Value." } } } }, "auth_ref": [] },
"rani_ShareBasedCompensationProfitInterestsGrantedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationProfitInterestsGrantedWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share Based Compensation Profit Interests Granted Weighted Average Grant Date Fair Value", "documentation": "Share based compensation profit interests granted weighted average grant date fair value.", "terseLabel": "Weighted Average Grant Date Fair Value, Granted" } } }, "auth_ref": [] }, "rani_ShareBasedCompensationProfitInterestsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationProfitInterestsVestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Vested", "label": "Share Based Compensation Profit Interests Vested Weighted Average Grant Date Fair Value", "documentation": "Share Based Compensation Profit Interests Vested Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] },
"rani_ShareBasedCompensationProfitInterestsWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "ShareBasedCompensationProfitInterestsWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Grant Date Fair Value, Balance at September 30, 2021", "periodStartLabel": "Weighted Average Grant Date Fair Value, Balance at December 31, 2020", "label": "Share Based Compensation Profit Interests Weighted Average Grant Date Fair Value", "documentation": "Share Based Compensation Profit Interests Weighted Average Grant Date Fair Value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable at September 30, 2024 (in thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r47"] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at September 30, 2024 (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r47"] }, "rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails", "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfUnitOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Granted (in years)", "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue", "crdr": "debit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Nonvested at September 30, 2024 (in thousands)", "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Nonvested at September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price per Share, Nonvested at September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] },
"rani_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Nonvested at September 30, 2024 (in years)", "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r109"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of RSAs vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r408"] },
"rani_SharesIssuablePursuantToTheEsppMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SharesIssuablePursuantToTheEsppMember", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Shares issuable pursuant to the ESPP", "documentation": "Shares issuable pursuant to the ESPP.", "label": "Shares Issuable Pursuant To The ESPP [Member]", "terseLabel": "Shares Issuable Pursuant To The ESPP [Member]" } } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Offering price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r70", "r979", "r980", "r981" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r68", "r979", "r980", "r981" ] }, "rani_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant Accounting Policies", "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r96", "r199" ] }, "rani_SouthLakeOneLLCAndAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SouthLakeOneLLCAndAffiliatesMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "South Lake One LLC and Affiliates", "label": "South Lake One L L C And Affiliates [Member]", "documentation": "South Lake One L L C And Affiliates." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLiabilityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r142", "r168", "r169", "r170", "r201", "r226", "r227", "r229", "r231", "r239", "r240", "r288", "r325", "r327", "r328", "r329", "r332", "r333", "r354", "r355", "r357", "r360", "r367", "r517", "r653", "r654", "r655", "r656", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r686", "r707", "r729", "r742", "r743", "r744", "r745", "r746", "r908", "r942", "r952" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r80", "r83", "r84", "r155", "r182", "r183", "r184", "r204", "r205", "r206", "r208", "r216", "r219", "r221", "r238", "r292", "r298", "r311", "r369", "r434", "r435", "r446", "r447", "r448", "r451", "r458", "r459", "r471", "r473", "r474", "r475", "r476", "r478", "r489", "r518", "r520", "r521", "r522", "r523", "r524", "r531", "r534", "r553", "r626", "r638", "r639", "r640", "r664", "r729" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r204", "r205", "r206", "r238", "r534", "r597", "r652", "r675", "r678", "r679", "r680", "r681", "r682", "r683", "r686", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r703", "r705", "r708", "r709", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r729", "r813" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r150", "r222", "r384", "r909", "r910", "r950" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfProfitsInterestsActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r204", "r205", "r206", "r238", "r254", "r534", "r597", "r652", "r675", "r678", "r679", "r680", "r681", "r682", "r683", "r686", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r701", "r702", "r703", "r705", "r708", "r709", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r729", "r813" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r830", "r840", "r850", "r882" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsScheduleOfAmountsChargedForServicesAndRentDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Equity-Based Compensation", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r954" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r11", "r38", "r79", "r80", "r104" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan, net of shares withheld for tax settlement (Shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r11", "r79", "r80", "r104" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of Class A common stock in connection with the IPO, net of issuance costs $10,686, shares", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r79", "r80", "r104", "r653", "r729", "r743" ] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common warrants to purchase an aggregate shares", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeiture of restricted stock awards, Shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r79", "r80", "r104" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrants", "negatedLabel": "Number of Options, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r79", "r80", "r104", "r398" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [
```

```
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r11", "r80", "r83", "r84", "r104" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan", "negatedLabel": "Issuance of common stock under employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r79", "r80", "r104" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeiture of restricted stock awards", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Value of stock related to Restricted Stock Awards during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r104" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Stock Options [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r812" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r80", "r83", "r84", "r97", "r688", "r704", "r730", "r731", "r806", "r820", "r944", "r973", "r1037", "r1068" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity", "periodEndLabel": "Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r52", "r53", "r57", "r155", "r156", "r183", "r204", "r205", "r206", "r208", "r216", "r219", "r292", "r298", "r311", "r369", "r434", "r435", "r446", "r447", "r448", "r451", "r458", "r459", "r471", "r473", "r474", "r475", "r476", "r478", "r489", "r518", "r520", "r524", "r532", "r553", "r639", "r640", "r662", "r688", "r704", "r730", "r731", "r747", "r819", "r944", "r973", "r1037", "r1068" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquity1" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r101", "r200", "r353", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r369", "r480", "r732", "r734", "r748" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r525", "r562" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r562" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r525", "r562" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r562" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r562" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEvents1" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r561", "r563" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited1",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"rani_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "rani_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r876" ] }, "rani_TakedaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "TakedaAgreementMember", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Takeda Agreement [Member]", "documentation": "Takeda Agreement [Member]", "terseLabel": "Takeda Agreement [Member]" } } }, "auth_ref": [] }, "rani_TaxReceivableAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "TaxReceivableAgreementMember", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Receivable Agreement", "documentation": "Tax Receivable Agreement [Member]", "label": "Tax Receivable Agreement [Member]" } } }, "auth_ref": [] },
"rani_TaxReceivableAgreementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "TaxReceivableAgreementPolicyPolicyTextBlock", "presentation":[ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Receivable Agreement", "label": "Tax Receivable Agreement, Policy [Policy Text Block]", "documentation": "Tax Receivable Agreement, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r961", "r1047" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r868" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r875" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r895" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r897" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation":[
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r350", "r365", "r479", "r514", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r627", "r794", "r795", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r807", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r969", "r970", "r971", "r972", "r1028", "r1031", "r1032", "r1033", "r1035", "r1036" ] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation":[
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r898"
```

```
] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [
"r899" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [
"r899" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r897" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r897" ] },
"ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate
Available" } } }, "auth_ref": [ "r900" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": [ "r898" ] }, "rani_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ranitherapeutics.com/20240930",
"localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand
And Twenty One Employee Stock Purchase Plan [Member]", "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]", "terseLabel": "2021 Employee Stock Purchase
Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation":
[ "http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r157", "r158", "r207", "r208", "r209",
"r210", "r222", "r252", "r253", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r310", "r311", "r314", "r434", "r435", "r436", "r437", "r438", "r443", "r444", "r445",
"r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478",
"r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r515", "r516", "r530", "r531", "r532", "r548", "r549", "r550", "r551", "r552", "r553", "r598", "r599", "r600",
"r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative
Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by
collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r460" ] }, "us-
gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "U.S. Treasuries", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United
States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes
(intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r763", "r786", "r788", "r794", "r1059" ] },
"rani_UnauditedInterimFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"UnauditedInterimFinancialInformationPolicyTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim
Condensed Consolidated Financial Statements", "label": "Unaudited Interim Financial Information Policy [Text Block]", "documentation": "Unaudited interim financial information." } } },
"auth_ref": [] } }, "rani_UncalledAmountOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "UncalledAmountOfDebt", "crdr": "credit",
"presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncalled
amount of debt", "label": "UNCALLED AMOUNT OF DEBT", "documentation": "UNCALLED AMOUNT OF DEBT" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype":
"pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r894" ] }, "us-
gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Change in uncertain tax position", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "totalLabel": "Unrecognized Tax Benefits, Period
Increase (Decrease), Total", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [
"r1024" ] }, "rani_UpFrontPaymentArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "UpFrontPaymentArrangement",
"crdr": "debit", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCollaborativeAndEvaluationArrangementsAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Up front payment arrangement", "label": "Up Front Payment Arrangement", "documentation": "Up Front Payment Arrangement" } } }, "auth_ref": [] },
"rani_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "UpfrontPayment", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureEvaluationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment",
"label": "Upfront Payment", "documentation": "upfront payment." } } }, "auth_ref": [] }, "rani_UsTreasuriesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "UsTreasuriesMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsRestrictedCashEquivalentsAndMarketableSecuritiesSummaryOfAshCashEquivalentsRestrictedCashEq
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "U.S. Treasuries", "terseLabel": "U.S. Treasuries [Member]", "label": "US Treasuries [Member]", "documentation": "US Treasuries [Member]" } } }, "auth_ref": []
}, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates",
"label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with
generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r134", "r136", "r139", "r140" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel":
"Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r864" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureLongtermDebtAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Warrants", "terseLabel": "Preferred unit warrant liability", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance
with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r810", "r811", "r814", "r815", "r816", "r817" ] }, "us-
gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": {
"en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding",
"terseLabel": "Fair value totaling", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a
specified price." } } }, "auth_ref": [ "r1031", "r1032", "r1033" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Warrants exercisable period", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding
warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS'
format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1031", "r1032", "r1033" ] }, "us-
gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsSubjectToMandatoryRedemptionMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Warrants [Member]", "terseLabel": "Warrants", "label": "Warrants and Rights Subject to Mandatory Redemption [Member]", "documentation": "Warrants and
rights that embody an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to
occur." } } }, "auth_ref": [ "r7", "r10" ] }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Not
Settleable in Cash, Fair Value Disclosure", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": [ "r1029", "r1030", "r1035" ] },
"rani_WarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname": "WarrantsTextBlock", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants [Text Block]", "documentation": "The
entire disclosure of warrants." } } }, "auth_ref": [] }, "rani_WarrtsExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ranitherapeutics.com/20240930", "localname":
"WarrtsExpirationTerm", "presentation": [ "http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Warrats Expiration Term", "documentation": "Warrats Expiration Term" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementUnobservableInputsUsedInFairValueMeasurementDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } },
"auth_ref": [ "r497", "r580", "r753", "r754", "r707", "r1051", "r1053", "r1056" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted
average Class A common share outstanding diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares
Outstanding, Diluted", "terseLabel": "Weighted average share outstanding diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating
diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r225", "r231" ] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails",
"http://www.ranitherapeutics.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted
average Class A common share outstanding basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding,
Basic", "terseLabel": "Weighted average share outstanding basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other
shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
} } }, "auth_ref": [ "r224", "r231" ] }, "rani_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "xbrltype": "stringItemType", "nsuri":
"http://www.ranitherapeutics.com/20240930", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "presentation": [
"http://www.ranitherapeutics.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerClassACommonShareDetails" ], "lang": { "en-us":
{ "role": { "documentation": "Weighted average number of shares outstanding basic and diluted", "label": "Weighted Average Number Of Shares Outstanding Basic and Diluted", "terseLabel":
"Denominator:" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end
Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are
```

```
Outstanding and Unvested" } } }, "auth_ref": { "r862" } } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
```

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/860/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-

02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r240": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" },
"r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" },
"r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r249": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r253": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r259": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r261": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r263": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r267": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r273": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r275": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r277": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r279":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" },
"r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r283":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" },
"r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r290": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r292": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r294":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)
(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" },
"r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479310/326-20-50-16" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r311": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r313": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r315": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r317": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r319": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "90", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)",

```
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482000/835-30-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-10" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r642", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r654", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r659", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r664", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r665", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r667", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r668", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r669", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r676", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700", { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
```

"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r779": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r781":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r783":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r785": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r787":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)
(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r789": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r793": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r795": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r797": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r799": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" },
"r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r804": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r806": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r808": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r810": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r812":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r814": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-
6" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r820": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240",
"Section": "12", "Subsection": "b" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12",
"Subsection": "b-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" },
"r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r825": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "j", "Paragraph": "a" }, "r826": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r827": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r828": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r829": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" },
"r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"C" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "D" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r837": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r838": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r839": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r840": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r841": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r842": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r843": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r844": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r845": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "2" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "3" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r856": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r857": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r858": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r859": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" },
"r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r863": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" },
"r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r868": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" },
"r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "3" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "4" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
```

```
"Paragraph": "5", "Subparagraph": "i" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "i", "Sentence": "A" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r908": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r909": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r910": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name":
```

"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210-13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210-13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 79 0000950170-24-126763-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-126763-xbrl.zip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}^2&7S$^[),,$9Z"Y9H+@'DZH(((M[AS[X?D)P@.3@SSV1QFH.\Y8"M]%G:"G"S@A M,)9S-R[&=KI^3R?PL*:,QH7]G)^,J%)!_273HQQ_KX5;EIY/1_ZH/CT9C(-G)LR.?4*YN5?,H MRS.< W*040AM5>S9HW80}?ZT>$;JFZ.!/T:.RG#VE_K+%KXJCV<_UBGE8?OC M*__Z,9^\&J8\I=__MS\>W&R0%06*5-ES=,*0T&%>B)Y$62:0MF7AM*0$E)FUR2,F=F\.=Z7B,DPAJ MT0_^:_ OQBV%"97:[P1)0?FS86:7N.>$4M3*@*A82L!0C2 M6[,Y"U!+,Q3#G,GEK9W1X6$]PL,WV,'%+ @.!0*GS5X,MADMI8),X3!$ V3O M%*2$9UL4S3 5#"3&%$1F>\/{#^_WGH,$;>]M83T OAY/,[#TY4.WPB4AA2/_M2^?GR-Q(BDB/=>%<\VSN,O0LS(1&Q])\#83R9,FSAE%C#311>UO\U_P&(&DT!K'5BF4DXMURM["M"*6. M"?I?X%FV$KP4)+\,3F$!QV08^ 7X%! @&Q!M'.]TT_/"[UQ+AFX+>,FMU\0 MKFPU+3J X50M?.E"'?KKHP.$[P"A0GOL8(RC1:U)%EKRR9W$[GRPU$OCN25!20M2-E 2N#"D),M5=%$Q(1XM;LWMK"Y^ MJQ/^7NH\KMIAYTN5\\ZK?S\OLR[>O'A#.M.3/_)A@%>D M&LZV\Z$-%_Z>OP??C# OQJO-TV>[Q\TVQ_J9M'ORTNV?[DZX$@PR+UOA! MWLMQ.JXG0+RSQ_[R]-*W ,88YLF@GEXV T>MS#GY@(D?3Y#*?H E$80R^. D M.2?G3J8RG5XZEY'GSRQ^7{SDZ;GENVHU@],CP, #!}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{C]$P'__AQW_FR>+K84X+"_LKG=B5^Q_L+>DS $!>$[6Z$,2DI4D@UE6,J7%<-K7=7P]&G[<_MS^/#MU,PVGV33^-8?C_>@0GY.!H?[Y97L-,+*)79D9&@QJ0T',TZ$='K8] MW4]8&VZ4R@OE,\D)+=),2!!"4^TA',/]#X+$$Y}+L,U3##6(>T=K$4 WO,CK7U/8S.,$<*.$1S L9 MP0!T&0Q YS-3C)L,.G8-5[+59+A^%]805O6V3H7UW%.V5H.1(6%]N2E$.B$(M "-!BJ7">6YM4?VWI,^!5K9CG!Y.!W!AVL44*+QHG_P49_RZU&S,.32G4BU MNE#JP+SPL$;2!@T]J LQ0F4J$RO*]]./)SR'R44/VFQU +Q.\W _P>DX{QYAM_A,F+QRC+^WUV[NBVLNSLD0AN;3S60(V]IW4F&.,M*P#3 M':<@0WPAEI!(O//4>\9E=KTU?S=!;"?:YZ9!:**{(#3G8@ZP]B0%Z8AD1H)Y M+C,I2A<9/>FV#6CG.T$$@)NQ,#W.KT:[OBC>N(`?0(3W7DS/8M9,48B+YCS M9@()$K&%\[.!<",96*8"]EQ M:6+J;7#;Y1,;G?;N,F-VW#JVC3^TV+8ND7*(":"R()PK!G1K,$$F!!*]2-HC MO6765[KMV/%[=\'#;NYSZ,XFC2(7RC.Q((":(Y%$3+S(C('R*UMH8(EL5A44>)>%_S+,,U=DL YEFF(W$;)0F8;Q\_Q`_>V:L[(P8O!),{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`>)5WYTX,JH252)!!$&DE(HXGACQA@OIKLQ3ST\+VCJ&%QY.5HG*._S#IX][#K) H-Q3@C'=845=IBYEM^@L[M"0I MV20M2H&M>ZR=NZT6(,V,UWQI(O,"6&)S-APS"1&'V9"!LLC4H#B%EW M&_)F*W)S6V?:MK.;[3"],,N>@65R.K2TK#KWXYW&LV.]T9M:#/VR4/CU4K0P"YYQ3VS/6,L;S5L.5W61?6@M:L.'$)T&A@9%B1C&39KB=5< M$1]"=#. 0$Z]S2;NR7[OIAC_"C:?0[1:",:6)MF C2)LI L5(DE39)! #9DLW MH-=$^!9? KX_16+?6[PG41GN9IM4$1%!E)?AT \=1ZW0/#HN*!]9;[D+RBJ53RCTWA'DH8A\(UTA#,S'<&B*C MDB08R8E//#BJ-`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`)L#/WC*I,K$E@R:.1A#+;,"+6A)1C*.PSYL,A:=BDB5>\@#*.M0"GBN0;SD<.!4XH16[G&FTY1HE-F'N;F2FE=]Q^Z^!QRR:.M[*$ UH*?%3#8R^-/=`(>1#7)<\L<|<],ZL#%4]D-)O 2U #PFL:I,,Z MV=[N2?8F7& Y)9RR0)YG:PBS(5 %0=BM:,D2>U]<2.5T M(CGYUH-ZD%=\K MA,E2<8U]'76((% 4]L1K(XE6 BS8+(]0O:US="]>]!.;[MZ'CVDU]FI6)F5# M(V@1FP%H)$V<,XH8,W3.5 ,@EN[!6)D/ BMG0G&*<,4MD1+3.VGD@+(B2]$9 M..G;P*U^B>TUD9R=TDXP7":,J/<@.6W"(B):D!B"C)P*KG)O2WO=@{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{,&@)1SAV5YK1]+/TN:BA"N]+1;1MW(>?5#M+A63 P MG<+LW,))CE8SF<'.=.MJ6 :EN=<*ZK,6SZ++L*1,8+E&Z0UQR>$>C689E%7* MJK=&8H_JLR();LQ4-P[LP(836]CVZ9KV,]"^BPL5EQ8@\7I@:,/ZNIR/YZ.# M .9UO+ ^2C@_%88XMR5C*EAA]*0@828F3Q1.O3">&QI*2S?R>\[UU&M:Z1(Q M%!.#B9[8X%#>"?B).R"8I$5*WAAEEQYL\KV,TIV[MD3E0-O"XY@'V\FW>,F) M)!.C"EXX.]8=+J_<=Kj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{?_>,1_,)HV'LR!8=K_# \\WAWF%X=`@]%QSNUJ+JQ4 MO/W'7%-A?,[9$L=@)26S@GCF%4D\QLBHE2KU%E_^X+VBY?C,N62!18"]BT] M4W@BP6=*M'#"6YN1K@K0MB>MLZ.F1I^.\XEC\>@"$XLAY8P9GV, M+Z#9V;%E4X,I2FD;IK4/D42="D YZ8B7)A&>DC)&Z2@1@KJ^4L8FS7Y:]R8TN M%)M+.\PSDZ#^B3,V$*HD-X5'87AOW98;,\32@;YU@"X2QIY)D!DF,.*T-$3' MI'EB.DG;6_.O!YVPNN13)XSRL1!O=" R%DE@:.1*A0MMBDG%Z^:UA;KL22]U> M6%/,[DR0Z>+G-FMYX1CRTQ1:9)N@!HS??6#NMIL9V+KGUY<]>^[FQ5"X!M MK/B0,H#O;#UQ$NL.6)Z$Y)KE_E7S6[-574&5:!Z\5MI2$@2LI>3!8IQ8 .#,.MHE3%TA!ZEYWV.*O.U2V@@:.30A9@.DN+X1N46+"_2"}]LZ1AJ=+2"X,<0H_= M5.+)[B2>XH3+;SB<),!8$[5=@*1[O7,Z4\W758_UT-RR]B5E7[@8ALK5& M*%*O?YGTC)'K"51.&JUU#FQWNK"GO2I[W4%B"[%K.+%.A!20B'1%*8P>A50 M>1"&:2[(N:18T(&=,_M$N:LF"=YQJR(CHE7KC+MG>2;'D16+?V';*%^X!NF2Y*+T=FO_9O[WMA'(N[WW.X.W M F/1!8$. 4:D#!B]FR(1&7F7:,/ZVUET&YZ0ZD$;M'AJ<+[X$@23E-/+\>@0 M;>#II V[WRTO_'@(\K-YF\=[!WZ,*.72!UQJ+C?39F\. ![C9'\$ M7)G\9#0&SDWY*BU@G]$W[X @F+8QX+PV8UH]}(,358MU](C]X M/$Z'11M$RM)0GDB1%-T@(8 6UY10&V()3,307PE^HX2S$,/W_YVG# _5HVDS M_/UY-!H#@%H7S"2IT8*F!+#5@4(4S!&G>2$V";N%\\F$WB!$[$]U:7N@[4]Y M.,W_ 0?!XMP]PA69 I8]1C>_Z[===:<6=<09.?.EC/C/F3FO1WX((G>.PHYO MVIIH>1;=735N9]7C)!/:^,"![R5ZDT,BCOM$=-+"L13=.C3U[= M1311DX@)NTXY8B46.XM,L%*TCV7=}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

*MP[Q>WH6'EQ^BA_?5M&D&>38]'TSO,3V&2]J/-?/'>B[D+VLV*_O7MEY,P/4\5R@_75$VV9W_)]U[[>O379_HHL M>%!211,<,Q8T+GF,582D! '!D@5G70 N$OK&C5Z_]8E HDHKG:@7NB!DXMD]IF1Y3KU'.[.1,;+$N&YF'[%W27[=_XT5WV2/<6 MB2998SWXG ((RSP833)8$!0FUJ2H5]Q;ZR1\7*!N9!),[\'2R]51=j*@FRS* MT>MEC1S5(V'VE*.B8(H;,MDXZQ48XRO&>Y M:,A1R%'(4==E<6F,P^2.!"R&!C4X4(XJ+ ''T7R1(,Y2@Z%(0C2R%+ M',TP>\I296OF6*YM) 0KC"`R!B<\ T%(9E,,8BN9+I(9 LI2,*A8SW*Y]K^0 M&/H+KRJ(H<.PW\>BL?KEP>7HD<2C09%Q +!9S,;Z+6O.!..:L^N#X\ / +3+IV8 M'5<5'G)^A,4S,7\9^17Y]2#VXU2OGC>"Z,;!8*5P9)5@1-)ALO$N:'Z-7"OH\ MQ@';.,.2(ZSF@_R*_(K\>A#[FQDWF8!?++"E=H4^]77XU"&<$V,B8VEH1TX M,_S*AY8<84U=Y%?D5^37@^!7+@)E+'.@7IC:]+V8KK6H0Z1,6Z&%ICETZ?;N MFE^U07[]*7[=0C+M.K[P_7=VOT[SP7C;8!VUPXH?[:"4)Z]>!YKV{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{]=.NCMRV^"&H-I8CT6N8TI[E13V#M22]X,9OL_+,W_VY!P]ZDR/[MRI,_26%WGF6=D7XX2P,7PO2\_/*7VHEF,IV7"]OC=9.+139\L! MZO,U#<&T7_?3SW6JRA5/+T=?9/YZFNM$KEJW^5,RQL7T=0'O7R4_VF/47Y^_M"OQ9'J?/$$>SU/)$N?X<3YY%D?`Q=A]>5H_O,[?E>273U=^\S(ZNWSCGXMF_H/LI? KB337@!1$]=3)M1=>`J0&KOYZ.Z.9)K-OG\0,KX,2*5Z5[0=K%*ULG:^`MKJ"SV0TE,I[.RyJ!LO)FER*]_4&9-7;RU\R[?Q?%+VSC{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|BZ/F8NR^/*V27M_O:Y1NM!3'951K M^<-8_%\U&E+]<2:.:]%-(D/KN8-J/WK,T=O."B3=' -3 M_[#?6F>_?*OFUJFE)27':[*]V^T5-1 ^?F.=KJRW;!25YDWG#A,1/59VNY+V ME]K_6$K,3\>QBPEX=_+ZY>##KR_>G;Q]\=N'EZ?O!{^^>?7\Y>M_?S\!SNS%E[_7SF)DTUZ0XN+B[2++@F/=O1 M9)Z^>?W\Q>OW++YX/3F]JOO? 7PQG<0Y7OVRB*2C]=3GG1]8/W'JZ<_G]U3;QX M]_Y_R_#)'X\>/"2B]'\RV&80AU/SE_*E,S/IHO&36+SUS4W69MXL .Q3+L6 MQV]79N=>RJ+'&Y1'[\'4#T:X_&.]\=/1O/QF>-"8VSWH9;NO;UA? EY9,?;[MV)11U.]#,R>G/JX]^41N;.U]+PE=?S<'M_3XSZ,&)Z3\3O-0'%KOLY=BNFSJK'S1U_JF31%>/O<&9Z6Y?]TWW2'66#DX& MI]^S\]+EDV]X^#?]OS47RD%,N^S!]"\N$33>P^3O"!F'S;=BP'!*FN*1Z7$%_M-=Q']1{7:'$-]U&JQS5:7,.]E.IQC1;7NC//E9'#]+FHF.((!P8/@^3YX0EB<+\;MZ;,W\L,T&]PN!?MJV]"QAC!" M&#T<1LJ3'H416FZ(&D3-]U'S>CJ!T^G7#J)7!?01.@@=A,YWH?-A6O8WRPS? ML_*L]-&O^?,]A>P3/6L%ATTD;Z<=UBC!5 KL\?_VM.?V[&&[M)2 ,W+Y9.2.>^ M[!DX!0X887SS915]D+E Z@&510_(]**$)}89WP64WK=BE#?MR$L.+2F5OI[Z0-WV7_LN MY6VR2S&R',+=P8CS2$B.&VVY] (X];.0G-!@5>80]`0N:!MC-G=)+DFOF8BU M.X C($QTX)DJUW@O JNMLVI'RIT8,&)(*1IL2&% [++$XTV#,%94:%8K Q7WN5 M1!#,,7 D,!!1:AX2M22N=,I=#VMF!CR';(=OLK3F2[3;&=-CQ1:BQ$C0.(M4-N4]J- BLB,YRX[G<ZR'4^!VN@5%.N.@DBIL)T/! IKUNXD4GA&}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{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{Z4CI2.F[<($X95(6JB8>!U^+MA9,VE #CO-B0N?H3%BA M7!5R-DDKR%Y5%X@R8)RR-8$YV)PRI\SNFC)_4 .;,$.17Y-!#D(5?O0-'DX.<>%1". ^? BBH?"!.UL, IXZY:.UH/1-8,'M7?9,<.B MW&M^I6(HN42"W=0A$BRRW<{IRZ99M*=(IKF6VCZ?UIL6&)1%7%;'()U?C*=? M4K!\\V(Q"V>N28.+L9L;!Y,TK][7\]V /78'55"G^`PQJYHKS4;3%$SD>W&)YO9+,R^Q_+9 MN>DNKX]2TK/F#VCO{[4=\@`.?KZT&^(WY]4[$[Y$)'/';*W$B?H],X(C? M7HGTS2M>P#(5-)N<2/G /0R2:!Z5#V8\S#B)E!HYR L&,S(6G1DE^U\/ MB=?1)P[>"0.":.)&,P\Q1T:C*D\6 WH8](P&6$MYPVEPJ4T+;=/?&LQ_0Q6$ M*NBA.=R<>1M\!B)"*BI(9K"*.XA, ^Q#XC*U'N@Z^6_O4C.?C<(AQ1L%)8J MJ2WOOWSC']/9!_?YORI@I^:.W!UA IS99-)VO[&-U 8K<>}`.B M%P6,^.V# 2_^$;^(7Q0GN@8N70/$.YZJ9H916KB=0G&\P1;*A4D-3;4;]*-MSW\[B?]<-//]CFL^3$?:5G<..W;A1?3D[=Q6CNQFUP[Y<.*,CX"]!.,] M_WQ:+O.ST9^'C9LTT*39*"/3H:6"E@H"'.6 $>!(\#W,$80X CP?@LF1.H/UX=!M$Q"_B%_&+ ^#UN<2)^CTS@B-]>B)U>V0" M1_SV2IS[X6P]^.YW*@;&-7/1@66CNPF[2P=PS"70G%-OE? 6)Z4W74CN=3HJ,F_)0 M,_)OD]&\Z,QG*3$]<^WNH'?=GBA,I-2=4RJ-1"APA#I*&"&-D=({ZN$#SS+ M1%@1@DL<&-4)!"T;$\LAY"\M)+RP.3*(1=#RI:%,0(R6@LB\@3.YP19.Z.2 MMD)3MZ6-R9'M1_90^2//H8319MGW[#&LIM;...N$P+LFQ5I{2}&E>U OJ_M^P\;%@D4..)W3P:, ^$7\(GY1G(A2%/@>C [QB_A%_")^49S'&@:)T8D4F 2- M P AM <,L@<.B%T8(VU:MK[84>.ND.KWAHWI72_PW9.#OT^S3**1E_1= M"M./D_8N;2BEJ7850THLQDX.6^N80/ M?.\B>#*$: V*&@]")E?V+C1 (%()*0P6@G.1PG4P>Q?""".Y=D!51PL?,BD[0 MF*R18%GA0N%3!$ *GU++E+TQ<@BJ[K?)I>\"*8D@9>G2P\K.A=?2?#">-@V& M"OH/DL,V'7 'C;$^Q" B%P6. ^V# 2_^$;^(7Q0GXA<%O@>C0_PB?A&_B%\4 M)^+WV 6.^.V5./] .K=237"? M;G/T2/F0*XK\B.7F M'NN.:,OFMH7F9NDL39K1IS3XZ$98;NXQZ/%E#.79];/6@0Z.Z7@4'U> M^O'XT8_Y,Y.V'K"=}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{L$BP2['X2[,%7RM+ <<6J9 >Y]{4&:.!2A8 M&%E9XP2WP0>>5^NL1L9DH, $<<6@SAFLM1XLC]D288IM3'=- X ^KLK7)^JS[M2^)8IA#9' F\CVRN0LJ620DQ<@_".PTNNP35$M=1,V7CBI/8!L7K697_ M)&' !*_ Z$+DUDK&Q$K*!7ZRN=%#]C52.E(Z4CI2^K92EYVB+!)B0&LK0-C M:MH'!9LEHY$PIO,*Y5+MJ.12-0%!&$%JX5&0RC!(C) O!7+'%=TVYW_2518L\P%8L8^M=UQ*B8T$!<Z*O-Y\E)964"/.T./CG&I'!=(=A+=+F3*3<$"-4F\ MC01'}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{}L5:, ^XB31I7M0+ZP/L/&F1)%#CB=T\&C/A% M_")^40R(7Q3X'HP.\8QX1?PB2E&D-'J6[VLB@*0 JGV:?1BM&(RCO4IA^G+1W:8,I'<5.V : MCK&$JP]9YR(I[E1:.."Z#4ZEV9A(:1^S_M\A0R,[EV0%5"'Q\R*TCC.@S6@LL@=)@ MB61 &,6:LN0]Y]NJ],#'K"B&1/2M"MM64N>P^- JR^%]:#\,3IL%00?]!N\ 1 MO[T2YWX$ @^^7*EFUGBK!3"6(@BC(SC%,V@E{!5!"&/B2BH\MT&1Q(&(R$!D M4@.GY1HCC9,&96Y,N!LX?3N;EL=Y-6TZKT6]AKIWV>O'W&$;Z?_ 9^]=F]M(MCX31O{QX3W'CD!IZWZ1]OW H30>[2N+'DFSCO-IHZYDVR :1@.2Z>9_]KH! M$B0HB8($1<Z*O-Y\E)964"/.T./CG&I'!=(=A+=+F3*3<$"-4F\ MC01'}PFJNVV7K?9 M>B7./=G?X(86\8OX1? RBP!& _>S!@Q"_B%_&+XD3\HL#W4^ (

*%YV-MO9[&HZM-L/]UHU<&=HI:=@K'GIJC&?;PS.E_>2#H?8%X[-M3MG.(U3^A>-6VJ;$H6N-KY5N_^U3RQ-=/4K3)8!0\|=5ZX()]H #G=CDW65K?0L6SVV_:A_\W49_ES_+F?_RBHC7>9B^D%A/M4^&QV-)@?C%Z'>MF,G27K_#7Y?-64;ZZ7;\N+_9^T>W38BG+K22-XNO)N"DM-M[5Y.45#4G]+-Z3)9<^,L-6>U}>-!=!?4!R(J9#9+:)*'SZ14;J4=#(!W2S$"F MMGNZ^0,L:_MUU]FB,,#$G:4V_DAD"X75Q2&47Y? MH]0MBCLL83W/+BD=*95_@$_AE25H[C9JI+2C#BOK-&B#4B=#3 9SN\I*4N<2 MUUK^-_MNV=\YOIG=^#;^Y.,'S,#,,K'R[.7XJE? U#$81]N[%+U-_"<%[.K?T& M0GF$#3W2PF_#(;#2N1L.WD^Q,1'Z.(@O\"MNO?H!T/WL^GX1P[1RJE>-)T MMW2]+6U.N[IDC:I785FW6WUI,S3=N&KQ3ZYB74=9Z.0H1_KZ>#MQ=3#/,A/7;R",_MI=%AI-'&6EXG8E!1 M6&U)Q^*W+-'/XSERZ<]P!1S]>GV?)XM]AN&'! PC#KZO?Q@ [T!7R.CR2K1X MQ7C2>#(&)IO->INT(P5&M!9)AK^^K^%)+=-M"O4\ X?5[ZDNKKGUY1O!!:M% M1E;>n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

M"&&\4!\++"UJ>H8X$4<$46C4=P;6'B[3HM9%)3{AFC%VO0+=%@ M6+N""%8GA KH@K>%?%R%&RCDH93!)GO(HC->4]STR=<@%YQ[%A744&*+!NL*

M"ZO!+^UV'PHY<$MN5]%2FYPC$6PZ(D/%B6.((AF(3=680_U+6S5K"MG@B1"-MI KL'<(JSH(%:6462E@E\W8%:SA/<3Y,[_-A/B;X7 H MY;+J=;,/+37H1[_H&-X8%%C7"D}\:*

YVFL|AKOI3&@S'33/XOCQ)/&_@!^;'-M5[:?D)=\NRN6W"?,I3^E=P2KYW6^|!P#DW5$Y^VGVT)8!%-^#0?'I'HKO*K0E M.GG_WCIY?]EV\O;(>P=-<.U95L^R>O30>[*L&^F.S.V 2_LC M2#",3W/K(B90Q$\6D?@QV%UFEMV)R MK?<[Q=W.^2XFL3+3]K\Z(,;(-E*K&=W*E/$LA>0P?\Z"M*H47!$GG3=6DH$:D#sOI5: MAV2W:AP255]9O+0.1JE?*

*0>V[9<\N'XI96Y\HG1HES+A'IDR-6,$5"SERQ M+&+\%V%5N::+3-#%-#,/*@>P8<=)9$J+@4@ACJ59/RBWM"9<{MWP&_G-^"/V? M/T?]OY2[[,WR[*7:-PL.]42NJ1>,,$L6$28JJC/(I8^I|(%X;0;C(RIM^\8 M)O=/G7]4$>_;<\P&YIV",,9T"[=Y[2F1E);'&<9*CTE8* MXZ/- IEERG,?I"&5=\|OJ[M2K3VU6YQRO.*DT5D8C-+*55Q-!8$5Y5H']P(42TAU__MX+1-S,803-O0IK,*

*M:A35\/B)FY6Z_?*6]L$MDMCB.2[F)$O(X4@I) MO(P$%!%VZ=TI<.Q?4?=0C;$#5"H/=(<_P7)?TK:89P-Z%BEUK3=SK'5%€9J MNDSEWBJ'G5UJE?YO%>#;#79WKSH++*

[.K5Q7;,KIH"]!=I>_]G M.3Y?7A'Q.@_3%Q+K:2KJ'A:TSB|&KV/=3(;N\A7^NGS>RJ];MX3;.4+;+[K2 MX@4-EUM)&L77DW%3$/E>%2BB^E-.G\E2(?QR0ZWO/L?YKM.:

<[SE>5U31(Z MGUZAD7HT!-(!'NFFW9YN_@#+VG[=U367#9BXL]1ZG(G+0."OW/"SNVRZBM2' MH],#TN7BBJ(BE=_7"6+X@Y+6,]4QVY):3>NQLWPL-9MDEOHYS=5=:,]95>]C

*M^S+X(X54?RIBZ,W9-*6KZ?XO2F=9E_YU QK"='>)LMT-/O[QIA7 (4V1VZ > MT^H.WWWX:O/L,?&@)QK4-B;6I\IR#XC(:S]: AY8H0I>#.2QU"S^) M[[X"@@=B?GP!6@QLH$^C!+.%P)7 E5K$STD?0G@%9QO/>@92.@[?HQP]M ^Z UXI@_E/48\8C*9V%R#GY###MX,$%R!W%4 !W\R.-IZANN"8UXJ+[-S\-]N8 MU>=Z.(3QPE[^F5]=9WV8H&*-*

NY$5]6NVN>2N4\X6]^^,[Z!Z*!S75-#NRUX M2C2S!15,W&59H,_C^3 ."GAKN]7'AE_&E8^[\4R"K@R1O)++$583%FVV(1N> MU%9TQ@MC#'I&G,;^'SQH8D001!MMM4^&.5?

MP2]|6RAD';[LAHAE>AM?<#2_ MP$!WDT;?_??/-!T?$V(94./10=6A)6>*4(Y;G7*###8P6:*HJ;)E246ZU:[%*

M)!^9=9&$F#21HN2;]$BDIB%IE[5RV|DF||S]Z{3%INA+A2=+K948$Z'AU>W4O1 M2]Q%ZXQ8R(!-_;(W4_H9XEIDEKI-I\@^0Q&I0D12K<,5#V>-B23 4A/I/LT|0#%Z@N\HE-T0/J6UW;">*G^=)*[=?;D.7;],QU\."\":OV* MF.#!%XATLE08)BW.^,)9.(V5^N,3OJ=9B@XM#(G_>V=,0V|MA!DST@:=>1Y[5G MXS9QDSM;:::4F$/$FOY;3PZ^PA$^G/R

*MLQL@"[CL1%Q.L %(:@B UR2%M]WXX&;^9G<*10 /)-$Z[D!!2HQ6(F#L>N MQ9,%37(^13[F%D9U^7IAQC7SR638?KT.1OX;WKXTPU>PY&CAO/F41O,T^_X M 5G@N\ED/)VAYH.L[^-"@9Q=(,'Z?O-QV#)@NGA,Z|S>? 6RUT|U3*V/&SET MF4*S-:IF.9C6J>[.X!%GR(8G4Q)!02KGHH<.;%SE'HJ-\ O%"B9%7.!31)&*

*MO.85J*U.5Y4QM(),*0_2INR<#X3E:.$>28F+&316[T,RB<G^1+&G4UU/P;(NY 8"M]/C(0;A*>MC5D"T8'@Y,$"^^M(H9F!Y(C)D.WH'|@_X>BB $/4J"%*/T50@FX(Q,$;0D3&&#Z)RV+*

*M.SHBJ;A)PFBP;>$_(C-CQ&CMB8XL9=A_8?F6YF&-S1: 30EX!_C-;%.9U() ME:B,+"OGKQ))%\UN?IV.+]XVS1SAP=]E%+H'(@AVG!P"|/F"=UA?7,#Y;#MD MH)@\.D(0&ELI*E*

*B8>=1B<3>ZB*1*AHAM>;267T(X8%;ONJ3"/PBO2E,"1LG M_?)U<:.%ZQ>,M3AUGT?P8?8YI=`@'5BM;,&RXH'@A4)^3J'S2W3?3666+DH+*

MEW(I"K+J_"*5O^9+GCO\1&9JWQVDEM"E4:GJ73$\ "<@Z9LJ*D2WZ[:8I1Q M;9P@SENSCVC'HS/L^+,DV)4,9E.S;JEM,I].QLW27=*^OVZU[,,,+"",X9H*

*M4:7;]YO3P=O1,H1KG4AI*9IHQ%X>Z=(,-HBQ=0H(:(:9$B"><6)_MQDH|\^/MX>GVA|V=PEZ""?=^/D6INHSG,:Y5NXQ T:W)5KQ+B|YORRU|H,Y-+E1.>TI4 M%!3[-8&&(:*

*(G7%0RBB|QQ+9)9H[D6A"720\G!.PB?A"8/OE'"^.F'KKGWS MS/^]FRJVUMT\S3AW4AK.X?V@Z%X2["$,!KR%-W+6KNI^Y'Z^'HOK9O)BT4= MX*KN,+I7AC)0TS0M_+C*

*:=+_SN';LNI#]*4V,S<W? 4YU@@8=?>F[A_^<.OQ3/_9L?6I?L%&9> M;CK!<.]D[H=U:<" 2Z, M'?)2175SP"E2MH"MFE ,%_^"[+]=W7U^G:M%3L1_NZ@FV?Z>/L4:C?XB.SVE)*

MZBCYPV=K-(MQ%GZ7A<\L5GGEFWL"Z830++_;:7@_0I=0UZ(AL\^%L/4)6V4'8X^5WAUH" M;"%Z.^.GA G-G9:VI]?.*G"T,% PSWD*?+@N&<#I2A!L/)_AZ\J;RWA/!V^.*

*M*P#\U'DP*6?.]/V45B*O"+DNKK=2\8^~!56*@N*F.+P0##1I@R26YXH$;JV@ MRH/"$ \1QGID%@@02:'_-W5-(H*X9%AROS_@/&&U;YWL0RTH\A^;.&Q4)F" W M,;.[K568)%I[Y0Z8]*

|F#(^.+?P(KL,6UNB5IS=Q1FS]_RJ2[PL 7[<76>'H= M><3,Q3,W+ MS>>$<[V"QO9;R&GH=[+]Y9ZB4RB++YB\FP+MT8R^11#KD)?!6]KQ<-MU/UF_H-%O;42VO*

*JD@]T#2(|,\09+0D%;851X9/*6_&]^_4&[R8.C7O\D8L M'->B;_FWUD[fF.3QR2(I9F5?=CI%LW1B7-5*(NQ]*1YR3=? \!OKY_$.=Y0;3-*

*'@[I=\J2NLI033Q'+&PO';%22E)A]QEI]>9F"SH[5US*BFM2 M90[F8R4SL8I3XI+)BB;E&)-?2Y]>F9)_+#R<8%2^7U@H;0(<*+WO\]\UNIU0*

M>3A81YM/32$WC.%=^L;]#V%/*%'V'E)1ZR7-AMA=@^L@TI%^,.!I$U5$9^L M)30S2QUW3*>M0.L#2YNNH]_A7_I^&GU+;9/A3@#!]5>ME36_[/)FLT;VL M>4E'K)K)*

*7A+DGI\L.(=]00(9T2PEKI*O7HL@9-F8^?QX<2,;07 M,;TY\]0=+,9#BW8V3OK+IS7(P[S-X$\KY_HXI;[<,50EO05$W1*64B:39 M$1LD)3;Z%$-F\,56SN-=1,)FBO0_X,0F VL*

M.WRZ#]M#/G1_\B/M87@SW7)_R+XW_9[$],.'9U @>(5#*A>8/9-N/HF7/$L@\F10AC@;/#$I9".SX=SSPTN[G]QT>@F:\#68#[ZJW"Q{(*NZ[C >+G=;@@O9#KK<+>*CR47/-"&9=2)*

*(EBY1H5%3&*AP5^ZTZ2E38OTT[K(W//0YCM,L]:D.$B;HBX7IYUAMM MO=%/VJP3J9V,,9LQAM6DCBJZR{Q2C8+<)SK;:7=Q?N/T^'H7#RC=QHD35*

MFVL/UBFYKYC^:NO)@P(E,!.5G"E#C&481Z\,\N5'!9]E?.!T_3WH:3>@(OO@I9VNM58!VM: MZX]Y=#=G%L38L5)K+!%_$L"='O%28I!\F2#$_P@.>@_IYRPL3<V%-KG=3.;3R_76I"-*

*SKH6\IMX9CX-Z_0)7EF;D.&:.1O5 MB_!&801,BXGMX^MFV2VV=&KMH*1V=5RMFS6\-D1ONQC#.@SK?Z;A)0&WC@A^_MV>+W=]U;"[3Z"8*7CPM(W/#R!/2*

*|897+H\!7EJYUPZ\TL.TJ@+(AD=LUNP: M>-.^#\&ETR@6DXM'Q8)TI3Z#N:><,9E(#*U71$B6!^<,DJOBWM*?;*(L@*.M7 M/Q71^G;TCU$'N0B<'^W7OWU_0>FMVLWN21-*

(H.0988D6#,;GR&^<"M@A/1/+&R9Y:V%P!E: =K/ +2&LQ!77WUJ/CP;VG;9>GK?S[?P:#XG(+V.X< M5@H1"-L'EHJKJ48=>6)7/:PO=H1_NQ-K;QC)<*

*M/+?]JGWP=QN^P3^+3/WRBHC7>9B^D%A/6Z1:A#F<7XQ>O[]9#-WE*_QU^;Q5 M0+5N:;B+0+9?=%NZ6,5R*X$3]'IQNE\5'1-,Y/69+'W97V|HL+Z/C+]K(,, M1VL%*

*|UU(:I.$$]=7:*0>#8%T@%;=M<O3S1]@6=NO.]3)L@<$3=\;4'!Q&3C. M*S?\!"Z;#HSQX>C?t'2YN**K88+?URAUB^(.2U@//'U8|.IGMB*0\3],/YZYW^K\H7AM.]PU6SP&W:^*

*MAG49E(4Y5M?_0:DN, ^MDCHP$;Q21+EAB5 #UVCH?_/_/WILUMXUD"\+O\RL0 M'M>]]A< "QM!T.[!H%+9U>YQE=VV:RKFR9$ $A+:.(,#&(IG]Z!|S3F8"X&9M ME$2*61'MIK*

*D,D^>?4LOB&-G)X=1]VVY5_'O%U9G\4F1_)KE;8,.(=V=>QCW M$/VL]16DZ-+,12-LZ0_"CN]MPY1K!-U#,;G'B0 G^8CH1'<|->D4)9%Q0H>6 MP@OU.37-;IH]B|I&'5A(?J2_*

^;B+BWWT3;1)PN.0TFWDY8P_KVVL>G/3^8 MS'DRW;H#;S1U;MW]>A0^?+-NQ[_?9MT'-=FK,B/#'V,Y|[JQ^'I/!<6N-_"" M<$>LH$|*

>XBDOIMD+>YJA0_;2WQ\12_Q&Z6>/|K^WT8WW ,^/! ?>)HOK|&6_6 M_6%WPQOKI&GO S0?LHNY9EF;9>WX^(/C8UG#P_0T7|(HM1N4\C1/63=TO&< M^W-]50S]9:R!\?31/_?_I}*

](03D|YT9/"2X;ZLK;A\VF##.V<1+1<5@8/FQYUG3 MP',Q?X'\4NSB;/6?JF.I\'8#|96I&>)Y73LPSLQLPHG3+'B9T WUF.Y), M$=4V&"W?=3M!US'MB7.LE;QW[2FH&9)F2/O#D.

(@C((T#:VIXT>6[|/ 8I$; M6@%+8S\"!N6&:XG>8S^;1)XSMB;!%-L1Q(D5QCRV["3UTRD/[92QAV5(@1E.

M7,V0;L>0M#=[U|ZH7WE1PCWMC\)'41_CFO6>]6:M0_HCIK97P0G+$R%l, S MOMD/5+9-W; "/3U4JNN^7LLCU:X?W414-Q&]O3$T]4,7=%K7XFF,5:^^;X7C M-+

(F<1QY>&[JYMYYG?QOOC"+X$'T'O?[28,O8AI4S[^D-/YY1UOV0L$2NH;]F[M;?.B)W%@N_XDQDX0L>7'$VQJ%:96Z(1!XH)QY_MKA=CAW+=FRP6Z:Q;T6^8UO,#:81FX:!

M,UD3MKLHQ5_7)/Z$GR!V&]. V$U/]"%,_8IEEE5-KW32UE[I8GF]\-,F]?-Q M.N%ABLH5F"B^,V%6.+$#:SJ9A)Q/W4F)]. M0-!L_+#9.)B"T?B:^E;@Q6

S14YB3NLYT_>"}6W4AWE,YD3-$%$W8>SD<&3&SQ)8TCH&7VU[JL2"=Q.M-IW>Q_L:=@X\{(#C0;OX^TC>L>=#7&S MABP'VO=H[UW'ESDVC"+

<^>^]!K)8[%;#4U$G2<32U(W^]&^;=>N^<%$U& M!FAVP3_SN*VR)N/UF^]QWB8\>5N5L]:^G\QZ[YZ=M^5Y.EUYSLO+FAKR-'2._MU2"B;M0=H'$OZPQX!K42;C)+*

*|85J:%EQ8'+4^)PVI.|[OM+FYUZ:^]Q<2BC2 MC2B?6ML=?Q3NI.-/YKXA]-UQW5UTYU#KYT^K@X6NNG.*OA.Z!@% MW6A'-]K9:R ?%YO275%THQV-4KK1SKZAE,ZUN*//_B/+T _R#C>*UTVM,R+H ^%@2E6V[JP4>^MM3N^ZD;6D4VM-IQ"}G+E-NA8XWM29!&(?3F 5NXFF;/RBBT"6,=Z2NSTT9?S/*.1UE MIY7{8Z(=+5"6\(H7AM%T,K%X O_XJ0.*(0=-*

*,HI&/(D\UV539U6@<'_L!OXD MM8(HMBU_S)G%@HEO!6//27SNI9Z_EDZP;P+%L4UWJ@7*D2_O.&E^.O72,0-* M]SG'"MM@;$5T9KL_=:,(U$L[6CLI;NR$?.S;W(KM26#Y8*U:C+FA-*

0Z=>|Q- MF#>=)OM.\X$YV9BV?9PTH7V1=R2NOUA5L4+|((^+;+0H&8|2(F (IA,K2 = M3RT_22,KM*>A%3%0$>U)((C-?71BQPGGD;>%4Y"

*MR3B<[K|H&4\VU1UKFCBBY1TIR0>AYR:.8Z5^@MHCFUC,#AS++6)WSGEQ,D(] M59)/0*E_[ZUC+GO>6GVEJ\H^]HW8]=RX"R M@+\]PD,9Y*?*

*+]51X^ECQIC?*HJ$F+EZ%X&:>.&X+F: 6.CQKE)+48\[CE36P/ MKJ3:Y. ^F5&I_I(+0)UXW519CB6=-X>U6 MZY+'1D1:L P%"W,F*4NX;\&/L>4SYEA3-XBM2<)"ED:.$SKQJF*

)X]1V_3BV M4AZ$EN^.$Q!+CF_Y?AQ$410'+-[l;*EPZFFQ>),X=B>5O!KZ+!7B#86.3-YX\?M5YY3'2EQY.TW'@6-RV7<[M.1#XWI[/.@(1E$3, MV2PS\\8D43 M&_YD3N+

*[P<3VQVMIM?=-S/CW?<=([*BHBCY+4X-[43AXU98*]7W8S!QN1V9*7>&-3**.1 [JA,WPZ"U.63O)^F^T[OH0'@V MW%&GU-[)K=Y)=LFJ1+LGl;DV^ER;NI@X?3:UPK%CQ>/ M?*

QPXF(VEF\@%9N M.CJ.?2]8$ITUN.(X[R>6GWB^%?K3P/(\VXFF)/X&4;SOHLEYV//=#_V0 M%\U7-%^Y84R>\|1FJ>6E(1JUH,U0JXU<1EPCV RF8S7VH"G@61LE:!&[W(DL

M8#54[G%DA%JZ8338SVP M0G,8S6$>[/C8))U.@_'$BO@8>,38GUK,30,KG80NGJ,Z#F(|%Z?B[!N"\3PS M'#^L2GSX'.8!3LO)O#O(0%)E74:RW.D7XU0<.R+:,26E492-/(.$#AGA^!,*

*MUP:7&$^'G^!S^,;<(5IERV5IQ?3(C#?G96*P/#E10;D M.L(S7I=/=?DQ "XY?#WAP#4!@CS!=(N(KQSZ N1*4P H< ->;^[+4 M@]X8-*

*GQ^^)VFI8N#:4R<[+J;JZR0QJ(#5XYI.6A|AX##=)3+!,0W> UO9 M1;X20.[ATYMA?ZP)SJX.DV[CF M_VYA?F\NX)ZVWE0!*FL.'ERTEQW?E^=ZTF%1^*6MSQS:-OF.L'(Z*%I""#>*

M/BEQQ(<]WI\4]\M&1_;@:&S(V3LXKS&=S?"!*1CD+CO"N-#W)0H%% @F$.9 M:I!^3IP8V"@;'CDV5Q!D"H+&"WP3Q:!KOU9#_A#F!*SS^]5QF37G(,3@,\ * MFQ8Y/Z{2]>"]DN$Q L[&(Q1%H-2BV(#I> M&2^RE\8FD7<#..X^(YF%?A2DH34>)[[E3Z:V-?7XU'(]/[03VXW#\5I\;I), MTB"9IA;W0S <,;. RP8Z[4E] A2{X26]0Y M'* 8P#1P\;4F)OI1-O9#3=%OPWQ*

H=F!;G4RGED-'S8_C%,)H#BPW M#"=IZL;Q)%[S=]X@9"R/2RT=F'ZA/*<- B@?=_2'OF?\KRG">_+%1#-/E@ M?7?EXWDF_&^?4&?5@EME.RB0 *<_]3X#^<"3I^H!A5FF*

9.+ST$LYKG!XE@.M8Q+,&X.D$3<@]+F$H0`=@:2]PS-6YC4'$\'^0B>V MO,@>`I)IKZ[=]HV2^Q@S.S0"CUDD\P/K @PU7(''O&G*7.B=*FPY]$QUCPX MG-VHV7U(4T#?*

*XDQI8,*5L7K7B,%4!YPL>RW3"83K880:X5+1R+641E.1S'7IQ[$Z39*T.C3,[!DR/+)Z&$;,% MBZW(22,K<2/?BQD|FMJ3_4-WUP_,R;B0T#TCQ5BYG_[1YHL>G\D!%Z-E@0 ;*

M':W9B,2^22EB=,XTK^*L)O=;-IOO) ,B!" .3K=&MQYP!OR=2 1M-K&%@&WG MC&ZR!D5.LQG[GP:Z/X5[MU P]ED,0VT=|H\F$3C<,HRYGZ0.L3$')1"O^X

MP73L<&\23Q.VEH$Y15T_'(,M&$VQ#?/$&@EP"B?A*B*UMFMB.T=D4*AW_/L]@W!2=]0L.H.T/9%=O+[DOZ"5%!0> MI\[$\P(P5"T[GC#++=R>1-8U

GPLBD'EIPB:NNU&,,PT";^H%@37FC@NJ7_1 MG9M.K3#@:<1=/XK&^X/O[E5";[1?WI 5; LE(]#9OJS2>*&[IHA"\;]),4.HL$$CST#-(J0Z;IA%-A^_MZB2>OQ96'[K$"'5VZ?*

*\X6'S9JB*1\%66*0+0%@YJ&F75Q?%0+XX=X M/}PP)NDEC>.]<.F,]48BWS+B=ND"\]_8:XMU&:.\KXETEF-W1%/[-!1; M1Y\!KXYM=<+WE=U91I+@]0\Z36AF:*KS1B=TUO9/4?*

#:%[\#I$C<[QV&NBD; M3U-W:B61.[;\<6!;4V<26$Z8AJ&?8!7YF@D9.;[G,W!B)0D/+-]Q BMR 6&# MT'$\;ML1<]82\#]*Z&%NT3NIEWRH/@.V?4A%.&8953__VB%C,$1&:WSEB3NC

MO6#\'0.4S"-B-(48"E)&U.0:9[#QRCHQ<[PWY1SD6]2 C95O5P%38\7-8;+ MV(+TQV@Q1$#A#.24NT7#EOCIC.4=QH&EAKT9(>KG0(HE^O+.]UFO/O5@)&!-$(-MC)RWL^)UDM6*

*F(M7>+<;KRI\CR03H9-V%N"'33Q04Z56+%\GK.5@S-+8(K%[P MX4Z+=SOU\RYNXN/X[;IFSO *">\A%++*'1>K>]{5N2 .E;=L$KNZ?(-'*NX M++#X5T@=,,@8&(*

A>+I0VO7K\|DBWJU|^OE\\W2%>JB-VBUCW M7Z5R+RE7 I4&,+S!5X0Z(%.AV/#8A1NG0QV+HW[B!2IAD,,*Z0G@Y"|-MHY M/"3C'2@,&8IZD,H-O%4+O:26<0^#U2*

*&Z]C*HEI6;OL>;:<@N6_Q&353')Y> M5^+_O.R!9&K\77&\5AH@%C@E@J+*0.F/(^N94;>@$=8U_$8EHO&;2 T?-9K% MG,,S)WAN "],H-*

1!7:]0"5%KHP>!UD_+RN\]Q(NL@8=!O%'!884'YZ(B"3+ M$]5PJTEN];@7.+MS8PL4U-<9); ^KE?\"2M@WXW,,@P.P12;'BYMLQTLU4EOT M>HUJ.-XBP&@!$OWZ|ZCR]

M(AH(")'EAF<#^!?U%I_L5G?LT!C$!&U*9DLH"QFF1 JT*9+@9 HSS\I*4 MB5G^15/]KHE#PZM+?'$PM0').IA(DUBRG\1&C$AH0 M;-ZL;B35UN@KH&F,=1S4!9;?)5,%*#;*

GE7P9$GL&!]YD!#R0^2%QF.)|$ MX" !4)$Z\9UH(0SO(2S3MJ(O+<-T"9@##6&;%19E?B)#/ F9U"01=941WE) MY(ERS__!0/|!0%V/

LIC$Z@L^A>L$K^C.#H85URE5$A,3K;:>3__6N0P#O%IV!)1Y'-P!O\(2,[6TL|4BO3[TT\IDW!,H8\-P7(4C1\[IEV@UHI%0]M;C*@CZ';X*G#JM M6#"QTSIN![9>2583GOW9D|TD]J*

M0W2KR^7E/IP%JA7 E"1L.Y6@ ":.08X8OL@(8[0\:A^S9\|/<]X.KSY M#HA.Y3(?!)E+#\O>>?FX'21>FJ3K6[IY3M!;(7Q>&R%?CR=COUXG^P783A1 MBD?

A!%9JQZ|EPPC$8!N%DRCPOY';"PE4OGP1#/43EK7ZJI1!!R[O"KS=V M|RX_$%C:WNWTE/D8)8BLV.,O=)CBH;R 38Z+TCB(DM6W/^G(-M@69W MGY^Y(I6EPU]

*(X4[$HHK^O4&+0M@ W'[(U&[E93&/2GA@!LFB-Z#&6_6J<"' M'B[MO]?^^]OX[P/MO]?^^WOSW]__^DA^PZ)F7|VO\ +@&CD;O@*GB-NZ1L5M M+ ^]. WS7|+B)XQI.9&>*

*[(^+T#5V?Y_=!:CP?|)P7+/%W5&*KE2>3O&XW48] M<Y32;=[0(Q_FTN^TX+]6^- WQ[G<;#\X=?V2 CS^\D?)[^]^?W-'U\DKGPV M?GWW^?3/SY_???C#./GC5_C?R?*

O_]_G=9^/#VSU"=.,H=^OMNS|_CA]=_+> M./WPQZ_OOJ@!J^O3FY_OO^ 6&1\^OOET@C<^[_UN#?V!TY$=3'XZ6'?@!7VF M_Z]L#5#^6]#^0742MD8?

*NNDEW7^C3WZ);,,!TRI;2ME5P+CC)<9=|8R|![@W M6#=GG((2Y^W'|]N'M0D5E>#[F^Q%OZC?*M9"#S[0151$>$##81SD|5)3-4@)8 M5@A+5EA.LIT-*

SVM^B=$282K*&OI9@JK]WP!<@;CCAA)?(LQ6,>_V MEI9##! M:T0+3(6B,AB?&O32P>6>"!MN_7/_IVL;A'4]O]C'GF>@%P/;Y5>D6.$$_E[,N\C'$D='DPXT6[<=M';>X&3A*

M|^L0372=5]0T8."N0!!S86O%INQB:!IQ64OMEHE5OR82P\8_U5]OX3K(]GT-MZ#Y[; 4WJW;],Z2C%4PB[5!3.,/]^],N4D6WX4(7K+H.#N\64B/CSR+G->;I*

*M"K8QB;/*R4C7[N!&A7|)"CEKH'3 MY "" >K0S[5,? 7Y14WMM^&)!YNWT>2'"UY=9/Q2*[&/']/^BYA9$;<9P5V M*$5. S4GRHBH.A:CNG6DH(D(USUFG5Q(KW?*

#X_ "YGN6"2!"\&D$<6\!/I MAQDW.#0^&0O%*XG=A_I1+4OK3U$$TD#FUJ*K*#X>>A(P 4+],B<'W:8O>M?PF9@[6GNW#$9I[^:@EQZ*|?JHPW&-(> Y?*

*P5PC!09!^9=R?,G01.H,%40.8A[$ MIKK7I/J950D|M$!@S<\9*)0Q38$, MR)3*B]#[-LYNT.S:A.Z)H MCNKM ,P(0U";4;4;) MF;! $6B2\/0EXC'F/#%&]H7_!2Q_P83YFJES8OP69-*

%94+.>\6PS/$|CEF M)25*80>\/"N+-LYY25<[# 9+!<10DR,[ ]:5<*LRQ+I(^G(A%N^-"65;=S@YK]><8,]"V9DD4+!T5YEL6P-N0- MC#C,#5K3:^%>5EH8+E [@,<"!#9$MDL%$P*

MP"%1$@SF;)&7+*DEF%S;_]__[83.Z_<(G3P#Y26Y-F# ($:H)DH4.2+U>F) M<6:@.F9SP9 -"M\F|!.6H4(\^IA8%ZZ6%%F 0HR;6PQ[F,$C=&WX9%H2!TJ-E M.0"Y"+:?

XTZ!A6MV7AIS(IT-02>,88E#;3TDKOFPJ0%G[RE?9FL#+X!<=&V M|]+0E'R<\BR/3+DIVW9=6*!K!93 >H^4P"%*C;6>4(IV?QI07]8P7Z'7C M*C,9X-*

*O*B@1\B5<LHP1G3+P7%8_X >E@$22, ^ZD&4>|T8|4MYC%E,A&;Q>>$ M0? 4K&6^3)63<+62C3<2/D<"E1@ZR%0V9\3J1+;V9L75,V3E6=<2.&;-@W M5*

H+ZJB${U)#CY'Q&R"A\'<(-1'Y6O\1P!X B;/ZG-(FI7:-^JGYBT@!$}1,T&LFE+^RYCT.2R>7**H77B$ WYL65%78 MYY,Z8V*]73UN3E!32=#"Q_N-+R0M4&9TJ<\U4F8E.E=&I,O>?*

*^G,$VM,)ME[HB@+11 MOT0?I,>37X)$H5*6I OPQ*^C+K%JD-]9X+ND*"MV*778Q)&B$BNWG%^CP$X M5O&$>&BVP3*"" EX9M*,W2?HQ9: MUR"/^]BHL/L1C,N:C/*

*128IXWFXLQ0(0U6QV^6;K?I4*29I/TPFZVT1V\JB"P\/ M4 >]@GCN#?P?O!?S_CW29Y1-AB,J4YE(#VKXF=#LE]H4R6!B>2|*YSL M"D_1G90(W3%K.H4989?G7$2/T3$*8%T(B^?*

*F$!.!+J'-BSU595-W67M=*0WTOHG8I&9+(($.7Z6OPZ_5OPJXH &5>XM57IU1HMP M@^_#E#L.\G6V84D#*7B-H0C&AZR(_%]+M@?) $8==XS.O,M4O<>C>EO#'T#G=*

MIK.8)+2(P%G=;8MHS0.L45B%#U[.P)\XTN O.WMYC \JGE#15\|%QSV|" M44|6O>=#EDE3H4T)6M_$"=!?>G#4I"V(67UNTK_#>FG)^=&(D_1H(P9! 3# MC('GGCWR5<,?;EO?*

O(#;.38U"N?\2);X:B4.9:YV!>7PYB/4L-JY?;ML_>#XREJ7:++M5>K;> O[*WK9;/VKL321_MTIZU(*^>7C>T8Q(0:VMM[l*|=WJ\?49>'>FTH#N4;S=@8'+4R=V>#S)_3&]*

MZ\WU.L=22'K'OF>4]_*=C><>^.A 3W3OGD;RZ?=Q_*8,/=?76AMS8X$]-#7P<6(])V MS3FAIS"F9/(/'K.B(7',2R3YAA90>(:.."14@K;LMX,Y]_ST1"@#+6X4WRPBQY1_#C*

MFS6UCD>9TK.0"4)LHPCX3O<0#8=9(=^2CC.F.Y57HL%+&0%=,@;%L,.+U&I7DV+(J2'&X\)N MKQ@R+>DG)=@=J=RU;I;W0177M\6 M>*5-XM^P;5<+(@Y;50@9B96H>+U-*

*35/?/%96L.\?Z6#(\J1IX*4_8;MX*7,^D M\B(FWT4U^8^CQ%VXE";-7TOA=HDVIV&20=M[FFW:7$&T<,ML|8H0_ESHLT$1DU;.Z(X#<4C&VU)>I&,(T M&/1&D$?*

]5XSV=\4Y67|L"PZ"3&FGSIL2'UQQT9G[$?OM"@/P]2@D]ZKW\$ MD,1@BR^U%5@:IZL9_K-KV7':.?5T"-2^F5-?*_&O;-.|<35 ,.N;U52Z765U*

M7PLFRLZN6<:8<R!2$@A^H!A:W*9;>8^+\RFH&8"-8O7VV$WU#EN1)^.M.U44'J!MOQ5!,@79H_$U"=(L"*+4IG!D]5[L?-P'$Z%L0=5!?5+IHN.1_9-Z

MGMR,\YJ_JCD@/3"5#5KA,_H^3!3@B^R.A,)AJ_4 .HI>"SI=*SZWG@RDH"!YJ3>[(OGJO M_O9S4ZW1B#2$0F ($8N_G56@$226Y"8I_;>9FUP"90HK\96P%?'")O)2J;62*

M>0F&MHF=,9#FX<.W9XS||\4(|:UEY M>,.-09JAH433/FS\.92XI?Hs:FV_"ZWKS;K6M1&JFA0U=Z1%#4EKKE&P;RY M)5+\ %B"\&QO+|"ER423R0!(O--*

DHLEDB4Q\32:K_C5JHWMC[8U<^OJ6PRT MD<;|5=|`@\1DKK#\4@?NNI&E>&\4D}[^$CYJ_O!3>^_^H'I3-R# MWO4=(K0FX<=>KR;AFY.PXYBN:Q_TMFL:?D(T_'";>?"D^\(?CPZ;*

M. G?88M_VG7(09MV-P'_;]1H,A>=70=EKQ>;0T&'@Y/*E6N#A\^:;ESH^CI M84JFL1FL|#"_+X3I,@V>-,IH#|$YQ-/B${$9>&/-(32'.!QC15NF1=,G?'H*

ML/W"VC)].OT+D9V'=Q>6J7N(END7:IQ7WCR%;K\14FN=>Q#3. +UTW',R72J M4_-*52OT+SB"EXQ,<.QME4UKS@@\T7;JM>W53UOM$--8&_9OK95'S>*ZNW"*

*M5O4.T59|CV=H4"/C,=&MGR9B3<2:B+5EITEX/RV[^^BH=H\>Y0S[S"'32OT+SB M*T8;,)>OZQOM$,B?1);_>C9J;-37OVZYV{^T&)4SV@9MIQ""^\"OW26N M.-*

Y!6'%\@%%@=T9K&FJ+&H;%N7<:$JC.MZK"KS'/LK9C+|>.!XJF,'.G9P MKVDPYG27&6PZ=J!YA>853Y173$WG"(X T+Q"\PK-*^YL!N_TI#O-*O;:=/;!-MF-;!SQ^:QY|8D1E?*

*SCF\S%M88VW\O,JL TSHZ;VE|6O6H5G'HI[.. MQS*CGRK'<(-='LRG&<;>$]#]&=/P \W!+='@Z<@.)C_M40AX928_^KAX%$=^ ME37PT7@KB(PAB&X'|_>*R1P0)#[QFK,J/]>ZW%_Y!<_+^0QN&6]63B;?E)28U'"=.Q=..1_9-Z'C8N9_.:OZKYG%6L MX0H&I)F(H9^M^58OLCJ+LCQK%J_4 !N=IO2|(!A-IQY^\3O"!6(*H(>(."%NZ(1_0V MPWV;?3>Q:7>UNH?K_!P&[_#W>6V\ M_14E,3[S>~<-G$;\,SS9OB3#7"93N R@?HB^KYDV;-^V@*_7Q\2;7=]]N1JKY MCR;3HR>3]Z/ FDQT/L\=/+H!?V0(+6DP8]HR_61&K.=+D#/TX="XKN7TJGH.A MGQ@1+5B\KUL?/;6*.UTLO=0OW0RNP7WW>==?=#<L<3<*:A*_:lL#T@Z,[]. !-MRH2?IB;TEL48G\AX,1HST';JC.4U:3]U_G&==:SY,GGF/EE(IC0^{6;U6 M=C3E'B?E3B9'1{G:VW-+,/ERGL'ZYZOJ%D;-JXLLUEK-TR>7H^6-$^W T72[M)^O5=`OMW7;-J7MTA]YIO\TML>4#GOBDF:%NEJ*;I6Q5A)Y^ S;M*VGVH-G#M[=C#^.DW4MI/)].PO.QXS_'\4C8LUQSZR17|ZQX?]Y76X$R.H6)?]W2:86B& ML0OSSS%=]]YTO,/F&# H73'4HX)1\%2+_Q,>@Y);4 W^\_'(-F"$'!._LV)[MJ;\L]*\-*O3G\#^L-IR55&W(UZL-#2V$U0E4VXY[^:4]*-9MQ8%ZKG$QP M,*QY.(U+>'!>90 S6$W7:E*$)=S=T;3(OY)2XTIX5MMW,@%M@2;^+2VKF)O&JC9$"4E"#RW1_[F5S8GC*DI$(2R&398@$G&0%0, MWH&-C/.L0/JBM|H_Z]9-X.VEEIE|T+M@OUIS'\1_WE.W:H_&UV>I6'KF1K3#%AB4U:"BY9I M"H]4"(RZK5@12D7"[V)I MG>[J.A&8N7KE+7P?-L,T3@')8,%%QD;W3W/WR!CWF*NSVPH"(A]HDM_^Q>2 M';XT8:Q&\\0]X8D=[0E*X<\45"L9'^F47"@L?OC@(VV8%,#]&Y?]EGC<5E1(I-ST/,DNT-+X&_P_Z'JLKL$N MPB9+ F $+% +>?5L$R536Z4Y2[*CNK@"/#DK9(.F"?T>8(EL\+2Q[8Y\;-"N M28TK+HF! 4UPHG(]_R'_/[*\EZG.?]N"4X-\,!N3NVL>)\UD]3QGBU=XMQNO MCP)D C6D^UQ<^%=;-UFZ4%A"KU]PP;_G99W1V%1V"G)QN)+,.^/Q^3OOS+@1S M6TM!Q2SD@&#R-.CT!FU@B-9<8#3*.\Z2KV=/D&@%5]8HLZ8WW6CM*#)6N&S:HU)2H*5'WF=LQ M(>IVC)L,>GH=HR:3&Y).KXFDU7OVCDKSOBN4^IW]:X=8(VC<*859UV&P$I)-M[G R7:\MGO8C:?/A^.FQK5T;D!^B]HJ4L]<9Q/ M6^H)=#'70;6WT#V&_?+ 2?@.6_R3;N/SF.#_;6M9XX&CY!ZUZM#= MUYY>]S4G-/UPA\<4/9T.,)I%:!:A601E'IF!O\-3/C2+.#(6\:0W\^#)^X4#M)'C0FZUMTX>R3>\2=W1W89NZAVB;4HM959)ZDRRZ_49(K7;N053C"/1+$2]M<:#U3\TK-*_0O.**PP1<,PAVJ,U]7G%OOS);^;^D_<+=0A5$ MVX6MZAVBK?J^K&O99;!KH73@R*CEB98G6_-R=FQ/CJO?:H211.Q)N)M1+QK MHT\3L29B3<3:LM,DO)^6W7TT53O KAS4M%[VB7_!NT,'"GYU0>/>H),N:M^M M--3KU8C\A#?VV-:K$?F);NRQK?> $5F7<#V00ONN6#[IB$YA0R7W>CKM?MM- MVO6A711;0.*8OGUU:U>]V9IRG]AF'CSENF;@'G;P4%.NMQCI-P7?C Z,,K5 MX89#*K2UIRJ=M+FW-.N9] E]SO-2S.GI@X;1NUI&<-QR##-*S2ON%|>,0DU MK]"\XA"M&&VR7K\.^-3SXYZT]VD?I-2.1AUO8Y;N/SC_X(V1E[4N6CHLH[; M@M_&B6F;87=84B6E=9[:-36+,B,/#-W#[N^OJ?DI4K,VTFY0QN2/G(/>[,,@ MX7VPU^X25QSO(*PX/L"HHK+N#-8T51:U#8MR;C2E490%/5:5>8X]%C,9?COP M/-6O QT[N-?>OU-S,MVAP-+!-\TL-+-XHLS"#7>0MKK(V_EWD"IG)M&N^*>*3%V;ZX MDSMRD2B3LD70[PU5/D*+| *RS3'MR;U9S2M0.S+YIGF'YAU/FG<$9CC9 M8TI]V=.PP\T"+=$A*EY>8O2"\-A5/ M=AMXW(VK_FKFL]9Q1JN8$#]AQCZV9H+12*KLRC+LV;Q2@VPT3=*WPN"T73[X1=__M(UQP=G*I .COKY_]O.U'%T/%&ZJ]4]7)O7X(HVKS<*?#[.OE]7)EX*VHC*/-D> MC\D*;OP.?Y[7QAO08!+C,Y\W?!;QRO!L\Y.XLMB#%!DO#:-&>@[5<,RFO2?NIW\XQKO>?) M$|^QLDK/G(XG>K,UY>['>C7E7GNW?3-T=]B$]SV6_M[;HDM7\XS6/^<53]\74OCWOBU],C:>6AE3K-,33'V$5\WS5M9X?IC$^)8_R@1\50D0I&P5.M-M_TIX#%]J327\SQUWY!@P1(J9WUFQO?Y?%OO7!A7[67LPKN-R6]6+,9-^:\RLH$Q*Z!J 2G508P@[5T327%2WEY"6,N MI:F+9@0X_V#D=]-/6FH!=]TXT:N!U3Q;VE9Q=PTGONC??LTD/-AC@I +`"Y M/9IN?F5SRIB:`JZSR6;88P$F&0-1,?@<`I+.LP+IB][JB;-H&WEYIC'E/[M@GU8[&.U(OF-%[R2"'&2P%-9W52 Y1=<=T[9:\X)8G#(,,|&^\B6]W%/6:<[ML]_.NU1L)DEAB.D8-*CNG=@,G*[XIY)ADPR*;LQ$AEFL1(C%4*M;BM6Q!P9MZ"QK9]6)-VO>8#L:AH/+,8&OI"*M=S%8ISU@^P/^G*M7WL*HL!FF<0HX|@LN M.K8#3KS?6'Y1@J=X&[9N+(@'W7DB6I-*$L1K-E_;$+W4$0!K=@ [I4LR#0* M#HC^X'R(];PS*I#LW#>B%5BUCTW3:MR1LVHLN("B/UDU2NZAN738YXW%:4 MO"_X]1(/D(.K[E2"!3CKHR<\;I;[D2?9!9H&?X/_!^6,U348,M@820">@ YZ M'^^>;>((U HSA)L=BZNV*-Q5LBF2A/Z< VV91I8Z1<^=B@0Q:5UP2 P.Z MX43E5/Y#>/][E>6]3G/^W1+,%!;'9C:6?$ZR>IYXA:O&XW7N^WSP2*28>W MN/"OMT27=84PC5ZU %->5\LZH[&5A1DW'EG;7X_9HFX5T([I[:F\PXHS[|/7 MD*=`H?-]\4>R K1[F$8# E#LZ?(- *NX+)MPT0;,V1D7D06+I8#7KUA^R1:U MI*5T?WBZ0[Q43Y#"3O<'F+]&<;M%K .UA@0JW3/AW$5B#?L9["[I-_MUF" M2ALR\U.V1UEO?.(U<.GX;N;/CF>Z6M:/J0<+"Z MLH8^.?4%B*NY[J?-6GDZZR>[-!@%*K/_&C"J+/A4*88D /3N& Y{(<]E:U ML,%@,TSRN6?WGL*1\9>PRN,&M5/F M,%'A4;)9*,&B+V"RH@%]E!8N56,XC/AE KA\2;7-+IL5 MK5 MKR~%^18X(SPQ1J?P ^$E<4A%,/+4,U+X+6OW(^..%H]<@>#0I^55HJS M#I&-#)8RIPJ8\Z3NM>3WWW\0-|_6,&2V6P;9?8-3;FL+F)T0(2"#"]AWO& MR5G%N9@'O@.?/Z0IK\0\0)0)< ?Z,HP7 -^+1HX&?X) "$%P3=MA;_ --'&+)B M8"6 #^HU@A[FD0T-R,T>G?T32_DV:PLS-D-W4IH[8*<&I0;?1W%F% MZO4ZU:V^)U",S>`)[QF&?@'5GCMVKQZ;H-&@EG@'*@31M2"I'2U #=HE39Y> M07;K4%K;,4UZ!TMZ?Y070F<4;GK4^YI0;=%)/%I[B]P|W^K_|=N]|[FF[3 M;?^U2X'U].BSU7@>ZN=%BPH:RUFUP & P* &>#>K4+W&3YV>9SPUWGP'JB9; M\(.(ZDFD?3YV;1/6C_0*]$2_38,#'L;T=#=WA]1=#SY:F>W9N?$K*)Y"$7:D M(@PXUP*!P&1:U#D!/JCR]H;**]VCY3D6'\0)P.NS$NTZM3+%(^.1,T=H$ T-J MI4"00)X_PTNHXLMWP.IK"3+O4(I^LO/LM@$%3H&"B=;HB(%M9#2"!4LUCH MVL,->-M]Y2NH4>]IM%HI4WP$)A FVM'$_VK2M :[W-M ,8!-\P0[:@9WZ)H'P>I]=I*NUG(K5C0,WH.MIWE9!.*_@?F:)9$),4E+ TD.]!0ZSB$!0[5TN8%RR@|_- M)>>]W!%HV\XQA):1$;%+IB5.3KP.B-C>PB<$+"L^8R"% $V7IP"K?"\<&3! M6PS61\EAZV>4(VBO+:V&=P _@UF,Q5M5K8(Z0M>=&HSQC&K3+!"PH,:IT##5=(!&2',8#(J"\U@R06O0 7@%^1,$),O M1"AP@'",734[\H,D); _)S2,=+_F"3'O2V.":%+9,=P _QO%9:S%9@]H@-&U)QMI3_!DH%;PU7RG<"W45ED>2Z*Q'PY()0HO>F7,-52HH. 7,VSS/*1A&Z.)XC MTP463]_&F/)@$[=BA&:2FYDD,T[A66Q2#%?>")G[&4S>>H"LQ/F>K5Q]E+L MQRG'1CEVZSYSQGF8R7&?I'9_#4,.RdL__OH=&3\)31WP2T+_JYIO'[.,KS MXXJ$\@&0Q(2O>VI?O;2-.9M5;=.,^"LE_Q%N.-+EI>_@@ =]"T<-!-D^_;^4MJCB@&$\Q86=L+_,E^IR1LSPA\6T:@,5Q624[(O=D1QI3GN%AGA7('GA$]D8KD!<$N6Z? M]&;)Z@;BI(7W72@$I?JH=V@TNA@[M,S;(,A'XO7L@O[#OQB=2RHEE=GMSK#SQ,T=#!S#=<16=WL EKG0(8) 5@VZWM^6H$LZMO5/$;9(|+V3-P4NS"@$ MH-.C=`K4K=.C')T>I=.C=`K4?<3P* ?!>-N*U(%/Z)RJA#@X5B$*A356+1> MNW0&5(]E,L7Z2;8JRO[IB^4X/FJM9Q6;#33'CU7Y&Q_8;,*?N8-D"K,S".M[MSI$0FCW,4&6ZX+.8EX!I)%6)/D%8!P ,U0L1U1=?YT(QKQ@&$X9.@8&:@+Z>MKJ1%9,50OGE%"R%IZI.S\OKF^4L# MC'I#IP6F,Y7SD1G2YR/Z?.WU-M7O RT37DJN%G"DPU3*"-R&W"&&$'.]G1#9_I M-U<$[RZ[J7XKRDOC\QC3*2BL'WZ_W)3){1R95QW%8]!0Y3TBK!WH>TIY@/ MW%68^0.:0$H=IO5L3VL3'6.BB@.CD.(101E5.+0304C"Z<=3SE@T58 Y#HI MX-VKZXG5<5,PN%P#,F(ZE6%(FJA/S?I#JFI@"[R="TA?H_9NF/(G^+C_'K^ M7U>GLNHXI647PM79)]E)O\MP$)9,,H$+2@8A(3$G<4QF'@/7=5$;&28+.Z(:OBDY$(IR?ME/1+09&6DCU9C#G!XIKPAU>2<0@R3>&-5E#E,]28('MD."3*R8W0YHG@MZQ/ MS,U@,7$SR/;Y&KH7<{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l;Y1#)_M>=QX F&O5 MSF6?)-'$309;!CT%-*YJ7'TXR0_+IM*]FEU0L1#H>B^HMY;K0H(8MJGS+ZLM&]4A@'CUC+..V]]+MUK'Q5\C"IZ$P[I/ANZ3<9,^&^L^&;1/QB[!9&@3 M1@4ON_LFX<|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`391:ZFU?DW4 M!<9]YR($U76(H0,LU(K,5?S>2G1RB;(I=;Z0_3%@L=%B$,<"!;_F5+9VEI<1 M8I_2CE;:A L)$>-ZAYXQXN7) 8P<)DN3DO(A!DAF(DVA]_.*V"[LW5LA*,0I M!=?HZMGU%A_T"'N7?YUCT3:!;;_4-&-XV-VCSK=")VK4,\:#O@R8.SYN ;<$PGA%[AOE^AF/P(*4SY,$F]?\5=$;! M>YO7;O...PI#S^[_N]4@>HWXRL]-M88PT@D7 D%$+/YV!NI3D5B2ZZ3TWV:NM,W"!*\E7MB$;R";&O5)+D*$M[FOW>A2GA?_[%%Z.JNR_51IT6;L&DR^] MB?>N2?3]Y>H!@?#6_SQSG_T8$UK5X4CYF!/H)A%)*EW85T2#!"OQV?&[MZ'\O7G\X#2$6^+/#ZF:-;V](@)N&R%U+Q1U-1[=[_JO37*:HG9.4$] O:WLUWSH/D0GFRD^8\F$TTF5Y&)I\GDSF*:G%CK(T)I$'WN|FH1O3I,C M.PRN-B7V>=-.Y!%:];QM%B$[YK!9*Q9Q*-XI88Y=P"HS3MWA>(VS,3",89C MVC|(X=L7M>Z+.'#VAGEWFJGOBD3=D8LTBFFL .%'9.N/8$%?!Q('S^$]V_3M M'9K9/P3:@?%XS3$TQ] <8TTG#,VQ-]42X*BA.J.1U*;<3:S=]M>6]Z#$1NBDAN5^5PQ.>>/P*-&1:Y8&$4G68LB[F>-^%HK&YA)O\DR%P^]H_(M(^,7AF6ZJFEB,[28IE%Q54]#,VNKBDIK103]PA#<2%-U3\7/6)6HGD'7 MJ_"A_^X8=FC-RH1*S0IN++#B#B]CJ@<@J.DN[P81RWKZT:5$;I,]&+#%Z?P>?. M:X,7>'3R^BY0 1U5-2?B)&;^/1-MRU4E60>)U0f/|:?:MYCS9- C\=W'#Z;QMOF2#NC%5(XS5AG1:LJCH&QS[.RRN@B&Q&)0G V@OG98L@-1<|OR"6[0\!3&. MQ'(]=KH53)M+FO:/^H.):(S<@1_$H?NH5;F.6_S@CX&U>7G86IEY.T]BX7T?M0*]9@F:DN(4=\0N2]+`0O4:-(C%>4(EBV=9 E_7+5W?9]+LM:/.Z@(X70"W MC\5AQ[!&G?2NLWGOF.T;2$S>%=#]@>KW[T+]?K.N?NM$7UV/HUF3+C30]3B:M3#29["N9Z']HIJG_P1KAOVEIT5^R]GGUW*1V(/*@4;YW8?W,Z>.$& M9N@[1[#O+S4U/A%=U=2\1,U>:#[&X1'L^V9JUA4[=U6'9,M*ZE?:GZ6M5:(# M):'2[0[>-[I3$PW/&S6J=.J->D>))>D&YC@,CFVWM>]GE\I.W]%;*SNZ'E'7 M(UZ-,1-S&NR0Z3Z=U/929'6"-M%=<=]W1YH2XOO&T\P0'#^MYX^!Z5%^H0HF8=FG7L-K' -6WOWMK5/!'>\8,: MY?VK!OW6L,/70[6R9H/B\G?+3%D==*G[M91?0EJXWG;C *^^+R2W&8-\-R MR@P++ ,%P1K0ZZ.V46>/.BJ(SDMQ9/ASWQY-C?U'. 3P+HO!9FC4%38K@;=|MISMQ>>6(T.V5IX.A\0C;JA'G-Y9IBH?.1@N#3I"V(JIOQ)\X7M3B*_P[_J:Z MZ.>..[*79IAPV)DX8Y1G.'S5[H$S,DZZXS+SA2]}1U_Q/$*WMY%@[6!(PM+F M:$&+6EO)R@L)3WF%%?WJ<%GQ0K TY^$[XK]7W8O58'.L<31XLS<<4>_MC;-"EGU.Z/> 2&79Z,9BOO4B44@6NN"0&!BK%BYVSQ"N[VX_6NCTQ0IO09B O_:NLF2Q>*2.E5"T#Y>E]6 MA"BO*HI"Q5[PX4HZJ?K]F]+S+OSJMCK&#4BEVZTA3X]"Y]4*CF1%#]@=#,@^(M-7.SI\@T_[@LRX1^.LC OGC$5](UZQ_)(M;EGM>7]XND.\5$^0CD3W!YBZ MAG&I;S#++#>7]*1E_QUDOTR=DOQ?>4?:/O7Z 7RWQ\VR+FA[ ]N(_NK MEO]0#.>29?V#[Z' OWZ3<4*P]\EA&. GH..8@*&(>]9 M)!=9O>P7]H6^:{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l26+9H^V:&<[(>(^0$JD+ E+'ZI5X M2^V6J-2ZE#KJ)5_63B_*_$*HPFC@G#%5BRR2Q GGC '.=4G]J.')TF>,79 N M3Q$-488P'&IM$-+*314*+^=9L25O C_4QTI6.ZI9@IG&R@^A:JM53NK(^$2!MZ;Q+CVAPR>9PVKA(++F8ANYV.F(4EF-MP)*Q\K! M1,$>3N?&=>EY?FD-*6W:4;VCFA_9^E68RY3X..3N3>04-J3_3D M08E!F64ZSQ)3P4E;5:@S=9'GH:$?/M%8O*2O;.1F<)H0!M%XC|WV##3\N1:;OODI'RX]6=DTD=$-@WI1HT\2+L00E) MKA)1PP5&<4;MAA;"WW&Z(>+\+=-M)6F!,I@$P64&R"J-U"'S]=VO23MC9NN*.FRK/+D$CV574N@eF,?2 JLTR=9BG;4U$7FQLL!V;TAF$[3U+,SMD _Y%$;_/'=- GQZPN0$!<-M-M55''0P,>+*+7+3MN)7]V/E"W/;QBDRHIY*Q2\"G/SX"H?-J.4D!;*E5AO MJ6B-W Q49I#>]F E-D3QQ* 4H)L&!KEH&-..O+N95D9Y@<6BY8+NRC%4PU M\2 ($/H4*BZZ^N1^(V*RLA+<[51M)B5K]KM%.+P"1$])VQTDM?[1'8%R)D*AMJED7H#R5MQ)FB/WI,KN'{)HV04;/-H#YXV^68[NFS#KDL"#>-K+<&X^#[GJ. M*"*

M",;)A$NV<1=Q[^EB0RHHIY)]CB!+-2U$;I$?3TT#%'48P IX3NC4-2L3 MC@,8HF<*W2CF'"7=MD"]:8DCI-V01ZOM?-FZS4V64UU!M]64]+]=,QG@G?&M MP-;,P-,%-@'/D#>R>JBV*EQ#$"/OX8-^C

(\ZR@EH6-.,%@U//%[L7N&0J3\M57>GKKJ!CU>M8P65)2&X4DL,LB&+%YSLF.+2,4,:(&XPR+0\JJ(8F, M=10[($V*@->U5)XE.I#(4 1[&6=LW2)RNMJWR!,3OQA\T0 57Y>GLR03PR8M$W#5N%.X)%D(;.5&/4M15&A9"^H@96)$G^>I"%I797MV+MV4!2;7R!R >MFB M,Z^&I+G1ZI/H!!A0RP2)#=1$R 4C)6W<2 "+|9?1?;E6'/]J7~>UF.TC5MY^ M=;^V!< 0#Q _65OW'PS_CBGX.9&9]9+HR(-V"O _@^+Q\K\]J?P_\PPM%Z MXOXHBT?H_MFCD_R-S) ^E7 S_L14 MJ\\$MP&2.X1^'(3VO\+,^%>A)7P=E$QJ1-Z$R/[(^!T/,?DLM!! Y#C1>:F MT()-]Y?5B6ZW3G2;Z$0WG>CVF(ENNQ2LXWU-=-LWD3H>&==KB/NHPO0&2X4W ML ^^OBK+XHP6[.(L))]Y^92QP_(F;6'SBV99OIV,K]+S8BF*>3L:,.TUM|HS"M$C"33SS|GV>G7_W089-QY%FVYXXM%[*%K.GML6|=#Q.O=B=VO8SHV SF"&/ MDU=8:N[8T=@YJ2IV2,#;G)T],P1D 36_@|0AUI:RO.9;INK9KA-.,.<\;YQ8 M?LI<*[0GW!KS<6+'*6-3S[_K5$'QW=%L0R<(IN$DLN(IFUK^=#]UH@3>:<:+ MCR,OLGG]!:*P7ZI9T=P2KA[WF.=;=NQ,+'_LN5;DV1.+C2>N/;8]QQOO&][7 MF^SCV#T=E2_!ZA9_/U8"F]9VM;9[:VTWU-*

JNUG8/LJQC5=4-OO+OYUF4-=II MM%'###4;&&PF@_5-L'R[2W^?JIEARGHF^WU0H+\%###?$2D:50%5E|CO7OXL#V M[N@CT4W@U>&DK1\F'P$)8?Q-GG"_10Q(CHJ3008+<\?'+53RE9JF%(N.-B_M^R?U @4DYS5_5>-)HJSA&T3#,YH S"3A-CS4N2_OE(#J*?@L:0#$'UP^M,V M*22$WZ9WG%N\,[6O?.EO/S?5VF*DV IAMR(6?SNK,(AL2?Q-Z,~_^'L)(!0R M_960[^AA$QR6);?M@'BD1N4QRR5Z"91[WYLQY7XQXY9" M]7JE^O<&L6.BK%^I8&;^ZMCK@/LC#DD"I=%@)-RY"4H_=O.MK;,FR-D!5N\\3 M,&ZT_TVTF%"@!GG%7H%YQXX&W'57^K_Z'<>?+R\M1S>/167GO\TD5GV<GJ(;(8M4M!=9]VH/P1P$[>>8[:D%.T&T(%*?N^\/(UU27Z M\F?5:J;KDOML.<.+4QI[W3\US^_.<5G_|'"Q-R "N:YMJ[O;8W,VQ1\[_]P2H6_,W MQ=^_6#.+?W?LKP^KD!$7 +8Q2#C_V)?Q4*7OMP6V==G7N'=7XQ3<7C?9S[\ MKWOX+U81#Q-'V_<=ZEU/=JB/>`),)1"P?AF;-;[ZH]KX.YB/\)/%1/UOU'4& MS0K@[=0.H3^ZA$IHLT*SGL=3K)RGQWH>V6'TV*!8X4&>|W_\]+?_5 UJ!.C9+';O@OV.!8#?KK9H>=RNRCI?'5"<&>W9U+N.%X8#I!VW8U M.WI,=N1J=O3$Y9&!^QH_;6X5IXT.UIC1RYH1V'<>/Y3,$ZT>;,;*B[]58W$ M..C7GXU5.;/PY^CPZ'75MQ_O_VKK4G<2"*?MI?T9AL MHHE;%&&CQC7AH;LDA4kBPR7Z=;7DTVX>!XB[_WKG3 \[)]=GJ=#4@'6]A;4/1$GW"0J_Z0]MH27L2HQE84[&Z(\T7Y**+?-?> MO[MPQV&/CZ3L)'7'A,$DB\P:FB1; M&'&X7:MK%L'@<'X<;@L56]\?B6=%|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l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f/3\>=:'S(.H@.]74=C M7D=B,X?=.6HJS0?CXX?*P5A]._XY^&C?_IH__Q^]_7S:DR 2IH9V1A(M 4'W;W6-V-[.=WOD/H:\AWTF8+ETW MVH=@QfPA'[/K8_4F=^S:LM=_J.RU9%^5**,<-!*TW[:\IRT5[F'X?Y"QGIP M+N=;G*2QI[Y(+N_0+\MU^=N+?<.K-?G&"//V,'_DU?>N4]H6[9LN=_JNPY MD$&4#I(OO>U>SSN W*/Q'GL7+SL0V>"7 &1LWT.LM*U[W=SE4(@?)+|JZQ96_M]NPM)X7$"G:2]4NJ(DT<2_;E0V;M_3W'RI;FE-! M.9FWG>O[8$=!X-Q'8.U_PA"NDN]-'(.!1=&KWKU:I01C[=F5Z;*.%VF7)=)O M^WS,%WJ+ X<9W]+#FM!)')91?:6WCEEW]5-E53@E14DBF];.-1T6V]*-4 MVC;FQ\]K&L'YOF!!S$_[FP$U4O16SG[=LQ'}4-D+T?-N*GEM1=3%)+. ,^*JDG+ M!E7-0RH/PMMF';-9$+3O@?N8R.%2^&QKJY8M4UAY@.[)J.V\U^Q:\Nl:-JAJ"&&=$>W1MCTl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}!A)O@_>T%NF6=]5> L;$I.G]M1)_*1) M0!AUP93WCEW%Z353)@P"0"/!:BP&^CX5.GX=L;TOXJ9)8!]>7OT4:\#{?>.M;U\_LBTGJVKOK[^>)(D,3[*XZZ5#A9OD,WE]72-'P8#-7V\?4",0*E+S4.G MCW#+"':MZ)WJ&SIP@.04X6)7.;V=+>VA-;R-<;R(M9Z;JPU"'X11$)Ol-9#*& M$]'+"#><8LMQ4<3E=L67>+.F&8[QZGVW'$6HYIG9$RO'%OP MQR1$SHT?L'<9Q7=$L? %=S+R2S9J9/NHM9ZEJZ&\|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|Q M!%WR<7^7((\>I[=3<^2ID="7^UP47;NUG(6JZ58&=`Y[&?3O=PEZ(X\3@2]J MS]9FM8$$'9? (!.=^L$^QEW(/Y7^9"\W,?! M#U'\|-X/T_>>OWW/V[QW@N [|$(d/,9X4SA56:=/1++*E)+ST:/[^PTOB_7>1 M9TJF^Y?O$G^[" :W[S7-C/P=APE9L!.R=LX^2(^<9RV=L6<=;1T_'#[I IEQ MYDR'-GB[3V.CYVPBL8HLWTD1&-W?XJ/LD4Z_C:=_ MT)'DQMGDW'OT\G/F=.(Z>NRQZ$,=97R!^POI!N/GXIY,/T\^?:0\]>D> MS4XBIP1Y4'[,)& G13NLQ.,Q=L]_TEU"TAOZ? H\^?@#FI*:4O.4Q7Q5:RI0 M^D_LS0OQ \3#7COWN,-U!VLM=X,3\|/)QT\G'_]>ZRB-L9TUSA.L-XY5TD> M/_'>IMXI>OHL"CVPF'NUL=9%AF&D$T&9LG,L/3/<:HCY_=2V CK',+XJ VQP M?19&QS!FU];Y*,MI!WQ'R6^_ALZ>R,38:UL1+<2GM@ZP9S%^A&?[" 8.B.<)R M MM(\QF=M3E9G2?4FT#6#Z)M&87=_U5M$^Y&S>) -/TAQ?)#,/DH4;YSQRJQ3C MAO\)J=]AZJ<'R0#3Z6;I0V@R-VI!?KQOX.-^Q(2N$^@63I7$)_?>"]R::H9# M]@I\U/CT]AENCFO5ZT09&'IR:RADC+$6J[&^R5NV*Z9\MZNV+S4KG';#C.[) M<#^BIB4,#8"PW04-C8-9.1]*V+2>QZ&1QF3UE\'T$*LI@*6ZKF1322,?\6= MH)!Z?*BJ[Z%9G9P3HIF=[@???^2,*3T4>/VN!V0I/2UH[BL1LQ.YI,WT.JZC4-7,+W"]2!BI6S MIZIHW.N\U1.P+,?VW:+& IE/T+32'_NOT.W09:9J2HJY"KWHE3;VSFK"NHO&(MZAO0AF0_6NG-/K+ ^R).8H<8TM'ZD04U+SU2GHZ%]UXX7,73/!73W$1Y?>Z MGMNC24_FG!U5'?X5$#3L8BH5'6.9,;\- #WKF@08;6--MRL:C\=0,&6)2:W)$++1HM"W7TN);S 7256#DR4T#O\';64L\=U9V6K5@4/7SV MH68_AD4/S\?1G8:U6N,*'$5[&JO0".?9]V&+T&&)B:] (X%S3&O4?//+5H1XT*\!+,$9):I)7>U(T MS7%G--"N#/$Y#EY7O1.Q'7FK2<\X@FHSHY%@MU\3D_'6P$8MGZM./C$MHF%'W4^B0D2F.BE]2')++DN#]LH$CM]"4_-M)(P5T M6(;9M7&2>SJ3??+RX#@[N@GO<9 FXB=TV>B2\1_\HV@:S:VA)??X00Q+-^?C+ M=[V[OI?%(+Q/5R'1%O;,N>)LHSCU_XTJ.#0PQYL8;_W]EGOF-3SVH6"-S_'";@W1Y& <47+SAV_02#4H(W M^] 3IB!Z'97G.XB4M6V0G+^9_TD*G+TG!\AQZPY.Q\X3^92$2GE+SM/Y'AS: MY&7Q(Z_35U3;V=[.\5C$FWWL/A+U)A?P.31?W9.U]K(7BU?_+K[0-'0VJ2) MB!V#&?PW%M4-MV0OX@H\];>$^F^]>^Y(2M8VZB9PPB_,%\7?B#1+6U)H'GQY(:3)Y!=<9\+ MF+3R,K?VT3O]'1AK11XPP MSW:>_"77/1*[-M#F[OI_")O$EY:D?=-ZN1\ 3? NS8)LDM/:VPMGXAJ!TM,M+W$D8,@E5];YV[6 M&&*"+[56[U/R.84>>19JM3%56VM3SX38IMA(*2_2L@>B,"[$1S8)7_KHVQ/3 MHBVY&'SW+(IWH$5C$,BN9=%:93I M*#>.I]5;!\]MK$V7Y6#*"+;,8@W&P[7ST}{=NUM[Q$'D>BT$D&0FYQ.#WD3 MC]Y)_<'98&#F=T;?&)Z6IQ_R^_%93 MZ'#"]L1WHEYA7,16/L>)&_L[&6^H++]W]-*M_V:?NM 5LICT!MVWM9-N,PIY MSV\VA=8>P5T;OU\'W37/;XAT3W)%*NGV8:S#HZQ>>Q M\UP^_UUZV%/;&*2\I>SI-DFL{O\'\]TH3'BUE50D-?Y#%M4,;GEI*Z<5FF@ MI9-5M;HF? B=WN;2*.OV(6'0&Q$04 Q>ME!25_S!+CZIU$73L;M'[2=87S*78 MD{U=*JE4%'Z@!-%,;6YC.(-]@&MH-Y7.I'L?=&OV2)"32"5A,.BQ$#;1S#* M4)H?2G+[GT7D^DQV$;6)L6 C,)0U> O:.]E[+N6T-?]X.?E/6GTAQU^OYV[*-MBV5D+PD/VH5XRV:IH&-G>|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|872;59$'XT3507'-[MQE (R2?K!.!=XL"@(@96M<\-K0T)>F?1$Y'DU;)HJ??V3EP1'N:Z+4"\KKG] MN*XO,.V=D%2%RL+P.@=?E6K), &NK+ZU17V9FXA-[;Z<$XL6>]N:GKG=W:PR6 MH:$H2%<--^]V%O>&>=[_Y]>/9_LD)8O++ KU&7N-7>S)';40Z6MF.H'#TI:Y MU|!1/E-9KWM[>];0@-+% MGMK]P[_+.B-IM\XC]D="::+@*/Y- ;_C$XP"2@Z@)!J"?L*+17OU'R#V[#MPK M-Q"}8^T), -]M[(RPC]H?78ZEHYH[%/MT$SO,;BXY-=%,?5UZZ/[X&?3 H>V[,W%^*_4(4[=)X3:I>ONWNZ>.!6|SANI4R@AOJ8OUHV/M>O'_N!:)=E*-L PK25<@C MHFAX1|TWU+F_-1;_X\3N*1]X)%|.+ ZG(HDPAH>>Q"8WQO,$]R-/"$[M;Z MT0FK\7^EJ$\:)0]Q-)FHK?OAUCLYFZ@80]ILPN>B:>=KYZ7N4^M)Q4B8,ZM+ ME+E^Z:KC277+?ZVNM8V@U/)LJ8'>'P!10;N ME1W,K=Z[T-AE4HY,QG3)Q|(.@R%RH%D^KB9B? MU-1F("ZU]%=`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|-M12B%+;ZMVN;3N."[7-ZVHU3*5DP-9HD%*DLF X$G40L4=P2A^8GU-M56R-49,Y]N/8=%E@!]4)IF&HM!CMA&,Y3'", Z.U1^[TUA?W$988H@I%E>GR M==+0FL:W4-W6+((:,*1R<R{AR EK)WZO:H6-)32"\ MH#@2T1HB46R_3;'\#&RW<4)J.2K1YD@BL\76*]FRQ=%L$I'&&W2Z8U;G48OH>]1WTD#-IF$\[IW'6!6M[7HZ-T" G5FPH1OT D/U!=G]YC_ M#H)NB,2,//]fZQM:K3S+,5C%7!CF;5,/O&&+P7_L4:=KR6BK@J*H?-&C$HNU M.>B6EN!:2XDTMOC-C7MTWWBIE(65#.]L/T4>KC;3.#8%+ZK:V0X+IM=IH6E T MM*>"9_9/&HZ\ [@/JGCUR.EI*J;1CX9%AU5)AXQ&XKT.72OY=[']PI2 8%M. M:%,/*61N=<5;;>PRBFUWR8;L:N%5-Y^(A;QG?ES'SJ,9^(EV$O,")E7QK[FM M4>MT29JIM5.KVTFL$ZES9.GI04V@83LB"-><,.7D6>*\-1DN@2+A9U H M+'"G/(1X)KT'"_"E7"!6KK"[4=7XS"9AILWJKL4LWH&YJCK8;6LZ3B"P7+V] MI3V@<1GL9=DF]DL-TC.*T?0N>FXAB><)GSNIHPZ+;VUN6YWSHO9L#F530VM] M'KDTY.E_]9V8+&!P(#=!%*N6N:ZE;DS*T*4YG@Q85EF1L;Z=43'@+ J3*/ A MI-;C9U#]VU;QX1+R_Q2[V;8F+#NBXC>VG:P@L.E*>N1QKK%(3@(?K.S^+_M;CEEMF6C\;>YCSVMU$D>2[["HA.1BD?!O)##;$YM5Y/NY10^%*RQ>>H$(O> M/6*<7L (\/76:S&US2WND[BSY/("#W$E]Y|"%V:L'N.G8V^]55RLS^|UL M5#[) V)6HY,'UKQ:- U15JE6FPV.JY:[EL.6@;;SIS,_D.IL%[7M)W$]=WYI M;81ODH')D>6.V5KSF*K5-($]/SLIF)ZZ*=W'4)18*+AT%1T1#E[M;=7C *YF M3#6E)9%*UM2BD)X'09-DC4-F(27+W)A+VW8R!Y%)A=I@$;1D>M1@W_G9 MRRX0<56LS$Y-&+"(M6,&Y74&]3BDWY]%2? HE2O^.4ZC*2<[DO\ER4GNI2*3TDOJM(?4-MX(CGH3>G$]I:O4. JFK1\_E![*!H6Y#?[1/'Z^=W_ JQ-?79Y\|-MN=G0HN\UV!9=>UE.YVW!WYH,\|8+E.L KKVTO:ZU1K],E? F;^MD+G^$YHSSJ M6@3"@*)3F^K;U&4"(3/3\[19Y$D!DM6/H&D_.@L5[4K'WG632'84:D)]Ij=>5BDF59[']5.3.4 MZD3P3$I>"N ^+@6H443N-[] MU1L7CB=F43Q@-W(F(M?7(E4V-1N;_>CCS<4\+>3Q IEUM-KY;X_YO:STQ4,KK_-8WGYX%5!G#3I"C=GM;&D2:"V5N5 M*NH_X>9N]BV^S)I5YQ2M.$0A8#QT:Y=NM2AOX]=2WWX*IMN6 HE=-M>EAC@U\| <)3H_0+2%%S/<#X.K4<=.EID"L.G4$Z"FMU MK:9ZNQ&UF[Q-B>\VFX%&&,JH:RD/("17I@?]\154+H/L.5,"&R.1CR2B>]OW MVZT3'XBZVI3_6>=N.Hj$;?QB#M*YBF_A"2R 4&>_`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|+88U/<]C#3N&F,UZ4YZ,Y*)V BU <-76IOX8Q0=@+ LOXK2Q20SG9>53,FTDCX()=[M/L6;*,;IZV /'V'];82 =ZA2W=9M ,'Y>X_'V[FM;78>&/O:^R3PVYIL+K M6B.L4/E5*,%EU'VM?4A,HM"+# '2BQ\NTZ"KVUO,5^8JJ?P>7[$65*>(A4C[2P3J2, M%&JIK<5;;_0ZCM#$K@Q%O!&[N2TB/@Z>TU2LW]<'B>GN4=%]J4P,;A;OFNW MOI9]7Z#I,+M H^=+;C9I%'+7(.1QKIJ238A]DO53:FH^F;>,INO|$A'=I/_C MI>YK-N)2A$/>N3ATB.!5D[V@;F=O%Q1US11+_S5T, P#=_'B/L)=_,6I5%RL M;::[)H("$N.*:%9AR'QOH&^O'XNH&)G/D!:Y.*H!,\X8XT35W<38)8U|UPG@ M+>%_7<<^>)U)-86W7U_[@.K"HE+G?;FTTRU=0A:#QY-"DV[_UJU|!.2C<5]-M:TYL;7O[*3(2C'R;1-7<;+,1#+ C%F.M %&1T,^*GC@:9.N"KT&1@#XX0: MP%GQ#NII8S\F4ZY%6&CM-Q5LHN;2=LJV1@7$S\Z+O]VK(W>JOY]L L*1B0?Z MJU&=[>_QM7.?7%^?U;^ JF;V90EZ,;*HA,W7A'4VMLD5RCZV(8"YL'/6""2I M;CL97(-S"$6OM2K4M3;DZ|"\<:+"4-G-KZUHUMAT"E=)^ZTQ-4%,LBKDY4/_MZL/D"A5S5FZ_6C8|\A0#,OFS[789FII)4 JDF!H^>A#0K1%36_$O9/F@=0-AN M%\7I/B3? YB6$F=PTA#UWZ6FL52N7&%91SI]MG&FAJYG7M?,;IP.21?JAA,*1[*(7F1XBS&\%-D

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|:*AY$[Y$ M3PZY%fO@$M0UG9K=FJE+'J&$@GUZP^NM.$!C2.SZD9M+/>60KX/86R?#5> MTFH[JY4#*Y]5> MTFH[JY4#*Y]5=E^V3#9MIK3N*R;S"'/^^"-/2*(YVZVI*MW!()^;BYRQ0<#33HED6T=G(OE-J;CJ?HE$2L;*H;HHR7B 1G'EDLN-6$U8Y"M*YY%1 -,=A&+(\X"B)5FD;-IV0M(+";]K.X9?LQ5*%@A7VP_K^(0BO8_*Y4/ MKM$%WJ6G;J 0'HR+SW$"A^R&_!4<&>268ODSJJ/9WLG^XE^%,_+X7>,G'/$8-M_(PT|)B(\[VN& C]95-!DMYD)E- ^HM7K5MO>KN)+]/4F7>Z]-#\G3.JR3G> M^&Y3GHNRW52EWD:VX|K@>Y/?]HK%U$,D5Y$\|+F+2ZG YEVRD _7MD&Y&_AP^^P^)U|OO"KP2P3/;Q[5J MZUD4D)_0TK9/6-)62_$1AW\$|QFHW M'+XQ9!O%B(@/6;!V% 9]!8P'?7G.##X&++#T&UZ$DNV;KX?#UAQ_[FP7OOQ=EB9KL>#PA8*XDA0 M1^L(K3EW9K|#4;@LF'^GP&J>8+7T/-*&""%)Z@3_Q]!:#?9!AE-*%7&R"\0(M(T(9 >EY,!18Y24SV1=@:4JOH8"9]QC%-)Q?"FXO)NT.,J>L$"\8P%TR|(+^ M%^%\!@L49X&KE5\B)_00Z?\,IBF"$-G,"E_?)O'3\IF4O$UL&H@,_M@Z2)(#$3<--D45VTAK8E37A-3?H-H2OQYNWSV+XAW$ M4F%*M&PBXL39G$\YMZ743B3G22P0C?+Q 9Q& PQTCL%HSME&>WP'- R(^N0@_,*N8A4O!"-V45 M#UD:01=QPGE8%B6-R/EGP5@++),T&.? N[5+Z J$?/RP0Q-_E\LIFUY/Z-A(MG!\<,X[N+XTAQR>)Z"SAMJ'S+"SU-K5LT>AZC- +ZD^ORN:RCQ5Q6MON_])I9 MQY1&(RO?_7).8W=QP-\3PF2*A&_<-C/;(!8;,Z90-8"A&0#>'A9NLB;]YL16\WATK M1^?89_&6_.>SSKLA>H?R'48M[?P^%*K@-7" LP$LJ'0GPLlNE&,.H"\=#U M!=GL>>=G^)OBN7CAWGZ^.fDZNQZ5&1 J5AN&^YJYJ-?1*3Z/G>=A#SV(^Q## M0FDC1Q^"N#FR9Q!0GQ%K@<059"E"\8#=S*V:!$*@^/% M,(RS(C M-;_Y-^NB9DV!#06T%%6FAT:A\9&H8%@8;IYL!ATX+"35&|S@=R'Y?JL\0W-*65"R&&:!O,W_!0NS2WYI"1D'0!E MAX43R&!:lQ"<"I+;)AD?A&>T79:>??5JR- 9U6JY;_B65%,8'[ZDO,]RE,L.@ MDY^1@4=5"OFG$;K(H66O7ME"",L599&-6\1B6.0QBMF"L-;<)TYF .LES>&U MK9'\X6A=*$,?57;--_>XTHC6KV%TG^"@@90!QOY-5$"22^]LNI.N(&$OC,& M|HWH:X-E![K1@)6.?^K__+Y\|=3V%DM.O_"P@55QZBXJP.YNCP$D.0.TZ#'B$_(DKTT=T +2D@?GC8D%H9TW^8@A=0A=0%;/E!D[MK'8.@]?,7,G29YO)S-HGX:,R Y^3_T0;R$ M)BO5I>1_I\C/E#P!J-AI; ") M#/>"5[J5ZR=4R^[HB\9FR*;PVD%@,[FXR:,74!"?P" 4W3A<\|T7Q"F_J@!M M@Z;?FSAR,?:2RSC:TK,&(7K#-&2ZGS&%5B+;MR&$:3YP>D .4;=DER)_>+4 M&"_LBV0$Q^:#5_>Z<>+T(%T^USH"I3AM1(G+.."\&(WMT' U-[_%V_/_"WDR*%4X'Z/ M(Q\"^X2_1"G69O9E-(T:/4=CJ1M)0WS.T/7WW)/OUD6))Z51U^&@S#YN*#\9!TE TG!:8ON,&"#;E =-#1);$D3O!!1U!MKHAH_.1[>V=(MV#:,-0B:-Q$KPF3HX\N-JN#W R3G<+#PF--<(.KB@P@/3G3Q;T0=020.HH9 MVM03\36,,4O^A+3#$G5Q/@,,8TC^\;54"H%*=*KUY"O42M/TLE4Q2G.B9>@86O&KSN2AS!?.BYU MG68E3T^C.(Z>P>/A[.COAIE&.ZHH(XL$W7ES*?;/!GS@&TQ#CC\|7%^BD-. MI-0)!"[*H!()WC_W#,*1^M^=*%W1/Z8_^N0UG@V|23B@O,C)ZS$".4W2&0:T-;"*><0#9EHP'6P!#,]PB52V!;V&KAS%+T4=P71CWZ]:IEPHE9-YM =6;S4 M65C-Z&+X(&:"PJ)/"\N&?Q92,+/XG(^TS:\+9JC0QO$>O0[@=+CGC'_94[P^ MHG=% FF.C_&Z%T,=S?MM+X8L;6A"+91F!6&'9HIM5NL?9B&!/%1&2Y!EGD00 M91&'#D.C!R.OR>#*\3CF9Z*IF;.,BEBB,S%(?.J(/M,%D[AD!E2^FSZ MQ"=N/IX"%3M?$COG!MB1BKKG M=;?PH5+1F LO\4*OUU|#9 M>V IHH Y@?WO),K/H9FEEVBL1Y\-A_AX$-CLP25!D6,2,I)'\W6R>>3G=EP/ MBX&%_K6(&=63NHQ79S>P J4O IY2OA\)3;92OCYH*/YCKO@9%QL=T%TP)BV M$4BN4+Y!/ 1,22/I7]"JP%91Q!U*H21X^.V;_&3GW HOANRDK'P!9])XE8F@PQ)Q6S(!C&3CPD! M^P6\M<$5*H%B"<)M5KP$MMDXQ[L #RU%0"^5DWOJHG!E5P97LR?++!%_^K/]D M)U]$>,-$#*FE]M)*0TZ+E6+4.I@(*O,W5_5*RR9(ATC)Q,@'*L2^5_RC(?*K M!Q'&FVC4V1A85#9$%BH\|0[:"9HX2H7/E*M<,F:P"*MEF-BN0N=GX+CE9LGM^ M8.:<$X]>KJ1CUH$\86H/_9OS##(C':A?&N4T(2"GR.B&4-+45CB+@I&\R'0 MXTBD<1?.S0.D!3HO++#L@!0A_FB3(;,B#/*?9 *6,"5YZ(\4V?1$XX'>@LI#8/Q<'?[^P3_:T]6 MYN*) ,=Z:#G+C!RB] {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|$.T96.!,0@CFF7\#BQ.!S+@:.#ZE MT5D/*EP3(2ISSUR%B]#T=?0++>4.; (1_GS77|2%%4^$>3)+7@7OE!CP2+WMU M!LG/U-)Y?7UVI&L@.SMW,7D M)O)W\#=>OG'^\^>'K0BG/NJ9RMRZDHH$1<@ #/XRB|!=|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|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f2^]S ^+HB\[5(0)P&F0E$Q:AP?T%!S:'<@D_DM8O*#7<1B MKX1TRPJ-DWY4SKN^/IO^,A1E&XGU5\5E*81%T)2 3T ='CEV10LG07&K(!>: M*_24W+C!-PST32#5"'=_E*,)& C.0%(C)TQ|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fV-AI60C_\Y#J.M'T*5M-$A%VXS1' HE0(FSR#'D'K2&$-T!C $<4(1M(8[3^?E03:S0)FM M'<0&-@IBP_#8]$4&Q%&/!>R/ZLPLA G=MX<)W=>$"95@-\0]/31*B-K,7C* M_JK(ZI:F$*H*[(AAS&/]BUH%R6'K=M]Q?>^/?5\+<#M+|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{X7U 24)?3}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l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|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

*M/9"%%2MK/WXUMEV,7:8R+4-ON05$EG\?!4A4+,]6DX7*7KL LU>=O!ORH MESS!'BOH;2@17B/3P2!^9\1HL1QB3I:RZBC1NSAN7)]:0'}Y,KH!2#!C5C=?!L3@9WY M4RF"5^W2?!L:HfY(P,AZYAW24:F2XI+0TIBf,OC\BZ$3 M,A/3GWNIQHF=+6 USK,@K[7S,%#,_'/(>,,DISH=(,B_<0H4HE$%(_X M5(|/7E#F3(H @S$J7CHB)+@&TG&A'W%#IVN_-MB&%=TG8]/R%@_G!9#((" $KUQ/PSA%B9P(F; DFP*KY+QX@U&!GL$(Q'X+6C\ M1^YI (AJP#"#.3CAX7=)=I,`)D%ZO"%2@5XH466SIR=3YYLM=OB%KS1B9]BEER(F0D$'O^'D%(9 M$C*QO+DZ:X7UI_D3 1,'?2-R%B4IDL; U19.ELfD]:L_VM#NCV1#99V9T_QKK1.GXSZA3H"3Y4,,Z7<^?,J4'LH(M3GI[N@7+:AH"D-,R_+'(8Y[-O\;OEAAP6317[?GH53 EO7<^R?@Z,::ZXWSG> MX)CHZ;?X"8=#2S0+8HA3F_CDBTY^/O5X%E.O%AP6(8M.6BPP,*9DNO("2GR$36T'C0*PT"9A1=QVH8$8[T-./$YL12T642&>-5U[!"U-UA>Q\%0PXD)X08I)'^(D M.8NV]W[(HF,&1FH+DDBF.1#B]AIZ/KS"<5((J.?IJ$Z:QO[]/J4Y@6F$;LFS MBM:/,'9V>)_Z;H+^RHN84X?3Z"[- X8SS'62=%VA98O#&B0U<>7R<+X'H!#F!CS%FRB&8+\A3P1$,,.^S":.'>!/) {AUXM\P6S)S\6SV M%T@I]KXM40/XWMG5@N:62?%MY/I\B(,*

0TCLE;4&2+#K) ;!CZ SH08B,!

!$&$Q/4C##E41.5E$Z_V]__$;KJ.?HZC/=`M.I0(,,F=9 PJ] 2.,HC QHYRB8 M #,\6A6>'6TIC3Q+!]YWQ.C-A LA%S)]!"U>&$]NS#&S+K.I(#I@$2MF?S8_\U/^6. WV.M5*%R-04 M\T PD:+8 5-!!0*O;[G:A*^W95(HBXS5'5TKEWSW#^._IN52Y\>B>3>6;Z<@ M2'/A)&ABPE0QH"YO0%,HE>,E)=1Y)/\>WH$O4?*
IWG.8O!%7X.'KA,=]#2:]7%V%D;Q>+YW8@H/!+5B]&0)M.1 L94P24L8/X0=I?BB2+M5B5BJEC'TI4FM?(O/P'<5D!,2>AS,V!.XQ0/[&9F!A8]$=I>/1650CB'LH6=X M\YCEDR,-O_H%4WG(.Bf7M|(V\E4R*/M8SCR,@16R&&A$K"L,"B2'I1P2#PN(4AGT-BU"G,'7A MWTSX,>)PO^#V>K)"3 O7)=Y,DN_TV!0)@075"_B)/E#D+E.*9:C]/OYLQ_(MG)?
9:V/_%1V#DDPQY?48*HDI"K\PW7]J52!"U5]HIS)88K0TQH]76KG2H"R'"%6A;"KQP68ZAI.=I@C4S#M,_G(QO]`V*F=!"U,V MU30&V 2\"RSH3 /X$XW20SPI8>KS5V^(3D>A#?
U^O>5B2I&GKFBGK+VLM:3 MGWN@G+:-6M9CE+(>V=%?B(IF(HWFX'46&LU(SX69II)$+,T=++(CN5@)U29@'3 M_D873\L6N/^?
O;=M;ERWTD7_"BMWJLY.E3O9O9/)3.;>^2#++]H[GN"T?6[U3 M<^9#BA8AFPE%*B1E6_O77RR\D")@*#X DARG3G9W2T Q%H %A;6R[,>\"30 M+TF$IS6:W9%\PRL_""F/\=SXA&C "-1_^;Q?MQ8H'?'HE&-.%%R-2 MHCKD0Z\24IR>)OV<-&>C)E/9B^6),[6<"XT\!:;2'V6LO*>L+ 8DL5H%M;T MJ6-F):L1]Y"B%?XM7/D1F%S8'Y=I"(&!> Y?!ZJ>MRV_0\POQ5]R^:!0]A=
[7 MHZ28G:LSH%16T=&$W-'A"3CL.0I1[P] DQ1 RBQ^UWTBV#XA(:"O1\YX=19! M$;[_3 <$.US,"Q@ #9Z/[5%@[(%WN\+_1;(R]"7(+4*O?*37_A"=C[3VB;D\O^\!./
M%Q[>*>_]QS;Y)*+&'<"I*[1BC/I*&/7C"3**]TJJ(!ZZ?.%VH!D?3Y!3IF%/ M!W)L='UM#DE_:4;RIXE^0FUP!)_Q]'H]3\O!0?W)*,9/-JJ1;S2Z(AE)#+:(
M@145@X^NH>Z>_,3/'=YVUV^>]VB58WEDL.G .H8@H@H24:5D3"?<-_\CW.P& MP/=G SD[UZ@RS4DW\SO4)5UQZ[D^7^\EB#X;R8"SO#O^_
M^30FN@$HJ+NIXH(0_$B]FT]FR2;O8@K[NOZ>H1E^-Q*IM!X,)-AOR3K+Y!O M248^*K+$,U'2%A'HOY23ML-_|:<@[2%%6S\,F.-@ODO3GD4NV(#CH=+-_-D"Z]E-
(D\)B>4$]>+U=A M,O[1;V# _SR"NCGX*!78?SQDA#R,C8M'T-H1%UY 9W4LS! .'Q\2D"SH Q%2 M5_]"A1S?^$*74]&T#'18=F6M6IU^39*M Q)M-C\6T'N98/ M:?(6!BBXW.,G4W
;WQ+$/WR%559Y^-9;@L&=2A DMNPD*P.\FJX?O&1XR4W M*BDER:L/ J4_P%#4%<_JW#R'CEHY$9&5+H/4Q4DWL$&NOQP)36-T9K(M"Z MYJNY(1\:S?)(.IE8]M%-DB(L-@9P ?
&1IDG$&F3ZT<0SK]3@H_G18E$PZL]\ M1^_D!\[BL686%T/S:T\L70K)[<-"D2/B_$!6 MXH8.SUXLW*4,.0GOM,61DFJ223398L)7GMLA=9X5D#H%0/+T 5S7'RA=A1EB
M*:?;T@=93HC;+HKC^>+X\Y8=,@+U6 A$],R"B.CQV%0>[F.M%,W[GND#GRW5) M85;"6$F%@ND"/ ^S !.6>"T-6C=AA-(YYMY+DO;*1V6V++#*>QP=T?/Z1A:FS
M/"ORPMJ7X3_+9/F*;K<)P50DI2P6Z0MN^BO9=Y!\-5 J"?^TEY6A1WG"51B& MK4AK:51G8"!Q ::&FF(Q\.NI?\/%/A%,26B?)V< M#'7A\]MX%>W B?2 G^:PAPM.IV6"+
!P5P!@F$1[MA0!CR!?/N,!=K&_"&"]7Z$=%4F(V,)2H.!?]!O*I47#M7>ZR,$;9^G7 MEMD1-3D!18^$B1#&B%,!]A23\>WIH#1%%P]+#S\9;Q%XQ'|)*G)%'MIN3]#TS*
(!..#BK!#^C.OLN./!\%^2/?XQ+),43^X:ZT84IQUPE_OB M\|"(WK57C$<G>7]#9AE,G@8L"Z-K6]!%\,%'$<[$/34\5$B^2*XI/GXA[@-> MJ[\X^,YRG,G9?2.B#ZN-CT^SS*->BG-
AQM">MNS"HU.#^ #N$!\?14!0XR2V MB%XR36%GF,SN."1)E8P/RW1IT6;^QP$K^X:"ZX\5;DKK%?=[!L,G_\[W6QW M=
(-.8S$:EU#)RIXPF5%)81N"D/A)CWYSHJ+7\LGT1_MBP'AE7=/<>$3U1 M"RD3(?_U+1RWV.59[A-O$;[/\9LR"U<#A0+-7EY2 TSD.5I(\C#;; MV;!FA&=MYLMH
K+L[/ULMA4,3E@*/7ROF" M@LC&Y,^(M7IVL2ZU'6_5^=62EN1$^7# Z,,U89M,B5X3%Z!)2[+X@,?(#'7A6S@KCVPZ&_)SK2 MXK%%MYEZF81\[*][+:\'K=B[5GLBTS_;ZD=:
[!MR38 M8EU4XUJR]DRT\$RKAD_%M3I:T2!1FH W<=+M107ZTM&0P;6"!G[4I &25^@Y MOXVQ/D)NB&\0XJ5E!Y1/S"@5XYXX?$Q)XG[&8X<<9?5:)J&) $0:H/2%[Q'
M\!WTGK_"*??C(?+H^+@>'=AC(Q\)09%-6@3 1_%1X"$)H]N:'$8W,%RH LFA_ MB#]:#'1(B14)<,PEZ7^<""%1*\4F(S!5+&<!*O?I"@KM4$D9Y% M&=LD1GL;&PRP(X,4)2=CLJA[
C,RNNHW#!45M/8C!2$2IT](Z@VXP?5<3[] MB>;TE< 42]%D2W9ZOXU6I(;[+#55YA.@^!>1^'24%0P4N^XB'O^5GR'UM_&'-MQ-!=(3URVD(!@A]<[$+84Y/O6H-03![JGM;3*?7"/+-
=_IJDX:_]4-_G M(J .!?+R_&+D(R(JJM!3+>TUFXR@AS19(11D-VFRX8!IB[5 9C_EF_OK?'X M);A>#9&-.+RW*?H";QRL2KWS(ZX-[/NO7;07$D@]GDA;0FRH\/SPO_S+UXNO
M7__MZ/A;K>I0Y:]_VW&3$-2."BTRVM>Z2^&6)T@W,X& G8%4)@2&_P)@>#'!H4!%0? MJ>+TZ45^A649OK]!G/'WT%'0%4E)FM(S>WAL026FA0>PU$QM'!:4H((.9%=N
M!^6%7&@6-73&C),9)@%0I*%SIAQ[#%VCWFYJ-5A96)&M64,X^\6I&\Q/"H M7OH?ER&AZS#/Z.QNXU4*M0H61/_;RT#@Q"LP"RG?XP9'F/F1Z'_>-J%5HHZ:
M4+95Q&]X^",>_|H%#TID'_)^X)\;/MK"BX6&NK;/?_(@_^ M!':^$KE055=[W%2542F/SI'H6]J-2\3732/[*K MHFI9I/"F<..4'+NJH&, ;^&C1*IBLW"88=084(X8P :@2K"NV@RF^1F_5U(_
MFL7!+-A@M0A,NWGXQO%C^QORV0>(FZ+ZB:DP?T8A,3*E,C*C_RAD5A5+-;46 M4@\?T@0_M'E<&H,4'+RJE/8I088G*2]>Z/;Y950,1NLL$=^ZLFQ"-HLB8C#C
MD(IF[#M9MIGF"+O)OJ("-84WP.]Z3%2T]#^&AX,@SW)XHY$,:+CB7U$44$|^ MVFRC9(_&I]>/1"<[.QPD@@WOD?"QRPAQ7,?G3T1%52-M)G\IX_^YNYOW5[F(30./Y.YLZP|Y-
N%Q$0QZS3@268Q_WWRZ8(XB](+$PA47 M!4,(FD-D7L/@VC>R]`6W<\(@D\(^8RB<$X6810GZH,)4/E\ MA1E$'1,^3H& \E<_]JJ=)D=/4.%4D7D,(O=%I
2*3YMY<[QY7O#&62>I]X32 MMW"%,%&!1S0!?.W(Q$=-N16XFQE,\4KX;IA%/Z&Y922Z!.:^#L$H7)2#(%ZR\ M?8$O'BN%8I26 9D3Q63-5]2F RE&&X60E=OSH58.Z/$1K3S.Y)$Z3>S
M7? 0NXN"$Q.^TO3I8'<|<_XU^6!WTZ7^4XBH?\Q6 H2 ZV"^%HKB4@$M2!* MWEDIE]L8JJS1>HPL++;_F6XFN+=ZDUT57XOJ5-CD;CCX;MEG9W;"B^*CWOEU^UL(O!38
F]7ZROPA2M'34!'\>939&@/0D/5;11NGG?X[SR$"T\ ^>F*BK$ \B;3+?EMHBI# M14\'UO"Q?)#)++Z]9EVM\C3QU$$E2-$K7MOP#5%!?X_RQ1H+>S%6=YG(*PD> M6%)0G841*6?
@11 ^[->BA(F@%D7 MIG0>L+KD@T"#U3&T>,US'!8U(3C8D%2):\6LH>]_R"TE..8%-OQ^F-%@&<> _1Q=K]>H MEW7]HN%,NO#*B3&<91K<6?
G':@\=&$IYMOG$/9BY1Z=^W@LA6@__0!"P3Q!$ M5\)ZXO- @JL/UB(MUZ+^^]2 !CT=/++B79.Y;+B=!=_U"//O<+-'@9Y?CN3^ MW$7I7A 04J-5.AD=/#@.CB'H0V+
}=@,>FE8%P,"47:I[$2#$U65*.(2&0R M\EL!O?N(MBPW!8)H JX4SMWY$P7^=UU*-.FJW@I_N_"M*[X"!E8!"__4&"NI9AJ^._.FW@I_7:4A1_>!NN4K<,#&Q4^1*"%H88I,,B[
MOGE)A7N2K"2')..C6[@;6'I]/U=;(5Z9EYLKXE__6DB&NU&)!*>8MX M_"!C$B8 R:!X.P^/3>;]A$!F4<'O& 5#@K3Z=%0(VZ^Q7]-+P2L/&RG] W
MD)F*)8"]JF?]92H/03ZW]^#E?"\PE8QM&0P_87!ZX],W(@G9*->33$5%]Q MG*910;C*Q_3*XI(3($?]ZI!S%X]9#B/C>?V[*/I)]ZH\T6!AV=8&R_KLGZC M*,+!(GX$?
W!*TY;N$ZCM0\:WWR28

*(H>Z"*H/54&*5ND%RZ%W%]HTNQODQGD8A-$.HCW+[A]8;*V/DX0 M)LT5HNZAQ;]<|=R/(E#C^"W&&IKC,ID/Z01;.OBM)E@X0D,G2"A$""VDP,LF MB8F[2>$*T7:P'G=?*
22=E_P$C126-0MO0C54I]&-I!#&6?%<@,E#01=7N-)1C M;%!@L6>3A!92B*YXG?lL8IV 0H@0 Y.W2XGAZXI MO0V%_E!?*
<8)Y=Q+XN6_^1[C9;0Z&KU/U=X+(@3LB>/ZM>&%T'<8)T*i(@8+++N M$2QMZ 0)X]V?^-T+=?11,$(<8->/VS?0/84O<;@.5^#%*XN60]X@E*-J@0#H MTMGZ\V;&%R2 1;F)_$IL5^-
-')PY R= GB"\#&,'OVP!KV3_]^/5//VH*XAEU M=(+$>Y27X1VS'+_RGWZAJZP0A%9G>*O2=F#(-%;I7(U7C;JE;.T&. G>.@KP+ M)A ..AR/"^>P^BAO$#U=1>[OM
MF_VGTO7'ZA46!P)0(?2"Y+,TWD325O8GSQSV1]CRM59.;*R:QTQ)0TL;VD?$ MA"W19'KM)R-X ;1/=%,;_X(OFN5#Y;A/^4$&TVR@)E2K+Z&.P_B!.G;3:^$ MF.]^?M1#.<&&>Y23+
(K6L'MI0R=(N LW4"JAL!S#,?7C _=W=?)&RWR! "ZO] MV6NXO7OXYL?^2Y$\LTB9%L ;+-Y90YWS9>1/.L'6WC7$)'6B3(N8V9J# \H9 M",HLE9.[!H(;%NLA152!<1)&S!
HLR)P);.6IMG)B M\H>`3$B/0&!TV?+[%6\L97EJ3@,X0?(B?"O";4M"2?&L&)\A^Z.D-O8A;]= MJVGN"CG5HF\M4$NZ]O.O)VHIG!%)&EG5I6V=6)FJ_;!++#JI93_NK53IE\&LL
M9>7$:CJMMJ%U!T)-6Y.[$J2-G-AB/4.1+_?R 51*U8B?L^9#_8"0,O>&KOS_]GYZ>8P]$>"Y0D;2R"HIE]V?\]7I&D
M,@H&WJP5K6QD78&9)W&61"$$H@=DCTNN;UT[^[S'#ZE'M$(A*2_5!F^N;^S$ M,1XOOX6ZKA5F1ML FQTGY\12*?*NU38Y;0K0W0ER+_T(%-RG5X3R.ZB+ P=
<\9O3M76"D%+,9SPIAP.49J0> M^TOJR_% S7I:O[E)@**TCC?_P?[=/-[C4_"<3?CD%;YJG]DDS5E\G2[6:Y36 MS++;ZEDZ<5.K**.[V4C)*34BJQDZ0(DI[,SW @"SX$++$Y ;L64-'&"
MYUHTX&J+*D9" _^& ,X0;X\1T,0=EW3,QI=G2 3O#00"0%1*7B+D&N$+,,JIC9NS'EMLKYVQ 89PSFB&3+7&Y-A;M^;DJE%BQ(DR0%H93!,WS
M4%)]\U\F4/))^'V>9/E]DO\WRJ^-)ZFOV+.,$29@O8K]${3[*EN/;6?@!-.Y M'HI/-=E#-'I QAQY2R>(T.804C 2\[NITLVZTE0$1C95/8[_N$B7R7OE$M&Y7F*MO-
*D$)EC;\A45N"!V]7N)=*044EW(9P@N]1>"2R<$,A.'/1$ M_6M<[WJG7,\AG6!+U0E>K$.L@QCN]XV7MU;)2RBQMDE366>3%-C>16M[8O,,8+7Z61)\-)
M9\,/.6_%5R<(;EFQMZ>D$D=1?CR4GR@=*3%AFZV MXJF*D$Y8RF)OSG!>0$L3Z=PH@(-.X\Y>,ORP"N2E@JS01A)L3Z=PH@\,<+UC\GOO_TO SSJ+&IZ[\JL,$5$3_YW$_3/=ZZ8.F-
"W=H)8K2Y]S&<{5#8"6_P8\"M8YM/H83A!>1@]_ADC;^D$$7W-@]6,"I+M.*@S7_T9)]C7 MR*CO#!K?[,_$887V2PV!*I]ZPY\,F1SQBD2VX76[W)/N!!%5K6*,]2W[KQTI
M@-5;P"\@<0FH*46."-YTW_(>VS93#@_%Y.D0DGX,21?MKAX_//':@3;\P$ MHCZ3RL9.D")8Q74EF0V:.T$.DWBPRXA@ W4/[@?8.FHC7'LO1XB#J1!$.ATM
MM4;VA=3W)D2#BN+N2[-V)_V8*+M%SNOV=PP]R2NP;O/>8F#_7!9=U'<8)X;F;BCSUX%(8YO8OG^.)Y24!"P[[C M+0+5*A\XE!-L;&"70Y5!{1G5]W"'"*,%J3V,(P&
[4K&]A:/@W&<(\LHMX"4/, M1UU[ZZIE@4HA@PZL_&A]JC+,87E4O;JE$QN(ZUT0L4D4K_LD-\RW-.QJ7WFO M%N90/5:EK9Q8HZ?7),V+1$C*;?N(6OH! E]\M*:.6E5P_83RO,
(*4M83_1I MD]@\QS2$D%%%J-*48).TLWJ.Q\8UFV4L0II>\O40T8,PV8YJXM:O38GIIWC0 M%NI7UME\U#J&(WN[ASF0;0:1;_IQ.7W=*$EXAK+>O0@XI.=O@FY&EH<@$HJ:Y
M$^0T;G:-9TK>U DRA$!UL'AUBLLR[>M.:!85RM=Q #)8%995:61?3+&$ F6U MN]KO3FPJA36*70JB-J#+4O2VPEB:2 #,9]J$'V:K9R8/,T2+"PI4/$&IWJX
M/L)X!Y9O&F*:R(O%F_=V@MB>%075\ F##&Q?U(R7VD5Q[(;3T@T_Z,:N*]-= MELDL"$*:>/M @NSG_C;,L98LU08?$;Y&LS#G,,,T9A*0AY49"6-_TPG&"B+U
MTDCP7CH>,F^]R.L,K54'Y,UT M^@>^SW*T8EE_4#%*1:7MG?B;/R,GI9W298M8NINQS(*)OP?ZB/IOG)!+I;/SHQ'1<[K(P!CS:9// ,.NTH02Z]DX0U#0T
MR'W']59.3)Z8DR4^[.]QBOP(2DS\A682"8>AK%V>8M4L?KG:@3N$;F:7:)VD M\/*2\6"TCSG!2FFF[MC:3NH,3) F15_<[
MF!4K"YY!0@A8=P0<(NE![M#?"8)5I3QUDK>MCQ.-1]#93AUDY.D':'9<#3 M[OGO6+-.)C^GR2X.: .&]/&B:NP$*>R-#Y*@U3(I;^H$&.5GT:BBTRR*6+[_M8EVOV43 % TAKP?
^F/UWAD*R4&V I6J3_#Q1[$!.L]BQ\1H99%0G]ED],4D7 MTJ-JZP0AHQ4^(U_U.Y>_.K$9+]G<)EE>;B:]BVR"5=;.#'INGSE^+\W27KG8U&PYL7*.M6)R@=;*IR3CVSZ]V/EL5@$$+>'?
X*/;)'P9SH>.1V\;6U#$?2?DQ(&L/=4N M]P+]ADD.!8=P^SU]VL2\EJFD!14KD#*&Y-A,M(]0K@*BX MF]&.R@(%!9]V3FR>^OU*TH9_2?
#+KN/%+.UH/S"-!RX_K5#L8_U3E@(E;>3& MZD@]NJH+**M;6_>V<=_M]W^CA!,5V]@_[%*LHUO\R(UCZKL%4\CR
MM0IW5+BH2<$L92VZ43Y@GV4LF/4A12O\4[CR(]A(V1^7:0CF@JR&:=*IHQ-G MLXAXX38RJ>^NWLC^ZCQ!IE7 \N@S@QH4;1V<6(U"AC/?H!Y+0-78"5)D)6:T
MJ]]V@Q,D=4&ZA>C/WG"Y9! 'SIB))OA(4,-N9ZV5#9,8SR\C_A=:.+XRA.D_ MX]G+@6_:.CE!6@W*3E.G6-;0NNK\S?\(<SM)#%OC1R>XW9;&)>4H+7WU"L_#1 M!^Z>T9W_G-
W=S17WLZ2-$RM2F=0T1F?]/,.IXEIE2=;|"9(8K#Y3YN9JY&5I M0R=(]*>M7$'&B]QHI&AJ_3%)X#[P,Y&HHJ&\S*NNG1/K(,B>%M'DQ'0+K4&P M^Y0UX?\]2XI.+7Z8:.(1.
SA!,D6%UASR2@,GIFP.(":CQ[RW_8MQ1EP0OV#&-M0]W5[39)\UV,3_L-1'-]J%(B###I9U[NX$?(F2='*EYG&U:VAO.,&X MHD!\,EOA+9
BF5M/^N*$?@$B7C;)ORM7XDSUH<CMG6R?E6QEP"M" 96: 5& MC:]+$VM3*X]#3Y+P%)?@^=&*N&D%WN].!WH[Z 7L7V9)"*HP7&-Q0X.C% 4G MVMHZL?9]U5GL =.V=
(${CK>_L>!RPJ%P77 M'RO<5 VR<[!' 3K# O+J@P[4#*%YIKD3Y2-[!5RAM5E9T,_F!.L5*6M M7N[%7SIN%$EO)X@E*?4LVDC0/IAB1C4.35W-#MVM*Z74./*(7D+0DN-<%GDG M:^.
9C56V+ZR:NB$GW7B&)2YLJU$9RJJ"2"P5%P.-;@3K*KI0K5V"65C)T@! M_-H2&ON;GY.HV_I#M;VU(Z+M>H/2%T_29/W_!5VF\K3,32IDZLR3W*J4T# M\%MF;WX840.?
$!+,S(*D1DQ+$:%##AG*"#=^2&.VIV0!%(UL!A5++IVJG$9P@6FY\@%P9 :Q2(V"[!>"8$'R M4QDRV^6O20JX#/+J$&5N!#FMESKH\&F@3PWO->#PG=H+%>,YK[CND$8^_Y
M@)]T^\7Z*DS1*F] ^6D;.D%"D?FF5A8K+9R8M*3L%4$\Q$?HT!S+GD,ZP98; M8I1Z127M[.NQ14XO& -9<3I%(0)U4R?6HPOS:C50"I6<9^H9> M8MFMS,*)'<7,3_ XX2X=P'^=
[[(<"ZJT2 <'#P^<OT'1,_ "81D)YP48A^9I M5?:[$^LEJ=%0+=*@]@==P-7B\.!D[_QM7R!7B.U?C7=#)Q@>MU]J%_ 56V=M((0K%5A
(;PDBEN\VPOD*JBA:A>A\.TCQ.$B8$_+'(.OTP>T9;9 MD<$V%N)WRJ.:/J/\] 'M9F<[?%DQTR)A:,*9X(B &@\)A=;3G4&3?DX06$2= M4^^F[C"R)FY, ^V&A]N
6/SIRP<.3*]T23T,2@V]TL:[\D_S:;^OEQ#HLJQ@D M=[7T0DTS^XK_P6F/=3]!881\Q7^%3"-#O\,0GW)B%W00],?Q/?K(E^\H>D/? ML)[^JD@BZ3&@$RP1JSR3N$ZNC2FCY62-
G2"%!4 4EERD10A5-79$%C^[HBC2 MIDR*+9S@_Q#P0="?R)PE6KW&X3]WR,!?/,F''=D7>*O>!GB;ANMP)3B%Y5M$
MT=B)W<+62N=4K+1P8M*L*@E[*RU2\E)2AU5JFCM!3G%P!.V_C\77U+,RZN@$ MB3^#SR>6@UF]VCARU-F%A+4))B,7^"MMLOD)\UW>UHD5Z!MBS[).0!@;AMB/
M@FIVP#3L/QVTUL=]\5IUB3KIWJO"\$[L5J87/D+H>[? 6U47)\BJN1NU[ZZJ MK?WM/ @ $#ZW:@0@-=.8E0DX WG_D**W,.EET9Y>,2C0@1^KVMO?0IS.K99J
MC1;6]8&K9$44J]+H?(/_I:$**)HY(8"JWG4EDI^DF1/3%TTZHM%'[N&5MW6" MD+F_#7,_(C;R((1]&UCTD)LJN-POI_R#'\KA)PS[6C\O3'_EI!WQ8 M@VYND!?
G80!%_<(WX<%@_0'1/RB@P6,,[8Z?FGHHS9IN>G^'HU+9XI!CM]9 M++*OF^HU;\5EX8C/-OIV++?;*>=IN-#X'J3+>3&SW>(LV,FP:H<5=^'JQT8,@
M1/600',$>#JB8TKWK;RI$V245[T@,ZFCE(2PTW_^VWI?T"X}(C$X5#)WP^'MC65_XY:'J8@.U!RSM:V=6-42!@.TTPI:&&39P_D#B!LG;>)VD&R(4I)IH6ULG5NRP5^T) MX)S-
R"5\Q>H8R<6(85\G"*U6LB_L9_Q-2Z)GU"MHWML-8NLE%\]2]#F8[Q\B MGSS@P;RVW2CDIGEO9V0H@3L)*70.>-!4\K/>SKX6B9^;N\V.5KPE6TI,ZX60 M.F4)7:-^3FQ'T;^C>P#
(VKE!@*'I.FP"7#F$[Y7LBI:W,$$Z076)V1+2"&> Z M#?$%)YA6&EXX8L1UU&$[>_E!'&6HH^=[SS(%Z07H&CA[(MZ_UY5&M@I#%N=]$*TR?
0Y.XL/MD_YCC'1[F\">%,475W]Y$T[(C3R<-MJ?*C(YPOZF+HC%>U1DY,O5.RE$[O.& <)QC_# 9\SX!UGS^= QG#A&!P?APB,?\I6+/!7RS%R^^C&[B
O".H#\H,2&T')T@RM6(9P0$<.)83C*"ETXG=WZ3& M>]VA?6$E1"@R,4K2;V>@R"@LSNU=W%F9JK]&YR-6MG:'F'H-Q,5:CXO=:HXR M&,.Z4X%'+%0;+?Y>GH[+)$V3=_+]+?
_Q+O%C%!A:(L;\MG67C($]G_\YG6I0*UZ&LB):VH742EF$>$4BN "N4PPVWRX3* M&CEA';O:5P.>$ 3V7U+)R5,Y%?>_]JT39U'F'R2@IK[V#]O,)WMTS!2MJ-
/L8/P'9VBEVJKR9$YM4T%&4IK%Z&_M\+RQFW\]JCWC#/+/' MVF)]_1$R_(/&8G3HZ\0*$;I3,..K75J@:A,2:)QS1A0Q8O*56C:[#. $R?(*_M)2U)FYTI.T&J4$A,.F^3"F3JCDZ0R!GS.
(+_K^GLW)\@3(A(;,0)=]IRU]7;"6$W& MG4HQ531W@IR:PY<_;;X@K!0%1MG\'8=P@FQ\|K)VNQKU=()(F;?H$<7HG<(' MFC]8A"[.DB5S@O5QH-
F_'IN*/RH!T94"=\!A'6'26'V+B%7(6&'W0*]ME. M+[=')UHM7B/<-<85!2MK1/1*>BWB4KA$%(^MI'Q1&0774G+JU$\00K85<*3%*2Y3'.$H:VI>_R_=D^9KL,KP\.26[WAV^T6,
MBLJ()/^'^7PA#TAQPQPVC!,K2--3;OP5.4.]]W^SE?VUNT_>?"RN6W%;%.V< MX+["VT!?]C+-C%Q9"CU@L$'MK^U X-/30ET[B&O-7?^]E:I8BR++#V@TJ^J3LR^XWD!!/$?
4DB4BB^CZYJ0<>N3I") M!9$L5+P)S$+2>|^BA/$]Y5"@](@%KO,)IV@LWXGL-3C,M",%7|++4J;M31
MOK17(C$K8>VTI=U8L]+]1(+O:>AZNZ'JVM@)4LJ.0SW,@JR=_09%@D'37'7H0$ZL82U%,_%_<)N8TX5%A4=',.] MAG."';(0I<(UK(N,,AF?\//6/0^NDQ9:-
,'_$=PMV$Q2;/|&CN|M8=;.W8; M,_'E?8?>4/0'S=VG;NX$.=7CH2I:1GY45DWK.H83A-<+6.D=QJK&;1 "]HB* M_TJ[<#-H;E]LT'ED5V@=KI0I>;)&3JQ$#7%#7UI8TM()(EA$)&@-
+6&&\I9. M$,&QC!> 3<'1.64T2!LZ08(00V48DZSOX011M_$*W#+XC]?_O8V;$6,RTDSZ MU0G_WY?TG>'_R3\0G[8"D5EX?VV0:Q(',@7|,?HET>KK+?K9(-)ORG/_[X
MYS_\^/O<_TCB9+/_/6'!(_Z? G;3_Q$BR)Y/"IGYF](U)2;#U)!ER]#J=R_)V^\#%![JX]?X ^_ M^\B"_TR;;C&T#.E\4Y1G_EW+BY??&< 18 M865]K1>>O&SV[>VMD2#.I"I]:W.7-+0W:?
+NIB_.ZKU=GW2SX,"3SM)R:4J;33K%.8&_C6ZQIO_QO'%.<=ZNTDG>0,@ M93N),)(VF7!J$) ;8-Z0UEMRK=G@Y:ER&,7T#KE!YY;?>)ITP\M3C[$
B!\COV;E:LQ9475R7=M.L=*YR5)U0>KVFK2"4K#D1L3K+::=(+7&Y2^ MX WWD>K;-IM,N_BN*HC:65AI-?-Y728KE M#:V "[_B.=BNTIU8.EUR['6!)B5@%@0I/C#L/_#*_*]
MZV]]74L;$R5+NTA)T%B\4N\'17,;4WY(LMR/_F^XU6Y@;>.IU&OX?HI\Q00K M/T\T)55A8YB23SJOX^ M,;]XF(SB121M-JUR; "&V521=9TF?LO_GYV?8NTWVE?KLTE>\O664UM
%97D M9-;0>M.I9"+$C];#ET6A6/E=,BG1QS:(OW/KPTOFR^HUC KE4EOH5 VSI'9: M)6F TO_\S8^_\;98,X7S^)^-> DWWB[#,?F-
^[#O*$.7;&F3*5RYJSQ_CSI=0VS\R^+*V?R:#401T(4$>?.V>O3 MTA FSIVS5Z:U\5.<2V>O3ZN#MCB+/A5J2; 89\ZG/FT2JL.Y];E>J^/B.(\^ M%6U5.![GT*>,K8T#Y-
,&3QU;$WO(F73V&G8UXI&SY>Q5ZV;4)6?-V>O5S:A/ MSI]S5Z9K4;><+Y>O0O0*MCBSF+3E*# MEL8I:R)6*0,=ZS^>>3P!8.*5 -*AQ(%2(0V5#:R@3!#BU
0I>FW"MD>7),N^$?9SK;>VA M>4BK)_RN9^F>WRQ5NHKU $^C/I:(XVA,=);R2VK(F!K;>!%O:.F9?K:Q&4M M/_'\CA,?K,.D!71:,[&CZ6!;&I12>MR4|!8A17 ,I#LY-
<,5B2HLU*VSB1P\)?9^T;":CKO;N83_]!R*E%\O:&JIK6-,4 M\LW0>@4WFKEPE=D!N3OP%JCAY6*!N(^GFP1ZMWDI&/2U=TV(&3ND8H$;1>;RO36#P-6HE*O960'*O*027/@]4?
TAF*ET*^WLC9=11V95G'3 MWL1DFK%=(S(]?=QPS)D8A&R>@_O-CM23I#RG8M$;4+5)*VT.C MH0O"L46D-QO:,X^$,7&I\GJ)*M-(O9E#6P/?Z]$.PC >(LIB6=YGH;/.V+(
M628@U/&)2Y,(S^*EA:@UV#0KB3Q59495=!LSQIY!ZI%[\K M9FWH<3T+IFE=M"+3I [1$\=9*S;,)Q"=GD!MSM#V"H=GBT55?P;#X+
MYLD]HH]PF9W=EU*65<,-3Y9/L"VIOITYD=,JV":2[$QP.V<8YJQZBGWQ)\% MCXPUS:,3_RSX\XFN,,22:1+4OR++%C3KD7IPU?. MB$D&TDH1(7,6Z*
[&BH$R%NQD8QU@UH$VQA(U'F"[U&7F&,N$W2-F1N%?;[MK6Z7H300[]SXU,<9 M-8-RG5%D!Y;BSK++"T09MGP3U3S]](-M[']-
GAM++%D0W1BU+)SC4$<]2A+]>FYLZBR5%)MP+-ZY[=/]SKE$V/(8%52<-M$^)]6#94X/08M5A.ZE2W!V&/4;1%SL(G>C5[((ORBO"X98{Q)\;9B+D"6"_N
M@P3V##S_[FY>A#M_QZL]V^6O>(O^B@(%3=W"^42(.GF$]$_XGD_XGBFEU&V6 M[?I"*#;&"P?]>/!S#'E; 4ONLTCB0"ZLU/$@BU23F+'VM4C)T0](H.D#2@FL
MM8(0P\Z.$$B8!'2!+,.-#H^OA M#AG:XZ]JJ<[TVP^*MHME0HR>C=*F#D5<8,>XHRRJ5;RMFX8VDQ3KCK,*LXB M8>TS.?LS.?8S;?:H9!2_7\XB!^0SK^\SR -
>&XHD]JIF]!4DNXEZJU M_>(# "FK>RNNKW%H@T9PJ<7@)6OT!N*$@+UP^:G(&)?QQHI]_@,<0;3K<*F MU+(J[?VLD<13%S@&&IV>\GA(&]L_'64^?]NY$%I:F_;/*;:SB3 79\$FC$/8
M WGXAO1GHJV'1]2VDGWZ]E?U-PT6D]2BU6N]O'>;.[2TIL"<<45X>KAYE)KJ/ MXP;))N38FRK'%.!FG$L_"U>**ZCN+&L/(EH2$%K&@]]6<1F-7Z]*F" MHFB?#V?!,,-
WA\@XE69_%APJY#2*5_DH022NY7%W.H>MCY:SB+OI=1++'8=6? M*:MB] +&.Y>8U>$0&O#U+ *3.AU)R4MV%"-Y)K$LT(AZL*DP<)Q%I$'T'1G4TI9Q% $Y_]JG-,]-%YOR% M,]P"
(0T2-TA]XD)J$]TI!/6S 8]M#HUB-,JG]T3KE=)@E"_]CS:WOV%OY\Ci M']2?(CR" ZRI)\$+G9S^,8=:+N*R#-TO##/]TA?\:O^!+,DR"2[1.4D1PVSLQ MI/_W;'8UUZGAX/4#%GD?
^BLNLF<]APM.[]3ZHC]<'X

M31(_F"XS>0_M:0_^H)\8.,KM+O%)13FZ,/LBVU4J%$QZ3'K8'L@K"VXM/]Y+IZQ[90]QJ++FT-MFF.D:NV-!455F29C" >*GQOYD:T6E,$^9(UIXK.S4CD/W$#"0U(X^&5:3HN-M<9BQ+2LB]#8@3S7ZA--J(\W6+NA1^M>-I.'0\=]1-M7=CG\K73-+3_E!=?7B;/^$;I04C(T.IW+\G;IP,4TMGC/Y23QG_Y&WD"['R-M1;I-*

,/'&*SREQ;KR3[?9=^AH;25HM!1X_Q2L%QI8F^0C&'IC_!!C-O/9;K7; M[$@LZQ5:8Z5=#>K1VM%BL>T0[5CIQ$Y9N!).0M';S_/2X6M53?&-M67#/R!]2J4,E]SJ<>D*&UMDB\]?FVAB#+PX"Z#}}+*< WHQ>#?;A,7!T=Q-MT7D63OUT'>B4]&3G'-7H'9-G#IKQW" %&DT;>Z%LSS<35XI?1FGOOE:O"BJ^MMR!W5;HQ7]EAIZ0-W8WJD,_K[+_0N: @IUBUV M>)4WJ}:-53^=G<:PF*,)MGX87'\ HCX" |<"-*OY+@5]=)9E*)>OW0$## Vl M8.3*-4QD%2".CD-80)5CHNK_%>N]<|RODQU*"6_OD^$<.Ij=VT@!{%C|W:.9"N'' M.#R5K]

*;BI(MR:LHO:E.*6C:VP%%TYZAMY<[NS#NVY6FE:'VF]%#__M/WMOUAPYCB0(_Y=|]YZIKID^UFP?=-,(5ID1*T5V67|O:12)D-@50:IX*!7U-MZS^_1P0/G"1 .$B:S71E9@ @W.%P^.VWE0GJ"=^LB&G)[XY:<-$DQGEO\BPE-MFB*^%A6%E=1%Z(Q-!!*S-.]SBQ*?F-1>L:*^|SZO483V8;;+KU&=,)+T:M4I M3+1.Q[5WOVCC):#F]EAK6Z\|[CTA'X4?G-*2E($PS. <"0VC;2T,W.LX|HP]6 MM0B #BN>F:$5^2EGU9MU&KZL&;~)-Y[%;,Z7'CV.PN\34L>U!"#AKIC7&KMA^(WGFNEFC4).AKXG-P4:SA=YRIEFM3CON M/2ASQ80FNVHG|M7%21 M$QW<;++#"-M?")KH?UH[;RT3M#4 ^_QTDJ6C\G&LUUV2'-BSKK>R1@:I-B8 MYEJ?1,=59:NYYEI.8PS6AMUHK44VN'<51-9Z)V./F?_(**\QIQPV;M8L/WY1 M,,E>5U)""&V'6^5G8P#"F0!#+Y$[GB:SY.%@.ML=F$L^\J*?^>C5D*7<8@7W-M7I@42?*U4]HC2-PVT1-!!]$NKKTT3+]%\4N*DD+&>XC>|ZQ=V^/Z5$P79Y0: M^QRP6AF";&3.E+6#0$.\J,1]26.T*F\[=/Y%/#/FC$8&+DZ^O0W"OI1=RC9 MF)TSUQIH@HXR7;,*&'K&\"DZ>[2?+7CQ4)#W61X#\;?;#.M]=>4[_A% $33-.=F M? $MW22$%L3;&&F4?L50]+DHO?HOP;@^$EG]A2P/JZ^A.UV()\YP$+L$4:X?R M[;DBD).DG7.FN$%9G#;LZNM,TO-[+T-6\AJK1N4$$%DB[7V1%CNIC\6#.U= MZ*5-/9(DQYQN\6S*C@B=VR X(]X<.Z#\$G^@)!+FD/>&P3#OF3.YB.LC+B*L MSZ1=HXEBECE@$K M [T.B^B&.YK9.CP=B\"M!C[+!]XL H/F]9/KZYEUCLY4..XIH:9KH@NG_<_Y ML:N>N3*WKD9D^0+B W@.O1?\LI5\6+Z'5]EY;O=I=#*HH@'B&; +G@01EI^3 M|959Y^YO$% @MMXY-F@R;(=-(B45YHJ;IU[:/H^G3'^X_^F,D_MOID51Q MD@L&Y$YV#UR+9_5V^I?((+4&V%Z1](71BVY!NUK#-KGM9UC3K-78%4P0_6G M43PV+G(/Y#R|\WSRLMF1-DBW"EK>A/T|":8SC/E%?8T|)"U/B)"P!OAGTP M1LB//6N; 1GUT7YBCN-14@U)N2%'WB?H]QQ%_DE.QF;.M \6;6O*8G5W)BBP MTO,-D>,SO*G6 /O5(\5X^<'4[3%39>*(92GU^6N.CNXWEM]6ES=C3?>8>[8@ M[? 1_5J:7GV!#P=1"5;56BJRXB-FDZ$_)!%(;]X(!HL3%+Y&%Y<,"89Q-.\=1SCB_"&SJL.*O*6O2QO1. M\Y(1]%\$CB_*&<A-(HP?5IXMG9.;E#8YZR1>#7;CS@O'$[R)].)6.:W7Y9*-1I M\F\%@[9]#(0O>9=&Y?X1.X,D;C?*P'P#(>+ MR*|>9.A3SOS3BD-_EP#:)S&%6 F$_3OS7K>?'I M&&LRMP!&V.G=8/6=/;G$AO^XJRXO84.]RBY/G-8](< M?:R|M)/@WWF:E9)^?)%%MUX8/$0WWGN8>8?*?_J0ICD*&&"IKP-#$P+CTE]"-MW(Y]D?H@$3F/'"%Z0J#5IVE]CHPSZHXT+TF\IPEBCC5T|50YYJM(D M;Z '_^V"&OR7[T]>] (HHGIKV;-8JK%ZHKJ!*XIGF&D,Y$\ E@^!=AKG$>9?=Q\NCYOVWV916;.L]* M+[344-2TZ\H?'W+M,/5!85.*\"P=S2U,5'F2R1"58!0VO>)/3!/^,#YI'* MQ%6?.\$1U7+GY=M/7D:MF:HP&\"3=M[M9G_YQ_J9[I*>]O3Y&%UZ!K".YK@(.M,[A8%6U50Y/0^6;--H:^6%-/1V=;!BJZCKH>CF:-AIG&-(##KT@]Y{&I)E-; M!+*, ^R38"O2*W[^-S:E+Z(P@9Q$,L1>,FOTB223MOEEUJ@P$@75.4HKOA<0 ME0#N0.8I=W(&Q%DC4L!4&5.(6:/$'G,5F507@?9O5YIAIUU+-Q@A6):!>46W M7A549/!>1'$&B6BX]#D_'KT$BZ8W;^112QN!<)O]&6%K(!S%/P(U$&X(BM,: M!@(88=BWS^>|_S\AHM':=GT7M&W#8%*KDK>8(/.5W[H4KV"ISMT5D5T==!'&M M481K>2174&C*L6-"D#)Q,N^%PH0%_22#=#X2MM6SUY*AD*IT/+H!$EL@6&O3 M6.0/QZTQBXC?4^<6 MD7 1T7H.1D2O46G E>)O/YLYFU}]N8L"2%%LC8YOOI_D*" QE%&*R$EMR"(W M&%_XHXU3>_;?4) ?T&;?F>)D"%L%0P.^"N*2$OW]+_S0\|5%-+OX]|_1/CV MH[2|1^H0>TT#RHT\>P(_2M.!V]VC(M:4FM8.8Z;/$C@@>'OG<@G9&K/^Z2T#OB>VO H]^PN M0GW4PQPE1(%%].X=3Z%*TD>%T_]><2ISZV71^5>MZ(PS[P#)'M')]KO[\ YY M>9RO"0+6]HBA?U#W3+S8K[S? D.!=R9R=B@Z M;"]2!AZKWBSB;P6EW2S?T(?*.1SRS=K? IFJ89O=_>\(C2AXB M_Y 'Q!F5IE@/0\',^V3R3_65+/+8L+B7#;M.LMM499?&4?!06?KGT.8Y>"2G5 M.$XW"5;27Q./R7PE)\O5(:3%Q5:\BI[@M@ASX"!4M8E4K@BX"!4?28|GPPI# ME%LRIEAQ4P+$+@)ELA+TF;ZZLNPBL#2:BXG1//=8:#4NQM18%N'W4;Z4,NK4 MBCDJYC@*WB)\8UHP1E$]%^$$4T'>*!5W$4ZP(=CL:H/Y@;KHOFS78MEOQ:YRQU"Z^%Y$WT390JZ^4!M+J*YU<*974++)HZZ6#I?>ZU-MP13D^HX1F"=>+\)7,U(CE"- /@8@_=_*4$?IE$&DP@|BVT[GJ2^LO#; M/N#1>5R..U;Q@1%HDXOP+0Y$F:06NPAGXT 4RFG+B _X#A$,_=K{OR*@VM=_MV&BP"&_C,/P-0?A,];!3Q"X1O4I0[O0]I. M&)DE$7\@&;8A-[<;:'4+K*]Q5C:X5MWD-'2C=/!HR*B^CFDG&>O3UZOZ%-MA++!,3#"]WQ===Q"/68IGK>W:1^0:%=4V_)!XI:B=-#@#=>>PH=|S_-]CF'GI M(_D/"MADP1YLT7P1?. D+;*&&\|-^<|X?!W>"_+S[#4D2)"WV3_BQY+1Q#L/ MT*YFEP%)7U&VV>^\S[*5$EW3IHZTR!7P&3ZD:8Z"VYRT72KK-I2G^A7]*YB MLPBIR9J1C7GK+CRB+69/VV"F7=54!FB(EYBEO39CF9E/G'MA0CY"/GWE_YZ' M:4CQ#TL.T]\.%-)1LYH'0P_HC|-L?6TPH)(*N2;8_FB+_K+81RA(24P4V8L7 M^6BS;VR3Z3<3S0/A;. I)VX;_TL#U0]10WB7P"0SU^3Y)B]_+Z@L<[$_I@W4R(>.0+|&"1^2S=UY1=F!QNP_T>2W*8X,O\ M)BJ/&K",9DBP O|&O&J;_=8C_)O7\HTYUMB>&HC@;Z@Y$$;PW\ XKD8]3%X(MU2)R9&3CKU!),(0IT5@3CXRJM$-7!2AM C,B4*;FK3&B2):!*Y&A2 11'8" M>^;:,3,D(%JHQT G8603I<*-_6]V,5)_1N1*1./BHE;Q'B?:9-6')1 [5%XX7 ML#-7\]'&4+9X\% (N$#O:Z2P+4:,&&S4:K4A(9C/ M<F&MRR 9.U8Z)&1,T;/Z|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|%=@3"6FG5-.;.T:@N\-Q5^"Y&+?E9>O/0&\[97%-S'M224 D)#$)[PD)_N*0&MFP.RI2/U>&3M1A? 4$F+SZ$A]DE$]'3T+K^7^P5#N MW$]RKC6XUQK<,ZK(/3,PT"LS M;\RNA176P@H3L,$U!7Y-@=P<|<4>&"I4_/.Y%O3(""084>CG'Q!(U6!%KM_ MQZJM\\)E4K4DKOX^1<<_.H* M7\&/,B2<;^N6G&S-MM;NHOTK(H5U4'#U@?_U%3TAMT7!B\#!.":=`RU"RY,G6BU51H(M+)|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|_!:I]:+@F@O<=)2,5%\(BG45D@0Q G*"HR[PS.]3]T:P(DQ-CPYXH6OON?FMYMI#,8,&-[##0RLKY'8R3|SGC.R M0& ME"77!9T;C-"ZHA)*S>RO+34.HKZRO1=@]O1#Y612KPDS3WH1&=2ZRJY$ ME.MB"&] 1;=EV9Y[1Z&GZEI\0IR:,8X36+2(&DTCB]U]10Y T?1TL=MY4H^,.M-MR)X)HU/@:(2\PJ9PO!D/3[WPQ),U''#"7D6;*E.BWA:!(F3%WG;5K+3P+ MM?#@XDE[$;S9%JN4X^"BRJ? SKG@FZDPZ1GH=O]7<*V_R M"8\7UF^BOB9(S+!KVD)"Q1>#FG'.I^]_F[+@* 1\43D..US,!') TA';;M". MF*\0\O?E(H1V]2]L_&-)17M?O!0%1/Y!45J>T&P*!QC(;/? &X>E%P%06[!QA;ITV$!H[OA_B$RA.HNZ.0G;<3"!2 TPD>X^@<5 M;_3&R7?>(MBZBPB\6]NSY=AFRJ4Z&B$";5>PJ!:OO&+VRO*%5]6BCY""U'-4KB?Q.\1M6 M|#K=Q20NI_'|39QF7^/L7RAI0G[\&H5_5)\AFX)%L? VS;?MV9Y6IV\A3Z[U MQ'86NVMU"Z6&,%CT@*>L% MX5;GT[.^-11=)..*NSQO_0D=",$1WT\6&W!H;#P5E%@C\GNJR,=Y]G%3_ M1,;]-/6;3=_$6K]JQ.5!P=$T,BZ!^?:I=;=W^$/B%H$G,? U1Z8//0"0!1(M*8!&/F47<7V=O]<=O72!]03X?Q:6?@(GIZ_<<^&A\?>,?E^DA:?7 M(D/AYWWB=^/!?WR[^P#DIRMNZZEVU1:?/1-JJ/3^.C7$1 M)T0S^K8\LQWJGWNRY.CLHWF2RUJK9[A^Z&4HJ,,%6=.,1NE=&3$[$A.KTVS M%3B@[Y"60=1N23D,\^PRV<,(U4O#?5E&,JT9QB+K]UU&UQA M0+V6M=HULM27&3A2N1LT^EN(A'4N@K/PL_,#J<3-|: M=V9XE?#PTFOP27+2M\?: <A5E."D=&U%(@DU]R%FW6A-'O_^TN MTJH,3(@1&HTCK?\?9M*6SQ>%G8X>I7YMM$OI,]6BB MKT\MA#,%%5E96 &7$'8$EWSEX!Z =AL[139$#;:|;=1MP M$3Z'-_#]3S^]B^&&O&D!PD)?=U\&IH!7/$YDI.,YJLVT6"S>@+-(9M_3\!T0 M:258AP51N/<,^Q0PH77W !.'DR-,,W;62UI_[_M?_FL6KW0;]@D>X^X'H;ZYDE?4P>?EK MT)-JHGS >QEUD'E)!BJ2>?KLJ=DFM"ZN)-8DY.ME+1,&$ZXE,,8R&AV'Ol;* ML/"Z4L-"%%NO]:5<(O0!\2C:DT7_T>)Z0B|F"$B6;C"%>:QS Y=W4T%VM-MZ' M-D&IL-D<&(S ^?/1,;5I+.;HILL1],h]TUCYN=D-.:2\2H#VS>P3EPCTIT+@MOIP&+OY&4CO/):+5*-MK-JNEM24^FP67AG>H@#'XF-K1?*B(CFEB<=55,;-K17*R_VN%2AY^)+[M;NG6F_TVB? VLS//AN@#] TU'=WSPU%M5S<6OO.B]=D9WK52W<,ZCB110#O?)0V-\/#F86\\TG:K5[Y[V2%#5W4S<6B9N+1/G M%O)=8SI=U\M:*VXLM]%! 6NMN.G'"W6[V=;B310AG#CA&0-D# A-<,?TCU5]F0;*6,X>[D3F$MY M+7 (\@S5?,]FZAZRA5@7DCR[SY;/F9UX9P5!]8_NW M- =\11+YCS3^X^;CM0589#+77U5@60UMTVMOL??)O<^MWJP?0D#;'(]ZYF%6H M2F5H/$#5.K-_@!\;[.L!&.YD?.^-(;+*Z]L]ZJ7I4YL*4_8 /Z$#'.#.84CO+A;&- [__)}@/1W;)0H^O"M=0BK7EC@#,$=".QUI:6DGED M7%;__E^:TU5 !X(/1:>Z%=%$$@0P#4@W5N5]/"8R% ^;S (UR'IG()Y@M;J4] M4LN(|->$5N9WG$69.#' Y)>@Q)14ZP1P9",]DB0^YRQ!6;N#WW^>!=(Z.G75019M ML4B@O;:SXM?AHI=9.DJFN(86%&O<@;MH;BAK-G&MN@VX")\#V_C^-R//?$\U MD&\ 7=[%SIZ?$"DHAV&YB:- "#,Z]PPXE1^,/#/]D&X M)8U%I9SQZ3Q=X!+ "]D[S3,*X@+B=*"=T%HJ]#>F" (3D?0Y\$72|\V%D]W/ MBEZEV$2 VJR?&WLZ]2+"W9QE>E@;-EB%=[9/DPV]?Q%A>/ %;-7SFB!TSP4' M.?G','*'M=F7=31[8^\^R1^1DW[SP836B_30915]"U*OO.Y5U+;^ M6C4306G<$WY1L&3RAA_W6_2!#O$[V5C%6*A%'%5F6@/K%Q3AM_N |W85'+%H M0M'D9_CRX+QU.^;VC4 B:9#D3;>F%"XB?*_ "BJFL0>N8SSF:K](@2%RO/OT M#SG0?X]2"O.5ZRI\W^SDN(>3_=HJ1\3$_T!3B&/Y-?M&@]*63OD>)^X] MI@S4?';?HIO\A3R;Z>/C#?OBTH.!0- \;R_%B@KQ.%V?FK]PB$IA 6M-]AY' MD;>#,\$>$ B+SX4#$(LL!|[3@C[6VM8$YXMI%IA-8=]766$SW+(53N,8;Q3[T M0R(9ET(#_]64@?9>2=]/N.8XV'H@7RA?J+"K) 4 M8UFI_!Q+09>/9VT'U1T=9ZHF%!Z;KECA%0ZUWMJMRXY! R(-8TS;Z)] LQ M,:MK$FUC?1^YBV!D8MVDB2:&$K (3 W2(EK(8\A>B|"><6/"3 M>1=_5^- L-.UTF6AB7DR5%U9KU]4$]. -2&,>4L$QL,0F-AU<3"*2 TPD>X^@<5 M;']XBUZR^,B6"30/$9;4Y4 ?LT8XV'4XN1T#* MU+ZMO(.]VDB+%=]HT/W4.*PM=U5+]4.?XCW(E#'PMDZEYN81ML3-; ,&V:WGA\>0D& M"76HYE?@,?8B+*E45I73U6N"BM>?S?\%,[0'KYW\-^3_MDWB#!7:*?[3:^+1 M>974%(M1(]%K38]"X 3]4" TRV$5E(6-HT/W4."]XU^8&I_2$J /9=T M& ,J9Q$05_W9(TDI5Q]>>" BUGV TD&8#4,KK?X@:ZSU_>Q=?H-O%^ M=(4$F1E >_,F'71UC'-FC!5SN&8$?XM\[T"JGA2K4Q\#]CA[K^_!2]/-OM): M-\D3]=-2MQ*J4.1- L>7K4S4NK08RG^]1|)"1ZOVT_G'1\Y_4D&"<'T@U^]+ MEQ

*7MJUA4VFS\$YL=2LF^QI'/9:V,P1:EG_@=)=EIBU6]-MHKPGYHCOA+-\12P0N%-LBG'O7AC$)"*%@R;_;<4%4J[%#C=.3!L$C*V"*OO<'[,#\2\5[R@))8C06\D&>@#*

*MD0B'(WJ.TQ2S\LU^YWVR7V2E54"\S?SSH8Y$H/"(=1J+5YB$A+.+(4'-2(-_*X?!&1CA. (65W5NV//0-MB]&8#_3*#X%$ (CCV!&_"8*($4=K$BH_"IUH$\?!EG\,5"-7'$>,&J^D!KK, M!P-C#(S,XT&"_](#<1RM4JK,&F2">1S'A1HW$ 4"S0<9RHR!&U;D.%YDK<[. M5N]5Y@RTT S'85>4"RC!4O-!@/+M9Q"_H[6WW# M5';59V^8Y/|-W,;3P]=9ZTI,ON[$#(H"2-+U0YKF0`)&M088$$G:2*U\2M^Q. MNR,6@G!2[N0KM\.'L'7RQ28KF[*U0!.UN4%(4)&8!(3@8"7%EBA7AF"B;! H,!+ MX#@30 $AY@*B61!QO"4a>3 MD$U@I=UN0Z\.G_4$TIF.-ZD6.4@S.QQ-,BR34%\&F0LN%LV"TSNLZ'X\=Q M)LU"^+& D+&@X>Y0[>"S+IPT+L#2<=3(&7>E@S4745QJ<'BGXIB19[*L -!% M5-X;&$"ZB'IKBW1%&3GO;1)_*

MA)C>KD_?,&4\1!M\E;PLC%ZK4,,0I5/Z'[[3[!P\=W'R5D6>B2BPKDK+P,78U:$43B+,/+QD1T0YD<75_8NUB-8 M&_F4/9Y B2NNP$2+(9 'PSMX:)XJ&BSP.D&EWY?ISC M&*

*[,U3D7[]E10+6)!Y&2+P)79*2+UH#W*>C# +K|R?J,+M$%@9H0F.P%MYGT8#^2|?[B-MBD<>8_+I;|B-'4>,VJY;,4%K!W,+7I/D!\&6+!?+)5=`4N;M#QZ[YLW0*

*MYO(M"E"R>Y,NT*QK55@\+)%Q:\FK-MAGO P(26GJQC-:.%WR_^0R?\@'!TUSH5C*1IO;-.Z_PB4AZ%;<'67/AM#@79O]-M6?;PE.>UAG4@2QK[,T#O!K4C%WR\RT^!(4# MLWA-@S+-#!^\Z)VSL.L^^QMF_4*$U.GF^Y'1[!PX+MZC045HWZ'QA\.7!/.(8 MY1>T9&I'SA,W<#'KTG15)6@7M_-J[^-$R4(W>#EH+R%6#HZT,$>D+!X840. MPYNHC.!J.3PB?*

4ERLL6F1.,GH-W'.'K=H>1XBUY8X#"'0R-!BO5WM/G847VB M3)#=LY95OX%,%WI"/>1/%6E" 5'?Q)H@_NC@T"8<5EN"D) ,<<1HQX>UTH?&\AW MYCC25"+,.NCJ!70YCHKA,.:7C4J/!*

*(F2F>2B#*4$BTHM9^%4N=`HTWM9D%9D[-MHRGRJE5L:DSP$F1\0DI]-4M1)F.V6AAD&% <1]_PX"<6+V=$$T',,3.M5G!? M1L<1HUNMH,=L.8ZDX6I$)^K+*

<3SHT2',L/QYHE95)>+VW,<5$JET"'1@XZC-M;RJ1BQNKZ#@.Q\E=V]{E(3>(,"V5<7'M.&(,2&6]|%/'4:1'%E%|]#P1-E;" MX 3^.HXP[6+&\,ACQS$YE<2A'MSL.&+UFW],]W*

#5T!Z9(BUXSC2+6CT8K(= MQX^>1U.ET-MQA\GP$/5"R!W"T53/H7PLN^,(:?0.]B/C'>\BHO;3^J6G1!/-MJB8? 2_X\B;C+L-S!AP'+V:>-W@C/.'F^->)!M5*.?2<1\6XUT E9<-Q1$W%

MT6031!Q'IQX.QDXX643[RO$BBN-HTD-%*ED_CK?^U(.PJ3.(:*SL/."H]!ID M,_RF72CL79M'RTM7-C1AEP-CC;,7I$UZJK]68G#ALO(N_]+H3G'N)$T%2W45 MS?

*5_+H%0=2S%U6N"BH!3MRTYR=JA/#:FWT#]9QBKO2QRZ*G[_@=\/\+#FAC[M5J2I'-!,!NLX] -ORCGT0(+!@<:05'86EQ.V3(>]V'0$-Q5CFQ0Y9W8*&DD.*

M<[$8B'104;E8!0IW5Z]#=#&'\0\XZ0K5 -Q!_?;HJ0S:12]TH?HR?F%[ZH[_MAH%; F@BE@<'5E+2M#Q9%3=]N9?0X%5O>X=MU?6 75}.+ 2!S<6Q1XI4WAIQ!'V\B/0BY/=1-*

O$IB_:%\ZRM9#^.'MJU1F-;$VP/68ERV&?XNF2,)C= MQ19;Y92$6*HK@-+)^52_HMND{]A>6;4DO81;R\"NZM#RAZ/Z>N]8:;6)LR[]C3PZ$K+?)&(:LX%=& MB)P[8D>\S6U#94_"

*HTY*5L45083%R09BUU'$,JZ<6R5J'?\=P'T_2K?6]PT%#^A/_G^\5;ODE>\|>0_ZL(6 M7TG90XRIZSS%*$W3JR (2X >HGV<'(MQMRCSPH-%0[J3L3UG*KR)#WB?.8FF*

*M_4!|#Y7/^+GIKJ*S>FO[D%V#)2DH@H+;/ FCU_(:%A>WI8&WV.OX[_8'V M-DTI#DW?='^@WDYG2=;8,/L:9;/X+]^; ?=O(G>H]0U3R4(PV.5- MVWCXBHN@&M*J+|_YH4$BS=+!-U2U\/2W|EJ -%ETBS)RR0XO(V4 M_A,>5H_H=F% ^!A[4;&MXO.$B'A@AF37?R8>^H/<'VJE1I;PGSRC+4;]W @>9_5N+0:R.P3/7)5 M"'1./.SO.0"V;3I'_Y!?XXS\"%);]Q7^X;!/_Y7LA\)]*

*(^8#DO3 FQM$M?MXV M^]8_=;;M,,%F= ^%S?R@JSAL#+/;]+%O.W'E)A-^C|,KW\V->%$*Y17O\1K&[M5@HG0NM?":]%*H//4G+*BVY2M-+U?*

*2:L,%OSOG]),!DWJX9M]EC6P:BB;9,] M&$0K<$;;%]8=%LP# 5*SE*D0CL9@=R,-Y?)"#3C5(?-Z"L*)>E8!!@1L:II*QS(R0H9L0F#-?GL%*1*

M(\A1W.GYIVL'1O4G@89\;=\LAP!SZI5Z$+K-7,$=-3S.;0EW;0#M.;DINH-Z MFP? /"O7TU7DJL.R/6.0Z^L@ADU/D@N%&1QUQL G0/R_UT!R^D/(S&PFIY*

MRK'K26MRO'-L!]UQ+"GS9/W2Q?@0.Z7A.;B>OXBIY*I!$M 1@14R@3P_X "O$*E1&5$UPDS;B&TY!+0SSGQZ.7G+" 'KY&(6;\6-7# M;P%I2$@"AK",!). T4"%"%:DO=2&>]?*

5BKM77$)WKH#4YVG5'92GVPM9+_OM M%66 KD]E\ @]DX@U&L+VB]WP$[CI@UW>)(#4I#5]?MIV.T$L+@E-'6HOR_G, M]/ C'05>$J3?WHG1]B__^=-?__O_!8[4G.M@7;M'8@L]?

R&$%,HRT)4'/]) M' X*. XUYDR8 Q"&&*H@BWKS(T))^A:,*,XLV=$?!NJR82N1W+24/U@U!^BYU\ MR!YLC\5<&N7>Q(\E7!,A:"58:,|Q:1\%58#4UG#U&; O,6P3],Z%0=&//D7$

M++$A.L\-Z4B/)>0T11F_[9K"-A8EC*CH9$I:F]|@LHJ/"EVQFZZR)UB#9"Z MPW'MH"<249B5Y1UO\#O\&A.5A^A?]8B <|>&K@80?,9VN>_.T-66#;[E-YE1*

MK]KJ.VQQP3[3GT'1E2>4(@\3)GYO;M$',L3O16S?O8O%?,1D9X.Q1@@48\;H MA1,"]+M_/N&CC7)6L=?N,W(VN192H1D+++!6QU,>#3DD-@8E9FG>YO8E/B9X*

MIQ4+ISOO\QI%:!|FN_@:U<&&2.^VC<)$ZT10.Y>^.M,"4FB/M,;UNE3,;DINH-Z MFP? /"O7TU7DJL.R/6.0Z^L@ADU/D@N%&1QUQL G0/R_UT!R^D/(S&PFIY*

MRK'K26MRO'-L!]UQ+"GS9/W2Q?@0.Z7A.;B>OXBIY*I!$M 1@14R@3P_X "O$*E1&5$UPDS;B&TY!+0SSGQZ.7G+" 'KY&(6;\6-7# M;P%I2$@"AK",!). T4"%"%:DO=2&>]?*

5BKM77$)WKH#4YVG5'92GVPM9+_OM M%66 KD]E\ @]DX@U&L+VB]WP$[CI@UW>)(#4I#5]?MIV.T$L+@E-'6HOR_G, M]/ C'05>$J3?WHG1]B__^=-?__O_!8[4G.M@7;M'8@L]?

*R&$%,HRT)4'/]) M' X*. XUYDR8 Q"&&*H@BWKS(T))^A:,*,XLV=$?!NJR82N1W+24/U@U!^BYU\ MR!YLC\5<&N7>Q(\E7!,A:"58:,|Q:1\%58#4UG#U&; O,6P3].

F>L,..SU+:U>.W?!0&-W/H3>M:V:)#'NL2F>):Y/I3^.(M=M[""M&?I$L">;^H9?|_3I^9NH7SIGCF9N\S6.;N(§,Y#WN)"@2M-1\4TVYQ%/TKS+ M4M KDASP$|+-$Y+MD.WBW1NZ2]_?V3N5FVB[SB1I(EM&#SWG+_]&/M[@%RS0 MD@^>GE" CF*:'{2E%NAZ!;I%W]#*9Z8*5.V,_7_E!@*$O)=8D M_T'&,"!S]=IJ1@__Y(CHCMIEQV!!

((/4[:HD=_*Y*Z!B0,I%,H$12H7$\.VO(MW1FD$CF>OJ6!QZAA J@? Q!UBG|/2=F,CZ+8#<3,1U-BIP.S.'VS&CM'7%-_M_[2AD|,;WH49D?\>\,/Q$0:Y=V T<:"4[O57_$5*/JO8:I-W\+W77R'+$ DO=II./^0%>8-'H"N'I> HH MMT\ )433+F!=+35R/ & V66W>PG<'4\?:?XN!)9,) M"_+F+4J!NT^LDQ<++=+/?ASY*F#R"-)HVQYA)6PGN8WBMMJAC2AZ_ME+@.,%]6 M@5_#V'3!.+9>LDD*EA+|\TSODJ/9?B#49YDS=46\)(M7*4! MMV5+9#.H(36]%X4TB93>%X ME1O#M.:."QL':,$<-$WQK*X^#NM);0D.K'+$!U5$,S*AKSF)+0BR@79#ZRT9O M"" (PC()&P5K/0CX.EA.Q(7C1',@7Q>?F |,,.;Ŧ -6 [*]"K)/Q"K/H\914* M!9&(849W% /SZ:EC0B2Z=@%P_0_%].T%)PS9'V@48#M)',>"]C>6 @-Z_M M8D50-&?"#(W1@H&='@>3=U)29I?3%#6;,'%%R>/ !O9!QH)6'1<52C>IZ-" M!3(.4\?3<53007>U:MY*:2@]M%RV&C.1?._@YZ7&3WYNH4AK*MC3_I%&MX_O MPA3+GA_"@(D&U!Z!D)/SS&T(9+0FIL5?J.5).*VT>%]!9S'>52O-CF?3T MIQ!OB7Y85VF*,NK1E+_*DO=IL?13F!0C\1$N?D\#2+M+;=_RW8?#_MDGVAH* ZZU&W]BK+-?N=!.@/|8^B]D#:6O#,3!7*X:,QQ$4X! M2*{1;^?

6421N+WW#9TO^0\[T S^=1//,.K"4?0[CUT+Y=`;|+4NMD+#TY$#Q-@P^R(RNQU+#1DF,)1V#?YLD-P4_ER M'+W6363)3>X0+73HS#$K&H4X@A0Y=G6+]@C_&#PAK!

(X=)'9XC'67-Y1DIVV M6*#/\(4EQ_9.;B\6&IN62M#@24K+YT(*6R\,']{:[SW,, 2N0#F$&^NZZ^ZA MB&JGP*3ND??H$7DIJ@>?*#P<.J!"^?]+E_R&BD.]^+6=@4Y:=DQR%+2O1:$'

MTW1!Z#*[5670!4ODSA5)_!@Z7'}_:M7+2I&2H4.HO(L8N"?\XMOJ$N-H3>! M#|(<965*Q*Y!R+EZK0>C\/MM|M25,QH.FE PR=W!9]{2:D(!75YQX9Q$8N] MH1^Z_[:|H;)D^V-KF>\9SZJZ[HVR68>!8QJE[YTZQOVE8=F\ZJV&,ME?'0VRT M!0(BGZ?OL:(.9^D//%FVHS4=+QN3*>L.DYMHC.[!5E4Y:U+$6.17%>,I@4/V1 M-K=-,XNR-DX9^^(=%NA&E)%

6&G/G"G:1KMS+'9/$ULKJ?!(3 1R/GV+1,H[M1R&V*LRX$TAL+<[XTO*@V'GZ3"R[R6FSO\|S_(}5F8HV>%@!*D3RJO_!7R#$ M'C,.8(3)&7K8VR/"EQ\Q@#D?44Y-(^+._18%F"B{JHLOZ*>/A]:MO!S!S'A: M<#"@; PY,!$V#':K?%]-08/;OJ}GV]13)'XNO*9[']28 +(9!C|TS+6@$:I> MU1^N5(15AZQ?4J1:)N>D1^^$]-,29ZN0{0\1SYT6GE

R$)!@U=1|Z-.U+ M]A"E69(38+Y%W!%X&O[.@GA%AUCK.X,YL1F*VA_.@3S,50"NG8M=<0 M#3*.MFO3T*Q 5PPCM/P*0,#L4I($7)TI<'DB/QGU.&NZV5>< ^*#RTA#4-

M('|"3"> 7B IZB&"\#!/R5T=4G>;6.7)]$VY'(#OOO3(W4@%\0BG"BY* @5OT M@0YQX>BI9K@'*I*1AQY3T67KW6 *5LB)^@P\Z_HC4\M1NFQ((S5@>I6_H+ MBO"H

P;Q*CB&48B?/H_40.5>4^C RIUD%Z[_*|+H-'(+]49V!)?V5>LQ >VT M|$W^]0#]6K(0HJ21|K?=O;^L39_'670Z<=]+)P1+2R'<CC6006>1=

M%2[&8&N,%SYD5"A$LZR?!7_[W5%ST%!;8?;DTH!25"E) -TT@DZQ!]9P)4D: MO!;! 517\016$L:W*$'>@1B?_B<^D,.|XH41(9Q-= D)NTK"%/|TB_^*-X*2 M.

ZNT3Y.D$MEG_01WZ@D=^BZP 2T2#%'(@31)2U!,/ZR;.0,B&"-$L[&K0D2' MQHP7W5^Q&[EJYN&@*V3&ON>;G@|,")4HW-F21+WT[?X0_X E@>([2#:&$?X1 M!J0+QS<,PD-TM@)<^5B!859X<=^P@#X/HR\R)-](O'(=#P_1'^:N M8CQ4$1&{^_K_/0\3Q"V_U_?EQTWC#$^830DH8^O:96GVOZ'QLB2K6*FG)#P MEUM4_O?]J-U]^F^DRO\39@5W^SWRJ2*@RCUTF\

(D64M1Y?W:*QAJL\RU(UK# M,#93-<40\)AO^*4A@4AWQ_=#?;$*H["22)YC.4D22X5S'DBP3.B"'*%/('E_2+ MEQ'F<]KLN0P).E[\B/JR3B"U"\Z!9A.=P/R_U&P549HM1F2M"+GNF3?

0]6 MLRE@2^O&+8'K>!@]^S#SD =[AE>&PZ5-M\E,DN"P.P&;[*<;A@"[_MLXM#0A MW^S/Y'$3IT7EB#IB]$(ET*NGC63*%3,JNI.B8!?OO$_2K?2MM G=QXE D/XO

MZ*QI)+GXF!L5FVW1S9E,,E4P<5IR?X+;#8;(CF)G:%/.G^D=]+UO)

P!R86YI+65X,S)?,2YH=&U0 52P4& 8 !@!R 0 8ZP# end XML 80 rani-20240930_htm.xml IDEA: XBRL DOCUMENT 0001856725 us-gaap:AvailableforsaleSecuritiesMember 2023-01-012023-12-31 0001856725 us-gaap:NoncontrollingInterestMember 2024-04-012024-06-30 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001856725 us-gaap:NoncontrollingInterestMember 2024-01-012024-03-31 0001856725 us-gaap:CommonClassAMemberrani:RegistrationRightsAgreementMember 2022-01-012022-12-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-04-012024-06-30 0001856725 us-gaap:StockOptionMember 2023-01-012023-12-31 0001856725 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001856725 2024-03-31 0001856725 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001856725 rani:LoanAndSecurityAgreementMember 2024-09-30 0001856725 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001856725 srt:MaximumMember 2024-09-30 0001856725 rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassAMember 2023-12-31 0001856725 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001856725 us-gaap:ResearchAndDevelopmentArrangementMember 2023-12-31 0001856725 rani:LoanAndSecurityAgreementMember 2022-08-31 0001856725 rani:SeriesACommonWarrantsMemberus-gaap:SubsequentEventMember 2024-10-31 0001856725 us-gaap:ResearchAndDevelopmentArrangementMember 2024-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2023-09-30 0001856725 us-gaap:CashAndCashEquivalentsMember 2024-01-012024-09-30 0001856725 rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember 2023-01-012023-12-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-09-30 0001856725 srt:MinimumMemberrani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember 2021-08-012021-08-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-04-012023-06-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001856725 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 us-gaap:SubsequentEventMember 2023-11-012024-12-31 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-06-30 0001856725 us-gaap:RetainedEarningsMember 2024-06-30 0001856725 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001856725 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember 2023-12-31 0001856725 us-gaap:RestrictedStockMember 2024-01-012024-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001856725 us-gaap:RetainedEarningsMember 2023-06-30 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CommercialPaperMember 2023-12-31 0001856725 rani:RaniLLCMember 2023-11-012023-11-30 0001856725 us-gaap:CommonClassBMember 2023-12-31 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 srt:MaximumMember 2022-08-012022-08-31 0001856725 us-gaap:CommonClassAMemberrani:SeriesACommonWarrantsMemberus-gaap:SubsequentEventMember 2024-10-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-09-30 0001856725 us-gaap:SubsequentEventMember 2024-10-012024-10-31 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001856725 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0001856725 srt:MinimumMemberrani:PairedInterestMember 2024-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2023-03-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-06-30 0001856725 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001856725 srt:ScenarioForecastMemberus-gaap:CommonClassBMember 2024-11-11 0001856725 us-gaap:WarrantMember 2024-07-31 0001856725 us-gaap:SeriesAMemberus-gaap:WarrantMember 2024-07-012024-07-31 0001856725 rani:SecuritiesPurchaseAgreementMember 2024-09-30 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 2024-07-012024-07-31 0001856725 rani:SecuritiesPurchaseAgreementMemberus-gaap:CommonClassAMember 2024-07-31 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001856725 us-gaap:RetainedEarningsMember 2024-03-31 0001856725 us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember 2023-01-012023-09-30 0001856725 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-01-012024-03-31 0001856725 us-gaap:CommonClassAMember 2024-07-31 0001856725 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 rani:InCubeLabsLLCMember 2023-01-012023-09-30 0001856725 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001856725 us-gaap:SeriesAMemberus-gaap:WarrantMember 2024-09-30 0001856725 rani:ContinuingLlcOwnersMember 2024-01-012024-09-30 0001856725 2024-01-012024-09-30 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 srt:ParentCompanyMemberus-gaap:CommonClassAMember 2023-01-012023-09-30 0001856725 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001856725 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001856725 us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember 2024-07-012024-09-30 0001856725 us-gaap:CashAndCashEquivalentsMember 2023-01-012023-12-31 0001856725 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001856725 rani:NonCorrespondingClassAUnitsMember 2024-01-012024-09-30 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember 2023-01-012023-12-31 0001856725 us-gaap:CommonClassAMemberus-gaap:WarrantMember 2024-07-31 0001856725 rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember 2023-12-31 0001856725 us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember 2023-01-012023-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001856725 rani:SharesIssuablePursuantToTheEsppMember 2024-01-012024-09-30 0001856725 us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember 2023-07-012023-09-30 0001856725 us-gaap:CommonClassCMember 2024-09-30 0001856725 us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember 2023-07-012023-09-30 0001856725 srt:MinimumMemberrani:RaniManagementServiceAndInCubeLabsLlcMember 2024-03-31 0001856725 us-gaap:RetainedEarningsMember 2022-12-31 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001856725 us-gaap:StockOptionMember 2024-01-012024-09-30 0001856725 2023-12-31 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-12-31 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasurySecuritiesMember 2023-01-012023-12-31 0001856725 2023-04-012023-06-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2022-12-31 0001856725 us-gaap:SeriesBMemberus-gaap:WarrantMember 2024-09-30 0001856725 rani:NonCorrespondingClassAUnitsMember 2023-01-012023-09-30 0001856725 us-gaap:RetainedEarningsMember 2023-03-31 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 us-gaap:CommonClassAMemberrani:SeriesBCommonWarrantsMemberus-gaap:SubsequentEventMember 2024-10-31 0001856725 rani:TaxReceivableAgreementMember 2023-01-012023-09-30 0001856725 srt:ScenarioForecastMemberus-gaap:CommonClassAMember 2024-11-11 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember 2024-01-012024-09-30 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 2024-06-30 0001856725 us-gaap:NoncontrollingInterestMember 2022-12-31 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-03-31 0001856725 us-gaap:RestrictedStockMember 2023-12-31 0001856725 us-gaap:CommonClassAMember 2022-08-012022-08-31 0001856725 2024-01-012024-03-31 0001856725 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0001856725 2024-09-30 0001856725 2022-12-31 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-07-012024-09-30 0001856725 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember 2023-12-31 0001856725 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001856725 2023-03-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0001856725 rani:RaniLLCMemberus-gaap:CommonClassAMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-09-30 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001856725 rani:RaniLLCMemberrani:OutstandingCapitalClassAUnitMember 2024-01-012024-09-30 0001856725 rani:RaniLLCMember 2024-02-01 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember 2023-12-31 0001856725 rani:SecuritiesPurchaseAgreementMemberus-gaap:CommonClassAMember 2024-07-012024-07-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-03-31 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CommercialPaperMember 2023-01-012023-12-31 0001856725 2023-06-30 0001856725 us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassCMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001856725 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001856725 us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassAMember 2024-01-012024-09-30 0001856725 rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2023-01-012023-12-31 0001856725 srt:MinimumMembersrt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMember 2023-11-012024-12-31 0001856725 2022-08-31 0001856725 us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0001856725 srt:MinimumMember 2022-08-012022-08-31 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2022-12-31 0001856725 rani:RaniLLCMemberus-gaap:CommonClassAMember 2023-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001856725 2023-01-012023-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2024-06-30 0001856725 2023-01-012023-03-31 0001856725 us-gaap:ResearchAndDevelopmentArrangementMember 2024-01-012024-09-30 0001856725 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001856725 us-gaap:ResearchAndDevelopmentArrangementMember 2024-08-012024-08-31 0001856725 us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember 2024-07-012024-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2023-01-012023-03-31 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001856725 srt:MaximumMembersrt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMember 2023-11-012024-12-31 0001856725 rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001856725 rani:RestrictedStockAwardsMember 2024-01-012024-09-30 0001856725 rani:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-06-30 0001856725 us-gaap:SeriesAMemberus-gaap:WarrantMember 2024-07-31 0001856725 us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001856725 us-gaap:RestrictedStockMember 2024-09-30 0001856725 rani:InCubeLabsLLCMember 2024-01-012024-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-04-012023-06-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-07-012023-09-30 0001856725 rani:RaniLLCMemberus-gaap:CommonClassAMember 2024-09-30 0001856725 2024-04-012024-06-30 0001856725 us-gaap:SeriesBMemberus-gaap:WarrantMember 2024-07-31 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001856725 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001856725 srt:MaximumMemberrani:RaniManagementServiceAndInCubeLabsLlcMember 2024-03-31 0001856725 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001856725 us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember 2024-01-012024-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2022-12-31 0001856725 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001856725 srt:ScenarioPreviouslyReportedMember 2024-09-30 0001856725 srt:MaximumMemberrani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember 2022-08-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-12-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-03-31 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-06-30 0001856725 2024-07-012024-09-30 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-06-30 0001856725 us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember 2023-01-012023-09-30 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-03-31 0001856725 rani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember 2022-08-31 0001856725 rani:RaniLLCMembersrt:MaximumMember 2024-03-31 0001856725 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 us-gaap:RetainedEarningsMember 2023-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-03-31 0001856725 rani:InCubeLabsLLCMember 2024-07-012024-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-09-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-03-31 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-01-012023-03-31 0001856725 us-gaap:RetainedEarningsMember 2023-12-31 0001856725 us-gaap:StockOptionMember 2023-01-012023-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001856725 us-gaap:CommonClassAMember

2023-01-012023-09-30 0001856725 2023-09-30 0001856725 us-gaap:StockOptionMember 2023-12-31 0001856725 rani:CashCashEquivalentsAndRestrictedCashEquivalentsMember 2024-09-30 0001856725 rani:RaniLLCMember 2024-02-012024-02-01 0001856725 us-gaap:CommonClassAMember 2024-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2023-04-012023-06-30 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001856725 us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember 2024-01-012024-09-30 0001856725 srt:ParentCompanyMemberus-gaap:CommonClassAMember 2024-01-012024-09-30 0001856725 us-gaap:RetainedEarningsMember 2024-09-30 0001856725 2023-07-012023-09-30 0001856725 us-gaap:SeriesBMemberus-gaap:CommonClassAMemberus-gaap:WarrantMember 2024-07-31 0001856725 srt:ScenarioPreviouslyReportedMemberrani:OrganizationalTransactionsMember 2024-09-30 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-06-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001856725 us-gaap:RestrictedStockMember 2024-01-012024-09-30 0001856725 rani:LoanAndSecurityAgreementMember 2022-08-012022-08-31 0001856725 2023-01-012023-12-31 0001856725 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001856725 us-gaap:StockOptionMember 2024-09-30 0001856725 rani:RaniLLCMembersrt:MinimumMember 2024-03-31 0001856725 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-12-31 0001856725 us-gaap:NoncontrollingInterestMember 2023-12-31 0001856725 srt:ScenarioForecastMemberus-gaap:CommonClassCMember 2024-11-11 0001856725 rani:SharesIssuablePursuantToTheEsppMember 2023-01-012023-09-30 0001856725 us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2023-01-012023-12-31 0001856725 rani:RestrictedCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001856725 rani:RaniLLCMember 2023-11-30 0001856725 rani:TaxReceivableAgreementMember 2024-01-012024-09-30 0001856725 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 rani:PreFundedWarrantMemberus-gaap:SubsequentEventMember 2024-10-31 0001856725 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001856725 us-gaap:SeriesAMemberus-gaap:CommonClassAMemberus-gaap:WarrantMember 2024-07-31 0001856725 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DomesticCorporateDebtSecuritiesMember 2023-12-31 0001856725 rani:PairedInterestsMember 2023-01-012023-09-30 0001856725 rani:RaniLLCMemberrani:OrganizationalTransactionsMemberus-gaap:CommonClassAMember 2024-09-30 0001856725 us-gaap:NoncontrollingInterestMember 2023-06-30 0001856725 us-gaap:NoncontrollingInterestMember 2024-03-31 0001856725 us-gaap:StockOptionMember 2024-01-012024-09-30 0001856725 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001856725 rani:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2024-09-30 0001856725 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001856725 rani:LoanAndSecurityAgreementMemberus-gaap:CommonClassAMember 2022-08-31 0001856725 rani:RaniLLCMember 2024-09-30 0001856725 us-gaap:SubsequentEventMember 2024-10-31 0001856725 us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasurySecuritiesMember 2024-01-012024-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2023-01-012023-03-31 0001856725 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-09-30 0001856725 rani:AccumulatedOtherComprehensiveLossMember 2024-04-012024-06-30 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001856725 rani:InCubeLabsLLCMember 2023-07-012023-09-30 0001856725 srt:ScenarioPreviouslyReportedMember 2023-09-30 0001856725 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001856725 us-gaap:NoncontrollingInterestMember 2024-09-30 0001856725 us-gaap:CommonClassBMember 2024-09-30 0001856725 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001856725 us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-10-31 0001856725 rani:PairedInterestsMember 2024-01-012024-09-30 pure utr:sqft shares iso4217:USD shares iso4217:USDfalse0001856725--12-31Q3 2021-04-0610-Qtrue2024-09-302024false001-40672RANI THERAPEUTICS HOLDINGS, INC.DE86-31147892051 Ringwood AvenueSan JoseCA95131408457-3700Class A common stock, par value $0.0001 per shareRANINASDAQYesYesNon-accelerated
Filertruetruefalsefalse333115432397713904277000586400026127000426750001967000230800032371000508470005496000610500054270007180002460002460004354000012000-93960000-
728890003120000128660002655000125770005775000254430004354000057916000617200011220000198720003201800056270006635000184840002064700011799000178551179900017855000-38356000-52665000441400039000140300026260001337000131600039090003789000-12722000-18332000-40862000-53828000-5939000-9135000-19791000-26956000-6783000-9197000-21071000-26872000-0.24-0.24-0.36-0.36-0.78-0.78-1.06-1.06288360002883600025552000255520002707100027071000253800002538000-12722000-18332000-40862000-53828000024000450003700064000-12698000-18287000-40825000-53764000-5928000-9113000-19774000-26924000-6770000-9174000-21051000-26840000260360003000241160002000857620000-12000-728890001257700025443000175000830004500045000196900019010000387000-7483000-7296000-14779000100010002629400030002411600020008777600011000-803720007137000145350001100002210002210002810008500014000140000-10800010800021090002020000412900068050006556000-133610006000600012000264890003000241160002000900120005000-871770002715000555000011170002800000888300088830004470007100010001000-401000040100002183000185800040410006783000-5939000-12722000130001100024000298070003000241160002000970670008000-939600002655000575000252950003000241160002000758420007300038919000371490007400400081000-1240000-12400098000-9800022020002213000441500083720008460000-168320006300063000126000253760003000241160002000780180001000047291000308670006158900063000219000219000780000-9000-9000-540005400025720002569000514100093030009361000-18664000-53000-54000-10700025517000300024116000200080746000-63000-56594000240750004816900031900029000-29000420001590001590002000-6000-6000-12000251000024680004978000-9197000-9135000-18332000022000230004500025876000300024116000200083380000-41000-65791000172660003481900040862000-53828000120400001452200076200059500013320007800001740001740009400001851000-650000-341000660009180006800061000162800060000000-1332000-780000-26841000-387580005725000081500003972500063852000237000106200017288000165860001117000888300002210002190009900080000510000380001620001250000079660001370001587000-22035000636400027507000477700054720004731000058900057800029800016900029000188000025000000 1. Organization and Nature of Business Description of Business Rani Therapeutics Holdings, Inc. (“Rani Holdings”, and together with its consolidated subsidiary, the “Company”) is a clinical-stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company’s technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The Company is advancing a portfolio of oral therapeutics using the RaniPill capsule. The Company is headquartered in San Jose, California and operates in one segment. Organization Rani Holdings was formed as a Delaware corporation in April 2021 for the purpose of facilitating an initial public offering (“IPO”) of its Class A common stock. In connection with the IPO, the Company effected a series of organizational transactions (the “Organizational Transactions”), which, together with the IPO, were completed in August 2021, that resulted in the Company becoming the ultimate parent company of Rani Therapeutics, LLC (“Rani LLC”). The Company operates its business through Rani LLC. As part of the Organizational Transactions, the Company entered into a Registration Rights Agreement with certain individuals and entities that continued to hold economic nonvoting Class A units of Rani LLC (“Class A Units”), collectively referred to herein as the “Continuing LLC Owners”. The Continuing LLC Owners are entitled to exchange, subject to the terms of the Fifth Amended and Restated Limited Liability Company Agreement of Rani LLC (the “Rani LLC Agreement”), the Class A Units they hold in Rani LLC, together with the shares they hold of the Company Class B common stock (together referred to as a “Paired Interest”), in return for shares of the Company’s Class A common stock on a one-for-one basis provided that, at the Company’s election, the Company has the ability to effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. Any shares of Class B common stock will be canceled on a one-for-one basis if, at the election of the Continuing LLC Owners, the Company redeems or exchanges such Paired Interest pursuant to the terms of the Rani LLC Agreement. As of September 30, 2024, certain individuals who continue to own interests in Rani LLC but do not hold shares of the Company’s Class B common stock (“non-corresponding Class A Units”) have the ability to exchange their non-corresponding Class A Units of Rani LLC for 1,261,690 shares of the Company’s Class A common stock. Liquidity The Company has incurred recurring losses since its inception, including net losses of $40.9 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had an accumulated deficit of $94.0 million and for the nine months ended September 30, 2024, had negative cash flows from operations of $26.8 million. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $30.4 million. Based on its available cash resources and current operating plan, there is substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that its financial statements for the nine months ended September 30, 2024 are issued. The Company’s existing capital resources, including the issuance and sale of Class A common stock and warrants pursuant to a securities purchase agreement with an institutional investor in July 2024, will not be sufficient to enable it to initiate any pivotal clinical trials. The Company will need to raise substantial additional funds in the future in order to complete the development of the RaniPill platform, to complete the clinical development of its product candidates and seek regulatory approval thereof, to expand its manufacturing capabilities, to further develop the RaniPill HC device and to commercialize any of its product candidates. In July 2024, the Company entered into a securities purchase agreement (the “July Securities Purchase Agreement”) with an institutional investor relating to the issuance and sale of: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to

purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock (the "July Offering"). The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In August 2022, the Company entered into a Controlled Equity Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (collectively the "Agents"), pursuant to which the Company may offer and sell from time to time through the Agents up to $150 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company has no sales under the Sales Agreement. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues to develop the RaniPill capsule. The Company expects to finance its future operations with its existing cash and through strategic financing opportunities that could include, but are not limited to, future offerings of its equity, such as "at the market offerings" as defined in Rule 415(a)(4) under the Securities Act, collaboration or licensing agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern. Subsequent to September 30, 2024, the Company completed an additional equity offering with the aggregate gross proceeds of approximately $10.0 million, before deducting placement agent fees and other estimated offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of certain warrants issued in the offering (Note 16). The proceeds received do not alleviate substantial doubt about the Company's ability to continue as a going concern. 1261690-40900000-94000000-26800000304000002800000000446753000324675300032467530008900000150000000100000000 2. Summary of Significant Accounting Policies Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain prior period amounts have been reclassified to be consistent with current period presentation. The Company operates and controls all of the business and affairs of Rani LLC and, through Rani LLC conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any future period. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements and notes included in the Company's Annual Report on Form 10-K filed with the SEC on March 20, 2024. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company's condensed consolidated financial statements and accompanying notes. The Company evaluates its estimates on an ongoing basis. The Company bases its estimates on its historical experience and also on assumptions that we believe are reasonable; however, actual results may differ materially and adversely from these estimates. Significant Accounting Policies A description of the Company's significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except as noted below, there have been no material changes in the Company's significant accounting policies during the nine months ended September 30, 2024. Cash, Cash Equivalents and Restricted Cash Equivalents The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-

align:top;"> End of Period: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,277</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,972 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:right;">500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,777</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,472 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Collaborative Arrangements The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents amounts due from its collaboration partner as a reduction of research and development expense based on the nature of such payments. Revenue Recognition The Company primarily generates revenue from evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partner's drug molecules using the RaniPill platform technology (Note 6). Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The majority of the Company's contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Variable consideration has not been material to our condensed consolidated financial statements. Consistent with the Company's policies and practices as described above, the Company recognizes contract revenue from its evaluation arrangements using a cost-based input method, which most faithfully depicts the transfer of the performance obligation to the customer. Accordingly, the Company will recognize contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expects to incur to deliver its performance obligation. These actual costs consist of the internal labor efforts, in vivo testing services and materials costs related to the agreement, as the costs incurred over time will reflect the transfer of its performance obligations to the customer. The cumulative effect of revisions to estimated costs to complete the Company's performance obligation will be recorded in the period in which changes are identified and amounts are reasonably estimable. Such costs are expensed when incurred and are included as a component of research and development expenses in the Company's condensed consolidated statements of operations and comprehensive loss. Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes. Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date, none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2024 or December 31, 2023. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services (Note 6). There was no deferred revenue as of

December 31, 2023. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior period amounts have been reclassified to be consistent with current period presentation. The Company operates and controls all of the business and affairs of Rani LLC and, through Rani LLC conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any future period. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 20, 2024. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The Company evaluates its estimates on an ongoing basis. The Company bases its estimates on its historical experience and also on assumptions that we believe are reasonable; however, actual results may differ materially and adversely from these estimates. Significant Accounting Policies A description of the Company’s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2023. Except as noted below, there have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2024. Cash, Cash Equivalents and Restricted Cash Equivalents The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> End of Period: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,277</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,972 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,777</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,472 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet which, in aggregate, represents the amount reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> End of Period: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,277</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,972 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash equivalents </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,777</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,472 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table>427700049720005000005000004777000054720002000 Collaborative Arrangements The Company assesses whether its collaboration agreements are subject to ASC Topic 808, Collaborative Arrangements based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope

of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents amounts due from its collaboration partner as a reduction of research and development expense based on the nature of such payments. Revenue Recognition The Company primarily generates revenue from evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partner's drug molecules using the RaniPill platform technology (Note 6). Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The majority of the Company's contracts include only one performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition. In determining whether performance obligations meet the criteria for being distinct, the Company considers a number of factors, such as the degree of interrelation and interdependence between obligations, and whether or not the good or service significantly modifies or transforms another good or service in the contract. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring the products and/or services. Revenue is recognized only to the extent that it is probable that a significant reversal of the cumulative amount recognized will not occur in future periods. As a practical expedient, we do not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less. Variable consideration has not been material to our condensed consolidated financial statements. Consistent with the Company's policies and practices as described above, the Company recognizes contract revenue from its evaluation arrangements using a cost-based input method, which most faithfully depicts the transfer of the performance obligation to the customer. Accordingly, the Company will recognize contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expects to incur to deliver its performance obligation. These actual costs consist of the internal labor efforts, in vivo testing services and materials costs related to the agreement, as the costs incurred over time will reflect the transfer of its performance obligations to the customer. The cumulative effect of revisions to estimated costs to complete the Company's performance obligation will be recorded in the period in which changes are identified and amounts are reasonably estimable. Such costs are expensed when incurred and are included as a component of research and development expenses in the Company's condensed consolidated statements of operations and comprehensive loss. Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes. Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date, none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2024 or December 31, 2023. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services (Note 6). There was no deferred revenue as of December 31, 2023. 006000000 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for annual periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements and related disclosures. 3. Cash Equivalents, Restricted Cash Equivalents and Marketable Securities The following tables summarizes the amortized cost and fair value of the Company's cash equivalents, restricted cash equivalents and marketable securities by major investment category (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Current assets: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-

align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,090</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents, restricted cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,708</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">— </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,717</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:48.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Estimated Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Current assets:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,339 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,339 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,839 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,839 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-

align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (18 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,971 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,219 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,703 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (28 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,675 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-

color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents, restricted cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,542</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 46,514 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> All marketable securities are classified as short-term. The Company regularly reviews its available-for-sale marketable securities in an unrealized loss position and evaluates the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. As of September 30, 2024, the aggregate difference between the amortized cost and fair value of each security in an unrealized loss position was de minimis. Since any provision for expected credit losses for a security held is limited to the amount the fair value is less than its amortized cost, no allowance for expected credit loss was deemed necessary at September 30, 2024. As of September 30, 2024 and December 31, 2023, interest income receivable recorded as a component of prepaid expenses and other current assets on the condensed consolidated balance sheet was de minimis and $0.2 million, respectively. The following tables summarizes the amortized cost and fair value of the Company's cash equivalents, restricted cash equivalents and marketable securities by major investment category (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Current assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,090</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents, restricted cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,708</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,717 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Current assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,339</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,339 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,339 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and restricted cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,839 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,839 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (18 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,971 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,219 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,703 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (28 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,675 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash equivalents, restricted cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,542</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(28</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 46,514 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2090000002090000209000000209000050000000500000259000000259000026118000900002612700028708000900002871700033390000033390003339000003339000

style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">4. Fair Value Measurements The following tables detail information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of inputs used in such measurements (in thousands):
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;">
<td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;">
</td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr
style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td
style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr
style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Assets: </td><td
style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;">
  </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td
style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td>

align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,717</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,717 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;">

</td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;">

family:Times New Roman;margin-bottom:0;text-align:right;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">39,334</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,180 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 46,514 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Level 1 and Level 2 financial instruments are comprised of investments in money market funds and fixed-income securities. The Company estimates the fair value of its Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. There were no transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy for any of the periods presented. The following tables detail information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of inputs used in such measurements (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,090</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,090 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,127 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,717</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,717 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,339</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Restricted cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:5pt;vertical-align:top;"> Marketable securities </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasuries and agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,495 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Corporate debt securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,180 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>2090000002090000500000005000002612700000261270002871700000287170003339000003339000500000005000003549500000354950000196300001963000052176
style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands):
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-

color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">823</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Payroll and related costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 324 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued rent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 317 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued preclinical and clinical trial costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 183 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,867</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,726 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued expenses and other current liabilities consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;">

</td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">823</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Payroll and related costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 324 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued rent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 317 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 235 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued preclinical and clinical trial costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 424 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 183 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total accrued expenses and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,867</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,726 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>823000500000324000313000317000019000023500030000424000183000254000186700017260000 <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Collaborative and Evaluation Arrangements ProGen Co., Ltd. In June 2024, the Company and ProGen Co., Ltd. ("ProGen") entered into a Collaboration Agreement (the "Collaboration Agreement"). Under the Collaboration Agreement, the Company and ProGen will collaborate to manufacture, develop, seek regulatory approvals for and, if approved, commercialize a product (the "Product") combining ProGen's GLP-1/GLP-2 dual agonist compound, PG-102, and the RaniPill HC oral delivery device (the "Device") in the field of weight management (including without limitation obesity, weight reduction and weight maintenance) in humans (the "Collaboration"). Under the Collaboration Agreement, development costs, as well as operating profits and losses from the commercialization of the Product, will be equally shared by the Company and ProGen. The Company and ProGen each granted to the other party an exclusive right and license (except with respect to the other party's affiliates and sublicensees) to certain intellectual property to develop the Product for weight management and an exclusive right and license to seek regulatory approval for, and to use, sell, offer to sell, import and commercialize the Product in their assigned territories. The Company will lead the development of the Product in the United States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development in all other countries. Each party has the right to opt-out of the Collaboration ("Opt-Out") at any time upon prior written notice to the other party. Following an Opt-Out, the continuing party shall have sole right to develop, conduct regulatory activities for and commercialize the Product on a worldwide basis. The Opt-Out party shall share all development costs and operating profit (or loss) through the effective date of the Opt-Out, and all costs to complete the conduct of any clinical trials of Product that have been initiated prior to delivery of the Opt-Out notice, even if the costs are incurred or the trials are completed after the effective date of the Opt-Out. The continuing party shall pay to the Opt-Out party low single to mid-single digit royalties on net sales of the Product made after the Opt-Out date depending on when the Opt-Out occurs. The Company determined that the Collaboration Agreement is not a contract with a customer and is therefore accounted for under ASC Topic 808. The Company evaluates the presentation of amounts due from ProGen based on the nature of each separate activity. Reimbursements from ProGen are recognized as contra-research and development expense on the Consolidated Statement of Operations once earned and collectability is assured. As of September 30, 2024, no reimbursement has been received from or billed by ProGen nor recorded as contra-research and development expense. Evaluation Arrangement In August 2024, the Company entered into a contract to conduct evaluation services of certain customer compounds for oral delivery using the RaniPill HC. This customer paid the Company an up-front payment of $0.6 million upon execution of the contract. Upon completion of the evaluation services, the Company is entitled to a final $0.6 million payment for an aggregate total of $1.2 million due under the contract. In addition, if agreed upon, the agreement allows for joint filing of certain intellectual property protection in which all associated expenses will be shared equally. The customer has the ability to terminate the agreement at any time by providing 10 days' written notice after the effective date of the contract. The contract can be terminated for cause by either party based on uncured material breach by the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The Company identified one material promise under the contract, the obligation to perform services to evaluate if the customers compounds can be orally delivered using the RaniPill HC, which was concluded to be a single performance obligation. For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in August 2024 and will end the sooner of the contractual 1-year term or upon the completion of the evaluation services. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For the nine months ended September 30, 2024, no contract revenue was recognized for evaluation services performed. As of September 30, 2024, the Company had deferred revenue of $0.6 million related to unsatisfied evaluation services. There was no deferred revenue as of December 31, 2023. 0600000600000120000006000000 7. Related Party Transactions InCube Labs, LLC ("ICL") is wholly-owned by the Company's founder and Chairman and his family. The founder and Chairman is the father of the Company's Chief Executive Officer. The Company's Chief Scientific Officer is also the brother of the founder and Chairman and thus uncle of the Company's Chief Executive Officer. Service Agreements In June 2021, Rani LLC entered into a service agreement with ICL effective retrospectively to January 1, 2021, and subsequently amended such agreement in March 2022 (as amended, the "Rani LLC-ICL Service Agreement"), pursuant to which Rani LLC and ICL agreed to provide personnel services to the other upon requests. Under the amendment in March 2022, Rani LLC has a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas ("Occupancy Services") for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated, except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022, and the Occupancy Services in San Antonio, Texas continue until either party gives six months' notice of termination. Except for the Occupancy Services, Rani LLC or ICL may terminate services under the Rani LLC-ICL Service Agreement upon 60 days' notice to the other party. The Rani LLC-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively. In December 2023, Rani LLC provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024. In June 2021, Rani Management Services, Inc. ("RMS") entered into a service agreement with ICL effective retrospectively to January 1, 2021, pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. In April 2022, RMS assigned the agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000 square feet to 24,000 square feet (such agreement, as assigned and amended, the "RMS-ICL Service Agreement"). The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated. Rani LLC or ICL may terminate services under the RMS-ICL Service Agreement upon 60 days' notice to the other party, except for occupancy which requires six months' notice. The RMS-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively, as well as allocations of expenses based upon Rani LLC's utilization of ICL's facilities and equipment. The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:42.137%;box-sizing:content-box;"></td><td style="width:1.421%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.044%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.421%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.044%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.421%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.044%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 280 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> 889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">242</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"> 367 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">955</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,109 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024, one of the Company's facilities was owned by an entity affiliated with the Company's Chairman (Note 8). The Company pays for the use of this facility through the RMS-ICL Service Agreement. Exclusive License, Intellectual Property and Common Unit Purchase Agreement

In June 2021, ICL and the Company, through Rani LLC, entered into an Amended and Restated Exclusive License Agreement which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013. Under the Amended and Restated Exclusive License Agreement, the Company has a fully paid, exclusive license under certain scheduled patents related to optional features of the device and certain other scheduled patents to exploit products covered by those patents in the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. The Company covers patent-related expenses and, after a certain period, the Company will have the right to acquire four specified United States patent families from ICL by making a one-time payment of $0.3 million to ICL for each United States patent family that the Company desires to acquire, up to $1.0 million in the aggregate. This payment will not become an obligation until the fifth anniversary of the Amended and Restated Exclusive License Agreement. The Amended and Restated Exclusive License Agreement will terminate when there are no remaining valid claims of the patents licensed under the Amended and Restated Exclusive License Agreement. Additionally, the Company may terminate the Amended and Restated Exclusive License Agreement in its entirety or as to any particular licensed patent upon notification to ICL of such intent to terminate. Non-Exclusive License Agreement between Rani and ICL ("Non-Exclusive License Agreement") In June 2021, the Company, through Rani LLC, entered into the Non-Exclusive License Agreement with ICL a related party, pursuant to which the Company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to the Company. Additionally, the Company agreed not to license these patents to a third party in a specific field outside the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine, if ICL can prove that it or its sublicensee has been in active development of a product covered by such patents in that specific field. ICL may grant sublicenses under this license to third parties only with the Company's prior approval. The Non-Exclusive License Agreement will continue in perpetuity unless earlier terminated. Intellectual Property Agreement with Mir Imran (the "Mir Agreement") In June 2021, the Company, through Rani LLC, entered into the Mir Agreement, pursuant to which the Company and Mir Imran agreed that the Company would own all intellectual property conceived (i) using any of the Company's people, equipment, or facilities or (ii) that is within the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. Neither the Company nor Mir Imran may assign the Mir Agreement to any third party without the prior written consent of the other party. The initial term of the Mir Agreement was three years, which could be extended upon mutual consent of the parties. In June 2024, the parties agreed to extend the term of the Mir Agreement by ninety (90) days. The Mir Agreement expired in September 2024. Expiration of the Mir Agreement does not affect the assignment to, and ownership by, the Company of intellectual property conceived during the term of the Mir Agreement. Tax Receivable Agreement Certain parties to the tax receivable agreement ("TRA"), entered into in August 2021 pursuant to the IPO and Organizational Transactions are related parties of the Company. The TRA provides that the Company pay to ICL and the other Continuing LLC Owners 85% of the amount of tax benefits, if any, it is deemed to realize from exchanges of Paired Interests. During each of the nine months ended September 30, 2024 and 2023, these parties to the TRA exchanged zero Paired Interests that resulted in tax benefits subject to the TRA. Registration Rights Agreement In connection with the IPO, the Company entered into a Registration Rights Agreement. ICL and its affiliates are parties to this agreement. The Registration Rights Agreement provides certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, ICL and its affiliates can require the Company to register under the Securities Act of 1933, as amended (the "Securities Act") shares of Class A common stock issuable to ICL and its affiliates upon, at the Company's election, redemption or exchange of their Paired Interests. The Registration Rights Agreement also provides for piggyback registration rights. In March 2022, certain holders of the Company's Class A common stock considered to be related parties were made parties to the Registration Rights Agreement. As a result of certain stockholders exercising their registration rights under the Registration Rights Agreement, in December 2022, the Company filed a registration statement on Form S-3 to register 6,009,542 shares of Class A common stock of the Company held by certain of its stockholders. Rani LLC Agreement The Company operates its business through Rani LLC. In connection with the IPO, the Company and the Continuing LLC Owners, including ICL and its affiliates, entered into the Rani LLC Agreement. The governance of Rani LLC, and the rights and obligations of the holders of LLC Interests, are set forth in the Rani LLC Agreement. As Continuing LLC Owners, ICL and its affiliates are entitled to exchange, subject to the terms of the Rani LLC Agreement, Paired Interests for Class A common stock of the Company; provided that, at the Company's election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. During each of the nine months ended September 30, 2024 and 2023, certain related parties that are party to the Rani LLC Agreement exchanged zero Paired Interests for an equal number of shares of the Company's Class A common stock. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022, and the Occupancy Services in San Antonio, Texas continue until either party gives six months' notice of termination.pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. In April 2022, RMS assigned the agreement to Rani LLC23000240000 The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.137%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">201</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 280 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">242</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 367 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">955</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,109 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>2010002800007680000889000410008700018700022000024200036700095500011090003000001000000006009542000000 8. Leases In November 2023, Rani LLC and BKM South Bay 240, LLC (“Landlord”) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the “Lease”). Pursuant to the terms of the Lease, Rani LLC is leasing approximately 33,000 square feet of space in Fremont, California, which is part of a two-building project (the “Project”). The initial term of the Lease commenced in February 2024, and the duration of the initial term is 63 months. Subject to certain conditions, Rani LLC has an option to renew the Lease for one additional 5-year term at the then-prevailing market rate. The monthly base rent for the initial term of the Lease is approximately $95,000 per month, subject to a 4% increase each year. Rani LLC is also responsible for the payment of additional rent to cover its share of common area operating expenses, including taxes, insurance, utilities, and repair and maintenance of the premises and common areas of the Project. The Company pays for the use of its office, laboratory and manufacturing facility in San Jose, California as part of the RMS-ICL Service Agreement. In April 2022, RMS assigned the RMS-ICL Service Agreement to Rani LLC. In December 2022, RMS was dissolved. In March 2024, the Company entered into an amendment to increase the Occupancy Services from 23,000<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> square feet to 24,000 square feet. The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless Rani LLC or ICL terminate occupancy under the RMS-ICL Service Agreement upon six months' notice. In January 2024, the Company determined it to be reasonably certain that it would exercise its renewal option for a successive twelve-month period through 2025. The Company accounted for the renewal option as a lease modification that did not result in a separate contract and recognized the additional right-of-use asset and corresponding lease liabilities associated with the Rani LLC-ICL Service Agreement in its condensed consolidated balance sheet. Under the Rani LLC-ICL Service Agreement amended in March 2022, Rani LLC had a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for a successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California had a term until February 2024, following an extension granted in July 2022. The Company accounted for the lease extension as a lease modification that did not result in a separate contract and recognized the right-of-use asset and lease liabilities associated with the Rani LLC-ICL Service Agreement in the consolidated balance sheet as of the modification date in July 2022. In December 2023, the Company provided to ICL notice of termination of the Occupancy Services in San Antonio, which took effect in June 2024. In March 2024, the Company extended the Occupancy Services for the facility in Milpitas, California for an additional six-month term through August 2024 and increased the payment for such Occupancy Services during the extension period. The Occupancy Services for the facility in Milpitas, California expired in August 2024. The Company's leases are accounted for as operating leases and require certain fixed payments of real estate taxes and insurance in addition to future minimum lease payments, and certain variable payments of common area maintenance costs and building utilities. Variable lease payments are expensed in the period in which the obligation for those payments is incurred. These variable lease costs are payments that vary in amount beyond the commencement date, for reasons other than passage of time. Variable lease payments are excluded in the total operating lease expense and immaterial for the periods presented. Supplemental information on the Company's condensed consolidated balance sheet and statements of cash flows as of September 30, 2024 and 2023 and for the nine months ended September 30, 2024 and 2023, respectively, related to the Company's leases was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash paid for amounts included in lease liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating cash flows used for operating leases </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,015</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 780 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> As of September 30, 2024, minimum annual rental payments under the Company’s operating lease agreements are as follows (in thousands), excluding short-term leases: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Year ending December 31, </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2024 (remaining three months) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">465</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,902</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,229</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,278</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,330</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2029</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">458</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total undiscounted future minimum lease payments</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,662 </td><td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Imputed interest </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,235 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,427 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Current portion of operating lease liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,410 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating lease liability, net current portion </td><td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,017 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 3300The initial term of the Lease commenced in February 2024, and the duration of the initial term is 63 months. Subject to certain conditions, Rani LLC has an option to renew the Lease for one additional 5-year term at the then-prevailing market rate. The monthly base rent for the initial term of the Lease is approximately $95,000 per month, subject to a 4% increase each year. Rani LLC is also responsible for the payment of additional rent to cover its share of common area operating expenses, including taxes, insurance, utilities, and repair and maintenance of the premises and common areas of the Project.P63MP5Y950000000.042300024000<p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Supplemental information on the Company's condensed consolidated balance sheet and statements of cash flows as of September 30, 2024 and 2023 and for the nine months ended September 30, 2024 and 2023, respectively, related to the Company's leases was as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted-average remaining lease term (in years)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted-average discount rate</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash paid for amounts included in lease liabilities:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating cash flows used for operating leases</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,015 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 780 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>P4Y1M6DP1Y1M6D0.1040.104101500078000<p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times

New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, minimum annual rental payments under the Company's operating lease agreements are as follows (in thousands), excluding short-term leases: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Year ending December 31, </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2024 (remaining three months) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">465</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,902</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,229</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,278</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,330</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2029</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">458</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total undiscounted future minimum lease payments</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,662 </td><td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: Imputed interest </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,235 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liability </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,427</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Current portion of operating lease liability</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,410</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability, net current portion</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,017 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table>46500019020001229000127800013300004580006662000123500054270001410000401700000 9. Warrants In July 2024, as part of the July Offering, the Company issued (i) pre-funded warrants to purchase 446,753 shares of Class A common stock, (ii) Series A common warrants to purchase an aggregate of <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-

wrap;min-width:fit-content;">3,246,753 shares of Class A common stock and (iii) Series B common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock. The pre-funded warrants are exercisable immediately and have an unlimited term and an exercise price of $0.0001 per share. The Series A Warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire 18 months following the date of issuance and will have an exercise price of $3.08 per share. The Series B warrants will be exercisable following the six-month anniversary of the closing date of the July Offering, will expire five and a half years from the date of issuance and will have an exercise price of $3.08 per share. The Series A warrants and Series B warrants include certain rights upon “fundamental transactions,” as described in the Series A warrants and Series B warrants, including in the Series B warrants the right of the holders thereof to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series B warrants) of the unexercised portion of the applicable Series B warrants on the date of the consummation of the fundamental transactions. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. As of September 30, 2024, there were 3,246,753 Series A warrants and 3,246,753 Series B warrants outstanding. Subsequent to September 30, 2024, the Series A warrants were canceled (Note 16). In August 2022, in conjunction with a loan and security agreement (Note 13), the Company issued warrants to purchase 76,336 shares of the Company’s Class A common stock. The warrants are exercisable for a period of five years from the grant date, as may be adjusted for certain anti-dilution adjustments, dividends, stock splits, and reverse stock splits, at an exercise price per share equal to $11.79, which may be net share settled at the option of the holder. As of September 30, 2024, there were 76,336 warrants outstanding. 4467533246753324675306330000P5Y11.7976336000 10. Stockholders’ Equity As of September 30, 2024, Rani Holdings held approximately 54% of the Class A Units of Rani LLC, and approximately 46% of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. From the date of the Organizational Transactions to September 30, 2024, 5,173,947 Paired Interests and 283,832 non-corresponding Class A Units of Rani LLC were exchanged for an equal number of shares of the Company’s Class A common stock. For each of the nine months ended September 30, 2024 and 2023, certain of the Continuing LLC Owners executed an exchange of zero Paired Interests and 83,377 and zero non-corresponding Class A Units of Rani LLC, respectively, in return for an equal number of shares of the Company’s Class A common stock. The corresponding shares of the Company’s Class B common stock included in the exchange of Paired Interests were subsequently canceled and retired pursuant to the terms of the Rani LLC Agreement. In accordance with the Rani LLC Agreement, Rani LLC also issues a corresponding Class A Unit to Rani Holdings for each share of common stock issued by Rani Holdings. This increases Rani Holdings’ ownership in Rani LLC. In July 2024, the Company closed the July Offering, pursuant to which it issued and sold: (i) 2,800,000 shares of Class A common stock, (ii) pre-funded warrants to purchase 446,753 shares of Class A common stock, (iii) Series A common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock and (iv) Series B common warrants, which accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,246,753 shares of Class A common stock. The aggregate net proceeds from the July Offering totaled $8.9 million, after deducting placement agent fees and other offering expenses, and excluding potential proceeds, if any, from the exercise of the Series A common warrants and Series B common warrants issued in the July Offering. In August 2024, the pre-funded warrants were fully exercised for de minimis proceeds. In August 2022, the Company entered into the Sales Agreement with the Agents, pursuant to which the Company may offer and sell from time to time through the Agents up to $150.0 million of shares of its Class A common stock, in such share amounts as the Company may specify by notice to the Agents, in accordance with the terms and conditions set forth in the Sales Agreement. The potential proceeds from the Sales Agreement are expected to be used for general corporate purposes. As of September 30, 2024, the Company had no sales under the Sales Agreement. 0.540.4651739470002838320000083377000028000004467533246753324675389000001500000000 11. Stock-Based Compensation Stock Options A summary of stock option activity during the periods indicated is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:36.867%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:12.703%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.56%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.222000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.703%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:1.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.222000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Stock Option Awards </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;">Weighted
Average
Remaining Contractual Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value (in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,639,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.48</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,377 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,154,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.74</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.49</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (18,757 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.72</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Canceled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(478,961</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,296,418 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.35</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,713,481 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.62</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.66</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Nonvested at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,582,937 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.46</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.99</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> As of September 30, 2024, there was $21.8 million of unrecognized stock-based compensation expense related to stock options which is expected to be recognized over a weighted-average period of approximately 2.8 years.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Stock Units</p><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">A summary of restricted stock unit (“RSU”) activity during the periods indicated is as follows:</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.799999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of Restricted Stock Units</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted Average Grant-Date Fair Value per Share</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,276,111</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (323,611 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.69</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(59,206</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 893,294 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.96 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> As of September 30, 2024, there was $5.6 million of unrecognized stock-based compensation expense related to RSUs which is expected to be recognized over a weighted-average period of approximately 2.3 years. The total fair value of RSUs vested was $1.0 million for the nine months ended September 30, 2024.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Stock Awards</p><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">A summary of restricted stock award ("RSA") activity during the periods indicated is as follows:</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.799999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of Restricted Stock Awards</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted Average Grant-Date Fair Value per Share</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,586</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (22,616 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.13</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,752</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> As of September 30, 2024, unrecognized stock-based compensation expense related to RSAs was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. The total fair value of RSAs vested was $0.1 million for the nine months ended September 30, 2024. Employee Stock Purchase Plan As of September 30, 2024, unrecognized stock-based compensation expense related to the Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”) was de minimis which is expected to be recognized over a weighted-average period of approximately 0.2 years. As of September 30, 2024, contributions withheld from employees totaled $0.1 million and are recorded as a component of accrued expenses and other current liabilities in the condensed consolidated balance sheet. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-Based Compensation Expense</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the components of stock-based compensation expense resulting from the grant of stock options, RSUs, RSAs, and the ESPP, recorded in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.08%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,275</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,477</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,247</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,040 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,522 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times

New Roman;margin-bottom:0;text-align:left;">A summary of stock option activity during the periods indicated is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:36.867%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.703%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.56%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.222000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.703%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.56%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.222000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Stock Option Awards </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Exercise Price </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Remaining Contractual Term (in years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Intrinsic Value (in thousands) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,639,811 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.37</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.48</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,377 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,154,325 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.74</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.49</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Exercised </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (18,757 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.72 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Canceled </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (478,961 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,296,418</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.35 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercisable at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,713,481</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.62 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.66 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Nonvested at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,582,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.99 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>66398116.37P8Y5M23D133770004154325 3.74P9Y5M26D0187572.724789615.36102964185.36P8Y4M6D2500047134817.62P7Y7M28D055829373.46P8Y11M26D2500(Balance at September 30, 2024 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:53.88%;box-sizing:content-box;"></td><td style="width:1.8%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:19.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:18.799999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Restricted Stock Units </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Grant-Date Fair Value per Share </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,276,111 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.16</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(323,611</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.69 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (59,206 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">893,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.96 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.799999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Restricted Stock Awards </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted Average Grant-Date Fair Value per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,586 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(22,616</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (218 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,752 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>12761117,163236117,69592067,378932946,965600000P2Y3M18D1000000335866,15226166,142186,13107526,15P0Y2M12D100000P0Y2M12D100000 The following table summarizes the components of stock-based compensation expense resulting from the grant of stock options, RSUs, RSAs, and the ESPP, recorded in the Company's condensed consolidated statement of operations and comprehensive loss (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.08%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,477 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,247 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,040</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,522 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>3563000527500084770009247000120400001452200 12. Commitments and Contingencies Legal Proceedings In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. Tax Receivable Agreement The Company is party to a TRA with certain of the Continuing LLC Owners. As of September 30, 2024, the Company has not recorded a liability under the TRA related to the income tax benefits originating from the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC as it is not probable that the Company will realize such tax benefits. To the extent the Company is able to realize the income tax benefits associated with the exchanges of Paired Interest or non-corresponding Class A Units of Rani LLC subject to the TRA, the TRA payable would range from zero to $23.1 million at September 30, 2024. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;">The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the payment of the TRA liability becomes probable at a future date based on new information, any changes will be recorded on the Company's condensed consolidated statement of operations and comprehensive loss at that time. 023100000 13. Long-Term Debt In August 2022, the Company entered into a loan and security agreement and related supplement (the "Loan Agreement") with Avenue Venture Opportunities Fund, L.P (the "Lender"). The Loan Agreement provides for term loans (the "Loans") in an aggregate principal amount up to $45.0 million. A Loan of $30.0 million was committed at closing, with $15.0 million funded immediately and $15.0 million available to be drawn between October 1, 2022 and December 31, 2022, which was drawn in December 2022. The remaining $15.0 million of Loans was uncommitted and subject to certain conditions and is no longer available under the Loan Agreement. The purpose of the Loans is for general corporate purposes. In exchange for access to this facility, the Company agreed to issue warrants (Note 9).</p><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Pursuant to the Loan Agreement, the maturity date for the Loans is August 1, 2026 (the "Maturity Date"). The Loan principal is repayable in equal monthly installments beginning September 2024. The Loans bear interest at a variable rate per annum equal to the greater of (A) the prime rate, as published by the Wall Street Journal from time to time plus 5.60% or (B) 10.35%. The Loan Agreement is collateralized by substantially all of the Company's assets, in which the Lender is granted continuing security interests. The Loans includes customary events of default, including instances of a material adverse change in the Company's operations, which may require prepayment of the outstanding Loans. At September 30, 2024, the effective interest rate on the Loans was 15.62% and there were no events of default during the nine months ended September 30, 2024. The Company is also subject to certain covenants. There have been no material adverse events in connection with the Loan Agreement and the substantial doubt regarding our ability to continue as a going concern does not currently constitute a material adverse event under the terms of the Loan Agreement. As of September 30, 2024, the Company was in compliance with all applicable covenants under the Loan Agreement.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, future principal payments for the Company's debt are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ending December 31,</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining three months)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,750 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total principal payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,750</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: amount representing debt discount</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(445</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total long-term debt</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,305 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: current portion of long-term debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,768 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total long-term debt, less current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,537</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p>450000003000000015000000150000001500000002026-08-010.0560.0010350.001562<p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, future principal payments for the Company's debt are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.823%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ending December 31,</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffffc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remaining three months)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,750 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total principal payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,750</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: amount representing debt discount</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(445</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total long-term debt</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,305 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Less: current portion of long-term debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,768 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total long-term debt, less current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 13,537 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>375000015000000100000002870500004450002830500014768000135370000 14. Income Taxes The Company's effective income tax rate was zero for each of the nine months ended September 30, 2024 and 2023. As a result of the exchanges from the date of the Organizational Transactions to September 30, 2024, the Company recorded a $18.9 million deferred tax asset related to income tax benefit associated with the basis of the net assets of Rani LLC. Because of the Company's history of operating losses, the Company believes that recognition of the deferred tax assets arising from such future income tax benefits is currently not more-likely-than-not to be realized and, accordingly, has recognized a full valuation allowance on its deferred tax assets. There were no material changes to uncertain tax positions for the nine months ended September 30, 2024 and 2023, and the Company does not anticipate material changes within the next twelve months. 001890000000 <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:63.913%;box-sizing:content-box;"></td><td style="width:1.8%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.143%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.143%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Numerator: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,071</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (26,872 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Denominator: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average Class A common share outstanding—basic and diluted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,071 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,380 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.—basic and diluted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.78</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1.06 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td></tr></table> The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:64.68%;box-sizing:content-box;"></td><td style="width:1.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.74%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;

wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Paired Interests </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,296 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,778 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 76 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-corresponding Class A Units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 893 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,413 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares issuable pursuant to the ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock awards </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 43,189 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Shares of Class B Common Stock do not share in the Company's earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. The outstanding shares of Class B Common Stock were determined to be anti-dilutive for the nine months ended September 30, 2024. Therefore, they are not included in the computation of net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.913%;box-sizing:content-box;"></td> <td

style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.143%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.143%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(21,071</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (26,872 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average Class A common share outstanding—basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27,071 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.—basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.78</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1.06 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table>-21071000-26872000270710002707100025380000253800002538000-0.78-0.78-1.06-1.06 The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.68%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Paired Interests </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,296 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,778 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 76 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-corresponding Class A Units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 893 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,413 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares issuable pursuant to the ESPP </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock awards </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 43,189 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,851 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>241160002411600010296000677800065700007600012620001345000893000141300041000820001100041000431890003385100 16. Subsequent Events Securities Purchase Agreement In October 2024, the Company entered into a securities purchase agreement (the “October Securities Purchase Agreement”) with an institutional investor (the “Equity Investor”) relating to the issuance and sale of: (i) 3,000,000 shares of its Class A common stock, par value $0.0001 per share, (ii) pre-funded warrants to purchase 333,333 shares of Class A common stock, and (iii) Series C common warrants, which will accompany the Class A common stock and pre-funded warrants, to purchase an aggregate of 3,333,333 shares of Class A common stock (the “October Offering”). The October Offering closed on October 16, 2024. Pursuant to the October Securities Purchase Agreement, Series A common warrants to purchase an aggregate of 3,246,753 shares of Class A common stock issued in the July Offering were cancelled. <p style="text-indent:48.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-

bottom:0;text-align:left;">The pre-funded warrants are exercisable immediately following the closing date of the October Offering and have an unlimited term and an exercise price of $0.0001 per share. The Series C common warrants are exercisable immediately following the closing date of the October Offering, will expire five years from the date of issuance and will have an exercise price of $3.00 per share. The combined offering price is $3.00 per share of Class A common stock and accompanying Series C common warrant, or in the case of pre-funded warrants, $2.9999 per pre-funded warrant and accompanying Series C common warrant. The aggregate gross proceeds to the Company from the October Offering were approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company, and excluding potential proceeds, if any, from the exercise of the Series C common warrants issued in the October Offering. In October 2024, the pre-funded warrants were fully exercised for de minimis proceeds. The Series C common warrants include certain rights upon “fundamental transactions” as described in the Series C common warrants. These rights upon “fundamental transactions” include the right of the holders thereof to receive from Rani or a successor entity the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Class A common stock in such fundamental transaction in the amount of the Black Scholes value (as described in the Series C common warrants) of the unexercised portion of the applicable Series C common warrants on the date of the consummation of such fundamental transaction. Pursuant to the terms of the October Securities Purchase Agreement, until 30 days following the closing of the October Offering, the Company has agreed not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Class A common stock or common stock equivalents, or file or amend any registration statement or prospectus, other than as necessary to maintain the registration of the securities offered thereby. The Company has further agreed not to enter into an agreement involving any new variable rate transactions until January 23, 2025, subject to certain exceptions. In addition, the Company’s directors and officers have entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 30 days from the closing of the October Offering, offer, sell, transfer or otherwise dispose of the Company’s securities, subject to certain exceptions. CEO Compensation Reduction In November 2023, the Company’s Board of Directors (“Board”) approved a reduction in the annual salary of Talat Imran, the Company’s Chief Executive Officer, from $520,000 to $100,000, effective November 1, 2023 through December 31, 2024 or until such time as the Company receives gross proceeds of $50,000,000 or more, in the aggregate, from equity financing and/or one or more non-dilutive strategic, licensing or partnering transactions (the “Financing Threshold”). In November 2024, the Board approved to extend the reduction in annual salary of Talat Imran through December 31, 2025 or until the Financing Threshold is met.
30000000.000133333333333333332467530.0001332.99991000000052000000010000000050000000000falsefalsefalsefalse